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ABSTRACT 
 
Background 
Sickle cell disease (SCD) is a genetic, potentially debilitating disease with global spread and 
public health concern commonly found in people of African origin. Nigeria has the highest 
burden of the disease in the world. The disease predisposes to high morbidity and mortality 
rate, increasing comorbid complications with advancing age and impaired quality of life. 
Understanding fine details of quality of life issues is important to guide the design of 
comprehensive care protocols. The Wilson and Cleary conceptual model of HRQL is a 
biophysiological model of health that lends itself as a tool to enhance our understanding of 
the relationships among the health concepts.  
Aim 
The aim of the study is to describe the health-related quality of life of people living with 
sickle cell disease and to characterise the predictors in adults with SCD.  
Pertinent questions were answered in pursuit of the aim, they included: 
1. What is the profile of HRQL in adults with SCD in the study area? 
2. What are the factors that ssociate with the measures of HRQL? 
3. How does the Wilson and Cleary model fit the HRQL data of the study population? 
4. Are there relationships among the bio-physiological variables, symptoms, functional 
status, general health perceptions, individual characteristics and the overall quality 
of life as hypothesised by Wilson and Cleary? 
5. What are the patterns and paths of the relationship of the HRQL determinants? 
6. What is the relative importance of each determinant? 
7. What is the utility score and its determinants in the population? 
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Methods 
A cross-sectional design was used. Sociodemographic and patient-reported questionnaires 
were used to collect data from a population of 200 adults with SCD aged 18 years and older 
from two sickle cell clinics in Ibadan, Nigeria. The Wilson and Cleary conceptual model of 
health-related quality of life was empirically tested using structural equation modelling 
technique. 
Results 
Findings supported the Wilson and Cleary model indicating strong relationship between 
objective and subjective health. Adults with SCD have significantly impaired quality of life 
predicted by biological and physiological factors, symptoms status, functional status, general 
health perception and some characteristics of the individual. Symptoms status, indicated by 
bodily pain, depression, anxiety and somatic symptoms, was the most important contribution 
to reduced quality of life in the population. 
Conclusion 
The study underscores the need to include assessment of patients’ quality of life as part of 
measures of medical outcomes beyond the presence or absence of diseases. The insight 
gained from the study can be used by clinicians to understand how changes in specific 
clinical characteristics affect a patients’ overall health outcomes. A multidisciplinary 
approach is therefore required to manage the disease because interventions that focused only 
on biological and physiological variables without considering the patients’ experiences of 
their symptoms will not be fully effective. Routine investigation of the patients’ psychiatric 
status should be integrated in the disease management protocol to be targeted for immediate 
attention once traces are detected to improve the health-related quality of life of the patients.  
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CHAPTER ONE 
BACKGROUND AND LITERATURE REVIEW 
 
1.0 Introduction 
Worldwide, approximately 1,000 children are born daily with sickle cell disease (W H O, 
2006; Aliyu et al., 2008; Piel et al., 2010; Frederic B Piel et al., 2013) and between 70% and 
80% of these are in Africa with a prevalence of 2% (W H O, 2006). Nigeria has the highest 
burden of the disease in the world with over four million people affected (Fleming et al., 
1979; Aliyu et al., 2008; Nwogoh et al., 2012). Sickle cell disease (SCD) is a chronic and 
potentially debilitating disease resulting from an inherited blood disorder associated with 
multisystem morbidity and high mortality (Juwah, Nlemadim and Kaine, 2003; Lucchesi et 
al., 2016). The disease is responsible for 6.4% of under-five mortality in Africa (Modell and 
Darlison, 2008; Ware, 2013) and is associated with reduced life expectancy and increased 
risk of premature death (Quinn et al., 2010). Studies have shown that SCD patients have 
poor health-related quality of life along with their families when compared with the general 
population (Tunde-Ayinmode, 2007; Brandow et al., 2010; McClish et al., 2016). Hence, 
the need to focus research efforts on disease management protocol or practices that will 
provide better quality of life for the patients (Ashley-Koch, A., Yang, Q. and Olney, 2000).  
1.1 Statement of the Problem 
For the last 30 years, the World Health Organisation (WHO) has collaborated with 
Thalassaemia International Federation, several sickle cell centres and organisations to 
prioritise hereditary haemoglobin disorders on the health agenda of member states (WHO, 
2007). Both the United Nations (2008) and WHO (2006) have emphasised the need for 
research in countries most affected by SCD to improve the lives of the patients and educate 
medical professionals, care givers, and associated personnel (World Health Organisation, 
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2010). Furthermore, the WHO African Region has developed a regional strategy to promote 
awareness about the disease, engage in preventive activities that would reduce incidence, 
morbidity and mortality and improve quality of life (WHO Regional Committee for Africa, 
2010; page 3).  
In developed countries, studies have been carried out to explain factors that influence HRQL 
in SCD patients; some explanatory factors including the role of socio-demographics, disease 
severity, depression and the presence of complications have been discovered to explain 
HRQL in SCD patients (Palermo et al., 2002; Barakat et al., 2008; Palermo, Riley and 
Mitchell, 2008; Panepinto, 2008). However, such studies are mostly limited to children and 
are lacking in African countries including Nigeria. Moreover, there is a consensus on the 
global need for models to explain causal factors (Ferrans et al., 2005). Researchers posited 
that a major focus for future research is the need to characterize determinants of HRQL and 
resolve methodological issues through empirical data (Wilson and Cleary, 1995; Muldoon 
et al., 1998; Berlim and Fleck, 2003; Ferrans et al., 2005). Studies on HRQL of people living 
with SCD have been few and the focus has been on selected determinants (Fisak et al., 2011). 
Again, there is a lack of research that has examined multiple determinants of HRQL in SCD 
patients, in most cases, single determinants were studied which is perhaps, a reason for the 
limited scientific knowledge of correlates or predictors of HRQL that exist in literature 
(Palermo et al., 2002). 
Evolving research has shown that disease management is incomplete without the evaluation 
of the HRQL of the patient, hence the increasing agreement among clinicians and social 
scientists on the need to conduct ‘quality of life assessments’ considered as adjuvant to 
clinical and physiological assessments in many chronic conditions (Harrison et al., 2005), 
 when evaluating medical intervention outcomes (Bowling, 1995).  
Furthermore, evaluating HRQL has become important in measuring the cost of healthcare 
because low HRQL has been reported to have inverse relationship with cost of healthcare 
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(Seid et al., 2004), meaning that interventions and policies that improve HRQL could 
significantly reduce cost of healthcare. To improve HRQL then, factors that predict or 
determine HRQL need to be identified and path of relationship understood. Significant 
determinants may then be categorised in order of relative importance to set up priority 
variables to be targeted for intervention. Understanding causal factors or predictors of HRQL 
is a major goal of healthcare interventions (Berlim and Fleck, 2003) and is important to 
healthcare researchers and providers in designing interventions that will enable patients to 
have better quality of life.  
In previous studies, individual predictors of HRQL in children and adolescents with SCD 
have been identified, some of which are pain (Barakat et al., 2008; Schlenz et al., 2012; 
Menezes et al., 2013), socioeconomic status (Hijmans et al., 2010), disease 
severity/complications (Palermo et al., 2002; Panepinto, 2008; Amr, Amin and Al-Omair, 
2011; Fisak et al., 2011; Adeyemo et al., 2015; Sehlo and Kamfar, 2015), comorbidities 
(Wrotniak et al., 2014), depression (Sehlo and Kamfar, 2015), frequency of hospitalisation 
(Amr, Amin and Al-Omair, 2011; Dale et al., 2011) and stigma (Adeyemo et al., 2015). 
However, these and other predictors have only been studied individually but have not been 
modelled in any study to provide understanding of pattern and pathways of relationship, yet 
our understanding of factors affecting HRQL may be limited without modelling (Wilson and 
Cleary, 1995; Ferrans et al., 2005; Sousa and Kwok, 2006). 
This study therefore aims to examine the predictors of HRQL in adult with SCD and test the 
conceptual model of Wilson and Cleary in the study population. This will help to clarify 
relationships among the physiological/biological variables and the psychosocial variables 
and HRQL and the causal path of association between the predictors and the outcome 
variables. This would assist researchers and health care providers to learn about the 
conditions that have greater impact on patients’ lives, evaluate the relative significance of 
different approaches to patients’ care and consequently translate the clinical relevance of 
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HRQL (Wilson and Cleary, 1995; Sousa and Kwok, 2006) to contribute to the development 
of the study of quality of life of sickle patients in Nigeria. 
1.2 Aim 
The aim of the study is to describe the health-related quality of life of people living with 
sickle cell disease and to characterise the predictors in adults with SCD.  
1.3 Objectives 
The specific objectives of this thesis are to: 
• describe the HRQL profile of adults with SCD attending haematological clinics at 
Adeoyo and UCH Ibadan, Nigeria; 
• characterize predictors of HRQL in adults with SCD attending haematological 
clinics at Adeoyo and UCH Ibadan, Nigeria;  
• test the Wilson-Cleary model on the HRQL in a data of adults with SCD attending 
haematological clinics at Adeoyo and UCH Ibadan, Nigeria  
• create a hierarchy of importance of the determinants as targets for potential 
intervention; and 
• determine the utility score and the associated factors in the sample. 
1.4 Research Questions 
1. What is the profile of HRQL in adults with SCD in the study area? 
2. What are the factors that ssociate with the measures of HRQL? 
3. How does the Wilson and Cleary model fit the HRQL data of the study population? 
4. Are there relationships among the bio-physiological variables, symptoms, functional 
status, general health perceptions, individual characteristics and the overall quality 
of life as hypothesised by Wilson and Cleary? 
5. What are the patterns and paths of the relationship of the HRQL determinants? 
6. What is the relative importance of each determinant? 
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7. What is the utility score and its determinants in the population? 
1.5 Significance of the Study 
One of the current challenges of research in quality of life is devising appropriate models to 
clarify the elements of HRQL and the causal relationships among them (Ferrans et al., 2005). 
Identifying predictors of HRQL in adults with SCD will help to guide therapeutic 
interventions so that life will be worth living for the patients. 
Leading health organisations (CDC, 2000; Healthy people, 2011; WHO. 2007) have 
identified HRQL as a goal for all people across all life stages (Bakas et al., 2012) and quality 
of life issues has become major concerns of policymakers, researchers and health care 
practitioners (Till et al., 1994). The findings may also help in counselling and advocacy and 
health education to improve the HRQL of SCD patients.  
The responsiveness of changes in predictors will help to track changes in HRQL for clinical 
research improvement in healthcare. Prediction of changes over time in HRQL due to 
specific interventions will be possible. In literature, attention has been focused on HRQL 
either as a measure of the impact of chronic illness on functioning or as a measure of 
treatment outcome, only few studies have examined the factors that determine HRQL in 
SCD populations (Fisak et al., 2011). In Nigeria, studies in HRQL are rare, only one study 
has been found which investigated the perception of stigmatization and HRQL of 
adolescents with SCD (Adeyemo et al., 2015). No study has attempted to model and 
characterize several variables that have been hypothesized in previous studies as individual 
predictors of HRQL in SCD.  
The Wilson and Cleary model allows a simultaneous testing of several variables and a link 
between the biological and psychosocial variables does not appear to have been tested in 
SCD population anywhere. This study is thus the first to test WCM in a sickle cell population 
and in Nigeria.  
26 
 
Measuring HRQL is important for evaluating different aspects of disease management. An 
empirically tested theoretical model will assist researchers and practitioners to better 
understand latent relationships between HRQL and the determinants. This may influence or 
guide researchers in the development of appropriate means to optimize both the physiological 
outcomes and HRQL of people with SCD. Furthermore, understanding the patient’s HRQL 
can offer a unifying theme for diverse health and social service, and economic programmes 
which aim to improve population well-being as well as bridge boundaries between 
disciplines and between social, mental, and medical services. This will supplement public 
health’s traditional measures of morbidity and mortality and help determine the burden of 
the disease or assist in counselling the patients. In addition, proper analysis and 
documentation of the behaviour of the outcome variable HRQL, can help identify subgroups 
with relatively poor perceived health and help to guide interventions to improve their 
situations. These can inform targeted health policies and promote the practice of needs-based 
allocation of resources, as well as guide healthcare strategic plans development legislation 
as recommended by the World Health Organisation ((W H O, 2006). 
1.6 Contributions to knowledge  
This thesis makes an original contribution to knowledge in the following areas: 
1. Quality of life has become a major concern of policymakers, researchers and healthcare 
practitioners (Till et al., 1994) but a major current challenge is devising appropriate models 
to clarify the elements of HRQL and the causal relationships among them (Wilson and 
Cleary, 1995; Ferrans et al., 2005). This is the first study, as far as I am aware, to test the 
Wilson and Cleary biopsychosocial model in sickle cell disease. This thesis contributes to 
research on quality of life by demonstrating the applicability of Wilson and Cleary model in 
sickle cell disease. 
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2. Globally, few studies have examined the factors that determine HRQL in SCD populations 
(Fisak et al., 2011). Few studies have examined HRQL in Nigeria, and this is the first study 
to characterize predictors of HRQL in adults with sickle cell in Nigeria. 
3. This study is also the first to investigate preference-based health-related quality of life in 
adult with sickle cell disease in the Nigerian population; only one study has derived utility 
for SCD previously, in a UK population (Anie, Steptoe and Bevan, 2002). 
.  
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1.7 What is health? 
Health is a multidimensional construct (Kalnins and Love, 1982; Eberst, 1984; Laffrey, 
1986) and both health and illness are difficult concepts to define (Curtis, 2000). This is 
because individuals have different ideas of health and illness which influence their health 
attitudes and behaviours (Boruchovitch and Mednick, 2002).  
Health is a valued resource that can prolong duration of life and improve wellbeing and 
overall quality of life (Curtis, 2000). Health and illness are not distinctly separate concepts 
but there are degrees of illness and wellness. Antonovsky (1987) viewed these concepts as 
ends of a continuum and noted that “we are all terminal cases, and we all are, so long as 
there is breath of life in us, in some means healthy” (p.3).  
There have been various definitions of health without consensus. Balog (1979) categorised 
definitions of health into three major views namely; traditional medical concept, the 
ecological concept and the WHO or official concept of health.  
The traditional medical concept assumes that health and disease are objective and observable 
phenomena and regards health as a condition free of diseases in which there is no symptoms 
and signs of ill health (Curtis, 2000). This view was promoted by developments in anatomy, 
bacteriology and physiology; the drawback of this view is that it conceptualises health by 
laying emphasis on illness, and only focuses on the body part that is affected with disease 
but neglects the total individual (Boruchovitch and Mednick, 2002). This is the philosophy 
behind the biomedical model of health (See 2.2.1).  
The ecological concept views health as relative and places emphasis on interrelationships 
between the environment and the individual’s quality of life (Boruchovitch and Mednick, 
2002). The focus is on evaluation of the person’s level of functioning and adaptation to the 
environment. Thus health is conceived in terms of an adequate functional capacity that does 
not hinder performance of daily activities or in terms of quality of life which gives the 
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individual a sense of happiness, success, fruitfulness and creativity (Hoyman, 1962). This 
view is criticised because it fails to clearly distinguish between what constitutes a healthy 
and an unhealthy adaptation. For example, individuals may adapt to sick, morbid or disease-
provoking conditions or otherwise, a sick person may still be able to perform some social 
responsibilities (Lewis, 1953). Furthermore, if terms like normality, proper functioning and 
adaptation are culturally and socially defined, what is reckoned as healthy in one context 
might be unhealthy in another (Parsons, 1958).  
The World Health Organisation states that “health is a state of complete physical, mental 
and social wellbeing and not merely the absence of disease or infirmity” (World Health 
Organization, 1948, p. 1). The WHO concept of health, freely quoted as the official 
definition of health, was viewed as more holistic in that it de-emphasises the negative 
concept of health (absence of disease) and focuses on the presence of absolute and positive 
qualities. This concept supports the importance of evaluating psychosocial factors in 
measuring health status and well-being and in identifying health with subjective wellbeing. 
According to the definition, health and illness are conceptualised as multi-causal such that 
the components of physical, mental and social domains of life are recognised to influence 
state of health and illness. The WHO concept of health therefore embodies the social model 
of health, referring to the multifaceted and holistic view of health. The definition integrates 
two essential components of a health concept: firstly that man is an entity of biological, 
psychological and social elements and secondly that health is based on the individual’s 
perspectives (Barenthin, 1975). This definition therefore has been widely accepted as 
presenting the holistic view of health and regarded as a significant milestone in the 
development of quality of life studies within healthcare (Galloway, Bell, Hamilton and  
Scullion, 2006; Gurková, 2011). The definition gives a positive dimension of health as a 
complete wellbeing and has shifted attention away from preoccupation with disease to give 
recognition to the interaction between individual and their environment in determining 
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health such that health is viewed as an interaction between biological processes and 
psychological and social factors (Edelmann, 2000). However, the wide acceptance of 
WHO’s definition has not insulated it from criticism; there are those who described the 
definition as being over ambitious (Downie, Fyfe and Tannahill, 1990). The criticism has 
been based on three major issues: difficulty with measurement, impossible to attain, and not 
relevant to changing disease demographics (Larson, 1999; Bowling, 2001; Jadad and 
O’Grady, 2008). 
The concept was perceived as difficult to measure because the definition is broad and vague, 
without specificity to be defined operationally (Lewis, 1953; Bowling, 2001). This limits its 
use in practice because ‘complete’ is neither operational nor measurable. The idea of 
complete perfect state of health is argued to be unrealistic and unattainable (Banyard, 1996). 
According to Huber and colleagues, this is an unintentional contribution to the 
medicalisation of society because setting complete health as the norm will mean that most 
people will almost perpetually be in a state of ill-health (Huber et al., 2011). Huber et al., 
have further argued that persistent emphasis on complete physical wellbeing would identify 
many people in the population as eligible for screening and expensive interventions, when 
perhaps only one person might benefit. Additionally, the demographic shift in disease nature 
has also contributed to the near obsoleteness of the WHO concept today. Disease patterns 
have transformed over the years from acute to chronic nature leading to a global increase in 
the number of people living with chronic diseases and many countries now carry significant 
burden of chronic diseases compared to seven decades ago when the definition was first 
published (Kanungo et al., 2010; Huber et al., 2011). For example, in developed countries, 
over 50% of all adult deaths are caused by three chronic diseases: cancer, heart disease and 
stroke (WHO, 2004). Huber et al. insisted that the WHO definition has declared, “people 
with chronic diseases and disability definitively ill” and has by so doing “minimised the role 
of human capacity to cope autonomously with life’s ever changing physical, emotional and 
31 
 
social challenges and to function with fulfilment and a feeling of wellbeing with a chronic 
disease or disability (Huber et al., 2011, p. 2). 
In the light of the perceived weaknesses of the WHO definition, there have been various 
calls for a new conceptual framework of health that will characterise a widely accepted 
direction that could serve as reference (Huber et al., 2011). The Ottawa charter for health 
promotion (WHO, 1986) has suggested a definition that emphasises social and personal 
resources and physical capacity. Huber and colleagues also supported the Dutch’s approach 
which views health as: “the ability to adapt and self-manage”. The implications of this lack 
of agreement is that health research is better approached using a conceptual framework 
which should encompass the physical and mental and social domains of health (Huber et al., 
2011). 
1.8 Models of health 
Three major health models are discussed in this section. They are the biomedical, the 
psychosocial and the biopsychosocial models.  
1.8.1 The Biomedical model 
The biomedical model was the dominant concept in medical science in the twentieth century 
arising from the influence of Rene Descartes (1596-1650) who theorised that mind and body 
were separate entities. The biomedical model of health and illness rested on several 
assumptions. 
One of the assumptions was that health and illness are opposing state of bodily functioning 
where health indicates ‘normal’ biological functioning and illness is a deviation from the 
norm. Based on the doctrine of specific aetiology, the causes of illnesses are known and 
knowable; they are mainly pathogen, such as virus or bacteria or genetic defects (Naidoo 
and Wills, 2005) and the only means of treatment is by rectifying or restoring biological 
functioning by chemical means or removing the faulty parts by surgery or radiation. Current 
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knowledge has rendered this assumption faulty in that diseases like diabetes and heart 
disease result from causes which may interact with one another, for instance, heart disease 
may be caused by a combination of genetic factors, diet and lifestyle/behaviour and each 
contributes to the treatment process (Curtis, 2000). Another assumption was the mind-body 
dualism, from the Cartesian postulate which regarded the body as separate from the mind. 
This assumption reduced illness to merely biochemical process devoid of any social or 
psychological processes. This ‘reductionist’ approach explained a complex phenomenon 
only in terms of disordered biological functioning while ignoring the multiplicity of factors 
which combine with biological processes to cause illness. Attention was on failing or failed 
health and identification of treatment without considering promotion and maintenance of 
health (Engel, 1977; Antonovsky, 1987; Boruchovitch and Mednick, 1997; Curtis, 2000). 
The reality is that the mind influences the body and vice-versa.  
Though the biomedical model has greatly enhanced our understanding of biological causes 
and treatment of disease, it has several limitations. Research has shown that health is not 
only determined by disease and biology but partly by social factors such as living condition 
and personal habit such as smoking, while social and psychological factors have been found 
to influence treatment efficacy. In addition, there have been cases of people who seek 
medical help for distress or illness associated with ‘problems of living’ without any 
identifiable disease process (Kellner, 1985; Barsky et al., 1993). Furthermore, patient’s 
experiences of illness are poorly addressed in biomedicine. This often increases the patient’s 
level of distress especially when disease processes are not evident, for example, more than 
50% of GP visits are for the non-disease based complaints (Carson et al., 2000). Thus, a 
biomedical approach to resolve such complaints might result in unsatisfactory treatment and 
a continuation of patient’s illness.    
The biomedical model ignores the social, psychological and behavioural dimensions of 
illness  (Engel, 1980) and is therefore criticised because it is considered to rely on costly and 
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sometimes harmful treatments and fails to promote prevention, health enhancement or 
individual responsibility for health (Gordon and Fadiman, 1984). Also, it has been argued 
that biomedical models treat only the agents of disease and ignore the hosts, Blaxter (2010) 
argued that the concept of health and ill-health are asymmetrical; they are not simply 
opposites as conceptualised by the biomedical model, he opined that the absence of disease 
may be part of health, but health is more than absence of disease.  
1.8.2 The psychosocial model of health 
The psychosocial model of health presents health as a product of social, biological and 
environmental factors with less focus on the role of specialists but more attention on why 
people are healthy, emphasis on self-help and environmental activity and people being 
helped to take control over their own health (Naidoo and Wills, 2016).  
In a study of the combined mortality from scarlet fever, diphtheria, whooping cough and 
measles among children up to 15 years, Illich (1976) noted that about 90% decline in 
mortality between the years 1860 and 1965 was outside the introduction of antibiotics and 
widespread immunisation. He claimed that improved housing and better nutrition were 
responsible for reduced mortality. He also identified poverty and poor nutrition as factors 
responsible for frequent occurrence of diarrhoea and upper respiratory tract infections in 
poor countries. Illich insisted that environment is the primary determinant of the state of 
general health of any population. He identified food, water, and air as correlates of the level 
of socio-political equality and the cultural mechanisms that keep the population stable and 
argued that these are the factors responsible for determining how healthy grown-ups feel and 
at what age adults die (Illich, 1976). In line with the submission of Illich, social scientists 
who belonged to his school of thoughts argued that the biomedical model was not adequate 
to provide understanding of health and illness, they therefore emphasised the need for 
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alternative approaches to enhance understanding of the concept of health and illness as it 
affects the individual (Curtis, 2000). 
The concept of social health recognises social factors such as poverty, lifestyle or behaviour 
as important in a model of the causes of ill health. The social model locates biological 
processes within their social context and considers the person as a whole rather than a series 
of distinct bodily systems (Illich, 1976). Antonovsky’s (1979) ‘salutogenic’ concept of 
health involves focusing on what facilitates health, rather than what causes or prevents 
disease, that is, to focus on successful physical and mental coping. In other words, 
Antonovsky identified why some people remain healthy and how they cope despite adverse 
circumstances, change and stress he labelled as ‘sense of coherence’ the human ability that 
involves understanding, managing and making sense of change and suggesting that these 
human abilities could be nurtured or hindered by the wider environment (Antonovsky, 1979, 
1987; Naidoo and Wills, 2016). The social model projects health as a positive state of 
wholeness and wellbeing explained by an integration of multiple factors which include the 
absence of disease, illness or physical and mental impairment as well as social and spiritual 
dimensions (Madjar, 1992). In addition, the psychosocial model encourages prevention and 
health promotion rather than relying on medical intervention which often carry high financial 
burden and health risk. The psychosocial model has been described as a more realistic model 
because of the role that lifestyles play in disease (Sheridan and Radmacher, 1992). For 
example, studies have shown that behavioural factors are involved in seven of the ten leading 
causes of death in the US (Raub, 1989). 
1.8.3 The Biopsychosocial model of health and illness 
The biomedical model and the psychosocial model follow different paths in their concepts 
of health. Observing the gaps, Engel (1977) has proposed a biopsychosocial model to 
harmonise the divergent health concepts in the biomedical and psychosocial models to 
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provide a better understanding of health. According to Engel, to properly understand and 
adequately respond to patients’ suffering, and to give them a sense of being understood; it is 
important that clinicians attend simultaneously to the biological, psychological, and social 
dimensions of illness (Engel, 1977). His holistic model draws attention to the 
interrelatedness of body, mind and environment emphasising that no single one of these 
factors can sufficiently influence health or illness but rather in conjunction with the others. 
The model recognises health as an illness-wellness continuum thus creating a balance of the 
negative and positive perspectives. 
Engel’s biopsychosocial framework outlines the complex interplay of biological, 
psychological and social factors in the determination of wellness or disease outcomes. The 
biological system, including the immune and nervous systems, consists of organs, tissues 
and cells; the psychological system which include experience and behaviour is made up of 
cognitions, emotions and motivation while the social system includes society, community 
and family as subsystems. As systems, they are constantly changing and have components 
which interrelate. Health then operates as a complex interplay of factors within these factors 
(Engel, 1977). 
A better understanding of health and illness can be achieved by examining the interactions 
between social and individual factors with biological elements. Health is determined by 
behaviour, attitudes and affective state, which is in turn influenced by aspects of the broader 
environment, such as employment and living standards. Evidence showed that social and 
environmental factors have impact on health (Khanna et al., 2007). Therefore, any model or 
explanation which does not take into account this multiplicity of factors is likely to provide 
an inadequate representation of health and illness (Engel, 1977, 1980; Kazarian and Evans, 
2001).  
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Engel viewed biopsychosocial model as a more complete and inclusive conceptual 
framework necessary to guide clinicians in their everyday work with patients. He wrote: 
Biopsychosocial thinking aims to provide a conceptual framework suitable for 
developing a scientific approach to what patients have to tell us about their illness 
experiences (Engel, 1997, p. 523) 
In summary, a biopsychosocial model can be applied to study health in order to understand 
the whole person or adopt a holistic approach. A holistic model of health implies that 
professional health workers can only address some and not all aspects of health or ill-health 
which necessitates that health workers work in collaboration with others in order to achieve 
optimum results (Naidoo and Wills, 2016). The biomedical model diagnoses the disease to 
show the required intervention and summarises the morbidity and mortality, while the 
psychosocial model reveals the impact of disease condition and intervention on the patient’s 
health. The integrated concept then makes it possible to clearly understand the condition of 
the individual and interventions offered will be directed towards meeting the patient’s needs 
(Bowling and Ebrahim, 2005).  
The usefulness of the biopsychosocial model in health research and practice has been 
acknowledged in literature. Wilson and Cleary (1995) described health as a continuum of 
increasing biological, social and psychological complexity and employed the principle to 
develop a conceptual framework to link clinical variables to patients’ perspectives. 
1.9  Sickle Cell Disease Overview 
The following section provides a general overview of the sickle cell disease 
1.9.1 Definition and aetiology  
Sickle cell disease (SCD) belongs to a group of diseases caused by inherited disorders of 
haemoglobin. These disorders are generally referred to as haemoglobinathies (genetic defect, 
37 
 
i.e. abnormal haemoglobin in the blood). Approximately 5-7% of the world population are 
affected with heameoglobinopathies (Modell and Darlison, 2008). SCD is the most severe 
and common haemoglobinopathy affecting over 5% of the world population (WHOQOL 
group and others, 1995; World Health Organization, 2008).  
Haemoglobin is an iron rich protein that transports oxygen in the blood and give the colour 
to the red cells. Haemoglobin molecule has two subunits namely alpha globin and beta 
globin. The problem in sickle cell was brought about by a mutation in the beta (β) globin 
gene at position 6 of the beta subunit, and a replacement of the normal glutamic acid with 
the amino acid valine takes place at this position (Sant’Ana et al., 2017). The disease 
damages and alters the shape of the red blood cells into a crescent (sickle) form. The sickle 
haemoglobin (HbS) is insoluble when deoxygenated. As the oxygen uptake of the cell is 
low, the shape of the cells is distorted from a healthy round disc to a crescent or sickle shape, 
a distortion referred to as sickling (Pauling et al., 1949). Thus, the disease is known as sickle 
cell disease. The rigid sickle shaped cells are hard (insoluble) and sticky compared with 
normal healthy cells. The hardness may obstruct blood vessels, or they may stick together 
and obstruct blood vessels. These obstructions are responsible for harsh painful 
complications (vaso-occlusive crisis). The disease is also referred to as sickle cell anaemia 
(SCA) as a result of the frequent breakdown of the red blood cells (haemolysis) resulting in 
anaemia.  
Due to haemolysis, survival of the blood cells may be reduced to as little as 20 days (Wilson, 
Krishnamurti and Kamat, 2003) compared to normal blood cells which lives between 110-
120 days in the blood stream (Allison, 1960). The consequence of haemolysis also includes 
jaundice, aplastic crisis (red blood cells unable to mature resulting in worsening anaemia) 
and retarded growth. 
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As an autosomal recessive disease (Pack-Mabien et al., 2001), SCD is determined at 
conception. The genes that children carry are inherited from their parents, hence having a 
sickle cell is a consequence of the type of genes the parents pass on to their children. If the 
child inherits a ‘sickle gene’ from one of the parents and a normal gene from the other, he is 
a carrier for the sickle cell disease or said to have sickle cell trait (SCT) 
1.9.2  Sickle cell trait 
Children who inherit one copy of the sickle haemoglobin (HbS) from one of the parents and 
a normal gene (HbA) from the other parent are said to have a carrier status (HbAS). This 
carrier state is known as sickle cell trait (SCT). Though people with SCT live normal, healthy 
life, recent discovery has shown that some complications could be present in people with 
SCT under conditions of severe biological stress. For example, SCT has been indicated as a 
risk factor for sudden death during physical training (Eichner, 2010).  
In a study of causes of sudden death in athletes ages 8 to 39 years, Harris et al.(2012) reported 
that 0.9% of deaths in a cohort of 2,462 sudden deaths was associated with SCT and 2.6% 
of footballers died suddenly of SCT-related complications. They suggested that vigorous 
exercise and elevated temperatures may trigger sudden death in people with SCT (Harris et 
al., 2012).  
Individuals with SCT (HbAS) have been found to exhibit higher resistance against malaria 
when compared with those with normal gene (HbAA). This survival advantage (discussed 
below) is linked to the high prevalence of the HbS in malaria endemic regions of the world, 
for instance, HbS occurs in 8% Americans and in 24% Nigerians (Harris et al., 2012). This 
discovery gave rise to the malaria hypothesis which is discussed later in this chapter.  
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1.9.3 Pattern of inheritance 
The pattern of inheritance in sickle cell disease follows the principles of heredity as proposed 
by Gregor Mendel (1822 - 1884). If one of the parents has SCT and the other has normal 
genes the child cannot have SCD but has 50% chance of having SCT. If both parents have 
SCT, the child has 25% of having SCD and 50% of having SCT (Mendel, 1965; Mendel, 
Stern and Sherwood, 1966) (see Figure 1-1).  
Unaffected carrier father     Unaffected carrier mother 
                                                        
AS            AS 
 
 
 
 
       
AA (Normal)  AS (Carrier)  AS (Carrier)   SS (Affected - SCD) 
 1:4    1:4   1:4   1:4 
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Figure 1-1: Pattern of Inheritance. 
1.9.4  Classification 
The chromosome structures of the SCD are referred to as haplotypes. There are four main 
African haplotypes and one Asian haplotype of the beta-globin chain genes. The African 
haplotypes are, Bantu, Benin, Cameroun and Senegal haplotypes. The Bantu (Central-
African Republic) haplotype is the most severe disease phenotype reputed to have twice 
increased risk of complications (which include higher incidence of organ damage, and renal 
failure) and early mortality when compared with other haplotypes (Powars and Hiti, 1993). 
The Asian or Arab-Indian haplotype has a mild disease phenotype associated with higher 
foetal haemoglobin (HbF) which has been indicated to be responsible for reduced severity 
of the disease and improved survival (Tewari and Rees, 2013). Several forms of SCD are 
related to these chromosome structures. 
The most common form is the homozygous (HbSS) often referred to as sickle cell anaemia 
(SCA). This is a condition in which the individual affected inherits the sickle haemoglobin 
(HbS) from both parents. The resultant HbSS genotype is the most severe form of SCD and 
accounts for 70% of causes of the disease in African population (Rees, Williams and 
Gladwin, 2010). The other common but milder form of SCD is the HbSC which is a co-
inheritance of the βs and βc alleles to form HbSC. The HbSC is present in 25-30% of African 
population (Modell and Darlison, 2008; Rees, Williams and Gladwin, 2010). The HbS /β-
thalassaemia is another form of SCD found in people of the Mediterranean origin. Other 
variants include HbC, HbD common in Punjab HbO among the Arabs.  In a study of 143 
patients with SCD in Jamaica, 70% had HbSS, 24% HbSC and 6% HbSβ – thalassaemia 
(Gibson et al., 2013). In a longitudinal study of 230 African-American people with SCD 
Soghutlu et al. (2011) reported that 71.7% had HbSS while 24.5% had HbSC. They are often 
classified as severe, moderate, mild or very mild as depicted on Table 1-1.  
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Table 1-1: Classification of Sickle Cell Disease 
Sickle cell disease Characteristics Population where 
found 
A. SEVERE    
HbSS Inheritance of the double 
‘S’(homozygous). Most common 
form of sickle cell disease generally 
known as sickle cell anaemia (SCA) 
Africa especially 
sub-Saharan Africa 
HbSβ0 thalassaemia  Most prevalent in the. Almost 
clinically indistinguishable from 
sickle cell anaemia. 
Eastern 
Mediterranean 
region and India 
Severe HbSβ+ thalassaemia Most prevalent in the 1-5% HbA 
present 
Eastern 
Mediterranean 
region and India 
HbSO Arab Rare  North Africa, the 
Middle East, and 
the Balkans, 
HbSD Punjab  occurs worldwide 
but predominant in 
Northern India 
HbSC Harlem Resembles HBSC but clinically 
severe, double mutation in β-globin 
gene, very rare 
 
HbC/S Antilles Double mutation in β-globin gene 
results in severe SCD when co-
inherited with HbC, very rare 
 
B. MODERATE   
HbSC 25-30% of SCD in population of  African origin 
Moderate HbSβ+ thalassaemia 6-15% HbA present Eastern Mediterranean 
region 
HbAS Oman Dominant form of SCD caused by 
double mutation, rare 
Arabian origin 
C. MILD   
Mild HbSβ+ thalassaemia  16-30% HbA present African population 
HbSE Uncommon and mild Southeast Asia 
HbA/Jamaica plain Double mutation results in low Hb 
with oxygen affinity, very rare  
 
D. VERY MILD   
HbS/HPFH Group of disorders caused by large 
deletions of the β-globin gene 
complex, typically 30% foetal 
haemoglobin. symptom-free 
 
HbS/other Hb variants (rare 
combinations of HbS with HbD Los 
Angeles, HbO Arab, G-Philadelphia, 
among others) 
Hbs is co-inherited with many other 
Hb variants 
 
Source: Rees, D.C., Williams, T.N. and Gladwin, M.T., 2010. Sickle-cell disease. The Lancet, 376(9757), 
pp.2020. 
Note: HbSS - homozygote for the beta S globin, HbS β0 (beta0) thalassaemia – double heterozygote for HbS 
and beta0 thalassaemia, HbSC - double heterozygote for HbS and HbC, HbSβ+ beta+ thalassaemia - double 
heterozygote for HbS and beta+ thalassaemia, HbS/hereditary persistence of fetal Hb (S/HPHP), HbS/HbE 
syndrome. 
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1.10  History of SCD 
SCD was discovered in 1910 when a dental student, Walter Noel, who originated from 
Grenada but studying in Chicago, presented to Dr Herrick with complaints of pain and 
symptoms of anaemia. The blood from Noel was examined by Dr Irons, who described it as 
‘having the shape of a sickle’. A subsequent paper from Herrick used the term ‘sickle shaped 
cell’ to describe the irregular-shaped red blood cell. This was the first published scientific 
article to describe the shape of the cells responsible for the disease. However, in 1874, 36 
years prior to Herrick’s paper, a Dr Horton from Sierra Leone had given a written description 
of clinical signs and symptoms of what is now referred to as SCD (Adewoyin, 2015). 
Additionally, there had been cultural references in Africa for centuries to an illness referred 
to as ‘rainy season rheumatism’ which appeared to be hereditary in families (Konotey-
Ahulu, 1991). The ‘rainy season’ coinage was probably due to their observation of colder 
temperature, associated with rainy season period as a precipitant of pain crisis in the affected. 
This was supported by a multicentre study across Virginia in the US which reported that 
adults with SCD experienced worsening disease condition during colder seasons (Smith et 
al., 2008). In the South-Western part of Nigeria, the Yorubas normally referred to this illness 
as ‘arun aromoleegun’ which translates to a disease accompanied with ‘aches and pains in 
the bones’. This is similar to a vivid description of the bone pain crisis that patients with 
SCD experience. This means that the disease has been known to people of African origin 
before the discovery by Herrick in 1910. 
Further insight into SCD continued in 1927 when Hahn and Gillepsie observed that by 
removing oxygen (deoxygenation), the blood of the person with the disease could be made 
to sickle, thus concluding that deoxygenation played a crucial role in the sickling of the cell. 
In 1949, two articles were published independently, one by Col Beet, a military doctor in 
Mozambique and the second by James Neil of the University of Michigan. Both articles 
revealed that SCD was hereditary and that people with SCT were heterozygous (HbAS) or 
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carriers for the gene while those with the disease were homozygous, had two copies of the 
gene (HbSS). In 1951, Dr Pauling and Itano discovered the association of the disease with 
haemoglobin by demonstrating that the chemical structure of haemoglobin in a person with 
SCD is different from that in the person without the disease. In 1956, Ingram, made a 
discovery of the actual amino acid substitution which differed from the normal haemoglobin 
(HbA). Ten years later, Welch and Goldberg introduced and described much of the modern 
terminology associated with sickle cell disease with respect to ocular changes. In 1971, 
Goldberg proposed a classification for sickle cell retinopathy (Goldberg, Charache and 
Acacio, 1971). In 1972, the US 92nd congress passed the National Sickle Cell Control Act 
which paved way for the commencement of the first state-wide screening programme for 
SCD in the US in 1975.  
The first reported case of cure was in 1986 with a bone marrow transplantation in a child 
with sickle cell. The cure was accidental as the transplantation was carried out to treat acute 
leukaemia, but the child was discovered to be free from the symptoms of SCD after the 
transplantation. Further interventions are noted in that Gaston et al. (1986) demonstrated the 
value of oral administration of penicillin in reducing morbidity and mortality in children 
with SCD. In 1995, a multicentre study of Hydroxurea (Hu) in sickle cell anaemia was 
completed revealing that Hu has the potential to prevent complications in SCD (Charache et 
al., 1995). The study of SCD, its clinical manifestation, search for cure and management of 
the disease has since engaged the attention of researchers, policymakers, health care 
practitioners and international organisations.  
1.11  Epidemiology of Sickle Cell Disease (Incidence and Prevalence) 
Sickle cell disease is the most predominant haemoglobinopathy in the world (Modell and 
Darlison, 2008; World Health Organization, 2008). The disease occurs in 193 countries of 
the world (Modell and Darlison, 2008; Center for Disease Control and Prevention., 2016). 
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SCD has been described as the fastest growing and most frequent inherited disorder in 
England (Pizzo et al., 2015). The prevalence is 1 in every 2400 births (National Institute for 
Health and Care Excellence NICE, 2016) about the same range as Cystic Fibrosis (NHS, 
2006). France has about 12,000-15,000 people affected with the disease about the same as 
UK (Brousse et al, 2014; NICE, 2016) and a prevalence of 1 in 2472 births in USA (Center 
for Disease Control and Prevention., 2016). Approximately 80,000-100,000 US citizens are 
affected compared with 30,000 people with Cystic Fibrosis (Smith et al., 2006; Brousseau 
et al., 2010). In India, around 40, 000 children are born annually with the condition and 
10,000 in Eastern Mediterranean (Piel et al., 2013). The prevalence in Africa is 2% or 1 in 
50 births representing approximately 240,000 births annually (WHO, 2007; Modell and 
Darlison, 2008). While the Democratic Republic of Congo accounts for 40,000 of the annual 
birth (Piel et al., 2013; Brousse, Makani and Rees, 2014), Nigeria with a prevalence of 2- 
2.39% (WHO, 2007; Nwogoh et al., 2012) is responsible for between 90,000-150,000 of this 
population of children born with SCD (W H O, 2006; Aliyu et al., 2008; Modell and 
Darlison, 2008; Frederic B Piel et al., 2013; Brousse, Makani and Rees, 2014; Carey, 2014) 
This figure has been projected to increase to 140,000-200,000 by the year 2050 (Piel et al., 
2013). 
The sickle cell trait or carriers is present in 5% of the world population (Modell & Darlison 
2008; WHO 2011). Sickle cell carriers are at risk of passing the gene to their children (See 
Figure 1-1). Globally, over 300 million people have the sickle cell trait (Grant et al., 2011). 
There are 240,000 people in UK (NICE, 2016) and an estimated three hundred thousand in 
USA (NCBDDD, 2011). Cuba has 3-7% prevalence of carriers (Granda et al., 1991), while 
Brazil has approximately 4% (Santos and Gomes Neto, 2013). The prevalence of SCT ranges 
between 10% and 40% across Africa but less than 2% in North and South Africa. In some 
West African countries, the carrier prevalent is between 15% to 30% and up to 45% among 
the Bantu people of Central Africa. In Nigeria, the estimated carrier prevalence is 24% (W 
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H O, 2006; Aliyu et al., 2008; Modell and Darlison, 2008; Frederic B Piel et al., 2013; 
Brousse, Makani and Rees, 2014; Carey, 2014) which translates to over 40 million people.  
1.12  Factors responsible for the HbS allele frequency 
Two major factors are discovered to be responsible for the frequency and geographical 
spread of the sickle cell gene (HbS). They are the malaria factor and the migration factor. 
1.12.1 The malaria factor 
Alison (1954) suggested that sickle cell trait offered protection against malaria infection. 
Further research has documented substantial evidence to support the possible role of malaria 
in the mutation of the gene. For example, it has been discovered that a significant correlation 
exists between incidence of malaria and the prevalence of the HbS gene (Rees, Williams and 
Gladwin, 2010). In addition, carriers are found to exhibit resistance to all forms of 
plasmodium falciparum malaria (Serjeant and Serjeant, 1992). Those who survived malaria 
did pass on the gene to their children thus acting like a selective factor that resulted in 
increased prevalence of the gene. The prevalence of SCD in people from the malaria endemic 
regions of Africa and the Mediterranean seem to support this hypothesis (Galadanci et al., 
2013). However, the protection against malaria is only in people with sickle cell trait. 
Malaria has been found to be a risk factor for people with the double sickle gene HbSS (W 
H O, 2006) and contributes to mortality, anaemia and other crises in SCD (McAuley et al., 
2010; Williams and Obaro, 2011).  
1.12.2 The migration factor 
Human migration especially across continents has been increasing since the 1960s (OECD, 
2014). In 2015, 244 million people (3.3% of the world population) lived outside their country 
of origin due to the demand for their economic skills, escape from crisis and better education 
(United Nations Population Fund, UNFPA, 2015). This, along with slave trade has been 
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responsible for the incidence of SCD in countries like UK, US and parts of Europe (Modell 
et al., 2007). 
SCD is found with varied incidence and prevalence in over 70% of the countries of the world 
(Modell and Darlison, 2008) but traced to people from particular regions of the world 
indicating that the spread may be due to migration especially since SCD is not a contagious 
disease. SCD is particularly common in sub-Saharan Africa; Spanish-speaking regions in 
the Western Hemisphere, South and Central America, the Caribbean, India, and 
Mediterranean countries (Center for Disease Control and Prevention., 2016) but there are 
current evidence of rising population of people with SCD in countries like the Ireland, 
Scandinavia, Australia and South Africa which were previously free from incidence of the 
disease (Ware, 2013).  
1.13 Pathophysiology 
Sickle cell disease occurs as a result of a single-point mutation (replacement of glutamic acid 
with valine in position 6) on the β-globin subunit of haemoglobin (Schnog et al., 2004). This 
process results in a mutant form of haemoglobin referred to as sickle haemoglobin (HbS) 
(Kanter and Kruse-Jarres, 2013). People who inherit two copies of the HbS mutation are 
homozygous (HbSS) and have the sickle cell disease phenotype but the heterozygous carriers 
(HbAS) referred to as sickle cell trait do not exhibit clinical disease (Kanter and Kruse-
Jarres, 2013). Other forms of SCD result when mutations associated with other aberrant type 
of haemoglobin (C or E) or β-thalassemia combine with HbS as a compound heterozygous 
mutation (haemoglobin genotypes SC, SE, Sβ+ or Sβ0). People with HbSS and Hbβ0 have 
been known to demonstrate the most severe form of SCD (Kanter and Kruse-Jarres, 2013). 
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1.13.1 Pathological processes 
Events behind severe morbidity and mortality in SCD are complex and yet to be fully 
understood. However, current knowledge has identified two major pathological processes. 
They are vaso-occlusssion and haemolysis.  
Vaso-occlussion occurs as a result of the sticky nature of the sickle cells. When these cells 
stick together they block blood vessels and obstruct the flow of blood. This phenomenon 
(vaso-occlussion) results in what is known as acute vaso-occlusive crisis or painful crisis 
(Galadanci et al., 2013). This event has been found to be the cause of acute and chronic 
ischaemia which is responsible for acute pain, organ damage and related complications in 
people with SCD.  
Haemolysis (the breakdown or destruction of the red blood cells) is responsible for anaemia, 
vascular endothelial damage resulting in many complications including pulmonary 
hypertension, priapism and stroke. In childhood, the major cause of mortality is bacterial 
infections especially pneumococcus (Barrett-connor, 1971; Gill et al., 1995). 
1.13.2 Clinical manifestations or Symptoms of SCD 
The clinical manifestation of SCD range from mild symptoms to very severe symptoms 
across the ages (See Figure1-2). While it has been difficult to explain these irregular patterns, 
genotype, the volume of foetal haemoglobin (HbF) and comorbidities have been suggested 
as factors responsible for degree of severity (Ballas et al., 1982; Nagel and Ranney, 1990; 
Powars and Hiti, 1993; Gill et al., 1995; Chang et al., 1997; Thomas, Higgs and Serjeant, 
1997; Ohene-Frempong et al., 1998; Ashley-Koch, Yang and Olney, 2000). Some of the 
acute and chronic clinical manifestations include painful crisis, vaso-occlusive episodes, 
stroke, anaemia, hand-foot syndrome, jaundice, frequent infections, delayed growth, vision 
problems, aplastic crisis, acute chest syndrome, leg ulcers, priapism, pulmonary 
hypertension and organ damage (Powars, 1990; Hernigou et al., 1991; Castro, D J Brambilla, 
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et al., 1994; Ohene-Frempong et al., 1998; Oliveira, Ciasca and Moura-Ribeiro, 2008; 
Scheinman, 2009; Ladizinski et al., 2012).  
lVaso-occlusive episodes. Vaso-occlusion or acute pain crisis are common features in SCD 
for all age groups (Smith and Scherer, 2010) sometimes triggered by physical and emotional 
stress (Westerdale and Jegede, 2004). Pain crisis is the leading cause for visit to emergency 
departments and frequent hospitalisation both for children and adults, these pain episodes 
with varied degree of intensity often occur in any part of the body system but most common 
in the lower back, knee and hip (McClish et al., 2009; Smith and Scherer, 2010). The pain 
can last from a couple of hours to weeks (Yusuf et al., 2010; Cope and Darbyshire, 2013; 
Brousse, Makani and Rees, 2014). Pain was found to be common among patients ages 10-
30 years; a study revealed that adults had pain in over 50% of days and people above 20 
years are more likely to die during painful crisis (Kanter and Kruse-Jarres, 2013; Brousse, 
Makani and Rees, 2014). High frequency of pain is an indication of the severity of the disease 
and vary between subjects and within genotypes. The Pain in Sickle Cell Epidemiology 
Study (PiSCES) which focused on adults with SCD reported pain in 54% of 31,017 days 
surveyed with 29% of respondents reporting pain in more than 95% of the days. The PiSCES 
study classified pain into three categories of severity using a numeric scale of intensity. The 
first category (mean intensity, 5.9±0.1) led to emergency departments or hospitalisation; the 
second category (mean intensity, 5.0±0.1) was regarded as a crisis but without use of medical 
care; the last category (mean intensity, 3.9±0.1) was not described as a crisis (Smith and 
Scherer, 2010). In a study of adults with SCD in Illinois USA, painful crisis was responsible 
for 97% of hospital admissions (Woods et al., 1997). Pain in SCD is associated with 
depression, anxiety disorder and has negative effect on the health-related quality of life 
(Brandow et al., 2010; McClish et al., 2016).  
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Source: Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. Blood Rev. 2013;27:279–87
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Figure 1-2: SCD Complications in Children and Adult 
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Acute chest syndrome (ACS). ACS is often triggered by infections (29%) and fat embolism 
(9%), the complication occurs at all ages and is the second most common cause of hospital 
admission, for example, 95% of patients were hospitalised on their first experience of ACS 
(Ashcroft and Serjeant, 1981; Vichinsky and Lubin, 1994; Stuart and Nagel, 2004) . In a study 
of 3751 patients, Castro et al. (1994) found that 29% of the subjects had at least one episode of 
ACS during the period of the study and an average of 1.9 episode per person. High incidence 
of ACS is associated with HbSS and is a predictor of shorter survival or early death in adults 
with SCD (Powars et al., 1988; Castro, Donald J Brambilla, et al., 1994). The syndrome is a 
major cause of death in young adults (Stuart and Nagel, 2004), a leading cause of death in SCD 
patients in US (Quinn et al., 2010), and responsible for 25% of all deaths of SCD patients in 
Jamaica (Serjeant et al., 1986) and in Nigeria (Ogun, Ebili and Kotila, 2014). ACS occurrence 
is affected by seasons of the year with a 3-times more likely in winter than in summer 
(Vichinsky, 1991). The syndrome is associated with pleuritic or chest pain, cough, fever, 
shortness of breath, wheezing and chills. Fever, cough and chest pain are the most common 
symptoms found to account for 67% in a first event of ACS (Vichinsky et al., 1997). Patients 
may also develop chronic lung disease as a result of repeated episode of ACS (Powars et al., 
1988). 
Stroke. Stroke occurs in SCD without warning at least with a chance of 10% in people with 
HbSS and HbSβ0. This can result in severe disability, research has shown that 50% of cases 
have long-term neurocognitive deficit with long term impact on the child and family (Cope and 
Darbyshire, 2013). In addition, stroke has been indicated as a leading cause of morbidity and 
mortality in children with SCD, studies showed that 11% of SCD patients would have had 
stroke by age 20yrs, while there is a 50% chance of reoccurrence in patients who have suffered 
one stroke (Pegelow et al., 1995; Ohene-Frempong, 2001; Inati, 2009). Stroke prevalence 
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among SCD children in Nigeria is between 4.3% and 5.2% (George and Frank-Briggs, 2011; 
Oniyangi et al., 2013). 
Priapism. This is a painful penile erection not associated with sexual pleasure in males. This 
manifestation is common in adolescents and adult males with SCD. Nwogoh et al. (2012) found 
the prevalence of priapism to be 44.9% in Nigerian SCD patients.  
Chronic leg ulcers is a complication in SCD that affects 10% of adults, especially males in 
US, 50-75% in Jamaica and 22.4% in Nigeria (Bazuaye, Nwannadi and Olayemi, 2010). 
Infections. Infections in SCD could be bacterial, viral or mycoplasma. In a study of autopsy at 
the University College Hospital Ibadan, Nigeria, Ogun et al.(2014) reported that 78% of deaths 
was due to infection alone or in combination with other factors.  
Asthma. A common complication in People with SCD is asthma with a prevalence of 8-53% 
(Knight-Madden et al., 2005). Asthma is associated with increased risk of hospitalisation for 
ACS and predicts mortality in SCD patients. 
Anaemia. One major complication in SCD is shortage of the red blood cells which normally 
results in symptoms of fatigue, shortness of breath and paleness (Schnog et al., 2004; Brown, 
2012; Kanter and Kruse-Jarres, 2013)  
Aplastic crisis. This manifests as a complication due to sudden acute decrease of haemoglobin 
because of infection (Schnog et al., 2004; Brown, 2012) 
Osteomyelitis. This is a common skeletal complication in people with SCD found in about 
29% of Nigerian SCD patients (Ebong, 1986).  
Musculoskeletal. The occurrence of musculoskeletal complications is high among adults with 
SCD patients, 31.4% of adults with SCD in Nigeria experience musculoskeletal pain (Balogun 
et al., 2010). 
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Pulmonary hypertension. This complication occurs in 3.6% Nigerians with SCD (Aliyu et 
al., 2008; Dosunmu et al., 2013). 
Heart disease. Heart disease is a complication found in adult with SCD. Thirteen percent of 
adults with SCD suffer from left-sided heart disease (Gladwin et al., 2004; Rees, Williams and 
Gladwin, 2010). 
Renal complications. Renal damage is common in patients with SCD and potentially present 
from childhood. Chronic renal failure has been responsible for many deaths in SCD and has 
been found to be present in 30% of adults with SCD (Platt et al., 1994).  
Pregnancy. Red blood cells play significant role in pregnancy, but the sickling process may 
reduce the amount of oxygen going to the foetus. Morbidity and mortality is therefore high in 
pregnant women with SCD. Complications include increased risks of painful crises and pre-
eclampsia, low birth weight, and heart enlargement. There is a 19% risk of spontaneous 
abortion, 21% stillbirth, 32% risk of premature birth and 42% of intrauterine growth restriction 
(poor foetal growth) (Oteng-Ntim et al., 2008).  
1.14 SCD and Infectious Diseases 
The SCD gene confers an increased susceptibility to infection which in turn promotes a cascade 
of SCD-specific pathophysiological changes. For example, repeated episodes of sickness and 
ischaemic damage lead to multiple infarcts of spleen tissue.(Booth, Inusa and Obaro, 2010) 
Pathogens such as malaria, invasive salmonellosis, immune deficiencies, urinary tracts 
infections and respiratory infections have important effects on SCD and contribute to a whole 
range of complications in SCD. For example, while the single HbS confer protection against 
malaria, the homozygous HbSS is highly susceptible to malaria infection which associates with 
increased morbidity and mortality. Malaria causes anaemia through a number of mechanisms 
(Menendez, Fleming and Alonso, 2000) 
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Low levels of zinc have been suggested as a contributary factor in susceptibility to infection. 
These infections may lead to the development of comorbidities. The number of comorbidities 
has been identified in this study as measure of bio-physiological factor. Additionally, during 
infection with any pathogen, changes occur at a cellular level which corresponds to Wilson and 
Cleary’s bio-physiological function. These cellular changes predispose to crises which often 
lead to pain frequency, hospitalisation and sometimes blood transfusion which make up the 
measure of diseases severity index in this study. 
1.15 Mortality and Life Expectancy 
SCD is a leading cause of high infant mortality rate in Africa. The disease is responsible for 
above 5% of all under-five deaths in Africa rising to 9% in West Africa and up to 16% in 
individual West African countries (W H O, 2006; Aliyu et al., 2008). Dacie (1960) described 
SCD as “disease of childhood” apparently because those affected hardly survived into 
adulthood. This statement was supported by a study carried out 13 years later where Diggs 
(1973) calculated the median age of survival to be 14.3 years. However, decrease in early 
childhood mortality has been achieved due to newborn screening (NBS), prophylactic 
penicillin, vaccination and parent education. These have been responsible for the survival of 
90-95% of children with SCD into first decade (Quinn, Rogers and Buchanan, 2004) especially 
in high resource countries.  
The increase in survival of children due to SCD has been gradual. Quinn et al. (2010) reported 
that survival to age 5 increased from 96.8% in the period 1983-1987 to 99.2% in the period 
2000-2007. In East England, 99% of children with SCD now survive to adulthood (Telfer et 
al., 2007), corresponding estimates were 97% in Paris (Couque et al., 2016) and 94% in US 
(Quinn et al., 2010). In Africa, education and medical interventions such as screening, vaccine 
and antibiotics have contributed to the increase of survival rate of children with SCD from less 
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than 2% four decades ago to nearly 50% (Makani et al., 2011; Brousse, Makani and Rees, 
2014). 
Life expectancy has significantly increased in the last four decades from a median of 14.3 years 
(Diggs, 1973) to 42 years for males and 48 years for females in 1994 (Platt et al., 1994). Recent 
estimates have also confirmed improvements in life expectancy, however, this increase is still 
low when compared with people with the normal gene (See Table 1-2). The life expectancy of 
people with SCD was found to reduce by 20-30 years when compared to people with the normal 
haemoglobin (NCBDDD, 2011).  
The risk of premature and sudden death is high in SCD patients in spite of medical efforts 
(NCBDDD, 2011). Risk factors for premature death include low foetal haemoglobin (HbF), 
acute chest syndrome, high white blood count, seizures, acute pain episodes, acute anaemia, 
renal insufficiency and infection in patients less than 20 years of age (Platt et al., 1994). In 
addition, adults 20 year and older are at risk of premature death as a result of accelerated organ 
damage (renal failure, congestive heart failure and stroke) occasioned by sickling and weaker 
ability of adults to tolerate or withstand painful episode and ACS (Platt et al., 1994). 
 Table 1-2: Median Survival of Individuals with Sickle Cell Disease 
Genotype US UK Jamaica Nigeria 
HbSS / HbSβ0 58 67 53- 58.5 21 
HbSC / HbSβ+  66 72  24 
General population   80-83  55-56 
Authors Elmariah et 
al., 2014 
(Elmariah et 
al., 2014). 
Gardner et 
al., 2016 
(Gardner et 
al., 2016). 
Wirenga et 
al, 2001 
(Wierenga, 
Hambleton 
and Lewis, 
2001) 
Chijioke & 
Kolo, 2009 
(Chijioke 
and Kolo, 
2009) . 
 
1.15.1 Shift in mortality rate 
While the increase in child survival rate is a welcome development, researchers opined that the 
mortality has only been shifted to adulthood as the adult mortality rate is still high. In addition, 
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patients surviving into adulthood carry increasing burden of the disease throughout their adult 
life as no universal cure for the disease has been discovered yet. This poses challenges to 
researchers and healthcare practitioners to develop comprehensive management strategy that 
will reduce the burden of the disease. Studies have shown that the chronic disease condition 
predisposes the affected individuals to several adverse conditions including disability, chronic 
end organ complications and other diseases associated with older age (Aliyu et al., 2008; Yanni 
et al., 2009). Furthermore, the psychosocial complications of the disease are pronounced and 
research has shown that patients with SCD have poor health-related quality of life (HRQL) 
which worsen with increasing age (Anie, 2005). 
1.16 Sickle cell disease in adults 
SCD is determined at conception. Once known as disease of children (Dacie, 1960), this life-
threatening disease has evolved in the last four decades to a chronic disease of adults 
(Chaturvedi and DeBaun, 2016). Better health care and nutrition has led to the increase in the 
survival rate for instance, SCD-related deaths among African-American children below 4 years 
fell by 68% between 1983 and 2002 (DeBaun, 2014). Medical interventions include neonatal 
screening for early detection (Wang et al., 2011), use of penicillin prophylaxis (Cober and 
Phelps, 2010), pneumococcal immunization (Hardie et al., 2009; Ellison et al., 2012), 
transcranial Doppler screening to detect patients at risk of stroke, blood transfusions (Malouf 
Jr et al., 2001; Lee et al., 2006), other therapies like hydroxyurea (Charache, 1991), bone 
marrow transplantation (Bhatia et al., 2015); these along with better nutrition, hygiene and 
public health practices have contributed to increase in the life span of people with SCD.  
Currently, more people with SCD could live into adulthood for instance, 95%-99% of children 
now survived into adulthood in developed countries such as UK and USA because of these 
interventions (Telfer et al., 2007; Quinn et al., 2010; Ware, 2013). In US, the average life span 
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has increased to 42 for males and 48 for females (Yanni et al., 2009; Lanzkron, Carroll and 
Haywood Jr, 2013). Recent studies have also shown that people with SCD now live beyond 
five decades especially in the high resource countries such as UK and the USA. An example is 
a qualitative study of 15 adults with SCD in USA (Jenerette, Leak and Sandelowski, 2011) 
where the age range of participants was 48-73 years. This underscores the growing population 
of adults with SCD. The disease has thus taken a chronic form which requires a comprehensive 
life-long management (DeBaun, 2014). Also, SCD in adults has additional complications with 
those found in children and adolescents with SCD. Because transition to adulthood is more 
challenging for people with SCD compared to the general population, people with SCD must 
learn to cope with multiple increased complications and restrictions associated with the illness 
(Thomas and Lipps, 2011). 
 Moreover, as patients with SCD grow older, they become susceptible to further disease 
complications such as vasculopathy, systemic and pulmonary hypertension, chronic organ 
dysfunction or severe organ damage, renal failure, thromboembolism and iron overloads 
(Powars et al., 2005; Aliyu et al., 2008; Ogun, Ebili and Kotila, 2014). These experiences might 
result in unexpected high stress level and negative emotions especially because the disease 
condition also predisposes to a life-long treatment regimen which in most cases are complex 
and multi-focused (Thomas and Lipps, 2011). The emerging adult population is then faced with 
the challenge of coping with the effects of the disease and its treatment.  
This has serious implications for the quality of life of the patients which cannot be ignored. 
Therefore, the need to understand quality of life associated with the disease has become more 
important and understanding factors responsible for HRQL in the patients may inform further 
research that may lead to advances in medical care. 
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1.17 Psychosocial impact  
Edwards et al. (2005) observed that SCD is complicated with psychosocial and physiological 
challenges which affects the patients, their families or caregivers. Adegoke and Kuteyi (2012) 
in a study of 225 caregivers of children with SCD treated at the Paediatric Haematological 
Clinic of the University Teaching Hospital, Ado-Ekiti, Nigeria, observed that caregivers carry 
significant financial, interpersonal and psychological burden. For example, caregivers, 
reported their inability to engage in gainful activities, the neglect of other members of the 
family, loss of financial benefits as a result of time spent on caring, and presence of tension 
and hostility in the homes (Adegoke and Kuteyi, 2012). In the transactional model of stress and 
coping (Lazarus and Folkman, 1984), SCD is regarded to be a potential stressor to which 
individual and family try to adapt (Anie, 2005). Studies also showed that SCD patients are 
predisposed to low esteem, feelings of hopelessness due to frequent pain, hospitalisations, loss 
of schooling (in children and adolescents) and loss of employment (in adults); these are 
conditions that predispose to depressive symptoms (Anie, 2005).  
Psychological complications in SCD was associated with pain and perceived attitude of the 
society (Anie, 2005; Edwards et al., 2005). Depression has been found to be a common 
psychological reaction to pain in affected subjects. In a study of 39 patients age 6-19 years, 
13% reported depression symptoms, 10% anxiety, and 8% behavioural problems (Cepeda et 
al., 1997). Depressive symptoms such as sadness, guilt, hopelessness and helplessness were 
associated with pain in SCD. Other psychological problems include social withdrawal, 
aggression, poor school attendance and/ or performance in children and loss of employment in 
adults (Anie, 2005).  
1.18 Public health implications 
SCD presents a significant challenge to public health due to the under-five mortality which was 
estimated to be over 5% and as high as 16% in individual West African countries (SCAF, 2016; 
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WHO, 2006). Added to this is the high rate of deaths due to SCD-related complications in 
adolescents and pregnant women in Africa (Dennis-Antwi, Dyson and Frempong, 2008). 
Globally, the chronicity of the disease and high rate of hospital utilisation increases burden on 
health facilities. Moreover, the disability-adjusted life years (DALY) from SCD has been found 
to compare with the DALY from cervical cancer and greater than DALYs of chronic kidney 
disease related to diabetes mellitus or hypertension (Ware, 2013). 
1.18.1 Burden of SCD on the health care system 
One of the factors that made SCD a public health issue is its high rate of health care service 
utilisation indicated by admission rate, number of hospitalisation, emergency department visits 
and demand on time of health care personnel. For instance, SCD is less common but has higher 
hospital rate of utilisation than diabetes, cardiovascular disease and cancer (Davis, Moore Jr 
and Gergen, 1997; AlJuburi et al., 2012).  
In UK, admission rate for SCD increased by more than 50% from 21.2 per 1000 in 2001/02 to 
33.5% in 2009/10 (AlJuburi et al., 2012). In US, it was reported that emergency departments 
visit due to SCD was approximately 200,000 per year translating to average of two visits per 
person per year, the number of hospitalisation was put at 83,149 adults with SCD aged 18-44 
(Healthcare Cost and Utilisation Project (HCUP), ARHQ 2004). This accounted for 66% of 
hospitalisation. In another study, Yang et al. (1995) discovered that 33.5% of SCD patients 
who did not use the comprehensive health care clinics were responsible for 71.4% of visits to 
the emergency department and 42.3% of hospital admissions. Hospitalisation per year was put 
at 75,000 SCD patients in US (National Heart, Lung and Blood Institute, NIH, 1994). The 
health seeking behaviour of SCD patients due to disease-related complications put significant 
pressure on utilisation of healthcare facilities. 
59 
 
1.18.2 Health cost of SCD 
In US, the health cost associated with SCD has been estimated at $2 billion annually (Kauf et 
al., 2009), medical expenditure for children with SCD in 2005 averaged $11,702 for children 
with medical coverage and $14,772 for children with employer sponsored insurance 
(Mvundura et al., 2009), in fact, it would cost an average of $8.7 million to care of an SCD 
patient from age 0-50 years in the country without taking into consideration other non-
transparent costs such as social workers time and efforts (Ballas, 2009). In 2010-2011, England 
recorded 6,077 admissions of SCD patients with crisis as primary diagnosis at a total cost of 
over £18 million, 91% of which was spent on emergency admissions, while estimated costs for 
all SCD-related cases was put at over £20 million (Pizzo et al., 2015). In the Democratic 
Republic of Congo (DRC), cost of care in a paediatric ward was estimated at $1,000 per patient 
(WHO, 2014). A recent study in Nigeria revealed that the average cost of blood transfusion 
among paediatrics with SCD was above $3,000 (Lagunju, Brown and Sodeinde, 2013). In 
another study of 73 children with SCD at the paediatrics ward of Ekiti State Teaching Hospital, 
Nigeria, the cost of care per hospitalisation was $132.67 with an average of 2.5 hospitalisation 
per child (Adegoke, Abioye-Kuteyi and Orji, 2014). This is high considering that Nigeria is a 
low-income country where the minimum wage is $120 and 70% of the population earn less 
than 1USD per day (World Bank report, 2011). Estimated cost for care of adults with SCD was 
found to be twice the cost for children with SCD (Pizzo et al., 2014).  
1.19 Clinical Management of SCD 
The complications in SCD are complex in nature. Various methods used in the management of 
the disease are briefly discussed.  
Newborn screening (NBS) has been institutionalised especially in high-resource countries to 
identify children who may be affected early enough. The screening programmes has been 
responsible for reduction in the mortality rate of children affected with the disease. 
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Pneumococcal immunisations and use of prophylactic penicillin have been embarked upon as 
preventive measures. These measures have been found to be responsible for significant 
reduction in incidence of infections in paediatrics SCD (Quinn, Rogers and Buchanan, 2004). 
Transcranial Doppler (TCD) screening has been used to detect early signs of organ damage. 
There have been recommendations that TCD be carried out annually in patients aged 2-26 years 
to detect the possibility of stroke and initiate preventive therapies (Kanter and Kruse-Jarres, 
2013). 
Education of healthcare providers on attitude to pain in SCD and parents and patients on early 
recognition and the medical complications have also contributed to reducing the burden of the 
disease (Pack-Mabien et al., 2001). 
Therapies for the treatment of SCD include the use of Hydroxyurea, blood transfusion and stem 
cell transplantation. Hydroxyurea (Hu) has been established as preventive treatment for 
patients with SCD. According to the Multicentre Study of Hydroxyurea in sickle cell anaemia 
(MSH), Hu was found to reduce number of acute VOC and hospitalisations (Lanzkron et al., 
2006). 
Blood transfusion has been shown to reduce the risk of stroke and prevent repeated ACS 
(DeBaun et al., 2012). However, patients may be exposed to the risk of iron overload which 
may damage vital organs such as the liver in the patients.  
Allogeneic Haemopoietic Stem Cell Transplantation (HSCT) has been proved in some 
conditions to be the only therapy for now that has potential for the cure of SCD. In a study of 
31 Nigerian children transplanted from their identical human leucocyte antigen (HLA) sibling 
donors, Isgro et al.,(2015) reported that the probability of those who survived without the 
symptoms of the disease after transplant was 90% while the probability of transplant-related 
mortality was 10%. However, challenges with HCST include finding matched donor especially 
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for adults with SCD, the cost and the association of the therapy with increased risk of morbidity 
including infertility, gonadal failure and graft-versus-host disease (Isgro et al., 2015).  
1.20 Holistic Management of SCD 
Managing SCD as a chronic disease requires a comprehensive approach to address not just the 
clinical symptoms but also the psychosocial manifestations of the disease. The need to evolve 
strategies that integrate the objective clinical measures with subjective psychological and social 
variables to solve health problems has been well documented in literature (Edelmann, 2000; 
Anie, Egunjobi and Akinyanju, 2010; Panepinto, 2012), subjective measures of social 
functioning and measures of psychological well-being have been found to be better and reliable 
in their accuracy to predict long term morbidity and mortality for example, in rheumatoid and 
arthritis, (Jenkinson, 1995) than traditional clinical measures. Moreover, it has been posited 
that these measures may have greater impact and relevance to the society and the individual 
(Rosenberg, 1995). This subjective measure is conceptualised as quality of life as it relates to 
health functioning. 
1.21 Management of SCD in Nigeria 
As in other developing countries, SCD patients in Nigeria - especially those living in rural areas 
- have little access to medical care.  
In high resource countries, factors responsible for improved lifespan include the availability of 
comprehensive care encompassing newborn screening for early diagnosis (Wang et al., 2011), 
pneumococcal vaccination (Hardie et al., 2009; Ellison et al., 2012), penicillin prophylaxis 
(Cober and Phelps, 2010), and use of Transcranial Doppler (TCD) ultrasound to identify 
patients at risk of stroke who are then placed on chronic transfusion programmes (Malouf Jr et 
al., 2001; Lee et al., 2006). Hydroxyurea has also been used to reduce frequency of painful 
crisis, acute chest syndrome and anaemia in children and adults with SCD (Charache, 1991; 
Heeney and Ware, 2010).   
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However, despite the high burden of SCD in Nigeria (Akinyanju, 1989; Aliyu et al., 2008), 
many of the standard management practices are lacking (Galadanci et al., 2013). A survey 
conducted by the Nigerian SCD network (NSCDN) in 2011, a body which brings together 
Nigerian physicians, non-governmental organisations and other relevant bodies within and 
outside Nigeria reported “deficiencies in the management of SCD in Nigeria” (Galadanci et 
al., 2013, p. 4). The survey which covered 18 responses from 8 teaching hospitals, a general 
hospital, a Federal Medical hospital and an NGO-run hospital showed that while all clinics 
administered folic acid and malaria prophylaxis, only 8 of the 18 clinics prescribed penicillin 
prophylaxis (Galadanci et al., 2013). The report also showed that none of the centres offered 
pneumococcal vaccine routinely but some clinics encourage patients who can afford it to get 
it. Furthermore, 8 clinics prescribed hydroxyurea and a local herbal medicine, Ciklavit, is 
prescribed by 8 clinics. It is important to note that all these clinics are in tertiary or secondary 
institutions where SCD patients are generally cared for and where the best care for the patients 
is expected to be available, however reports show a suboptimal care (Galadanci et al., 2013). 
In addition, despite the disease being among the priority top 10 non-communicable diseases, 
the country is yet to have a national policy on SCD. Despite a policy on SCD being sent for 
consideration by the National Assembly, it is still awaiting passage more than four years after 
it has been presented.  
1.22 The Nigerian Healthcare System 
Apart from inadequate facilities and absence of policy, the Nigerian healthcare system is also 
a main factor for the suboptimal management of the disease.  
Healthcare delivery in Nigeria is structured along the widely-used three levels of care. Primary 
care is delivered by the local government, state government delivers the secondary care while 
tertiary care is delivered by the Federal government(Asuzu, 2004). However, government 
commitment to improved and affordable healthcare delivery is low (WHO; 2004).  The 2000 
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World Health Report ranked Nigeria as the 187 of the 191-member nations for its health 
systems performance (Asuzu, 2004). This results from many factors including inadequate 
government allocation to health, high out-of-pocket expenditure and lack of integrated system 
for disease prevention, surveillance and treatment and low supervision of healthcare providers 
(Obansa and Orimisan, 2013). Most of these spending at all the three-tiers of government is on 
personnel (World Bank CRS, Nigeria, 2005).  
Delivery of healthcare is regarded more as a personal affair which means assessing healthcare 
depends on patients’ ability to pay for basic laboratory and physicians services which have 
worsened disease burden (FMOH, 2004). The high out of pocket spending has kept people in 
the poverty trap and hinders access to quality medical care (Aregbeyen, 1992).  
According to the publication of the World Health Organisation, in 2015 the out of pocket 
spending on health was 70% in Nigeria compared with UK 15% and US 11% 
(http://who.int/nha/database/). Out-of-pocket health expenditures presents a large and 
sometimes catastrophic burden on a household; patients find consultations and medications as 
the most costly relative to other health related expenses (Ogunbekun, Ogunbekun and 
Orobaton, 1999). The social insurance available, the National Health Insurance Scheme 
(NHIS) currently applies only to employees of the Federal government. 
Furthermore, absence of integrated system for disease prevention, surveillance and treatment 
is reflected in the lack of targeted efforts at outreach, health promotion and disease prevention 
activities designed to reach the people where they are (Obansa and Orimisan, 2013). 
1.23 Quality of Life 
The notions of quality of life are not new, for example in the Bible, the concept of the abundant 
life as proposed by Jesus Christ (John 10:10) emphasised quality of life as the goal of his 
ministry and divine-human relationship. His disciple, John Zebedee expanded the concept 
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many years later explaining that the abundant life of his master included prosperity, sound 
health, spirituality and satisfaction (3John1:2). 
 The term ‘quality of life’ entered the American’s dictionary after the Second World War to 
connote good life which goes beyond wealth (Campbell, Converse and Rodgers, 1976). This 
concept has since become an important construct in research, clinical practice and policy 
making as well as being a useful parameter for evaluating the quality and outcomes of health 
care (Moons, Budts and De Geest, 2006). 
Quality of life as a concept emerged in the mid-1950s (Rosenberg, 1995) and was introduced 
as a key term in medical indexes in 1975 while its systematic study started with oncology in 
1980 (Berlim and Fleck, 2003). This was to investigate individual’s view on his or her health 
status beyond what signs and symptoms may indicate in the process of measuring treatment 
outcome. According to Marks (2003), quality of life is basically a public health concern as the 
purpose of health goes beyond increased duration of life but should enhance a more satisfying 
meaningful life and to enjoy a better quality of life. Health should correlate with one’s ability 
to work, maintain activities of daily life and be independent as long as possible (Marks James, 
2003). In addition, recognition has been given to the study of quality of life and the need for 
its promotion in patients (US Department of Health and Human Services, 2010; WHO African 
Region, 201). This aligns with the goal of medical care to improve and maintain the global 
functioning and general health of patients beyond the traditional focus on physiological and 
anatomical conditions (Jenkinson, 1995) as targets of diagnostic and treatment procedures. 
Measures of objective indicators like morbidity and mortality have been relied on to evaluate 
the effects of diagnosis and treatment. However, the need to incorporate patient-based 
assessment along with clinicians’ judgements in evaluating medical interventions or 
effectiveness of therapy became a growing discuss among researchers and practitioners. The 
consensus was that such evaluations will provide more accurate assessment of individual’s or 
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population’s health with the potential benefits and possible harms that may result from medical 
care (Jenkinson et al., 1995; Fitzpatrick et al., 1998).  
Quality of life is a broad range measure of health status compared to the clinical measures 
(which use only morbidity and mortality as indicators. Quality of life has the potential to act as 
an adjuvant and is useful in documenting the impact of illness (Schweizer, 1995). In practice, 
quality of life studies has been found to discriminate between different patients or groups of 
patients and helps to evaluate the effectiveness of medical interventions and predict individual 
outcomes (Berlim and Fleck, 2003).  
Healthcare professionals need to consider the views that patients are more concerned about 
how they feel rather than what clinical evidence dictate they ought to feel. For example, the 
experiences of people with SCD are influenced by multiple social and psychological factors 
(Barbarin and Christian, 1999). These have impact on all aspects of their experience which 
play out in their physical, social, psychological and occupational well-being including their 
self-esteem and levels of independence (Caird, Camic and Thomas, 2011). Some of the 
concerns may be whether the various treatments in any way help relief these burdens; thus, the 
evaluation of quality of life puts patients in any way at the centre of inquiry and gives due 
weight to their opinion (Berlim and Fleck, 2003). This is the motivation for employing 
subjective indicators like health-related quality of life (Bowling, 1995b, 1995a) as a key factor 
in the management of chronic diseases. Furthermore, thee World health Organisation (WHO) 
defined health as:  
a state of complete physical, mental and social well-being and not merely the 
absence of disease or infirmity” (WHO, 1948 pg.1).  
This definition was recognised as a significant milestone in the development of quality of life 
studies within healthcare (Galloway et al., 2006; Gurková, 2011). The definition highlighted 
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the positive aspect of health and the importance of evaluating psychosocial factors in measuring 
health status and well-being. 
However, a major challenge is the absence of a widely acceptable definition of quality of life 
and whether the construct can be or should be measured (Wolfensberger, 1994). There are also 
individual and cultural differences as to what constitutes quality of life.   
1.23.1 Definitions of quality of life 
Quality of life is a broad concept that borders on the evaluation of the impact of all aspects of 
the life on a persons’ general well-being. The World Health Organisation Quality of Life 
(WHOQOL) Group defined quality of life as: 
An individual’s perception of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, and standards 
and concerns. It is a broad ranging concept affected in a complex way by the person’s 
physical health, psychological state, level of independence, social relationships and 
their relationship to salient features of their environment” (WHOQOL Group, 1993 p. 
153). 
This definition shows that quality of life is about the way individuals perceive how satisfied 
they are with their lives including health status and this may have little resemblance to his her 
actual physical health status (Curtis, 2000). Curtis (2000) further argued that the subjective 
nature of the concept highlights the need to allow patients to express how they feel about their 
state and treatments, rather than for caregivers to infer how they must feel. Additionally, the 
definition underlines the need to recognise individual and cultural differences in the study of 
quality of life (Szabo, Orley and Saxena, 1997) and to properly define relevant elements of 
quality of life both in a global and local parlance.  
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More challenging is the lack of consensus as to a widely-accepted definition for quality of life. 
Different authors used different definitions, and some were rather ambiguous (Tyrrell et al., 
2005). There is however a popular agreement that the term is a multidimensional construct that 
includes subjective measures of both positive and negative features of life (CDC, 2012) 
Researchers in quality of life have viewed the concept as elusive, multidimensional with 
diverse operational definitions (Felce and Perry, 1995) and without consensus agreement on its 
operational definitions. The definitions of quality of life are many and diverse (Liu, 1976; 
Baker and Intagliata, 1982). The lack of agreement arose in part from the academic orientation 
of the proponents. The 1970s witnessed researchers from economics, healthcare and the social 
sciences working independently to develop conceptualisations of the population ‘life quality’ 
(Cummins and Lau, 2006). The quality-adjusted life years (QALY) concept has emerged from 
the disciplines of economics and medicine; the health-related quality of life (HRQL) has 
resulted from the discipline of medicine while subjective well-being (SWB) has emerged from 
the disciplines of the social sciences (Gurková, 2011). Although these approaches are all related 
to health, the methodologies are so different from one another such that obtained indexes had 
little in common (Cummins and Lau, 2006; Gurková, 2011). There is however a general 
consensus that HRQL is a dynamic, subjective and value-based multidimensional construct 
which require conceptual models to describe its various aspects and determinants (Banerjee, 
Gurland and Graham, no date; group and others, 1995; Wilson and Cleary, 1995; Testa and 
Simonson, 1996; Haas, 1999; Vallerand and Payne, 2003; Padilla, Frank-Stromborg and 
Koresawa, 2004; Ferrans et al., 2005; Speight and Shaw, 2007). 
1.23.2 Multidimensional nature of quality of life 
There are two broad approaches to studies in quality of life: the social science approach which 
regards quality of life as a measurable phenomenon that can change and so can be improved 
upon; and the philosophical approach with a eudemonistic view concerned with the nature of 
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human beings and their environment, searching for better conditions in which human beings 
can be happy or flourish (Draper, 1997). The focus of the social scientist was to fashion out a 
distinction between happiness and satisfaction the two major concepts describing quality of life 
(Ferrans and Powers, 1992).  
For the health researchers and providers, the concept must be applied to their population of 
interest or patients. The term ‘health-related quality of life’ then takes on different connotations 
which include, well-being, psychological adjustment, physical functioning, symptoms and 
health status (Ferrans et al., 2005). 
 As quality of life is being used like an umbrella coinage (Feinstein, 1987), encompassing 
various dimensions such as health status, life satisfaction, socioeconomic status, physical 
health, life goals, affect, perceived stress, life goals, housing and neighbourhood, city and 
nation, self-esteem, depression, coping, and happiness among others (Ferrans and Powers, 
1985; Simko, 1999). This term was seen as too broad to be considered appropriate when 
making a health care claims (Bradley, 2006) because it evaluated non-health-related aspects of 
life as well; health-related quality of life’ was therefore to refer to quality of life within the 
specific context of health, illness and treatment (Ferrans et al., 2005; Galloway et al., 2006), 
the impact of disease on important areas of one’s life (Phillips, Davis & White, 2001). In this 
sense, quality of life is viewed as a broad concept that focuses on whether one’s ability to fulfil 
a normal life role is limited due to disease or impairment (Carr, Gibson and Robinson, 2001). 
Thus HRQL does not consider cultural and political factors or societal attributes (Ferrans et 
al., 2005). 
 1.23.3 Quality of life in Medicine 
Quality of life in medical literature is viewed from different perspectives. There is the 
philosophical approach which examines the the nature of human existence and the  meaning of 
the good life (Holmes, 1989). Another approach is the methodological approach which focuses 
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on the subjective or objective nature of quality of life and describes ways in which it could be 
measured (Felce and Perry, 1995; Anderson and Burckhardt, 1999; Cella and Stone, 2015). 
There is also the relationship approach which directs efforts at investigating relationship of 
quality of life to health status (Pearlman and Uhlmann, 1988; Padilla et al., 1990) and the 
resource allocation approach which discusses the role of quality of life in the allocation of 
scarce medical resources (Grabowski and Hansen, 1990; Anderson and Burckhardt, 1999). 
These different approaches underline the importance and usefulness of quality of life as 
complementing clinicians’ efforts at enhancing well-being.  
Quality of life in medicine provides useful information to complement data on the life-
preserving properties of medical intervention. Najman and Levine (1981) suggested that 
regarding increasing longevity as the main goal of medical intervention will be true only for a 
small proportion of care delivered; they submitted that medicine aims to relieve symptoms, 
improve mental health, restore functioning, or reduce pain and discomfort, therefore evaluation 
of healthcare should be based on its impact on the quality of life. 
1.23.4 Growth of interest in quality of life in medical literature 
In 1966, when the index of medical literature, Index Medicus, introduced quality of life as a 
category, only one article was published on the subject. Between 1981 and 1986 the number of 
publications rose to 1902 and to 8,820 between 1991 and 1996 (Draper, 1997). Moons et al. 
(2006) reported a total of 76, 698 articles containing ‘quality of life’ in a Pubmed search from 
1966 to 2005, they showed that proportion of quality of life publications increased from 
0.002% to 1.36%. A search through the Discover database of the University of Sunderland 
(November 10, 2016) showed a growth of 552% to 973% in publications in twenty years on 
quality of life and health-related quality of life respectively. (See Table 1-3) 
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Table 1-3: Growth of Interest in the Study of Quality of Life 
Year Articles 
containing 
Quality of Life 
anywhere in the 
Publication 
Articles 
containing 
Quality of 
life in the 
Title 
 
Growth 
Articles 
containing 
Health-related 
quality of life 
in the Title 
 
Growth 
1996-2000 258,467 8, 368  - 1,309 -  
2001-2005 484,294 20,287 242.4 4,134 315.8 
2006-2010 759,153 31,209 153.8 7,680 185.8 
2011-2015 1,059, 684 46,213 148.1 12,733 165.8 
20 years 
growth 
  552.3%  972.7% 
Source: Search of Discover database, November 10, 2016. 
Several explanations have been given for this growing interest in quality of life in health 
research and practice. In the first instance, life expectancy has generally increased due to 
improved medical therapies, better nutrition and other health promotion activities such that 
many terminal diseases have transformed to life life-long chronic diseases (Moons, Budts and 
De Geest, 2006). Therefore, those who otherwise would have died had remained alive which 
implies that mortality had reduced but the number of people with chronic diseases have 
consequently increased. Diseases otherwise tagged terminal have now transformed to lifelong 
chronic diseases. Such chronic diseases are now being clinically managed to avoid early death. 
Therefore, quality of life measure is a critical outcome measure for this group of patients 
(Moons, Budts and De Geest, 2006). Additionally, some researchers have insisted that quality 
of life should be used together with mortality and morbidity to assess outcomes in healthcare 
(Macduff, 2000; Moons, Budts and De Geest, 2006). 
Secondly, the need to consider the benefit-burden ratio of equally effective therapies has 
informed the requirement for quality of life measurement to assess the benefits of different 
medical interventions, health programmes and to evaluate both human and financial costs and 
benefits - a practice that has influenced policymakers in resource allocation to healthcare (De 
Geest and Moons, 2000; Galloway et al., 2006). Furthermore, other international bodies have 
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focused on activities that encourage quality of life assessment and research, for example, the 
United States Food and Drug Administration has included quality of life measurements in its 
process of approving new drugs, in addition to increased advocacy by national and international 
groups to employ quality of life assessments in clinical trials research (Grant and Dean, 2003). 
Other reasons include the evolution of quality of life assessment into a primary outcome 
measure in health services research, acute care and chronic illness which has coincided with 
economic changes and pressures to reconcile quality care and cost effectiveness as well as the 
current routine use of quality of life assessment to evaluate human and financial costs and 
benefits of different health programmes and medical intervention (Grant and Dean, 2003; 
Galloway et al., 2006). These have resulted in rapid growth of research on quality of life 
(Gurková, 2011). 
1.24 Health-related quality of life (HRQL)  
Quality of life became operationalised in medicine and allied professions via the health-related 
quality of life construct (Gurková, 2011). Interests in the study of Health-Related Quality of 
Life (HRQL) emerged in the 1970s as a construct to define quality of life in terms of the impact 
of an illness, its complications, and its treatment on the patient (Ferrans et al., 2005; Panepinto, 
2008). The term health-related quality of life first appeared in titles of published articles in the 
mid-1980s (Post, 2014).  The concept of health-related quality of life is commonly used to 
describe quality of life in relation to the effects of illness and treatment (Ferrans et al., 2005; 
Palermo, Riley and Mitchell, 2008; Gurková, 2011), that is, the aspects of overall quality of 
life associated with physical or mental health (CDC, 2000).  
It has been suggested further that, clear description and explanation of the patient’s overall 
health condition will help clinicians in their assessments of the burden of disease (Fayers and 
Machin, 2000; groSSe Schlarmann, Metzing-Blau and Schnepp, 2008; Gurková, 2011) beyond 
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clinical measures. This in part, is a furtherance of the WHO’s definition of health (WHO, 
1948).  
HRQL as a component of quality of life may help to advance the knowledge that relief from 
symptoms is not sufficient to measure success in care-giving meaning that possible impairment 
of the functional status, psychosocial and socio-economic conditions of the patient should be 
addressed as well. The Centre for Disease Control and Prevention (2003) considered HRQL as 
a construct to identify and track the health status of vulnerable subgroups and older adults in 
the USA. This would inform the need to develop and support programmes that reduce the 
impact of chronic diseases and disability, maintain the ability of older adults to live 
independently and improve quality of life (CDC, 2003). Marks (2003) opined that HRQL must 
transform to a core means of measuring progress in health. 
The main domains of HRQL are physical, social and psychological. The physical domain 
details the patient’s perceived ability to expend energy on daily activities; the social domain 
focuses on relationship and integration with other people while the psychological dimension is 
concerned with emotions and mental well-being. Spitzer (1987) has argued that we must 
include physical, and social functions, emotional or mental states and perception or sense of 
well-being to peoperly define the domain of HRQL. In the case of patients with SCD the 
unremitting pain and complications caused by the disease can interfere with many aspects of 
the patient’s life, including education, employment and psychosocial development (World 
Health Organisation, 2010) resulting in low health-related quality of life in the patients 
(Trzepacz et al., 2004; WHO, 2007; Dampier et al., 2010; McClish et al., 2016) and their 
families and caregivers (Anie, 2005; De, 2005). Hence, investigating factors that influence 
HRQL in people living with SCD and discovering the pattern and path of influence could 
contribute to reducing the burden of the disease and improve its management by designing 
appropriate interventions.  
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Research in HRQL is important due to its effects on the individual, the healthcare providers 
and healthcare policy. At the individual level, HRQL can be used to improve the quality of life 
and treatment of individuals with chronic disease because this is the major goal of health care 
(Omery and Dean, 2004). At the healthcare providers level, evaluating HRQL in clinical trials 
help to differentiate between therapies, and may suggest to the health care providers the need 
to modify or alter prescribing habits, treatment regimens and/or decision to cease treatments 
(Gurková, 2011). Quality of life is also useful in national healthcare policy to improve the 
allocation of scarce healthcare resources to address health issues. 
There are several reasons for including quality of life assessment in healthcare. They are used 
for the evaluation in clinical trials of treatments with curative or palliative purpose, to reduce 
symptoms or improve care or rehabilitation (Gurková, 2011). Additionally , they are used to 
document information about several problems associated with specific disease in the patients, 
such information have been observed to have potential to facilitate patient communication and 
help to determine patient preferences (Fayers and Machin, 2013) and establish therapeutic 
relationship (Gurková, 2011). 
Many clinical trial organisations have now introduced the assessment of quality of life as being 
a standard part of new trials. Such assessments have also been reported to have had a significant 
role in the interpretation and conclusions of randomised clinical trials (RCTs), in fact some 
RCTs have recognised that quality of life may be the principal outcome of interest. In addition, 
quality of life is important as some treatments have shown that, in some instances, the cure 
might be worse than the disease. It is also useful in understanding treatment preference by 
patients, to identify problems of psychological adaptation and aid medical decision-making  
Quality of life has been discovered to be an important outcome in evaluation of curative 
treatments, palliative care, rehabilitation and in facilitating communication with patients 
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(Fayers and Machin, 2013). Results of such evaluations have shown their usefulness to 
distinguish between two equally effective and safe therapies but with substantial and different 
changes in quality of life. Rehabilitation programmes can be improved or modified or 
completely discarded in response to results from quality of life measures, for example, Jews 
and West (1996) found that rehabilitation programmes used in psychological therapy, 
counselling, relaxation theory and stress management seemed to offer little benefit to 
myocardial infarction patients.  
Furthermore, quality of life can be a predictor of treatment success. Several studies have shown 
that overall quality of life, physical wellbeing, mood and pain are of prognostic importance in 
cancer patients (Davis et al., 2007; Takeuchi et al., 2011). Patient’s HRQL has also been found 
to be a strong predictor of morbidity and mortality. A study has shown that quality of life was 
strongly predictive of survival and recovery process in surgery (Jenkins, 1992) in addition to 
the prognostic value of quality of life scores during treatment (Gotay and Moore, 1992).  
Researchers have observed that within a target population, HRQL can be used to benchmark 
diseases across population to provide a better understanding of the burden of disease that 
patients experience, and this is informative to healthcare providers, patients, families and others 
(Fayers and Machin, 2000; Grant and Dean, 2003; Omery and Dean, 2004; Panepinto, 2012; 
Panepinto and Bonner, 2012). Impact of treatment on the patient can easily be measured using 
HRQL measurements and hence tailor therapies. 
There has been an exponential increase in the use of HRQL measures in clinical research since 
1973 (Testa and Simonson, 1996), especially in a clinical trial setting in patients with cancer 
(Basch et al., 2007; Davis et al., 2007; Takeuchi et al., 2011) and other chronic diseases 
(Panepinto and Bonner, 2012) including SCD (Thornburg et al., 2009).  
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Some usefulness of the HRQL concept has been highlighted. For example, it has been 
suggested that HRQL could be considered as central to measuring the efficacy and 
effectiveness of treatment interventions to predict outcomes and resource use and direct therapy 
(Panepinto, 2012; Panepinto and Bonner, 2012). Additionally, the use of HRQL has been 
shown to improve patient-provider communication and to create a more patient-oriented 
environment; several studies have shown that the use of HRQL data improves patient’s 
physician’s communication, is acceptable to patient and providers and aids in the care of 
patients with chronic illnesses (Basch et al., 2007; Davis et al., 2007; Takeuchi et al., 2011; 
Panepinto and Bonner, 2012; Fayers and Machin, 2013; Cella and Stone, 2015). Employing 
HRQL as part of medical protocol can help patients to become more aware of their functioning 
and symptoms when they are actively involved in providing HRQL information to their 
providers and they are thus better able to advocate for themselves to improve their HRQL. 
This, according to Panepinto (2012), can also help providers to react quickly to change in 
HRQL to tailor treatment especially when significant worsening of HRQL is noted from visit 
to visit. HRQL can be used in a home setting and can provide a means to track functioning over 
time and alert providers to any worsening in HRQL as Davis et al., (2007) demonstrated in 
cancer patients. 
1.24.1 The Modelling apparoach to Health-related quality of life 
The need to properly measure and develop a knowledge base for HRQL requires reference to 
a conceptual model (Sousa and Kwok, 2006). Conceptual clarification and accumulation of 
empirical data will help understanding of fine details of quality of life issues and guide the 
design of comprehensive care protocols. A conceptual model will assist to understand the 
relationships among the concepts and consequently translate the clinical relevance of HRQL 
(Wilson and Cleary, 1995; Sousa and Kwok, 2006; Bakas et al., 2012).  
76 
 
Models are of central importance in understanding scientific phenomena (Rosenblueth and 
Wiener, 1945) especially for understanding health and illness (Engel, 1977; WHO, 2001; Wade 
and Halligan, 2003, 2004). In quality of life research, the use of a conceptual model is important 
because it can advance the selection of appropriate measurement variables and make it possible 
to identify potential links between variables with complex construct of quality of life (Saban et 
al., 2007a). Heo et al. (2005) opined that researchers and clinicians can work better to improve 
HRQL outcomes if they know which variables are associated with HRQL and which variables 
are of less importance to HRQL. They submitted that there is high possibility of committing 
errors if assumptions were not tested. They cited the example of clinicians’ belief that the 
HRQL of heart failure patients was largely determined by the severity of the illness which they 
measured with the ejection fraction. Various studies have however, contradicted this belief as 
such studies showed that ejection fraction had not been associated with HRQL (Heo et al., 
2005).  Such outcomes supported HRQL as a complex phenomenon and assumptions must be 
subjected to test when in the process of developing intervention to improve HRQL (Heo et al., 
2005). There is a consensus among researchers that conceptual or theoretical models that 
clearly indicate the elements of HRQL and their determinants are needed (Wilson and Cleary, 
1995; Wood-Dauphinee, 1999; Ferrans et al., 2005; Sousa and Kwok, 2006) and without a 
theoretical approach, identifying patterns in relationships between the concepts and 
interpreting their meanings will be difficult, and the ability to properly assess the mediators 
and moderators of predictors, whether by the person, disease or treatment-related factors will 
be limited (Haase and Braden, 1998; Sousa, Tann and Kwok, 2006).  A theoretical model 
provides scientific ground for generating and testing hypothesis and may help to explain 
important phenomenon like HRQL which may likely have impact on interventions and 
practice. Haase and Braden (1998) highlighted several ways in which a non-theoretical 
approach fails. First, it is difficult to assess if or how domains are related to one another; second, 
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one cannot interpret the meaning of relationship patterns; third, one has no basis for specifying 
whether the dimensions are moderated or mediated by persons, the disease, treatment-related 
factors or all three, relative to cost and quality of care outcomes (Haase and Braden, 1998). 
Such models must be valid to achieve the following: (i) clarify predictors, (ii) understand the 
factor that has the greatest impact on a patient’s life (iii) evaluate the relative importance of 
different approaches and/or interventions to patient care, and (iv) establish clinically relevant 
measures (Sousa, Tann and Kwok, 2006). 
1.24.2 Models of Health-related quality of life 
In a systematic review of 100 studies that used HRQL models, Bakas and colleagues (Bakas et 
al, 2012) reported that three models presented the greatest potential to guide HRQL research 
and practice; they are the Wilson and Cleary model used in 16% of the studies, the World 
Health Organisation International Classification of Functioning Disability and Health (WHO 
ICF) used in 5% of the studies and Ferrans et al.’s revised version of the Wilson and Cleary 
model used in 4%. Bakas et al. recommended the use of one of these three global models in 
research to more quickly advance the science in the area of HRQL. All the three models emerge 
from the two paradigms of biomedical and social sciences and are briefly described as follows. 
The World Health Organisation International Classification of Functioning Disability and 
Health (WHO ICF).  
The WHO ICF model was designed to provide a description of health and health states while 
providing a unified standard language that can be used across disciplines and cultures (WHO, 
2001). The model is made up of components within two parts; one part focuses on functioning 
and disability (body functioning and structures, activities, and participation) while the other 
part addresses contextual factors (environment and personal). The drawback of this model is 
that it is not specific to HRQL (Bakas et al., 2012) , but also focuses on disease classification. 
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According to Cieza and Stucki (2008), the model’s categories under functioning can serve as 
the basis for operationalisation of HRQL but are not the only potential application of the model. 
The model serves more as a mapping and classification framework than a model in the area of 
HRQL. This model was therefore not considered useful to achieve the objectives of this thesis.  
The Wilson and Cleary Model of Health-related Quality of Life 
The Wilson and Cleary model (Wilson and Cleary, 1995) is a global model of HRQL, which 
has been used to guide literature reviews and the development of models and instruments, also, 
the model focuses specifically on explaining HRQL and can be applied in real-world settings 
(Bakas et al., 2012). Moreover, the model has clearly defined concepts and has been to be 
found applicable to individuals across all ages, lifespan, health and disease conditions as well 
as across cultures (Bakas et al., 2012). The model was the first and currently the major model 
that integrated the biomedical and the social science models of health. The model highlighted 
five domains of bio-physiological factors, symptoms, functioning, general health perceptions 
and overall quality of life (see Figure 1-3a). The aim was to understand the pattern of 
relationships among different levels of patient outcomes as well as pathways of their influence 
on the overall quality of life (Wilson and Cleary, 1995). This information could be used in 
planning healthcare interventions directed to improving patients’ quality of life. Clinicians and 
researchers need to consider and test potential causal relationships among the biological, 
psychological and social variables of health in order to contribute to the design of an ‘optimally 
effective’ therapeutic intervention (Wilson and Cleary, 1995).  
The model considers five main factors in a multilevel continuum which linked objective, 
biological variables at the start of the framework to the subjective overall quality of life 
outcome at the end of the continuum. The model hypothesizes that the biological and 
physiological variables affect symptoms; while symptoms affect functional status; the 
functional status affects general health perceptions; and the general health perceptions affect 
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the HRQL (Figure 1-3a). Individual characteristics and environmental characteristics affect all 
the variables except the biological and physiological variables. Although, the model portrays a 
linear, one directional link, Wilson and Cleary admitted that the relations between variables 
could be bidirectional and the causal pathway may not be as simple as illustrated. There could 
also be relationships between nonadjacent levels though there were no arrows to illustrate such, 
hence the need to test the model with empirical data (Wilson and Cleary, 1995). Each level of 
the model was clearly defined. The biological and physiological variables are assessed by the 
functional status of cells, organs and organ systems, considerations are also given to factors 
whose effect are mediated by variability in cell or organ, or organ system functions. Second, 
the symptom status shift to the organism as a whole and describe the patients’ subjective 
perceptions of an abnormal state of physical and mental, and cognitive conditions. Third the 
functional status refers to the ability of the individual to perform physical, social, emotional 
role and psychological functions. Fourth, the general health perceptions was defined by the 
patients’ global perceptions of their health, i.e. a subjective ratings integrating the other health 
concepts including others such as mental health (Wilson and Cleary, 1995). The overall quality 
of life evaluates overall satisfaction (Wilson and Cleary, 1995; Moi and Nilsen, 2012). This 
has been described as the discrepancy between a person’s expectations or hopes and their 
present experiences (Calman, 1984). Environmental characteristics refer to available supports 
from the family, friends and others while individual characteristics, though not defined by 
Wilson and Cleary could be inferred to consist of the demographic and psychologic 
characteristics of patients (Heo et al., 2005). 
The Revised Wislon and Cleary model 
Ferrans et al. (2005) developing a conceptual model of health-related quality of life, revised 
the Wilson and Cleary model. They retained the five major domains of the Wilson and Cleary 
model but broadened the scope by expanding on characteristics of the individual and 
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characteristics of the environment. They agued that the characteristics of the individual and the 
characteristics of the environment should have affect the bio-physiological factor. They 
therefore drew paths from the characteristics of the individual to the bio-physiological factor 
and from the characteristics of the environment to bio-physiological factor (see Figure 1-3b). 
1.24.3 Justification for model selection 
Several factors were considered before selecting the Wilson and Cleary model (WCM) for 
empirical test in this study. First, WCM is a global model specifically designed to explain 
HRQL unlike the WHO ICF which is more of a mapping and classification framework than a 
model in the area of HRQL.  
Second, WCM is the most frequently used model and has been validated across all ages, life 
span, disease conditions and across cultures unlike the revised model which has received little 
study. While WCM has been tested empirically in many disease conditions such as in patients 
living with heart disease / failure (Heo et al., 2005; Krethong et al., 2008; Carlson et al., 2014; 
Lee and Larracoechea, 2015), stroke (Mayo et al., 2015), adult Pompe disease (Kanters et al., 
2015), HIV/Aids (Cosby et al., 2000; Sousa and Kwok, 2006), Cancer (Wettergren, Björkholm, 
Axdorph, Langius-Ekiöf, et al., 2004), Parkinson’s disease (Chrischilles et al., 2002), diabetes 
(Shiu et al., 2014), generalized anxiety disorder (Wyrwich et al., 2011), asthma (Eilayyan et 
al., 2015) and obesity (Brunault et al., 2016); only one study has attempted to fully test the 
revised model in patients with haemodialysis (Kring and Crane, 2009).   
Third, a systematic review of the application of Wilson and Cleary model in chronic diseases 
has shown that the WCM demonstrates a good fit and proved useful in identifying relationships 
among the health constructs, and predictors of HRQL in the studied disease populations. These 
findings demonstrate the robustness of the Wilson and Cleary model as a conceptual framework 
to characterise predictors of HRQL in chronic diseases (see Chapter 3). These provide a basis 
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for compring the findings in my study which currently is not possible with the revised version 
due to lack of studies that have used this version.  
Fourth, a major revision by Ferrans and colleagues (Ferrans et al., 2005) was to draw path 
linking characteristics of the individual and characteristics of the environment to the bio-
physiological factor. In SCD, one characteristic of environment that triggers crisis in SCD is 
cold weather, however, this study did not collect data on weather condition other than that the 
period of data collection fell in the warm season. Low income/poverty is an environmental 
variable that may have affected the biological variables. For example, poverty could limit the 
ability of patients to purchase vitamins and drugs for medications that could inhibit the 
progression of the disease or development of new co-morbidities. However, it is unclear how 
an environmental factor like having a confidant can affect thedevelopment of co-morbidities. 
In addition, it is unclear how a personal characteristic like gender can affect genotype, a 
biological factor because SCD is autosomal. These unexplored relationships did not allow this 
thesis to investigate the path between biological factors and the characteristics of the individual 
and the characteristics of the environment as hypothesised by Ferrans et al. Also, Kings and 
Crane (2009) did not find any relationship between characteristics of the individual, 
characteristics of the environment and the bio-physiological factor. Further studies would be 
required to establish direct relationships between the characteristics of the individual, the 
charactertics of the environment and bio-physiological factor in SCD. The Wilson and Cleary 
model is therefore considered more useful to achieve the objectives of this study.  
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Figure 1-3a: Wilson and Cleary Model of Health-Related Quality of Life 
Source: Linking clinical variables with health-related quality of life. A conceptual model of patient outcome. 
JAMA 1995;273(1):59–65. © 1995 American Medical Association.) 
 
 
Figure 1-3b: Revised Wilson and Cleary Model of Health-Related Quality of Life 
Source: Ferrans, C. E., Zerwic, J. J., Wilbur, J. E. and Larson, J. L. (2005) ‘Conceptual model of health-related 
quality of life.’, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor 
Society of Nursing / Sigma Theta Tau, 37(4), pp. 336–342. doi: http://dx.doi.org/10.1111/j.1547-
5069.2005.00058.x. 
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1.25 The Wilson and Cleary Conceptual Model of HRQL 
Wilson and Cleary(1995) proposed a conceptual model of HRQL that provides a link between 
biological and psychological aspects of health outcomes and with the potential to guide quality 
of life studies and provide theoretical core. This holistic model focuses on two ends of health 
concepts, namely the clinical approach and the social science approach and proceeds to 
integrate both. The Wilson and Cleary model was the first theoretical model to address HRQL 
concept and has contributed significantly to a better understanding of HRQL concepts since its 
publication about three decades ago, transforming HRQL concept from a purely descriptive 
phenomenon to an explanatory model with clear explanations of causal relationships among 
the components (Bakas et al., 2012). 
 The use of HRQL has been on the increase in clinical trials research, effectiveness and quality 
of care because of abundant evidence that measures of HRQL are valid, reliable (McDowell 
and Newell, 1987) and responsive to important clinical changes (Wilson et al., 1991; 
Bombadier et al., 1986). The importance of HRQL in medicine and as a measure of health 
outcomes has been discussed previously (see section 2.4). However, despite HRQL being 
recognised as an important complement to physiological and biological measures of health 
status, there has been limited understanding of its determinants. An improved understanding 
of the underlying causes of HRQL is useful to optimise interventions to target these causal 
factors to improve patients’ perceived HRQL (Wilson and Cleary, 1995).  
Wilson and Cleary’s conceptual model integrates clinical variables of the biomedical model 
with the HRQL of the social science model. The goal of the authors was to specify a series of 
critical concepts on a causal pathway, hence the model describes specific causal relationships 
among health concepts (Sousa and Kwok, 2006). The model uses most variables typically 
included in HRQL assessments and brings together the two different health paradigms 
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belonging to two academic traditions, one belonging to the clinicians and basic science 
researcher, and the other belonging to the social scientist.  
These two academic traditions differ in purpose, methods and intellectual history. For the 
biomedical approach, the focus is on etiologic agents, pathological processes and clinical 
outcomes with the primary aim of understanding causation to guide diagnoses and treatment 
of diseases; the intellectual foundation was in biology, chemistry and physiology. The social 
science or quality of life concept has its focus on dimensions of functioning and overall well-
being (Sousa and Kwok, 2006) with the goal of accurately measuring behaviour and feelings 
and has its roots in sociology, psychology and economic concepts and methodologies 
unfamiliar to physicians and clinical researchers. 
 The social science concept aggregates and evaluates all factors that contribute to the illness 
and identifying the way the various social structures and institution influence individuals. 
Wilson and Cleary suggested that a clear understanding of causal relationship of clinical 
variables to measures of HRQL would be necessary in designing optimally effective clinical 
interventions (Wilson and Cleary, 1995). 
1.25.1 Description of the model 
The Wilson and Cleary model is a biopsychosocial model that makes it potentially possible to 
have a single unifying approach to understanding health issues. The model identified five levels 
of patient characteristics which include, biological and physiological factors, symptoms status, 
functional status, general health perceptions and overall quality of life. In addition, 
characteristics of individuals and environmental factors were included as non-specific 
predictive variables of symptoms status, functional status, general health perceptions and 
overall quality of life (Wilson and Cleary, 1995; Ferrans et al., 2005). The model 
conceptualised health as a linear progression across the five concepts on a continuum of 
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increasing biological, social and psychological complexity (see figure 2). Arrows were used to 
indicate higher levels of complexity from the cells to individual person and the society. The 
authors, having recognised the inadequacy of unidirectional models in explaining causality 
posited that the relationships could be bidirectional between and among the concepts 
notwithstanding the fact that there were no arrows in the model to so indicate. A longitudinal 
study of 108 patients in Norway who underwent heart surgery using structural equation 
modelling supported that bidirectional causal paths existed between general health perception 
and overall HRQL (Mathisen et al., 2007).  
1.25.2 Constructs of the Wilson and Cleary model 
The latent constructs of the Wilson and Cleary model are discussed in the following sections 
Biological and Physiological Factors 
The biological and physiological factors form the first construct of the model located at the 
initial end of the continuum. This construct focuses on the function of cells, organs and organ 
systems. They are mostly laboratory values of the diagnosed disease. Included at this level are 
health effects of characteristics that are mainly mediated by changes in cell organ or organ 
system function. In SCD, biological and physiological factors include the foetal haemoglobin 
(HbF), genotype, comorbid diseases, frequency of pain and history of blood transfusion. 
Frequency of hospitalisation and visit to emergency departments are also regarded as measure 
of the severity of the disease. 
Symptoms Status  
Symptoms status was defined in the model as “patient’s perception of an abnormal physical, 
emotional or cognitive state” (Wilson and Cleary, 1995 p ref). The assessment of symptoms 
moves from the continuum of cells and organs to the whole person to identify the underlying 
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factors behind deviation from normal functioning and the cause of the perceived imbalance. 
They suggested that symptoms can be classified into (1) physical symptoms (2) psychological 
symptoms and (3) symptoms that are not clearly physical or psychological such as emotional 
distress, fear, worry and frustration. In addition, Mechanic (1977) categorised symptoms as 
visible, severe, interfering and frequent insisting that each characteristic affects the individuals 
and their response to illness in different ways for instance, a visible symptom is apparent and 
may stimulate precautionary behaviour in the individual while symptoms that interfere with 
daily living may influence the patient to seek medical help.  
Symptom is a subjective experience conditioned by the complex interaction of biological, 
social and environmental process. The magnitude of a symptom varies in severity or its 
persistence (Mechanic, 1995; Wilson and Cleary, 1995; Ferrans et al., 2005) and recognising 
the severity of symptoms may encourage a person to seek treatment.  
The model depicted symptoms as being influenced by biological and physiological factors, 
Wilson and Cleary described this influence as complex and ambiguous because a person may 
exhibit symptoms without a clinically identifiable biological and physiological abnormality 
while it is also possible for a person to show signs of biological and physiological changes 
without experiencing symptoms. Pain acute and chronic is the major symptom in SCD (Anie, 
Steptoe and Bevan, 2002). Pain has been responsible for frequency and length of hospitalisation 
as well as visit to emergency departments (Yusuf et al., 2010) and is a source of depression for 
patients (Levenson et al., 2008; Anie et al., 2012; Ola, 2016). 
Functional Status 
Functional status occupies the next level of the continuum being influenced by symptoms 
status. Functional status, according to Wilson and Cleary, is the ability of the individual to 
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perform specific tasks and adjust to their environment, a concept that is measurable, 
subjectively or objectively, over a given time (e.g. ability to walk upstairs or walk a distance). 
The variable is assessed by four domains which include physical functioning, social 
functioning, emotional functioning and role functioning. These are recommended as the 
minimum areas that can be evaluated (Ware, 1997; Cleary et al, 1991). Other factors that may 
influence functional status include the individual’s personal and social environment such as 
perceived self-efficacy, family relationship, and access to health care and medical treatment. 
Physical activity in people with sickle cell disease has been a subject of research showing that 
SCD patients are severely limited in their functioning due to the presence of the disease (Ohaeri 
et al., 1995; Anie, Steptoe and Bevan, 2002; Adegoke and Kuteyi, 2012). This includes their 
inability to get employment or keep employment as a result of frequent sickness absence. 
General health perceptions 
General health perception refers to a subjective self-rating of one’s overall general health. Two 
components are seen here: subjective ratings and health components. While general health 
perceptions assess symptoms and abilities, they also consider satisfaction.  
The ways in which people rate their health are subject to many factors which include 
physiological processes, symptoms and functional ability that have been found to be consistent 
predictor of general health perceptions (Bjohner, 1996). To assess general health perceptions, 
question asking people to rate their health based on a Likert scale rating from poor to excellent 
has been recommended as a measure of general health perceptions (Ware Jr and Sherbourne, 
1992; Ferrans et al., 2005). In extant literature, self-rated health has been shown to be a more 
powerful predictor of mortality and morbidity than many objective measures of health 
(Dominick et al., 2002; Eton et al., 2003; DeSalvo et al., 2006; Gotay et al., 2008; Chase et 
al., 2012; Sloan et al., 2012; Cella and Stone, 2015). The single health transition question and 
88 
 
the General Health domians of SF-36 were used in this study to measure general health 
perception. 
Overall Quality of Life 
Overall quality of life stands at the end of the model. The concept refers to how happy or 
satisfied a person is with their life as a whole. Overall quality of life should be related to HRQL 
but is influenced by other salient characteristics and experience (Wilson and Cleary, 1995). 
Changing circumstances can also reflect in the way people perceive things in the light of current 
values, preferences, expectations and aspirations. Hence, general measures of life satisfaction 
or happiness or overall quality of life do not always relate to objective life situation in the 
expected manner (Diener, 1984). For example, lower functioning may not necessarily relate to 
lower levels of satisfaction; a disease condition or impairment which poses a burden to one 
individual may not necessarily be to another, and the level of satisfaction six months ago might 
be lower compared to the present, not necessarily because disease condition has improved but 
because outlooks and expectations have been adapted (Patrick and Erickson, 1993; Wilson and 
Cleary, 1995). 
Individual Characteristics and Environmental Characteristics 
Wilson and Cleary hypothesised that patients’ responses to clinical conditions and the way they 
value their HRQL may be limited to factors such as biophysical attributes or medical treatments 
but can also be extended to the way they interact with individual and environmental factors. 
These are referred to as characteristics of the individual and characteristics of the environment 
often measured with sociodemographic variables. Sousa et al. (1999) viewed characteristics of 
the individual as referring to specific traits or qualities that identify human beings and the 
characteristics of the environment as external conditions that influence or are influenced by 
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human beings. Wilson and Cleary have stated that these characteristics influence the 
symptoms, functional status, general health perceptions and overall quality of life.  
The interaction of the individual with the environment can affect their biological functions. For 
example, a habit of long-term exposure to smoking might affect the human-gene environment 
of the individual who might then develop lung cancer or chronic obstructive lung disease 
(Ferrans et al., 2005). Socioeconomic status has been regarded as an environmental factor with 
a potential to influence HRQL in patients with chronic disease. Studies have shown that 
parental income level and education affect the HRQL of children and adolescents with SCD: 
worse socioeconomic status (lower parental education, low family income) is associated with 
worse HRQL (Palermo, Riley and Mitchell, 2008; Hijmans et al., 2010; Amr, Amin and Al-
Omair, 2011). A study has reported that SCD in adults predisposes the patient to poor 
socioeconomic status (Jenerette, 2008; Santos and Gomes Neto, 2013).  
1.26 Health-related quality of life in sickle cell disease (SCD) 
There has been a growing interest in the study of SCD (W H O, 2006) and more importantly in 
the study of HRQL in SCD (Barakat et al., 2008; Dampier et al., 2010; Panepinto and Bonner, 
2012; Ahmed et al., 2016; McClish et al., 2016). In the last three decades, health outcomes 
research on chronic illness has witnessed a growing concern with patients’ evaluations of the 
effectiveness of care and treatment using quality of life (QOL) as an important indicator 
(Garratt et al., 1993; Galloway et al., 2006).  
SCD in the last four decades has evolved from a life-threatening disease of children to a chronic 
disease of adults (Chaturvedi and DeBaun, 2016). Medical interventions and some public 
health practices has enabled most people with SCD to live into the fifth decade (Platt et al., 
1994; Grosse et al., 2009; Lanzkron, Carroll and Haywood Jr, 2013). This has shifted the 
priorities from survival to long-term quality of life concerns (DeBaun, 2014). 
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Acute pain episodes in SCD which often result in frequent hospitalisation and other 
complications have impact on the quality of life of the patients (Anie and Green, 2000; Ellison 
and Shaw, 2007; Smith et al., 2008; Anie et al., 2012). Studies have shown that the quality of 
life of SCD patients are significantly impaired (Palermo et al., 2002; Asnani et al., 2008; Amr, 
Amin and Al-Omair, 2011; Dampier et al., 2011; McClish et al., 2016). Studies have therefore 
advocated the inclusion of QOL assessment as outcome measures in the management of the 
disease to better understand the burden that patients experience (Anie, Steptoe and Bevan, 
2002; Palermo, Riley and Mitchell, 2008; Panepinto, 2012).   
1.27 Impact of SCD on HRQL  
It is worthy of note that there has been significant volume of studies on the quality of life in 
people with sickle cell disease to investigate the impact of the disease on the quality of life of 
the patients (Brown, Armstrong and Eckman, 1993; Anie, Steptoe and Bevan, 2002; Dampier 
et al., 2010, 2011; Sogutlu et al., 2011; Coleman et al., 2016; McClish et al., 2016). Such 
studies have taken place mostly in high-income countries and expectedly reflected the 
characteristics and cultural norms of the society where they took place. However, the findings 
may not always be applicable to other countries (Caird, Camic and Thomas, 2011) especially 
the low-income countries of Africa where access to healthcare facilities and affordable 
healthcare is poor.  
To examine the impact of SCD on HRQL of patients and the determinants of HRQL in people 
with SCD, a systematic review of literature was conducted. This is presented in Chapter Two. 
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CHAPTER TWO 
A SYSTEMATIC REVIEW OF PREDICTORS OF HEALTH-RELATED QUALITY OF 
LIFE IN PEOPLE WITH SICKLE CELL DISEASE 
 
2.0 Introduction 
The aim of this chapter is to systematically review and synthesise studies that explored HRQL 
in people with SCD to identify the determinants of HRQL in SCD. 
A search of literature was carried out using the Discover database of the University of 
Sunderland. The procedure and result are presented below.  
2.1 Methods.  
The review follows the format of the Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) statement (Moher, Liberati, Tetzlaff and Altman, 2009). The 
electronic databases searched included Science Direct, MEDLINE, CINAHL and 
PsyARTICLES. Search terms combined keywords such as health-related quality of life OR 
HRQL OR HRQOL OR quality of life OR QOL OR health status OR patient-reported outcome 
OR Well-being) AND (Sickle cell anaemia OR sickle cell disease OR haemoglobinopathies 
OR HbSS OR HbSC OR SCD OR SCA OR sickle cell disorder) AND (predictors OR factors 
OR determinants). The findings are presented in Table 2.1 and Table 2.2. 
The inclusion criteria were: 
Articles published in English language. 
 Articles that focused on SCD. 
 HRQL measured with a validated instrument. 
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 Any reported variable associated with HRQL. 
Articles published between on the subject up to December 2016. 
Peer-reviewed articles with full-text accessible online or from the author. 
The exclusion criteria were: 
Articles that did not measure HRQL as outcome variable 
Articles that focused on instruments for measure  
Studies which were not written in English 
Search result.  
The initial search yielded a total of 13,414 articles. A filter ‘quality of life’ reduced the articles 
to 91. These were further screened on titles and abstracts. Duplicates and articles that did not 
meet the inclusion criteria were removed leaving 24 (14 paediatrics and 10 adults 18 years and 
older) articles for review. Additional articles (two paediatrics and one adults) were added 
through searching of reference lists (See Figure 2-1).  
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Figure 2-1: Flow Chart of Study Selection Pprocedure 
 
2.2 Characteristics of studies reviewed  
The articles originate from USA (16), UK (2), Jamaica (2), Saudi Arabia (2), Brazil (2) and 
one each from India, Netherlands and Nigeria. The mean ages of participants range from 
8.97±5.28 to 16.9±1.7 for children and adolescents and 25.7±1.4 to 36.4±12.67 for adults. 
Three of the studies focused specifically on adolescents while 13 combined children and 
adolescents together. Three of the studies were longitudinal, one a prospective study, 
seventeen cross-sectional, four case-control studies and one each of randomised double 
blind and qualitative studies. The percentage of participants with HbSS phenotype was 
Total hits (13,414) 
Science Direct (9562) 
CINAHL (3446) 
PsycARTICLES (232) 
MEDLINE (50) 
Not QoL OR SCD (13,323) 
Not relevant (53) 
Selected for further review for 
inclusion in study (38) 
Instruments (5) 
Duplicates (5)  
Outcome Not HRQL(4) 
 
 
Studies included in 
the review (27) 
References, related 
studies (3) 
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above 70% in most of the studies, showing that the HbSS genotype was predominant in the 
study population.  
2.3 HRQL in people with SCD 
The Tables (2.2 and 2.3) show that the HRQL was affected in the patients with SCD when 
compared with the healthy peer or healthy siblings and have impaired HRQL which were 
either similar or worse when compared with other chronic diseases. SCD in children and 
adolescents was associated with limitations in most aspects of HRQL (Menezes et al., 
2013). In addition, SCD in adults had negative effects on the biological and social 
functioning which got worse with increase in age (Caird, Camic and Thomas, 2011) and 
predisposed to high stress level and negative emotions (Thomas and Lipps, 2011).  
Comparison with a healthy group.  
Children and adolescents with SCD showed more limitations in physical, social and 
psychological functioning with significant impairment in 13 of the 14 health dimensions 
of the CHQ-PF50 subscales (Palermo et al., 2002) and five domains of the HRQL measure 
(Hijmans et al., 2010). Dale et al. (2011) reported that 53% and 63% of children and 
adolescents with SCD were ‘at risk’ for impaired overall HRQL and physical HRQL 
respectively. In adults, the HRQL was poor in all subscales of SF-36 (Anie, Steptoe and 
Bevan, 2002), their average quality of life scores were lower at 83.6 compared to the scores 
of the healthy population at 90 (Mann‐Jiles and Morris, 2009). 
Socio-demographic profiles (education and income) of parents of adolescents with SCD 
were lower, while educational delay (excessive failing and school retention) and 
absenteeism were common among adolescents with SCD (Amr, Amin and Al-Omair, 
2011). The disease in adults predisposed the patients to poor socioeconomic status 
(Jenerette, 2008), low sociodemographic profile such as low income and impaired access 
to healthcare services (Santos and Gomes Neto, 2013). Children and adolescents with SCD 
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were also reported to have poorer behaviour, worse mental health, and lower self-esteem 
and significantly poorer academic performance (Palermo et al., 2002; Sehlo and Kamfar, 
2015). 
Comparison with other chronic diseases. 
 The quality of life of people with SCD were compared with published HRQL scores of 
other chronic diseases.  
When compared with HRQL scores of people with juvenile rheumatoid arthritis (JRA) 
group, children and adolescents with SCD had similar physical health summary scores of 
HRQL but worse psychosocial health summary scores of HRQL also, when compared with 
peer group with epilepsy, children with SCD showed comparable psychosocial health 
summary score but worse physical HRQL score (Palermo et al., 2002). Furthermore, when 
compared with other non-communicable chronic disease children and adolescents with 
SCD reported worse impaired overall HRQL (Bhagat et al., 2014). Moreover, the literacy, 
socio-economic status and duration of disease, were comparable to those of congenital 
heart disease, nephrotic syndrome and diabetes while seeking for medical attention was 
higher in SCD patients (Bhagat et al., 2014).  
In adults with SCD, the HRQL was similar or worse than adults with other chronic diseases 
such as arthritis (Ballas et al., 2006) and comparable to the rheumatic disease group (Mann‐
Jiles and Morris, 2009). Adults with SCD also reported reduced HRQL in all domains 
except mental health when compared with adults with cystic fibrosis (Santos and Gomes 
Neto, 2013) and their overall quality of life was significantly lower than non-SCD patients 
(Thomas and Lipps, 2011).  
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Comparison with published normative data.  
Both children with SCD and their parents’ ratings of HRQL were significantly lower (Dale 
et al., 2011). The level of depression and depressive symptoms (32%) was higher in adults 
with SCD compared with 9.5% in the general population (Jenerette, Funk and Murdaugh, 
2005).  
Comparison with healthy siblings. 
 Children with SCD had lower HRQL scores on physical wellbeing (Hijmans et al., 2010). 
SCD also had negative effect on caregivers who were more impacted emotionally, in 
personal time and family activities (Palermo et al., 2002). 
Gender comparisons.  
Irrespective of age, studies have shown that females with SCD had worse HRQL than 
males with SCD and higher level of depression in adult females than the male counterpart 
(Jenerette, Funk and Murdaugh, 2005). One of the causes of depressions in females may 
be attributed to inability to marry or raise children as a result of the illness. For example, 
in a qualitative study of older adults with SCD aged 48 years and older, Jenerette and 
Sandewlsky (2011) reported a participant describing her life as ‘half-full’ for lack of 
children and husband. Adult females with SCD also reported higher frequency of somatic 
symptoms burden that the males (Sogutlu et al., 2011).  
The low quality of life associated with people with SCD therefore deserves that efforts be 
intensified and directed towards improving their quality of life. This requires investigating 
the factors that affect the HRQL to understand the impact of clinical and psychosocial 
factors (DeBaun, 2014).  
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2.4 Predictors of Health-Related Quality of Life in Children and Adolescents with 
SCD. 
The review identified ten main determinants (along with their markers) of HRQL in 
children and adolescents with SCD (Table 2-1). They were disease severity/complications 
(7 studies), comorbidities (2 studies) hospitalisation (4 studies), frequency of pain 
(3studies), depression/anxiety (3 studies), stigma (1 study), parental support (1 study), 
treatment adherence/barriers to treatment adherence (2 studies), child demographics (5 
studies) and socioeconomic status of parents (5 studies). 
Disease severity/complications.  
Disease severity/complications was found to be a predictor of overall HRQL (Palermo et 
al., 2002; Palermo, Riley and Mitchell, 2008; Panepinto et al., 2008; Amr, Amin and Al-
Omair, 2011; Fisak et al., 2011; Adeyemo et al., 2015; Sehlo and Kamfar, 2015), 
psychosocial HRQL domains (Palermo, Riley and Mitchell, 2008) and total number of 
disease-related complications correlated with worse physical health (r=-0.91) (Palermo et 
al., 2002) while the presence of SCD predicted 4 times higher odds of having worse HRQL 
(Panepinto, Hoffmann and Pajewski, 2009). In addition, disease complications had been 
found to predict the physical functioning, physical role limitation, emotional role 
limitation, emotional well-being and general health of the SF-36 HRQL subscales (Amr, 
Amin and Al-Omair, 2011) and influenced 7 out of the 8 subscales of the SF-36 measure 
of HRQL except the mental/emotional well-being subscale (Adeyemo et al., 2015). Disease 
severity also combined with social support and depression to affect HRQL of the study 
population (Sehlo and Kamfar, 2015).  
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Comorbidities.  
Medical co-morbidity and neurobehavioral co-morbidity were both associated with worse 
HRQL (Panepinto et al., 2008) while behavioural comorbidity predicted physical health of 
the HRQL (Wrotniak et al., 2014). 
Hospitalisation.  
The frequency of hospitalisation predicted lower overall HRQL (Amr, Amin and Al-
Omair, 2011; Dale et al., 2011), physical health summary and mental health of the HRQL 
(Wrotniak et al., 2014) along with school functioning scores and the psychosocial domain 
(Dale et al., 2011). The frequency of hospitalisation had also predicted worse HRQL in the 
patients in all the 8 domains of SF-36 HRQL subscales (Adeyemo et al., 2015). While 
increased emergency department visits was associated with higher scores on the emotional 
role dimension of the HRQL subscales (Dale et al., 2011). 
Pain episodes 
Pain has been described as the hallmark of SCD, in the review, frequency of pain predicted 
change in HRQL (Schlenz et al., 2012), physical functioning and self-esteem (Barakat et 
al., 2008), and low HRQL in the patients (Menezes et al., 2013). 
Depression  
The review had discovered that depression had been a determinant of the psychosocial 
HRQL domain (Palermo, Riley and Mitchell, 2008) and was associated with poor quality 
of life (Sehlo and Kamfar, 2015). Mediator variables consisting of internalizing symptoms 
and disease-related parenting stress also correlate with HRQL domains, depression 
predicted self-esteem while anxiety predicts physical functioning (Barakat et al., 2008).  
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Stigma  
Health-related stigma was characterised by discrediting of individuals and populations due 
to a health condition, this normally results in adverse effects on health (Weiss, 
Ramakrishna and Somma, 2006). Stigma was associated with worse HRQL in all domains 
of the SF-36 HRQL measure (Adeyemo et al., 2015). 
Parental support  
A high level of parental support significantly reduced depression in children and adults 
with SCD and predicted better HRQL in them (Sehlo and Kamfar, 2015). 
Treatment adherence/barriers to treatment adherence  
Treatment adherence had unexpectedly predicted poor HRQL in the study population 
(Barakat et al., 2005) while barriers to treatment adherence (e.g. transportation problems, 
financial problems, access to medication) predicted HRQL (Fisak et al., 2011). Normally, 
treatment adherence was expected to predict better HRQL, the unexpected negative 
association that Barkat and colleagues reported might be due to measures of adherence 
used which they agreed were neither standard nor objective as mentioned in the limitations 
of their study.  
Child /adult demographics 
Age had inversely predicted overall HRQL in the patients (Palermo et al., 2002; Panepinto 
et al., 2008; Amr, Amin and Al-Omair, 2011; Adeyemo et al., 2015), and worse 
psychological HRQL (Panepinto et al., 2008). Furthermore, all domains of HRQL on the 
SF-36 were negatively associated with increasing age of the patients (Amr, Amin and Al-
Omair, 2011). Female gender had also been associated with worse overall HRQL and 
general health, physical role functioning and body pain domains of HRQL (Palermo et al., 
2002; Amr, Amin and Al-Omair, 2011; Wrotniak et al., 2014). Moreover, lower BMI had 
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been associated with higher scores on the body pain subscale of HRQL (Wrotniak et al., 
2014). The association of age had shown that the HRQL was worse with increasing age 
apparently also because older patients had additional complications associated with the 
disease (Dampier et al., 2011). Females were also found to have poorer HRQL than their 
male peers. 
Socio- economic status  
Individual/family socioeconomic status were found to be determinants of functional 
disability, lower physical and psychosocial HRQL in the study population (Palermo, Riley 
and Mitchell, 2008). Higher parental education had predicted better physical HRQL 
(Palermo, Riley and Mitchell, 2008; Amr, Amin and Al-Omair, 2011). Also, 
neighbourhood socioeconomic distress had predicted physical HRQL and low family 
income predisposed the patients to 2.88 times higher odds of worse HRQL (Palermo, Riley 
and Mitchell, 2008), while low socio-economic status of the patient population had 
associated with low HRQL (Hijmans et al., 2010). Moreover, rural residence was a 
negative predictor of vitality and pain of the HRQL subscales (Amr, Amin and Al-Omair, 
2011). 
Understanding these determinants, their interrelationships with one another and with 
HRQL is important to design therapy and disease management strategies to improve the 
quality of life. For example, the non-modifiable factors such as age and gender may be 
addressed in the management of the disease by considering age-stratified and gender-
sensitive approach that will enhance quality of life. 
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 Table 2-1: HRQL of SCD in Children and Adolescents 
Authors 
Year 
Country 
Design Sample size 
 
Mean age 
with SD 
 
Main focus 
Investigated 
Determinants 
Predictors/ 
Correlates 
 
Outcomes 
Association/ 
Predictors 
SCD Non-
SCD 
Adeyemo 
et al., 2015 
Nigeria 
Cross 
sectional 
80 80 16.0±1.5 
 
16.6±1.4 
To identify 
sociodemographic 
and clinical factors 
impacting on HRQL 
of adolescents with 
SCD and effects of 
SCD-related stigma 
on quality of life 
Child 
demographics, 
Stigma 
Disease 
complications, 
hospitalisation, 
education status, 
age 
Adolescents with SCD 
have significantly 
impaired HRQL in all 
the subscales of the SF-
36 compared with 
healthy group 
Disease 
complications, 
hospitalisation and 
stigma were 
predictors of HRQL 
in adolescents with 
SCD 
Amr et al., 
2011 
Saudi 
Arabia 
Cross 
sectional 
180 202 16.8±3.6 
 
16.9±1.7 
 
 
To assess the 
impairment of the 
different domains of 
HRQL among 
adolescents with SCD 
compared to healthy 
peers. 
Socio-
demographic 
factors, disease-
related factors, 
family income 
Rural residence, 
Female gender, 
Family income, 
Disease-related 
complications 
Domains of HRQL 
were significantly 
deteriorated in 
adolescents with SCD 
compared to their 
peers. Increasing age 
was negatively 
associated with HRQL 
Rural residence was a 
negative predictor of 
vitality subscales and 
pain subscales 
HRQL. Low family 
income was 
hypothesized to be a 
risk factor for lower 
HRQL. 
Barakat et 
al., 2005 
USA 
Cross 
sectional 
21 43  10.5±4.55. To investigate the 
association of 
treatment adherence 
with QOL in children 
with SCD 
Treatment 
adherence 
Disease 
complications 
Treatment 
adherence 
Treatment adherence 
was found to be, 
unexpectedly, 
associated with poorer 
quality of life in the 
children. 
Treatment adherence 
significantly 
correlated with the 
child self-rated and 
parent-rated QOL. 
Barakat et 
al., 2008 
USA 
Cross 
sectional 
42 42 15±1.82 
 
44.1±10.19 
(caregiver) 
To examine 
association between 
pain, psychological 
adjustment and 
family functioning 
with HRQL 
Pain frequency, 
anxiety, 
depression, 
family 
functioning 
difficulty 
Anxiety, pain, 
depression, 
disease-related 
parenting stress. 
A complex association 
of pain with HRQL 
was observed along 
with the existence of 
potentially modifiable 
concomitant variables. 
Existence of 
potentially 
modifiable 
concomitant variables 
(anxiety, depression, 
disease-related 
parenting stress) that 
when addressed, 
could improve HRQL 
Bhagat et 
al., 2014 
India 
Case – 
Control 
105 
 
 
105 11.78±2.67 
 
10.98±4.23 
To determine 
HQROL in SCD 
patients and compare 
emotional 
problems 
chronic fatigue 
n/s Compared with the 
matched control 
patients with chronic 
Emotional problems 
may be related to 
chronic fatigue and 
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same with those of 
other chronic non-
communicable 
diseases 
small physical 
size  
illness, the overall 
HRQL of patients with 
SCD was found to be 
significantly lower 
small physical size in 
SCD patients 
 
Bhatia et 
al., 2015 
USA 
Mixed 
Longitud
inal  
17 
 
23  8.97±5.28 To physical, 
psychological and 
social functioning in 
SCD subjects before 
and after Allogeneic 
Hematopoietic Stem 
Cell Transplantation 
(allo-HCT) 
Effect of 
treatment with 
allo-HCT 
Treatment with 
allo-HCT 
Self-reported overall 
baseline HRQL was 
found to be lower, 
falling below published 
at risk cut off scores for 
chronically ill children. 
Also, parent-proxy 
report showed that the 
overall HRQL was 
lower than the 
population mean for 
chronically ill children. 
Overall HRQL score 
was found to 
significantly increase 
at 1 year of allo-
HCT. This was also 
observed for the 
physical, 
psychosocial and 
emotional domain 
except for the social 
domain where the 
increase was not 
significant. 
Dale et al., 
2009 
USA 
  124 
 
 
143 
 
 
13+3.3 To assess HRQL in in 
children and 
adolescents with SCD 
compared with 
healthy children and 
adolescents 
Hospitalization, 
Emergency 
visits 
No of 
hospitalisations, 
ED visits 
53% and 63% 
respectively of the 
children and 
adolescents with SCD 
were classified as “at 
risk” for impaired 
overall and physical 
HRQL and they were 
found to have lower 
overall HRQL and all 
the subdomains except 
emotional functioning 
compared with their 
healthy counterpart. 
There was a 
significant difference 
between parent and 
child rating of their 
overall HRQL. A 
weak inverse 
relationship was 
observed between 
number of 
hospitalisations, ED 
visits and overall 
HRQL. Increased 
hospitalisation 
correlated with lower 
HRQL 
Fisak et 
al., 2011 
USA 
Cross 
sectional 
78 
 
n/a 11.4±3.9 To evaluate factors 
associated with 
HRQL in a paediatric 
SCD sample 
Barriers to 
treatment 
adherence 
Disease type, 
Frequency of pain 
and Barriers to 
treatment 
adherence 
Pain episodes and 
barriers to treatment 
adherence were found 
to be robust predictors 
of HRQL in the 
paediatric SCD sample 
Barriers to treatment 
adherence was a 
mediating factor 
between HRQL and 
treatment adherence 
Hijmans et 
al., 2010, 
Case 
Control 
40 36 11.7±3.1 
 
11.6±3.4 
To examine whether 
reduced HRQL in 
children with SCD is 
Parents SES SES Children with SCD had 
significantly lower 
HRQL compared to 
Low HRQL was 
related to low SES of 
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Netherland
s 
 
 
 
related to 
consequences of the 
disease or to the low 
SES of most patients. 
their healthy siblings 
only on physical well-
being domain but 
scored significantly 
lower in 5 domains 
compared to the 
normative population. 
the patient 
population. 
 
 
Menezes, 
2012 
Brazil 
Cross 
sectional 
100  
 
50 n/s To assess the quality 
of life in children and 
adolescents with SCD 
and those of their 
relatives 
Pain, care 
overload 
Pain, Care 
overload 
SCD was found to be 
associated with 
limitations in HRQL 
particularly the 
physical, social, 
emotional and school 
domains. The HRQL of 
parents were also 
impaired compared 
with healthy children 
and their parents. 
Low HRQL was 
associated with pains 
in the patients and 
possibly due to 
overload of care in 
their parents. 
Palermo et 
al., 2002 
USA 
Case-
control 
58 
 
 
 
120 10.97±3.4 To provide 
information on 
HRQL and parental 
burden of children 
with SCD and 
describe relationships 
between demographic 
and disease related 
factors and children 
HRQL 
Demographic 
factors,  
Disease related 
factors  
Disease 
complications, 
age, female 
gender 
Caregivers of children 
with SCD were 
reported to be 
significantly more 
impacted by the child’s 
health emotionally, 
personal time and 
family activities than 
those of healthy 
children. They also 
reported that children 
with SCD 
demonstrated more 
limitations across the 
physical, psychological 
and social functioning 
domains of the HRQL 
compared to their 
healthy counterpart. 
Disease 
complications were 
important predictors 
of children’s physical 
health after 
controlling for socio-
demographics factors. 
Palermo et 
al., 2008 
USA 
Cross 
sectional 
56 n/a 12±2.5 
 
To investigate if 
individual distress 
and residence in 
neighbourhood of 
Depression, 
diseases 
severity, 
individual/ 
Depression, 
diseases severity, 
individual/family 
SES and parent 
Greater depression was 
associated with greater 
pain and disability 
while higher family 
Depression, diseases 
severity, 
individual/family 
SES and parent 
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economic distress 
would predict 
children level of 
pain-related 
functional disability 
and health-related 
quality of life 
. 
family SES  
parent education 
education, 
neighbourhood 
income was associated 
with low child-reported 
disability and higher 
physical HRQL 
education were found 
to predict 
psychosocial HRQL 
while living in a 
distressed 
neighbourhood, 
parental education 
predicted physical 
HRQL. 
Panepinto 
et al., 
2009, USA 
Cross 
sectional 
104 
 
 
74 
 
 
Range:  
2-18 
To determine the 
impact of family 
income and SCD on 
HROL 
Family income 
Disease 
severity, 
comorbidities 
 Children with SCD 
reported worse HRQL 
than children without 
SCD. Moreover, 
children with SCD had 
a 4.0 (parent-report) 
and 3.33 child report) 
times higher odds of 
having worse overall 
HRQL than their 
healthy counterpart 
Low family income 
indicated worse 
HRQL (OR=2.88) 
while disease severity 
indicated worse 
HRQL (OR=4.0). 
Severity of disease 
significantly 
predicted physical 
HRQL. Older 
children having 
medical or 
neurobehavioral 
comorbidities were 
associated with lower 
psychosocial HRQL 
Schlenz et 
al., 2012 
USA 
Prospecti
ve  
90 n/a 11.04±4.34   Frequency of 
pain episodes 
Pain episode 
frequency 
between Time1 
and Time2 
Caregiver proxy 
reports were found to 
be responsive to pain-
related changes in 
HRQL 
Pain episode 
frequency between 
Time1 and Time2 
were predictors of 
changes in physical, 
psychosocial and 
overall HRQL. 
Sehlo & 
Kamfar  
2015 
Saudi 
Arabia 
Cross 
sectional 
study 
(case 
control) 
60 60 11.93±1.72 
 
11.77±1.96 
 Social support, 
Disease 
severity, 
Depression 
 
Parent support, 
Depression, 
Disease severity 
Higher level of parent 
support was associated 
with lower depressive 
state and better ratings 
of quality of life. 
Higher level of parent 
support predicted 
better quality of life 
while higher 
depression and 
increased disease 
severity were 
predictors of lower 
quality of life. 
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Wrotniak 
et al., 2012 
USA 
Longitud
inal, 
randomis
ed, 
controlle
d trial 
47 
 
66 8.6±2.4  Hospitalisation, 
comorbidity, 
age, gender, 
haematocrit 
status 
Hospitalisation, 
Behavioural 
comorbidity, 
female gender 
Children with SCD had 
lower HRQL, 
compared to their 
healthy counterpart in 
general health, overall 
physical health and 
parental emotional 
stress but higher mental 
health 
Predictors of lower 
HRQL scores were: 
• Hospitalisation: a 
predictor of 
physical health, 
mental health. 
• Behavioural 
comorbidity: a 
predictor of 
psychosocial 
health, mental 
health, general 
health and 
associated with 
parental emotional 
stress, role 
functioning and 
parental time. 
Gender predicted 
general health 
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Table 2-2: HRQL in Adults with SCD 
Author, Year 
and / Country 
Designs Main focus Setting Hypothesised 
Predictor 
variables 
Findings Significant Predictors 
Adegbola, 
2011, USA 
Correlation
al 
To explore the 
relationships among 
spirituality, self-efficacy 
and Quality of life. 
SCD Association, 
mail-out surveys 
Spirituality and 
self-efficacy 
Correlations were found 
among Spirituality and self-
efficacy and quality of life.  
Self-efficacy accounted for 
34% and spirituality 6.6% 
 
Self-efficacy (+ve) 
Spirituality (+ve) 
 
Anie et al., 
2002, UK 
Cross-
sectional 
Compare pattern of pain, 
health service use and 
psychological coping with 
observed USA pattern 
Assess the HRQL of adults 
with SCD 
Sickle Cell clinic (2 
main hospitals) 
Demographic 
variables 
Disease severity 
markers 
Health service 
utilisation, pain, 
coping 
Poorer HRQL on all 
subscales of SF-s6 compared 
to the general population 
Clinical and demographic 
variables associated 
significantly with physical 
function 
Pain associated with 
physical function, social 
function, role 
limitation(phy) and general 
health 
Demographic 
Clinical (number of 
complications, 
haemoglobin 
concentration) 
Pain 
Affective coping 
Ballas et al. 
2006, USA 
Randomise
d double 
blind 
To examine the clinical 
benefits of treatment with 
hydroxyurea on HRQL as 
well as the effct of other 
factors like Hb-F level 
mean. 
Multicentre Study 
of Hydroxyurea in 
Sickle Cell 
Anaemia 
Hydroxyurea Quality of life in adults with 
SCD was similar or worse 
than patients with other 
chronic diseases such as 
arthritis. Those who 
responded to hydroxyurea 
therapy had improvement in 
social function, pain recall 
and general health 
perception and were far 
better that the placebo group 
or non-responders. 
increase in HbF level 
reduced frequency of painful 
episodes and improved 
certain measures of HRQL 
Baseline body pain 
Hydorxyurea 
HbF 
Caird et al. 
2011, UK 
qualitative To assess lived 
experiences of SCD 
Sickle cell society 
meetings 
Coping, building 
resilience,  
SCD in adults has negative 
effect on biological, 
Age 
Physical suffering 
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patients above 30 years 
and develop a conceptual 
framework to understand 
the impact of 
biopsychosocial 
functioning on this  
psychological and social 
functioning. 
The effects get worse with 
age 
Social support (+ve) 
Loss of control 
Emotional suffering 
Spirituality (+ve) 
Gibson et al, 
2013, Jamaica 
Cross 
sectional 
To explore the interplay of 
locus of control on 
depression and quality of 
life in SCD adult patients. 
Outpatient clinic Demographic, 
diseases-related, 
locus of control 
(LOC) 
A strong association 
between locus of control and 
both depression and quality 
of life. 
High level of external LOC 
found in adults with SCD 
Internal locus of 
control (LOC) ((+ve)) 
Jenerette C.M 
2008, USA 
Cross-
sectional 
To examine relationships 
among types of social 
support and HRQL in 
adults with SCD 
2 South-Eastern 
SCD clinics 
Social support: 
Affectionate, 
emotional, 
positive 
interaction, 
tangible 
 
SCD in adults predisposes 
them to poor socio-
economic status. 
 Overall social support and 
all its four subscales were 
associated with each time 
point of HRQL and overall 
HRQL  
 
Affectionate social 
support 
Tangible social support 
Jenerette et al., 
2005, USA 
Cross-
sectional 
To describe depressive 
symptoms among adults 
with SCD 
2 South-Eastern 
SCD clinics 
Depression Higher levels of depression 
and depressive symptoms 
(32%) compared to the 
general population (9.5%). 
Females reported higher 
level of depression than 
males 
Significant correlation 
between depressive 
symptoms and frequency of 
SCD crisis 
Physical and emotional 
complications (-ve) 
Mann-Jiles & 
Morris, 2009, 
USA 
Cross-
sectional 
To examine QOL in adult 
patients with sickle cell 
anaemia 
Outpatient clinic Disease type 
Gender 
differences 
Average QOLS scores of 
participants (83.6) were 
found to be lower than those 
of healthy population (90) 
and comparable to other 
rheumatic disease group. No 
significant difference in 
gender HRQL but in 
spirituality 
No significant 
relationships were 
found. Spirituality was 
however suggested to 
be a potential factor in 
coping 
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Santos and 
Neto, 2013, 
Brazil 
Cross 
sectional 
To describe the 
sociodemographic profile 
and the impact of the 
disease on the quality of 
life of SCD patients 
Association of 
sickle cell anaemia 
patients, Bahia 
Sociodemographi
c variables 
Adults with SCD have 
reduced quality of life in all 
domains except mental 
health when compared with 
cystic fibrosis patients. 
Sociodemographic profiles 
eg low income and impaired 
access to healthcare services 
 
Sogutlu et al. 
2011, USA  
Longitudin
al  
To examine the impact of 
somatic symptoms burden 
on pain. Depression, 
anxiety, healthcare 
utilization and quality of 
life  
Pain ins Sickle Cell 
Epidemiology 
Study (PiSCES) 
project, Virginia 
High somatic 
symptoms burden 
Somatic symptoms burden 
negatively correlated with 
all subscales of SF-36 
High somatic symptoms 
burden were more frequent 
in women than men 
Somatic symptom 
burden (-ve) 
Thomas and 
Lipps, 2011, 
Jamaica. 
Cross-
sectional  
To examine overall life 
satisfaction and its 
components and their 
positive and negative 
affect in adults with 
homozygous sickle cell 
(HbSS)compared to 
healthy adult peers  
Sickle Cell Society, 
Greater London 
Demographics 
Socioeconomic 
status 
Positive affects 
Negative affects 
Subjective well-being is 
compromised in adults with 
HbSS as Overall life 
satisfaction was significantly 
lower in SCD patients than 
their non-sickle cell peers. 
Positive affect was also 
lower in SCD patients but 
surprisingly had similar 
negative affect score 
Work status & 
occupation 
SCD status 
overall life satisfaction 
health functioning 
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2.5. Predictors of Health-Related Quality of Life in Adult with SCD 
In adults with SCD, some of the determinants of HRQL in children and adolescent with 
SCD were present and more that are peculiar to adulthood. Some of these included 
spirituality, self-efficacy, clinical and demographic variables, and social support. Table 
2.4 shows the summary of included studies on determinants of HRQL in adults with SCD. 
In a cross-sectional study of 96 adults with SCD in UK, Anie et al. (2002) discovered that 
number of complications, haemoglobin concentrations and pain had effect on the HRQL 
of participants. They stated that the physical functioning, social functioning, physical role 
limitations and general health were impaired due to pain episodes in the patients. Caird 
et al. (2011) supported this in a qualitative study of 15 adults with SCD in UK and 
reported that biological, psychological and social functioning of adults with SCD are 
impaired. In addition, Ballas et al. (2006) revealed that increase in foetal haemoglobin 
(HbF) level reduced frequency of pain episodes and improved HRQL. These studies 
showed that clinical variables have effects on the HRQL of adults with SCD. 
Adegbola (2011), in a study of 90 adults with SCD in the USA revealed that spirituality 
and self-efficacy associated with better HRQL. Caird et al. (2011) also reported that 
spirituality predicted better HRQL. Though Man-Jilles and Morris (2009) did not find 
significant relationship between spirituality and HRQL, they however suggested that 
spirituality could be a potential factor in coping with the disease which was in line with 
the findings of Adegbola. 
Sogutlu et al. (2011) using the data on the Pain in Sickle Cell Epidemiology (PiSCES) 
project, Virginia revealed that somatic symptom burden negatively correlated with all the 
subscales of SF-36. Also, depressive symptoms correlated positively with frequency of 
SCD crises (Jenerette, Funk and Murdaugh, 2005), and resulted in low HRQL.  
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Locus of control associated with HRQL (Caird, Camic and Thomas, 2011; Gibson et al., 
2013), additional findings also showed that social support was associated with HRQL 
(Jenerette, 2008; Caird, Camic and Thomas, 2011) reflecting the positive effect of support 
from family and friends on HRQL.  
Sociodemographic characteristics predicted HRQL in adults with SCD (Anie, Steptoe and 
Bevan, 2002; Thomas and Lipps, 2011) and HRQL worsened with increasing age (Caird, 
Camic and Thomas, 2011). Using a univariate analysis of variance, Thomas and Lipps 
discovered that the interaction of work status, occupation and SCD had significant effect 
on the subjective well-being of adults with SCD; for instance, unemployed adults with 
SCD showed less satisfaction with their health and functioning, social and economic 
situation, and psychological functioning compared with adults with SCD who were 
employed (Thomas and Lipps, 2011).  
Adults with SCD are vulnerable adults with elevated risk for negative psychological 
outcomes (Thomas and Lipps, 2011) hence their situation requires targeted intervention 
efforts to relief the patients of the burden of the disease. The opinions of care providers 
alone cannot be sufficient to evaluate patients’ outcomes, but patients themselves must 
be involved in such evaluation, in fact many researchers have argued that the patients are 
in a more vantage position to report on their experiences and to judge their satisfaction 
with the quality of their lives (Panepinto, 2012; Cella and Stone, 2015). Intervention 
efforts could also be reliably based on the information provided by patients with respect 
to the care and treatment they receive and the effects of therapy. 
This chapter has reviewed studies on the HRQL of people with SCD from which factors 
predicting HRQL have been identified. These include clinical, psychosocial and 
demographic factors. Evidence from the review showed that the predictors are 
multifaceted and significantly affect the HRQL either individualy or in combination with 
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other predictors  This gives rise to a potential need to characterise these factors to properly 
understand interrelationships and possible mediator variables as well as establish the 
relative importance of the predictors. Such efforts require employing a model of HRQL. 
A conceptual model that has been found useful in modelling HRQL in chronic disease is 
the Wilson and Cleary model (see 1.24.2).  A systematic review of the application of the 
Wilson and Cleary model in modelling predictors of HRQL is presented in Chapter Three.  
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CHAPTER THREE 
A SYSTEMATIC REVIEW OF THE APPLICATION OF WILSON AND CLEARY 
HEALTH-RELATED QUALITY OF LIFE MODEL IN CHRONIC DISEASES. 
 
3.1 Introduction 
In order to understand the application of the Wilson and Cleary conceptual model in 
practice, a systematic review of its use in determining the predictors of HRQL in chronic 
disease was conducted. This chapter reports a systematic review of literature on the 
application of Wilson and Cleary’s model in chronic diseases to examine the paths and 
pattern of relationships of the concepts as well as determine their relative importance  (See 
Ojelabi et al., 2017). Three important research questions are proposed:  
1. Does empirical evidence show the causal relationship of the dominant concepts 
as proposed in the Wilson and Cleary model?  
2. Does the Wilson and Cleary model follow a strictly linear unidirectional path? 
3. What is the relative effect of each latent factor? 
3.2 Methods 
This study followed the format of the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) statement (Moher, Liberati, Tetzlaff, Altman, et al., 2009). 
 The electronic databases searched consisted of Science Direct, MEDLINE, CINAHL and 
PsyARTICLES. The search term used was “Wilson and Cleary” (free text). Further 
related search terms such as, “Wilson and Cleary model”, “Wilson and Cleary conceptual 
model”, “(Health-related quality of life OR HRQL OR HRQOL) AND (Wilson and 
Cleary OR Wilson and Cleary model)”, were also used, but did not yield any additional 
studies. The search covered a period from 1995 (when the model was published) to 
December 2016. 
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3.2.1 Inclusion and exclusion criteria 
The inclusion criteria were as listed below: 
Inclusion criteria 
1. Chronic disease 
2. Articles published in English language 
3. HRQL measured with validated instruments 
4. Empirical study  
5. Wilson and Cleary model was used or tested 
6. Peer-reviewed articles with full-text accessible. 
Exclusion criteria 
1. Articles based on instrument development 
2. Articles that did not apply the model 
3. The disease could not be clearly defined as a chronic disease.  
3.3 Quality assessment of selected articles 
The Quality Assessment Tool for Quantitative Studies designed by the Effective Public 
Health Practice Project (EPHPP) was used to evaluate the quality of included articles 
(Effective Public Health Practice Project, 2010). The EPHPP tool was designed to assess 
quality of observational and clinical studies. The tool was used to rate each article on a 
three-point scale (strong, moderate and weak) in six components: selection bias, study 
design, confounders, blinding, data collection methods, and withdrawal and drop-outs. A 
global rating was allocated to each study. 
3.4 Results 
The initial search yielded a total of 2,018 full text peer reviewed articles (Figure 3-1). 
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Duplicates were removed and articles were screened on titles and abstracts. The full-texts 
of the selected 78 articles were screened. Of these, 59 articles were excluded: 14 because 
they were based on instrument development, 18 did not apply the model, 14 were not 
empirical studies and 11 could not be categorised as focusing on chronic disease. Five 
additional articles were added through searching of reference lists of the selected studies. 
The total number of articles reviewed was 26 (Sousa et al., 1999; Cosby et al., 2000; 
Wettergren, Björkholm, Axdorph and Langius-Eklöf, 2004; Arnold et al., 2005; Phaladze 
et al., 2005; Portillo et al., 2005; Heo et al., 2005; Hofer et al., 2005; Sousa and Kwok, 
2006; Mathisen et al., 2007; Baker, Pankhurst and Robinson, 2007; Krethong et al., 2008; 
Ulvik et al., 2008; Halvorsrud et al., 2010; Nokes et al., 2011; Wyrwich et al., 2011; Ade-
Oshifogun, 2012; Kanters et al., 2012; Schulz et al., 2012; Saengsiri. et al., 2014; Shiu et 
al., 2014; Carlson et al., 2014; Mayo et al., 2015; Santos et al., 2015a; Brunault et al., 
2015; Eilayyan et al., 2015).  
The flow chart of the included studies is displayed in Figure 3-1. 
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Figure 3-1: Flow Chart of Study Selection Procedure  
 
3.5 Characteristics of Studies Reviewed 
The 26 studies took place in 15 countries with one study based across four countries in 
Sub-Saharan Africa (Botswana, Lesotho, South Africa and Swaziland) (Table 2-5). The 
other countries were: USA (n=9), Norway (n=3), Canada (n=2), Netherlands (n=3), 
Thailand (n=2), UK (n=1), France (n=1), Austria (n=1), Sweden (n=1), Brazil (n=1) and 
Hong Kong (n=1).  
Thirteen different types of disease were studied: heart failure/surgery (n=5), HIV/AIDS 
(n=6), coronary artery disease (n=3), oral health disease (n=2), obesity (n=2), chronic 
obstructive pulmonary disease (n=2) and asthma, diabetes, Hodgkin’s lymphoma, kidney, 
Pompe disease, generalised anxiety disorder and stroke (all n=1). Study designs were 
References, related 
articles (5) 
Total hits (2,018) 
Science Direct (944)) 
CINAHL (862)  
PsycARTICLES (181) 
MEDLINE (31) 
Not HRQL (1879) 
Not relevant to study 
(59) 
Duplicates (2) 
Not English (19: 
French - 14, Chinese - 
3, German - 1, and 
Spanish -1) 
Full-text article selected for 
further review for inclusion in 
study (78) 
Full-text article excluded 
with reasons (n = 57) 
Not a disease or chronic 
disease (11) 
Generic or disease-specific 
instruments (14) 
Not Empirical study (14) 
Not Wilson and Cleary 
model (18) 
 
Studies included in 
the review (26) 
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either cross sectional (n=20) or longitudinal (n=6). The total number of participants was 
11,849, with a mean age of 50.5 years; 43.7% were female.  
3.6 Quality assessment 
Six studies were rated as strong (23%), 19 studies had moderate rating (73%) and one 
study had a weak rating (Table 3-1). 
Table 3-1: Quality Assessment of Included Studies. 
Author  Selection 
bias 
Study 
design 
Confou
nding  
Blinding Data 
collection 
Withdrawal 
and drop-out 
Overall 
quality 
Ade-Oshifogun 1 3 1 2 1 2 2 
Arnold  1 2 1 1 1 2 2 
Baker 1 1 1 1 1 2 1 
Brunault 1 2 2 1 1 1 1 
Carlson  1 2 3 2 1 2 2 
Cosby 1 3 3 2 1 1 3 
Eilayyan 1 2 2 2 1 2 2 
Halvorsrud 1 1 2 2 1 1 2 
Heo 1 1 1 1 1 1 1 
Hofer 1 2 1 1 1 1 1 
Kanters 1 2 1 1 1 1 2 
Krethong 1 3 1 2 1 2 2 
Mathisen 1 1 2 1 1 1 1 
Mayo 1 2 3 2 1 1 2 
Nokes 1 3 2 1 1 1 2 
Phaladze 1 3 2 2 1 2 2 
Portillo 1 3 1 2 1 2 2 
Saengsiri 1 1 2 3 1 1 2 
Santos 1 1 1 1 1 2 2 
Schulz 2 2 1 1 1 2 2 
Shiu 1 3 1 2 1 1 2 
Sousa (1999) 1 3 1 2 1 2 2 
Sousa (2006) 1 2 2 2 1 2 2 
Ulvik 1 3 2 2 1 2 2 
Wettergren 2 2 1 1 1 2 2 
Wyrwich 1 2 1 1 1 2 1 
Note: 1 = low risk of bias, 2 = moderate risk of bias and, 3 = high risk of bias. 
3.7 Aims of studies 
All the studies in the review applied the Wilson and Cleary model to investigate 
determinants of health-related quality of life in a specific chronic disease. The primary 
aim of most of the authors was to empirically test the Wilson and Cleary model to 
establish the hypothesised link between objective and subjective links in the disease 
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population in order to identify important predictors to be targeted to improve quality of 
life of the patients. Eleven of the authors explicitly stated this as their purpose of study. 
Using such words as: ‘systematically test (Baker, Pankhurst and Robinson, 2007), 
‘empirically test’ (Mayo et al., 2013), ‘put to test’ (Brunault et al., 2011), ‘apply’(Hofer 
et al., 2005; Shiu et al., 2014), ‘test’ (Ade-Oshifogun , 2012; Heo et al., 2005; Krethong 
et al., 2008; Santos et al., 2015;), ‘explore pathways’(Moi and Nilsen, 2012), ‘identify 
pathways’(Schulz et al., 2012), estimates pathways’(Sousa and Kwok, 2006), ‘identify 
determinants’ (Wettergren, Björkholm, Axdorph and Langius-Eklöf, 2004). Others 
focused on predictors but indicated that they were using the model as proposed by Wilson 
and Cleary to test the causal pathways of specific components of the model. 
3.8 Measure instruments  
Measure instruments in quality of life studies are broadly categorised into two; the generic 
instruments and the disease-specific instruments.  
Generic instruments for HRQL 
The most widely used instrument was the Medical Outcome Survey (MOS) Short Form 
36 (SF-36) (Ware Jr and Sherbourne, 1992), in both the full form SF-36 (n=10) and the 
shorter form 12 (Ware Jr, Kosinski and Keller, 1996), SF-12 (n=2). Components of the 
instrument were used to measure symptoms status (n=3), functional status (n=7), general 
health perceptions (n=9) and global HRQL (n=2). Other generic instrument used to 
measure HRQL was the Sickness Impact Scale (SIS). To measure depression, Patient 
Health Questionnaire (PHQ-9) (Kroenke and Spitzer, 2002), Beck’s Depression Index 
(BDI)(Beck and Steer, 1984) and the Hospital Anxiety and Depression Scale (HADS 
)(Zigmond and Snaith, 1983) were used.  
Disease-specific instruments for HRQL.  
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Disease-specific HRQL instruments used in the studies included the MacNew Heart 
Disease Quality of Life(Hofer et al., 2005), Minnesota Living with Heart Failure 
Questionnaire (MLFHQ) and the New York Heart Association (NYHA) classification to 
measure the global HRQL in heart failure (Heo et al., 2005; Krethong et al., 2008; Ulvik 
et al., 2008). The HIV/AIDS-Targeted Quality of Life (HAT-QoL) instrument (Phaladze 
et al., 2005; Portillo et al., 2005; Nokes et al., 2011) for HIV/AIDs populations while the 
Quality of Life, Obesity and Dietetics (QOLOD) (Brunault et al., 2015), Oral Health 
Impact Profile (OHIP-14) (Baker, Pankhurst and Robinson, 2007; Santos et al., 2015a) 
were used in diabetes and oral health populations respectively. 
Measures of the characteristics of the individual and the environment 
There is consensus with regards to age, gender and educational status as markers of the 
characteristics of the individual, but consensus is lacking among the authors on other 
indicators of characteristics of the individual and indicators of the environment. For 
example, marital status was treated by some as an individual characteristic and by others 
as an environmental characteristic. Hofer et al treated depression as an environmental 
characteristic in contrast to the general classification of depression as a symptoms 
variable.  
3.9 Analytical tools 
In modelling the data (Table 3-2), different analytical tools were used: 
stepwise/hierarchical regression (n=3), linear mixed model/multiple regression (n=4), 
logistic regression and/or partial correlation (4). Structural Equation Modelling 
(SEM)/path modelling was used in most of the studies (n=15), with 67% of those who 
used SEM/path analysis reporting the fit of the model. SEM has been found to exhibit 
superior properties compared to regression analysis in overcoming the limitations of 
regression by decomposing the sources of correlation among independent variables and 
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make it possible for each variable in a path model to be treated simultaneously as both a 
predictor and as an outcome (Eilayyan et al., 2015).  
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 Table 3-2: Application of Wilson and Cleary Model: the Predictor Markers 
  Measures 
1st Author 
Year 
Country 
Population Biological / Physical Symptoms Function Status General 
health 
perception
s (GHP) 
Individual 
Characteristics 
Environme
ntal 
Characteris
tics 
Overall 
HRQL 
Ade-
Osihifogun 
2012 
USA 
Obesity/Chron
ic Pulmonary 
Disease 
BMI, FEV1, DLCO, 
Percent trunk fat 
(DEXA) 
Dyspnoea (CRQ), 
fatigue (CRQ), 
sleep apnoea 
(ESS) 
  
Functional capacity 
measured by 6-minute 
walk distance 
(6MWD) 
Functional 
Performan
ce 
Inventory 
(FPI) 
   
Arnold  
2015 
Netherlands  
1. Chronic 
Obstructive 
Pulmonary 
Disease 
(COPD) 
2. Chronic 
Heart Failure 
(CHF) 
COPD: FEV1 
 
VHF: LVEF 
Dyspnoea 
measured by a 
questionnaire 
Physical functioning 
subscale of SF-36 
General 
health 
perception 
subscale of 
SF-36 
Age 
Gender 
Marital status 
Level of 
education 
 Perceived 
health 
competence 
scale 
Baker 
2007 
UK 
Xerostomia Salivary flow 
Clinical signs 
Xerostomia 
Inventory (XI) 
Oral Health Impact 
Profile (OHIP-14) 
Global oral 
health 
rating 
(GOH) 
n/m n/m Hospital 
Anxiety and 
depression 
Scale 
(HADS) 
Beverly 
2013 
USA 
Heart Failure Number of chronic 
illness 
Comorbidity burden 
(Charlson 
Comorbidity Index 
(CCI)as in index of 
severity of illness 
Diagnosis of diabetes 
Diagnosis of chronic 
atrial fibrillation 
Depression 
measure with 
Patient Health 
Questionnaire 
(PHQ-9) 
Physical 
symptoms 
measured with 
KCCQ 
 
Physical and social 
functioning measured 
with Kansas City 
Cardiomyopathy 
Questionnaire 
(KCCQ) 
 
First item 
in the SF-
36(v2) 
Age 
Gender 
Race/ethnicity 
Education 
Family income 
  
Brunault 
2015 
France  
Obesity BMI 
Type of Surgery 
Beck Depression 
Index (BDI) 
Bulimic 
Investigatory Test, 
Edinburg (BITE) 
Quality of Life, 
Obesity and Dietetics 
(QOLOD) 
-Physical QoL 
-Psychological QoL 
-Social QoL 
 Age 
Gender 
Marital 
status 
 
121 
 
-Sexual QoL 
-Comfort with food 
Eilayyan 
2015 
Canada 
Asthma  Physical 
symptoms 
(MAQLQ-
symptoms)  
Emotional 
symptoms 
(MAQLQ-
emotion) 
Self-efficacy 
(KASE-AQ) 
Physical function 
(MAQLQ-activity) 
n/m Age 
Gender 
Beliefs about 
medication 
 
Smoking 
status 
Healthcare 
utilisation 
n/m 
Halvorsrud 
2010 
Norway 
Chronic 
Disease 
 Geriatric 
Depression Score 
(GDS-15) 
SF-12 subscale of 
physical function 
Health 
satisfaction
: global 
item 
measure 
from 
WHOQoL-
Bref 
Age Environment
al domain of 
WHOQoL-
Bref.  
WHOQoL-
Old 
Heo 
2005 
USA 
Heart failure Patient interview 
Medical records 
Charlson comorbidity 
Index 
Patients 
perception of 
Presence and 
severity of 
dyspnoea and 
fatigue measured 
by 
Dyspnoea-Fatigue 
Index 
Questionnaire 
 
NYHA SF-36 Age 
Gender 
Educational 
status 
 
Social 
support 
(having a 
confidant: 
y/n) 
Marital 
status 
MLHFQ 
Hofer 
2005 
Austria  
Coronary 
Artery Disease 
(CAD) 
Severity of CAD (no 
of diseased vessel 
No. of risk factors 
Canadian 
Cardiovascular 
Society 
classification of 
angina pectoris 
SF-36 physical 
function score 
SF-36 
general 
health 
score 
Locus of control 
Anxiety 
Depression  
Social 
support 
measured by 
the German 
short form of 
the Social 
Support 
Questionnair
e 
Scores on the 
three scales 
(physical, 
social and 
emotional) 
of MacNew 
Heart 
Disease 
Quality of 
Life 
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Questionnair
e 
Kanters 
2015 
Netherlands 
Pompe disease Enzyme activity 
(fibroblasts) Skeletal 
muscle strength 
assessed by Medical 
Research Council 
(MRC), respiratory 
function assessed by 
forced vital capacity 
(FVC)  
shortness of 
breath, 
Fatigue assessed 
by Fatigue 
Severity Scale 
(FSS)  
Rotterdam Handicap 
Scale (RHS) 
EQ-5D 
Visual 
Analogue 
Scale (EQ-
5D-VAS) 
Age, gender, 
disease duration 
 Mental 
Component 
Scale (MCS) 
and Physical 
Component 
Scale (PCS) 
of the Short-
form (SF-36) 
Utility 
derived from 
EQ-5D  
Krethong 
2008 
Thailand 
Heart Failure Medical records- Left 
Ventricular Ejection 
Fraction (LVEF) 
Cardiac 
Symptoms Survey 
(CSS)  
NYHA functional 
classification 
100mm 
horizontal 
visual 
analogue 
scale 
 
Personal 
information 
questionnaire 
Social 
support-
measured 
with 
Enhancing 
Recovery in 
Coronary 
Heart 
Disease 
Social 
Support 
Instrument 
(ESSI) 
Minnesota 
Living with 
Heart Failure 
Questionnair
e (MLFHQ)  
Mathisen 
2007 
Norway 
Heart Surgery n/m n/m n/m General 
Health 
subscale of 
SF-36 
n/m  Global 
Quality of 
Life (gQoL) 
Norwegian 
version of 
the Quality 
of Life 
Survey 
(QoLS-N) 
Mayo 
2015 
Canada 
Stroke Side of lesion 
Stroke severity 
measured using 
Canadian 
Neurological Scale 
(CNS) 
Stroke Impact 
Scale (SIS) 
Pain: SF-36 (body 
pain) 
Vitality: SF-36 
(vitality) 
Physical Functioning: 
RAND Short-Form 
(SF-36): 
 SF-36 (PF) 
SIS (mobility) 
EQ-5D 
VAS 
SF-36 
(General 
health) 
Age 
gender 
OARS 
Social 
Resource 
Scale  
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Charlson 
Comorbidity Index  
Emotional well-
being: SF-36 
(mental health) 
 
Health Utility 
Inventory(HUI): 
 HUI (ambulation) 
HUI (dexterity) 
Social Functioning: 
SF-36 (SF) 
SIS 8b 
Role: 
Worst of SF-36 RE & 
RP 
Cognitive: Mini 
mental State 
Education (MMSE) 
Moi 
2012 
Norway  
Burns Total body surface 
area burn; 
Extent of full 
thickness injury; 
Presence or absence 
of inhalation injury; 
Number of 
operations; Length of 
hospital stays 
Pain and itch 
(measured by 
BSHS-N) 
General health 
(BSHS-N) 
Body Image 
(BSHS-N) 
Affective ((BSHS-
N) 
Mental health (SF-
36) 
Bodily pain (SF-
36) 
Vitality (Sf-36) 
Physical health 
(BSHS-N) 
Mobility and self-care 
(BSHS-N) 
Role activities 
(BSHS-N) 
Physical function 
(SF-36) 
Social function (SF-
36) 
Role emotional (SF-
36) 
Role physical (SF-36) 
 
General 
health (SF-
36) 
Age 
Sex 
Non-burn 
physical illness 
Psychiatric 
illness 
Living alone 
Housing or 
economic 
problems 
Unemploym
ent  
Quality of 
Life Scale 
(QOLS) 
Nokes 
2011 
USA 
HIV/AIDS  Center for 
Epidemiological 
Depression Scaled 
(CES-D) 
Revised signs and 
symptom 
Checklist for 
Persons with HIV 
Disease 
Body Change 
Distress Scale 
    HAT-
Quality of 
Life (HAT-
QOL)_ 
Phaladze 
2005 
HIV/AIDS Has been give AIDS 
diagnosis 
Has Comorbidities 
Revised Sign and 
Symptoms 
Checklist for 
Overall functioning Health 
worries 
Age 
Gender 
Living 
environment  
HIV/AIDS-
Targeted 
Quality of 
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Sub-Saharan 
Africa 
Persons with HIV 
Disease 
Years of 
education 
Has children 
Has enough 
money 
Life (HAT-
QoL) 
Saengsiri 
2014 
Thailand  
Coronary 
Artery Disease 
(CAD) 
LVEF 
Rose Questionnaire 
for angina 
Rose Dyspnea Scale 
(RDS) 
Centre for 
Epidemiologic 
Studies 
Depression Scale 
(CES-D) 
Cardiac Self 
Efficacy Scale (C-
SES) 
Functional 
Performance 
Inventory Short-Form 
(FPI-SF) 
SF-36 Vitality 
subscale 
  Social 
support 
questionnair
e (SSQ) 
Quality of 
Life Index-
Cardiac 
Version 
Santos 
2015 
Brazil 
Oral health Edentulism 
(dentate=0, 
edentulous=1) 
assessed by clinical 
examination 
Assessed using the 
question, “are you 
satisfied with the 
appearance of 
your prostheses?” 
Assessed with the 
question, “have you 
decreased or changed 
the type of food 
because of problems 
with your teeth or 
dental prostheses?” 
Assessed 
using the 
question, 
“compared 
with others 
your age, 
how would 
you rate 
the health 
of your 
mouth 
overall?”  
Age 
Gender 
Geographic 
location 
Monthly income 
schooling 
 Assessed 
with the Oral 
health 
Impact 
profile-14 
(OHIP-14) 
Schulz 
2012 
Netherlands 
Kidney 
transplant  
Number of active 
comorbidities 
reported by patients 
 European Quality of 
Life -5 dimension 
(EQ-5D) 
EQ-5D 
Visual 
Analogue 
Scale (EQ-
5D-VAS) 
Index of 
personal 
characteristics-
Mastery 
(mastery scale, 
Optimism (Life 
orientation test) 
and  
Self-esteem 
(Rosenberg self-
esteem scale) 
 General 
Health 
Questionnair
e (GHQ-12) 
Shiu 
2013 
Hong Kong 
Diabetes Time since diagnosis 
Age of onset and type 
of diabetes 
HbA1c level, blood 
pressure and lipid 
profile 
Self-reported 
comorbidity 
characteristics and 
presence of 
comorbidity and 
no of 
comorbidities 
Physical functioning 
subscale of SF-36 
Older American 
Resources and 
Services 
Multidimensional 
Functional 
SF-36: 
general 
health 
perception 
Self-
developed 
ratings 
Age 
Gender 
Working status 
Lifestyle 
characteristics 
Psychological 
distress 
Marital 
status 
Income 
adequacy 
Social 
support 
measured by 
6 subscales 
of the SF-36: 
role-
physical, 
role-
emotional, 
mental 
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Assessment 
Questionnaire  
measured by 
Rand Mental 
Health 
Inventory 
MOS Social 
Support 
Survey 
health, social 
functioning, 
bodily pain 
and vitality 
Sousa 
2006 
USA 
HIV/ 
AIDS 
CD4 Count Signs and 
symptoms 
checklist for 
persons with HIV 
disease (SSC-
HIV) 
The Health 
Assessment 
Questionnaire-
Disability Index 
(HAQ-DI) 
100mm 
visual 
analogue 
scale 
Ordinal 
scale 
n/m n/m Derived 
from general 
health status 
scales 
Ulvik 
2008 
Norway 
Coronary 
Artery Disease 
(CAD) 
Myocardial disease 
LVEF 
Angina (AFS, 
CCS) 
Dyspnoea 
(NYHA) 
Anxiety (HADS) 
Depression 
(HADS) 
Physical function 
Social function 
General 
health (SF-
36) 
 
  Overall QoL: 
measured 
with a single 
question. 
Wan  
2016 
Singapore 
Rheumatoid 
Arthritis (RA) 
Duration of RA, 
tender and swollen 
joint counts 
Hospital Anxiety 
and depression 
scale (HADS), 
Numerical rating 
scale (NRS) 
Health Assessment-
Disability Index 
(HAQ-DI) 
 Age, gender, 
marital status, 
employment 
status, 
education, 
ethnicity 
Medical 
Outcomes 
Study-Social 
Support 
Survey 
(MOS-SSS) 
European 
Quality of 
Life -5 
dimension 
(EQ-5D) 
Wettergren 
2004 
Sweden 
Hodgkin’s 
Lymphoma 
(HL) 
Disease stage (I-IV) 
Treatment modality 
(irradiation, 
chemotherapy or 
combined modality 
treatment 
Time since diagnosis 
Schedule for the 
Evaluation of the 
Individual Quality 
of Life-Direct 
Weighting 
(SEQoL-DW) 
Hospital Anxiety 
and depression 
(HAD) scale 
Measured as part of 
general health 
perceptions 
Physical 
Componen
t Summary 
(PCS) of 
Short Form 
12 (SF-12) 
Mental 
Componen
t Summary 
(MCS) of 
SF-12  
Sense of 
Coherence 
(SOC) scale 
Respondents
’ rating of 
present 
financial 
situation. 
QoL index of 
Schedule for 
the 
Evaluation 
of the 
Individual 
Quality of 
Life-Direct 
Weighting 
(SEQoL-
DW) 
 
Wyrwich 
2011 
USA 
General 
Anxiety 
Disorder 
(GAD) 
Clinical Global 
Impression-Severity 
of illness (CGI-S) 
Hamilton Rating 
Scale for Anxiety 
(HAM-A) 
Pittsburgh Sleep 
Quality Index (PSQI) 
Quality of 
Life, 
Enjoyment 
and 
Satisfactio
n 
  Quality of 
Life, 
Enjoyment 
and 
Satisfaction 
Questionnair
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Questionna
ire-Short 
Form (Q-
LES-
Q(SF)) 
(items 1-
14) 
e-Short Form 
(Q-LES-
Q(SF)) (Item 
16) 
BSHS-N: Burn-Specific Health Scale (Norwegian version). FEV: forced expiratory volume. CRQ: Chronic Respiratory disease Questionnaire. ESS: Epworth Sleepiness Scale. DLCO: carbon 
monoxide diffusing capacity. 
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Table 3-3: Application of Wilson and Cleary Model: Study Outcomes 
   Characteristics of 
Study 
    
1st 
Author  
Year 
Country 
Population Design Samp
le 
size 
Age 
Mean 
(SD)  
% of 
Female 
Aim of study Analytical 
Tool 
Results/Findings Percentage of 
variance 
explained by 
model (if 
calculated) 
Saengsiri 
2014 
Thailand  
Coronary 
Artery 
Disease 
(CAD) 
 303 61.2 
(10.9) 
26.4% To explain relationship 
between cardiac self-
efficacy, social support, 
biological and 
physiological (LVEF) 
symptoms of angina, 
dyspnoea, depression, vital 
exhaustion, functional 
performance and quality of 
life in post-PCI CAD 
patients 
Pearson 
Correlation 
  
Path 
analysis 
• Social support (β=0.31), 
depression(β=0.24), vital 
exhaustion(β=0.23) and 
cardiac self-efficacy(β=0.21) 
had the most powerful direct 
effect on quality of life of 
post-PCI CAD patients 
• Self-efficacy had indirect 
effect on quality of life 
(β=0.21, p<0.001)  
 
Heo 
2005 
USA 
Heart failure Baseline 
data 
293 73 
(11) 
53% To determine the bivariate 
relationships between 
HRQL and other variables 
proposed by Wilson and 
Cleary 
To determine best 
multivariate model based 
on these variables 
To test specific 
components of the Wilson 
and Cleary model of 
HRQL 
Multiple 
regression 
• Health perception, symptom 
status and age predict 
HRQL 
• Health perception mediates 
the effect of symptoms on 
HRQL 
• Functional status does not 
mediate the effect of 
symptom status on health 
perception 
• Final model 
explains 
29% of the 
variance 
Brunault 
2015 
France  
Obesity Cohort  126 40.2 
(10) 
79.4% To put the Wilson Cleary 
model to test by 
determining the predictors 
of postoperative change in 
each QoL dimension 12 
months after bariatric 
surgery 
Linear 
mixed 
model 
• Improvement in Psychosocial 
QoL was associated with 
lower preoperative depression 
severity, lower preoperative 
binge eating severity and 
higher weight loss 
• Improvement in Sexual QoL 
was associated with lower 
 
128 
 
preoperative depression 
severity, lower preoperative 
binge eating severity and 
younger age 
• Improved comfort with food 
was associated with lower 
preoperative binge eating 
severity 
Phaladze 
2005 
Sub-
Saharan 
Africa 
HIV/AIDS Cross 
sectional 
743 34.1 
(9.6) 
61.2% To increase understanding 
of the meaning of quality 
of life for people living 
with HIV/AIDS in four 
countries in Sub-Saharan 
Africa: Botswana, 
Lesotho, South Africa and 
Swaziland.  
Hierarchic
al multiple 
regression 
• Daily functioning predicts 
overall HRQL 
• Higher level of education 
associates with lower HRQL 
• Higher symptom intensity 
associates with lower HRQL 
• A close correlation between 
symptom intensity and 
functional status  
• Overall 
model 
explains 
53.2% of 
the 
variance 
Wettergr
en 
2004 
Sweden 
Hodgkin’s 
Lymphoma 
Cross 
sectional 
121 45 
(medi
an) 
45% To evaluate HRQL in 
long-term survivors of 
|Hodgkin’s lymphoma 
(HL) and to identify 
determinants of HRQL 
using Wilson and Cleary’s 
conceptual model with the 
potential goal of 
improving care and 
rehabilitation. 
Partial 
Correlation
s  
• Disease stage correlated with 
Disease index (SEQoL-DW) 
• Lower SOC was related to a 
worse HRQL 
• Poorer physical health was 
associated with worse overall 
quality of life. 
 
Ade-
Osihifog
un 
2012 
USA 
Obesity/Chr
onic 
Pulmonary 
Disease 
(COPD) 
Cross 
sectional 
76 69.7 
(10.3) 
35.5% To test a theoretically and 
empirically supported 
model of the relationship 
among clinical variables, 
symptoms, function status 
and health status of elderly 
people with COPD 
Path 
analysis 
• Function status, symptoms 
and biological variable 
DLCO have direct causal 
effect on health status  
• DLCO ad dyspnoea predict 
functioning 
• The effect of clinical 
variables on health status is 
mediated by symptoms 
• Symptoms, function status 
and clinical variable 
indirectly influence health 
status  
• Model 
explains 
29% of 
the 
variance 
• Clinical 
variables 
explain 
29.6% of 
symptom
s 
• Clinical 
variables 
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explain 
50.5% of 
function 
status 
 
Nokes 
2011 
USA 
HIV/AIDS Cross 
sectional 
1217 41.7 
(9.1) 
31.5% To determine if there were 
age-related differences in 
symptoms status and 
HRQL for HIV-positive 
persons aged 50 years and 
older compared with 
younger (aged 49 years 
and younger). 
Stepwise 
regression 
• Age was a predictor for 
sexual function and provider 
trust 
• Less depressive symptoms 
and less body change distress 
were related to increase in 
sexual functioning 
 
Arnold  
2015 
Netherla
nds  
1. Chronic 
Obstructive 
Pulmonary 
Disease 
(COPD) 
2. Chronic 
Heart Failure 
(CHF) 
Cross 
sectional 
COP
D:95 
 
CHF 
:90 
65 
(9.3) 
 
 
 
59 
(10) 
35.8% 
 
 
 
24.4% 
To investigate relationship 
between objective and 
subjective health in 
patients with COPD and 
CHF 
Structural 
equation 
model 
(SEM) 
• Biological/physiological 
variables in both diseases 
are not significantly related 
to symptoms but predict 
physical functioning 
• Symptoms predict physical 
functioning in both diseases 
• Physical functioning 
associate with general 
health perceptions in COPD 
and CHF 
• Symptoms directly associate 
with general health 
perceptions only in COPD 
• In COPD, symptoms, 
physical functioning explain 
general health perception 
• Only physical functioning 
explains general health 
perceptions in CHF  
• The 
authors 
report 
that 
there 
exist 
direct 
and 
indirect 
relations
hips 
between 
the 
health 
paramete
rs.  
• For 
instance, 
proxy 
for 
global 
HRQL 
explains 
symptom
s and 
general 
health 
perceptio
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ns in 
both 
diseases. 
Moi 
2012 
Norway  
Burns Cross 
sectional 
95 43.7 
(14.5) 
18% To explore pathways 
leading to self-perceived 
general health and overall 
quality of life in burn 
patients. 
Structural 
equation 
modelling 
(SEM) 
• Length of hospital stays, 
Living alone, and Painitch 
had indirect effects on general 
health 
• Vitality had both direct and 
indirect effects on general 
health 
• Vitality was associated with 
overall quality of life and 
shown to be the best indicator 
of biological and 
physiological variables 
Model 
explained 43% 
variance in 
overall quality 
of life  
Shiu 
2013 
Hong 
Kong 
Diabetes Cross 
sectional 
452 71.8 
(7.3) 
59.1% To apply the Wilson and 
Cleary model of HRQL to 
understand the relationship 
among clinical and 
psychological outcomes in 
community-dwelling older 
Hong Kong Chinese 
people with diabetes.  
Structural 
Equation 
Modelling 
(SEM) 
• Four determinants: general 
health perception, 
psychological distress, 
adequacy of income and 
social support have direct 
effect on HRQL 
• Three determinants: symptom 
status, physical functional 
status and psychological 
status have indirect effects on 
HRQL through general health 
perception 
• Four determinants: symptom 
status, age, gender and 
physical activity have indirect 
effect on HRQL through 
physical function status  
• The model 
explains 
between 
64% and 
72% of 
variance 
Santos 
2015 
Brazil 
Oral health Cross 
sectional 
578 68 
(6.3) 
67.3% To test the Wilson and 
Cleary model of the direct 
and mediated pathways 
between clinical and non-
clinical variables in 
relation to oral health-
related quality of life 
Structural 
Equation 
Modelling 
(SEM) 
• Dissatisfaction with symptom 
status are associated with 
worse functional status 
• Worse functioning predicts 
poor oral health perception 
• Poor oral health perception 
associates with higher worse 
oral health quality of life  
• The 
comparati
ve fit 
index is 
0.98 
indicating 
adequate 
fit. 
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• Final model shows negative 
significant direct effect 
between biological variable 
and symptom status 
• Age, gender and geographical 
location have direct paths to 
biological variable 
(edentulism) 
• Age and gender directly 
impact oral health-related 
quality of life 
Ulvik 
2008 
Norway 
Coronary 
Artery 
Disease 
(CAD) 
Cross- 
sectional 
753 61.7 
(10.2) 
26% To analyse relationship 
between disease severity 
and both mental and 
physical dimensions of 
HRQL. 
Linear and 
ordinal 
logistic 
regression 
• Biological variables associate 
with symptoms 
• Depression associates 
positively with LVEF 
• Symptoms affect physical 
function 
• Social function is low in 
patients with more symptoms 
of anxiety. 
• General health is negatively 
related to anxiety and 
depression but positively 
related to physical and social 
functions 
• Better overall QOL is 
associated with less 
symptoms and depression but 
related negatively to social 
function  
• The model 
explains 
43% of the 
variance 
of overall 
quality of 
life. 
Halvorsr
ud 
2010 
Norway 
Chronic 
Disease 
Cross- 
sectional 
89 78.6 73% To explore the predictors 
of QOL among 
community-dwelling older 
adults receiving 
community health care 
Path 
analysis: 
Structural 
equation 
Modelling 
(SEM) 
• Environment has direct 
effects on QOL and indirect 
effects on QOL with 
depressive symptoms and 
health satisfaction (GHP) as 
mediators 
• Depressive symptoms had an 
indirect, negative effects on 
QOL with physical functions 
• The 
predictor 
variables 
accounted 
for 37% of 
the 
variance 
in 
depressive 
symptoms, 
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and general health perceptions 
as mediators 
• Health satisfaction was a 
mediator between physical 
function and QOL 
 
29% in 
physical 
function, 
44% in 
general 
health 
perception
s and 66% 
of the 
variance 
in QOL 
(the 
overall 
model)  
Krethong 
2008 
Thailand 
Heart Failure Cross- 
sectional 
422 58.47 Ns To develop and test a 
hypothesized causa model 
of HRQL in Thai heart-
failure patients  
Structural 
equation 
modelling 
(SEM) 
• Biological/physiological 
affected functional status (β = 
-0.34, p<0.05).  
• Symptom affected functional 
status (β = 0.45, p<0.05); 
GHP (β = -0.27, p<0.05) and 
HRQL (β =  -0.48, p<0.05) 
• Functional status had impact 
on GHP (β = -0.28, p<0.05); 
HRQL (β= -0.25, p<0.05) 
• Social support had impact on 
symptom (β = -0.25, p<0.05); 
GHP (β = 0.19, p<0.05) and 
HRQL (β =  -0.17, p<0.05) 
• The effect of 
biological/physiological on 
symptom was not significant. 
Model 
explained 58% 
of the variance 
in overall 
HRQL 
Sousa 
2006 
USA 
HIV/ 
AIDS 
Cross- 
sectional 
395 30.4 
(8.13) 
Ns To estimate the primary 
pathways of the Wilson 
and Cleary HRQL 
conceptual model using 
structural equation 
modelling (SEM) 
Structural 
equation 
modelling 
(SEM) 
• A significant relationship 
between status and functional 
health (r= 0.56) 
• There is significant 
relationship between 
symptoms status and general 
health perceptions (r= -0.33) 
and functional health and 
• Symptoms 
explain 
49% of 
functional 
health 
• Both 
symptoms 
status and 
functional 
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general health perceptions 
(r=-0.42) 
• There is significant 
relationship between 
symptoms status and overall 
quality of life (r= -0.20) and 
between GHP and overall 
quality of life (r= 0.26) 
• CD4 count had a negative 
relationship with symptom 
status (r= - 0.20, p<0.05) 
heath 
accounted 
for 62.5% 
of the 
variance 
of general 
health. 
• Both 
symptoms 
status and 
general 
heath 
perception
s 
accounted 
for 38,2% 
of the 
variance 
in overall 
quality of 
life. 
Beverly 
2013 
USA 
Heart Failure Cross-
sectional 
265 62 35.8% To determine the key 
predictors of overall 
perceived health (OPH) 
Hierarchic
al multiple 
regression 
• Age, gender and 
race/ethnicity were predictors 
of OPH 
• Perceived sufficiency of 
income, social functioning, 
comorbid burden, symptom 
stability, black compared to 
white race were independent 
predictors of OPH 
• Physical and social 
functioning mediated the 
effect of SOB and fatigue on 
OPH as well as the effect of 
symptom on OPH 
• 39.2% 
Wan  
2016 
Singapor
e 
Rheumatoid 
Arthritis 
Cross-
sectional 
108 56.4 
(13.2) 
79.6% To examine the level of 
HRQL and its predictors in 
patients with Rheumatoid 
arthritis in Singapore 
Pearson 
correlation 
& 
 Multiple 
linear 
regression 
• Pain, functional disability, 
anxiety, depression, 
medication adherence, social 
support and tender joint 
counts were correlated with 
HRQL 
Model 
explained 
55.5% of the 
variance. 
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• Pain, functional disability and 
depression were predictors of 
HRQL 
Kanters 
2015 
Netherla
nds 
Pompe 
disease 
Cross-
sectional 
103 49.3 50.6% To develop a conceptual 
model for Pompe disease 
in adults and statistically 
test it in untreated patients 
Random 
effects 
linear 
regression 
• MRC and FSS were 
negatively associated with 
disease duration 
• FVC was affected by female 
gender 
• RHS was affected by FSS, 
MRC, FVC and Age 
• EQ-5D Vas was associated 
with RHS and disease 
duration 
• MCS was associated with 
EQ-5D VAS 
• PCS was associated with EQ-
5D VAS 
• Utility was associated with 
EQ-5D Vas 
 
Schulz 
2012 
Netherla
nds 
Kidney 
Transplant  
Cross-
sectional 
609 53.7 
(12.3) 
43.9% To identify pathways 
through which objective 
health affects 
psychological distress and 
to clarify how personal 
characteristics are shaped 
by objective health and 
determine psychological 
distress 
Structural 
equation 
modelling 
(SEM) 
• Impact of objective health and 
functional status on 
psychological distress was 
fully mediated by subjective 
health and personal 
characteristics 
• Influence of objective health 
was mediated by successively 
by functional status and 
personal characteristics; 
successively by functional 
status and subjective health; 
exclusively by personal 
characteristics and; 
exclusively by subjective 
health  
The model 
explained 32% 
of variance of 
psychological 
distress 
Mayo 
2015 
Canada 
Stroke Cross-
sectional 
678 67.3 
(14.8) 
45% To empirically test a 
biopsychosocial 
conceptual model of 
HRQL for people 
recovering from stroke 
Structural 
equation 
modelling 
(SEM) 
• Less comorbidity, less pain, 
better memory and more 
vitality associated with better 
health perception. 
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Eilayyan 
2015 
Canada 
Asthma Longitud
inal  
299 62.1 
(14.4) 
69% To identify direct and 
indirect predictors of 
perceived asthma control 
among primary care 
population. 
Path model • Symptom was affected by 
self-efficacy 
• Emotional status was affected 
by symptom and self-efficacy 
• Physical activity was affected 
through symptom, emotional 
status and self-efficacy 
• Perceived asthma control at 
baseline was affected by 
asthma symptom, physical 
activity, self-efficacy and 
smoking 
• Perceived asthma control at 
follow-up was predicted by 
asthma symptom, physical 
activity, self-efficacy and 
baseline perceived asthma 
control. 
• Perceived asthma control was 
indirectly predicted by 
emotion status through self-
efficacy and physical activity 
 
Wyrwich 
2011 
USA 
General 
Anxiety 
Disorder 
(GAD) 
Longitud
inal 
1692 40.3 
(11.8) 
65.1% To test the application of 
the Wilson-Cleary model 
to patient population with 
generalised anxiety 
disorder (GAD) using 
longitudinal clinical trial 
data. 
Path 
Model 
• CGI-S had a strong 
relationship with HAM-A 
• HAM-A at week 8 had strong 
path (β=0.5) to PSQI and 
moderate effect (β=-0.40) on 
Q-LES-Q(SF) 
• Q-LES-Q(SF) had a strong 
relationship with overall 
quality of life (β=0.66) 
Model 
explained 56% 
at baseline and 
69% at week 8 
Hofer 
2005 
Austria  
Coronary 
Artery 
Disease 
(CAD) 
Longitud
inal  
432 61.8 
(10.2) 
24.1% To apply Wilson and 
Cleary model a priori to 
patients with CAD in a 
prospective longitudinal 
design and to find out 
whether it is applicable to 
CAD patients and is stable 
over time. 
Structural 
Equation 
Modelling 
(SEM) 
• Physical functioning, anxiety 
symptoms have effect on 
overall HRQL 
• Anxiety predicts poorer 
HRQL 
• Depression affects physical 
functioning and general health 
perception. 
• Final 
model 
explains 
49% at 
baseline, 
62% one 
month 
after and 
66% 3 
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• The higher the level of 
anxiety, the more severe the 
symptoms reported 
months 
after 
interventio
n of the 
variance 
of overall 
HRQL 
Mathisen 
2007 
Norway 
Heart 
Surgery 
Longitud
inal 
108 64.2 19% To investigate the 
existence of a reciprocal 
relationship between 
patients’ assessment of 
quality of life and their 
appraisal of health. 
Structural 
equation 
modelling 
(SEM) 
• Baseline overall QoL has a 
cross lagged effect on three 
months assessment of general 
health 
• The path from general health 
at six months to QoL at 12 
months was significant 
• The simultaneous effects 
model demonstrated a 
bidirectional causal paths at 
each point observed after 
baseline 
 
Baker 
2007 
UK 
Xerostomia Longitud
inal 
85 59.8 
(11.5) 
76.5% To systematically test 
Wilson and Cleary 
conceptual model of the 
direct and mediated 
pathways between clinical 
and non-clinical variables 
in relation to the oral 
health-related quality of 
life (OHRQoL) of patients 
with xerostomia. 
Structural 
Equation 
Modelling 
(SEM) 
• More severe clinical signs 
were associated with worse 
patient-reported symptoms 
• More symptoms predicted a 
greater impact on everyday 
oral functioning 
• Worse functioning predicted 
lower global oral health 
perceptions 
• Both biological indicators and 
functioning predicted 
subjective well-being  
• Function 
accounted 
for 96.9% 
of total 
effects 
• 88.2% of 
total effect 
on 
functionin
g was 
mediated 
by 
symptoms 
status 
• Symptoms 
9% 
• Functionin
g 22% 
• GOH 24% 
• Well-
being 21% 
  
3.10 Research Question 1: Does empirical evidence show the causal relationship of the 
dominant concepts as proposed in Wilson and Cleary’s model? 
Adjacent Linkages and Mediators 
Wilson and Cleary (Wilson and Cleary, 1995) hypothesised that there existed direct causal 
links between biological and physiological factors, symptoms, functional status, general 
health perceptions and HRQL. Symptoms mediate between physiological factors and 
functional status, while functional status mediates between symptoms and general health 
perceptions, and general health perceptions mediates between functional status and overall 
HRQL. Eleven studies supported the direct causal link proposition between biological and 
physiological factors and symptoms (Figure 3-2). Markers of biological and physiological 
variables were found to associate with worse symptoms in the patients with HIV/AIDs, 
xerostomia, coronary artery disease, Hodgkins lymphoma and generalised anxiety disorder 
(Wettergren and Bjo, 2004; Sousa and Kwok, 2006; Baker, Pankhurst and Robinson, 2007; 
Ulvik et al., 2008; Wyrwich et al., 2011). The next level of the model associates symptoms 
with functioning and mediates between functioning and biological/physiological variables. 
This has been established in 20 studies (e.g., (Arnold et al., 2005; Halvorsrud et al., 2010; 
Nokes et al., 2011) ). More symptoms predicted a greater impact on everyday functioning, 
with symptoms status explaining 49% of functional health in HIV/AIDs patients (Sousa and 
Kwok, 2006). Functional status was found to have direct links to general health perception 
and mediated between general health perception and symptoms in 16 studies. Worse 
functioning indicated low perceived health. For example, worse functioning was associated 
with lower global oral health perception in Hodgkin’s lymphoma (Wettergren and Bjo, 
2004). More symptoms and less functional health may lead to a perceived decrease in 
perceived general health. The hypothesised effect of general health perception on overall 
HRQL was established in 12 studies (Figure 3-2). 
138 
 
 
3.11 Research Question 2: Does the Wilson and Cleary model strictly follow a linear 
unidirectional path? 
Linkages between non-adjacent concepts 
I examined the links between non-adjacent variables to establish whether empirical data 
show that the model allows non-linear, indirect paths.  
Biological and physiological variables were directly associated with functional status, 
general health perception and overall HRQL in nine, two and three studies respectively 
(Figure 3-2). For example, Kanters et al. (Kanters et al., 2012) showed that enzyme activity, 
a biological marker, was significantly associated with HRQL in adult Pompe disease. Direct 
links were established between symptom status and, general health perception and HRQL in 
nine and seven studies respectively. Furthermore, functional status was associated directly 
with overall HRQL in seven studies. In coronary artery disease, physical functioning showed 
high positive significant effect on HRQL (β=0.36) indicating that a reduction in functional 
health may reduce HRQL(Hofer et al., 2005). The studies assumed non-reciprocal 
relationships except Mathisen et al. (Mathisen et al., 2007) who attempted to model 
reciprocal relationship between general health perception and HRQL. This did not take into 
consideration possible effects between other concepts. Hence, the possibilities of 
bidirectional relationships between the abstract concepts could not be established in this 
study. 
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Figure 3-2: Adjacent and non-adjacent linkages of the concepts 
Adapted from Wilson and Cleary (1995): Linking Clinical Variables with Health-Related Quality of Life: A Conceptual Model of Patient Outcomes. (JAMA: Journal of the American 
Medical Association, Page 60). The numbers (7,9, etc) refer to number of studies with significant linkages between concepts (e.g 11 means that eleven studies reported significant relationship 
between Bio-physiological and symptoms variables and 7 means that seven studies reported direct significant relationship between symptoms and HRQL). 
Biological 
and 
Physiologic
al factors 
Symptoms 
Status 
Functional 
Status 
General 
Health 
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3.12 Research Question 3: What is the relative effect of each variable? 
The relative effects of the variables were measured in terms of the magnitude of their 
influence on HRQL (Figure 3-3). The causal links were labelled 0M, 1M, 2M and 3M to 
signify the number of mediators between constructs that were bypassed.  0M was a direct 
link between the concepts with the proposed mediating variable signifying that no mediator 
was bypassed in the link, 1M was an indirect link with one mediator bypassed, 2M with two 
mediators bypassed and 3M with three mediators bypassed. 0M, 1M and 2M revealed 
symptoms status as a consistently important factor that affected HRQL, followed by 
functional status. In 0M all four concepts: biological and physiological, symptom status, 
function status and general health perception were compared with respect to the effect of 
each on the adjacent variable. Clinical factor had the lowest magnitude of effect followed by 
general health perception, function status and symptoms status in order of increasing 
magnitude. Clinical factor was however on the same level as functional status when only the 
immediate mediator was bypassed.  
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Figure 3-3: Bar chart of observed magnitude of effects 
Note: 0M - direct linkage, no mediator between variables, 1M - one mediator between variables bypassed, 
2M – two mediators between variables bypassed, 3M – three mediators between variables bypassed. Figures 
represent number of significant studies. 
 
3.13 Discussion 
Summary 
The findings of this systematic review support the model of HRQL as proposed by Wilson 
and Cleary (Wilson and Cleary, 1995) and establish the conceptualised relationships and 
mediation. Of the articles reviewed, 74% found symptom status to be a significant predictor 
and critical mediator making it the most important predictor of HRQL by indirect effects 
through functional status and general health perceptions and by direct effects. More 
symptoms implied impaired functioning with consequently worse general health perception 
and lower HRQL. Most of the studies (73%) were of moderate quality; this was because the 
11
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General health perception Function Status Symptoms Status Biological Factors
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quality assessment criteria (Effective Public Health Practice Projects, 2010) gives low 
ratings to study designs that are not experimental or longitudinal in nature.  
Comparison with previous studies 
Both symptoms and general health perception were found to account for 38.2% of variance 
in global HRQL (Krethong et al., 2008) and studies also showed that general health 
perception alone mediated the relationship between symptom status and HRQL (Arnold et 
al., 2005; Sousa and Kwok, 2006; Ulvik et al., 2008; Shiu et al., 2014; Mayo et al., 2015). 
One of the most important symptoms was depression which strongly associated with 
physical functioning (β = -0.32) and general health perceptions (Hofer et al., 2005). Two 
studies found no association between the clinical factors and any of the health constructs in 
heart failure and diabetes (Heo et al., 2005; Shiu et al., 2014). This may be due to other 
profound non-clinical factors responsible for impaired HRQL in these populations. The non-
adjacent links among the health concepts showed that the model was non-linear, also the 
effects of the variable were not fully mediated by their proposed mediators. For example, 
the direct link between symptom status and overall HRQL indicated that both functional 
status and general health perception did not fully mediate the effects of symptom burden on 
HRQL.  
Possible explanations and implications 
The findings of Sullivan et al. (Sullivan et al., 2000) in coronary artery disease patients 
supported the findings of a direct link between biological and physiological variables, and 
functional status. Further studies of a longitudinal nature will be required to establish 
possible bidirectional relationships among the concepts and whether the factors exert 
reciprocal influence on each other. For example, while the symptoms of pain may reduce 
functioning in patients with sickle cell disease, the inability to function as expected may lead 
to depression which may further limit functioning and then lower HRQL. This study is the 
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first to synthesize results of studies on Wilson and Cleary’s model and to establish the 
relative importance of the constructs in determining the quality of life of patients in chronic 
diseases.  
3.14 Limitations 
I identified some potential limitations to this study. The systematic review focused on several 
chronic diseases which have different clinical statuses, prognoses and levels of disability, 
which restricts the ability to generalise based on the lack of homogeneity of symptom status 
and functional status of the patients. There is also the potential limitation due to publication 
bias as only published articles were used in this study. In addition, different instruments were 
used to measure HRQL in the included studies; while some are generic, some are disease-
specific. As there is no instrument that is a “gold standard”, researchers often select 
instruments sensitive to the health state they are investigating (Hawthorne, Richardson and 
Day, 2001) rather than a general measure of HRQL. Moreover, there are also variations in 
clinically important differences across groups of patients defined by diseases, conditions, 
severity level, socio-economic status and nationality (Samsa et al., 1999). 
3.15 Conclusion 
My findings show that the Wilson and Cleary model demonstrated a good fit and proved 
useful in identifying relationships among the health constructs, and predictors of HRQL in 
the studied disease populations. The model explained between 22.9% and 72% of the 
variance in overall quality of life indicating that, in some cases, the model may require 
modification to capture factors not specified in the model but that may be important 
determinants of overall quality of life.  
The findings supported the robustness of the Wilson and Cleary model as a conceptual 
framework to characterise predictors of HRQL in chronic diseases and to aid understanding 
of the relationship between clinical and psychological outcomes for patients with chronic 
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illness. Such understanding of specific directions of influence will aid healthcare 
practitioners and researchers to develop appropriate care protocols that will address 
psychosocial variables alongside clinical factors in chronic disease management. This study 
has demonstrated that symptoms are a major determinant of HRQL in patients with chronic 
disease, thus a clinical approach to reduce symptoms may help improve HRQL. 
Furthermore, in treating patients with chronic diseases, clinicians and healthcare 
practitioners should be alert for signs of depression because this study has highlighted 
depression as a major issue in HRQL. 
Further work is needed to examine bidirectional relationships. Studies so far have focused 
on an assumption of no reciprocal relationship but low health perception or low HRQL might 
also worsen disease conditions and responses to treatment. Further studies on evaluation of 
the Wilson and Cleary model should be compared to the findings of this study.   
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CHAPTER FOUR  
METHODOLOGY 
4.0 Introduction  
There are series of theoretical and methodological decisions to be taken in the course of 
doing research on quality of life (Streiner, Norman and Cairney, 2015). In health research, 
quantitative or qualitative methodologies or both can be used (Tonon, 2015, p. 54). Tonon 
also has suggested that the concepts of perspective play a major role in the process of 
deciding which method to adopt (Tonon, 2015). This study was approached from the 
perspective of testing theory in the disease population – those individuals with sickle cell 
disease - and seeks to understand causal relationships among physiological and psychosocial 
variables and health-related quality of life constructs. The positivist approach was therefore 
considered appropriate for the study.  
The positivist approach is based on the postulates that objective universal truth exists and 
assumes that knowledge is obtainable through the means of quantifying concepts and that 
statistical analysis can be conducted to verify or falsify hypotheses (Denzin and Lincoln, 
2011). Quantitative designs are ideal for exploring relationships among variables (Balkin, 
2014) as long as variables selected for study are identified as valuable to understand a variety 
of phenomena relevant to the subject. The claim that quantitative designs represent 
reductionism has been argued to be “inaccurate” (Balkin, 2014). This is because all 
quantitative relationships evaluate what is understood by percentage of variance accounted 
for in the model (measured by square multiple correlation), that is, how much of the 
variability of the data can be explained by a fitted regression, or the extent to which the 
equation adequately measure its underlying construct (Byrne, 1998; Kline, 2011). While 
what is unknown is represented by variance not accounted for in the model. Expressing 
quantitative findings as relationships therefore allows investigators to address contributing 
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factors to a phenomenon. Moreover, apart from quantitative studies being less prone to the 
bias of subjectivity, quality of life studies have been largely based on quantitative methods 
and are usually categorised as quantitative research (Turato, 2005).    
This remaining part of this chapter focuses on the research design, the various instruments 
used and the statistical protocol.  
4.1 Design 
This is a non-experimental research study. A cross-sectional, correlational design was 
employed to examine factors affecting quality of life in persons living with SCD. In a cross-
sectional study, data are collected at one point in time. The study was retrospective because 
respondents were asked to report on events, feelings and behaviour that were past (for 
example, in the last four weeks) or current.  
Data were collected at a point in time from each participant to describe their current level of 
quality of life, and factors affecting their quality of life. Cross-sectional design was 
considered appropriate for this study because it enables collection of data on quality of life 
and possible risk factors at the same time. Additionally, because there was no intervention 
changes over time was not being investigated. 
A cross-sectional design has been described to be best suited to describe the status and /or 
relationships among phenomena (Polit and Beck, 2008). In addition, cross-sectional surveys 
are economical in relation to time and resources (Bowling, 2014). Although cross-sectional 
designs are limited in their ability to provide robust evidence in terms of the direction of 
cause and effect, Bowling (2014) has argued that the increasing sophistication of statistical 
techniques can help to minimise this limitation because the generated hypothesis can be 
tested in experimental or analytic studies. Rothman (1986) also posited that when it comes 
to analytic abilities, the distinctions between study designs should not be too rigid.  
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Being a cross-sectional design also informed the correlational approach. A correlational 
design is useful in examining interrelationships and or associations among variables that 
cannot be manipulated (Polit and Beck, 2008). This was appropriate because independent 
variables at the various levels of the Wilson and Cleary model, (biological/physiological 
function, symptoms, functional status, general health perceptions, age, gender, genotype 
marital status, socioeconomic status and so on) could not be logistically or ethically 
manipulated. Also, with a correlational design, hypotheses about associations can be tested 
and hypotheses generated with respect to possible cause and effect associations between 
variables (Bowling, 2014).      
4.2. Sample and Setting 
The setting for this study is Ibadan in southwest Nigeria. Nigeria is the largest and most 
populous country in sub-Saharan Africa with a population of approximately 185 million 
people (WHO, 2016) and is the global epicentre of sickle cell disease (Fleming et al., 1979; 
Aliyu et al., 2008; Modell and Darlison, 2008; Nwogoh et al., 2012). The country is made 
up of 36 states including the Federal Capital Territory and is organised into six geopolitical 
zones namely, North-East, North-West, North-Central, South-East, South-West and South-
South. The official language is English but there are three major languages, Hausa in the 
North, Yoruba in the West and Igbo in the East.  
This study took place in Ibadan which is situated in the south west part of the country. Ibadan 
is the largest city in Nigeria and third most populous after Lagos and Kano with a population 
of over 3 million people and therefore have a large population of people with sickle cell 
residing in the city. The official language is English while the local language is Yoruba. The 
map of Nigeria highlighting Ibadan city is shown in Figure 4-1. 
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Figure 4-1: Map of Nigeria Highlighting Ibadan 
 
Ibadan houses the University College Hospital which is the teaching hospital of the 
University of Ibadan and Adeoyo Hospital, a general hospital. These are the two major 
hospitals in Ibadan with haematology clinics where adults with sickle cell disease are 
referred and treated. These hospitals were therefore selected for data collection for the 
current study.  
The data collection took place in the outpatient units of haematology clinic (where sickle 
cell patients are attended to) of the two hospitals, the University College Hospital (UCH) 
and Adeoyo Hospital both in Ibadan, Nigeria.  
A convenience sampling designed was used. A convenience sampling, otherwise called 
availability sampling, is a statistical method of drawing representative data by selecting 
people because of the ease of access, availability, volunteering or selecting units. In this 
study, participants were recruited based on their availability at the hospitals where the data 
were collected. This sampling technique is prompt, uncomplicated, economical and 
participants were readily approachable to be a part of the sample. The method enabled the 
researcher in the current study to gather information from the respondents in the easiest 
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possible manner and without burdens to the participants who were in the hospital on their 
day of clinic either for treatment or for routine medical check. Participants were recruited at 
each of the clinics as they arrived the clinic on a clinic day. The inclusion and exclusion 
criteria are listed below. 
Inclusion criteria: 
a) individuals diagnosed with sickle cell disease;  
b) 18 years of age and older; 
c) ability to communicate in English language or the local language (Yoruba); 
d) not under intensive care or having any cognitive disability  
Exclusion criteria:  
a) patients who were below the age of 18 years at the time of the data collection;  
b) patients experiencing severe pain crisis and/or on admission, as involving such 
patients may add to their trauma and pain; 
c) patients under intensive care or having any cognitive disability 
4.2.1 Procedure 
 The investigator recruited two students who were studying for a Masters’ degree at the 
University of Ibadan to help as research assistants. These assistants were trained to help in 
data collection. Part of the training included taking them through the aims of the study, how 
to explain the study to the participants, the ethical issues involved and the procedure for the 
data collection.  
On a clinic day, the patients were approached after presenting the ethical approval to the 
nurse on duty. The purpose of the study was explained to the patients present at the clinic 
jointly both in English and the Yoruba and they were assured that the study was for an 
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academic purpose. They were informed of their free will to participate and also that they 
were free to opt out of the study at any time. In addition, a letter briefly explaining the study 
was provided to eligible participants. The letter was written in equivalent of a junior 
secondary school student (universal basic education) grade reading level English for easy 
understanding and also in Yoruba (the local language). Informed consent letters (written in 
English and Yoruba) were distributed to the participants who showed interest in 
participating.  
These trained assistants along with the researcher responded to participants who asked 
questions or needed some clarifications before they agreed to participate. Those who did not 
want to participate were not persuaded. The letter of consent was completed by those who 
were willing to participate. The questionnaires were then passed to those who gave consent. 
Further clarification was provided when required by any of the participants to ensure that 
participants understood and completed the questionnaire as it applied to them. This process 
continued in both hospitals between 10 January, 2017 and 16 May, 2017 on their different 
clinic days. Data collection took place in a large spacious enclosed room in each of the 
hospitals to provide a conducive environment. On average, the questionnaires took about 40 
minutes to complete. The participants were also allowed to go with the biros provided for 
completing the questionnaire. Also, a token for refreshment were given to participants as 
incentives. It was discovered that in each of the clinics, the sickle cell patients have 
association and have elected executives led by a president. A meeting of the researcher with 
the president and the executives helped to disabuse their minds that the study was for 
commercial or profit-making purpose. This however did not in any way influence any 
individual, who was not willing, to take part in the study.   
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4.2.2 Sample size calculation 
Structural equation modelling (SEM), is a flexible tool which permits analysis of complex 
associations, use of various types of data (e.g., categorical, dimensional, censored, count 
variables), and comparisons across alternative models. However, due to these qualities, 
developing a general guideline for sample size determination in structural equation 
modelling is difficult and has been a subject of controversy (MacCallum et al., 1999). While 
some researchers had their study based on large sample sizes (Boomsma, 1983; Gagne and 
Hancock, 2006) others have suggested that adequate sample size should be between 100 and 
150 (Anderson and Gerbing, 1984, 1988; Tinsley and Tinsley, 1987; Ding, Velicer and 
Harlow, 1995; Tabachnick, Fidell and Osterlind, 2001; Muthén and Muthén, 2002).  
A simulation study has demonstrated that with normally distributed indicator variables and 
no missing data, a reasonable sample size for a simple CFA model is about 150 (Muthén and 
Muthén, 2002). There is evidence that simple SEM models could be meaningfully tested 
even if sample size is quite small (Hoyle and Kenny, 1999; Marsh and Hau, 1999; Iacobucci, 
2010). Iacobucci (2010) suggested that a minimum sample size of 50 is appropriate.  
There have been various approaches in extant literature as to determining sample size for 
SEM. One of such method is the ‘rule-of-thumb’. According to the proponents of this 
method, sample size for SEM should be calculated in terms of ratios (Jackson, 2003) 
depending on the number of variables or model parameters. Different ratios have been 
suggested which range from 5 or 10 observation per estimated parameter (Bentler and Chou, 
1987) for normally distributed data or 10 cases per variable (Nunnally, 1967) to 20 cases per 
variable (Kline, 2011). This method lacks scientific rigour as they can lead to over- or 
underestimated sample size requirements (Wolf et al., 2013). Defining sample size as having 
a linear relationship with the number of factors or indicators implies that the more factors 
and indicator variables there are, the bigger the sample size. This is not achievable in 
152 
 
practice. A more scientific approach beyond the simplistic single ratio is to identify factors 
that may affect the size of a sample in SEM. According to MacCallum et al. (1999), model 
characteristics such as level of communality across the variables, sample size and degree of 
factor determinacy affect both model fit statistics and accuracy of parameter estimates. These 
factors were not considered in the rule-of-thumb method.  
Wolf et al.(2013) has demonstrated in a Monte Carlo study that a one-factor, four-indicator 
model with loading of 0.80 required a sample size of 60 compared to one-factor six-indicator 
model of the same loading which required less number of sample size, 40. Sample sizes have 
therefore been shown to be affected by number of latent factors and number of measured 
variables, power, effect size in SEM (Maccallum, Browne and Sugawara, 1996; Muthén and 
Muthén, 2002; Wolf et al., 2013).  
In a Monte Carlo simulation involving two-factor, 10-variable model, Muthén and Muthén 
(2002) showed that a sample size of 150 will be adequate in a CFA model without missing 
value and 175 with missing values. Wolf et al. (2013) also using a Monte Carlo simulation 
observed that increasing the number of factors led to a decrease in sample size when one 
moves from two factors to a higher number of factors. For example, three was a sharp 
increase in sample size from one-factor, four-indicator model to a two-factor, four-indicator 
model, the reverse was the case when a third or fourth factor was added. In the same way, 
they observed that a model with greater than four indicators required a smaller sample size 
relative to a model with four indicators. While a one-factor, four-indicator model with 
loading of 0.8 required a sample size of 60, a corresponding one-factor, six-indicator model 
of the same loading required a sample size of 40. The decrease in sample size in spite of the 
increase in number of indicators was attributed to more information available through 
increase in factor and indicator variables, for use in solving the simultaneous regression 
equation (Wolf et al., 2013). They further noted that “mediation models with larger effects 
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tended to achieve adequate statistical power for direct and indirect effects with smaller 
sample sizes” (Wolf et al., 2013, p. 9) and pointed out that there is broad variability in sample 
size requirement for latent variable models and that sample size estimates vary greatly from 
model to model.  
For this study, an online calculator (Soper, 2015) that used a priori method to calculate 
sample size in SEM was used. This calculator uses the number of latent variables, number 
of indicators, effect size, power and the level of type I error (α). This is supported by findings 
in literature (MacCallum et al., 1999; Muthén and Muthén, 2002; Iacobucci, 2010; Wolf et 
al., 2013).  
The model for the current study has seven latent variables and 26 measured variables (Table 
4-1). Type I error (α =0.05), and power (1-β =0.8) and effect size r=0.3). The calculator 
yielded n=170 as the required sample size. Scholars agreed that a power of 0.8 is desirable 
and Cohen suggested that a medium effect of 0.3 is adequate(Cohen, 1988). The sample size 
for this study was 200 based on the 200 patients that consented, completed and returned the 
questionnaires. Approximately 1 out of 47 patients declined participation. This translates to 
about 2.1%, this non-response was considered to have no significant impact on the result of 
the study.  
4.3 Ethics 
Necessary documents for conducting the study in Nigeria were submitted to the Ethics 
Committee of the University of Sunderland who after reviewing the documents gave 
approval (Appendix 4). The University of Ibadan/University College Hospital (UI/UCH) 
Ethics Committee (UI/UCH EC) also reviewed the documents and approved the study 
(Appendix 5). Furthermore, approval was obtained from the Management of Adeoyo 
Hospital (Appendix 6). Written information on the study were made available to the 
participants (Appendix 2), the study was also explained verbally to the participants both in 
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English and/or in the local language. Clarifications were made in response to questions from 
the participants. No identifiers were placed on the instrument packets as there was no need 
for follow up and their medical records were not required. All participants were fully 
informed about the purpose of the study and what was expected should they choose to 
participate. Each participant completed a consent form (Appendix 3) before they were given 
the questionnaires (Appendix 1). The consent form clearly stated that participation was 
completely voluntary and that participants could withdraw from the study without any 
adverse consequence at any point. The participants were also assured of the confidentiality 
of the information they supplied.  
4.4 Measures 
The theoretical construct consists of seven latent factors (see definitions): 
biological/physiological, symptoms status, functional status, general health perceptions, 
characteristics of the individual, characteristics of the environment and overall quality of life 
(Table 4-1). Table 4.1 links the predictors identified in the systematic review of chapter two 
and the Wislon and Cleary constructs in systematic review of chapter three and the 
instruments used (see Table 3-2). The seven constructs of the Wilson and Cleary model are 
listed in column one, column two are the predictors obtained from the review of the studies 
of sickle cell disease in chapter two and column three are the instruments to measure the 
variables.   
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 Table 4-1: Latent Factors, Measured Variables and Instruments. 
Latent Factor Variable Measures 
Biological/ 
physiological 
Genotype 
Comorbidities 
Disease severity index 
(DSEI) 
Self-report questionnaire 
 
Symptom Status Pain 
Emotional wellbeing 
Depression 
Anxiety 
Somatic symptoms 
Vitality 
SF-36 Bodily Pain (BP) subscale,  
SF-36 Mental Health (MH) 
subscale  
The Patient Health Questionnaire 
(PHQ-9)  
Generalised Anxiety Disorder 
(GAD-7)  
Patient Health Questionnaire 
(PHQ-15)  
SF-36 Vitality subscale 
Functional Status Physical functioning 
Social functioning 
Emotional functioning 
Role functioning 
SF-36 Physical functioning 
SF-36 Social functioning 
SF-36 Role emotional 
SF-36 Role Physical 
General Health 
Perception 
General health  
Change in health 
SF-36 GH subscale  
SF-36 change in health (HT) 
Overall Quality of 
Life 
HRQL 
Utility score 
Single item question* 
SF6D 
Characteristics of 
the Individual  
Age 
Gender 
Education 
Number of children 
Employment status 
Self-report questionnaire 
 
Characteristics of 
the Environment 
Marital status 
Living situation, 
Having a confidant 
Income 
Self-report questionnaire 
 
* A single item question to evaluate participants perception of overall quality of life.  
4.4.1 Level 1: Biological/physiological 
Assessment at this level relates to function of cells, organs and organ systems, they could be 
diagnoses or laboratory values or factors whose effects on health are mediated by changes 
in cells, organ or organ system function (Wilson and Cleary, 1995). In this study, these are 
factors associated with sickle cell disease complications such as genotype, severity, and 
comorbidities.  
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Genotype in SCD has been reported to be a predictor of mortality and disease severity or 
complications (McClish et al., 2005) and of the age of death (Platt et al., 1994). Literature 
has established that the HbSS genotype was more severe and responsible for frequent pain 
crisis and debility of the patient compared to the HbSC genotype which exhibited milder 
complications, for example, Platt et al. (1991) reported that hospital utilisation due to pain 
was 0.8 episode per patient per year in patients with SS genotype compared with 0.4 episode 
of pain per patient per year in those with SC genotype. Moreover, genotype has been used 
by researchers to measure disease complications (Lutz et al., 2004). 
Several factors have been identified in the literature as indicators of disease severity and 
could be elicited through self-report. The measures were made up of events in the life of the 
participants in the last six months such as: visit to emergency department (Aisiku et al., 
2009; Ahmed et al., 2016), admission to hospital, blood transfusion, pain episode/experience 
and other sickle-cell related crisis. Participants were asked to score items on the scale 0 
(none) to 4 (more than three times). The sum score was used as a severity index (Carlson et 
al., 2014). The frequency of emergency department (ED) visits was evaluated by asking for 
the number of ED visits within the past six months. 
Comorbidity expresses the significant concurrent diseases in addition to the chronic 
condition and known to associate with survival and hospitalisation (Khan, 1998; Beddhu et 
al., 2000; Wu et al., 2005; Elmariah et al., 2014; McClish et al., 2016). The number of 
comorbidities reported by patients have been used as a measure of biological and 
physiological variables, in several studies and illnesses including kidney transplant, end-
stage renal disease (ESRD), HIV/AIDS (Kempen, Jelicic and Ormel, 1997; Sullivan et al., 
2000; Saban et al., 2007b; Paukert et al., 2010; Schulz et al., 2012; Yang et al., 2015). Also, 
there is a consensus among researchers that self-reports of comorbidity tend to be accurate, 
and are therefore a reliable and valid representation of actual comorbidity (Van Den Bos, 
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1995; Kriegsman et al., 1996; Penninx et al., 1996; Bayliss, Ellis and Steiner, 2005). SCD 
patients are a vulnerable, chronically ill population with a high prevalence of comorbidities. 
Eleven comorbidities were specified in this thesis related to SCD and participants were asked 
to indicate which of these they had. Participants were also asked to mention any other 
diseases they had that were not listed. The comorbidities were scored for individual 
respondents (1-12). This was re-coded as 0, 1-2, and 3 or more.  
4.4.2 Level II: Symptom Status 
Symptoms are an important factor in health-illness experience (Sidani, 2010) and for 
effective patient care management (Sousa, Tann and Kwok, 2006). Symptoms are viewed as 
markers for the progression of a disease (Lorenz et al., 2006) and are triggers of beneficial 
or detrimental behaviour in the individual which often signal a change in health status 
necessitating healthcare seeking (Sousa, Tann and Kwok, 2006). Wilson and Cleary (1995) 
defined symptoms as “a patient’s perception of an abnormal physical, emotional, or 
cognitive state” (Pg 61) and stated that depression or any other psychological factor may be 
regarded as a biological and physiological variable, as symptom status variable or as a 
functioning status variable. This study identified pain, fatigue, anxiety, depression and 
somatic symptoms as measures of symptoms status in SCD (Platt et al., 1991; Sogutlu et al., 
2011; Treadwell et al., 2015). Pain is a major symptom experienced by SCD patients often 
referred to as a crisis; such episodes of excruciating musculoskeletal pain are the principal 
cause of morbidity among SCD patients (Platt et al., 1991). Pain rate (episodes per year) is 
also a measure of clinical severity (Platt et al., 1991). Some studies have shown that pain 
intensity in SCD is influenced by psychosocial factors (Anie, Steptoe and Bevan, 2002; 
Levenson et al., 2008; Sogutlu et al., 2011). The bodily pain subscale of the SF-36 was used 
to measure this symptom. High somatic symptoms were found to predict increased health 
care utilisation in primary healthcare and general population (Mewes et al., 2008; Hanel et 
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al., 2009) and in SCD (Sogutlu et al., 2011). Anxiety, depression and somatic symptoms 
were measured respectively using GAD-7, PHQ-9, and PHQ-15 (Spitzer et al., 1999, 2000; 
Kroenke and Spitzer, 2002; Kroenke, Spitzer and Williams, 2002). 
4.4.3 Level III Functional status 
Functional status is a patient’s subjective perception of his ability to perform physical 
functions. Four major domains of functioning commonly measured and generally agreed as 
the minimum include the physical functioning, role functioning, social functioning and 
psychological functioning (Ware Jr et al., 1981; Ware, 1987; Cleary, Greenfield and McNeil, 
1991; Wilson and Cleary, 1995). In self-report measures of functional status, major 
dimensions including mobility, self-care and performance of usual activities were assessed 
(Ware Jr and Sherbourne, 1992; Aaronson et al., 1993; Schulz et al., 2012). This study used 
four dimensions from the SF-36 to measure functional status. They are the Physical 
Functioning (PF), the Role Physical (RP), the Social Functioning (SF) and the Role 
Emotional (RE) subscales of the SF-36.  
4.4.4 Level IV General Health Perception 
General Health Perception (GHP) is a subjective rating that integrates the other health 
concepts already mentioned in the model (Wilson and Cleary, 1995). GHP has been observed 
to be among the best predictors of utilisation of medical, mental and general health services 
as well as mortality (Wells et al., 1986; Connelly et al., 1989; Idler and Kasl, 1991). This 
study used the General Health (GH) and Health change or transition (HT) subscales of SF-
36 to measure GHP. The GH represents the persons evaluation of his /her health and the HT 
is a measure of perception of change in health in a space of a year. 
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4.4.5 Level V: Overall Quality of Life 
Overall quality of life is the overall satisfaction or happiness with life as a whole defined as 
a summary measure of quality of life, life satisfaction or happiness(Wilson and Cleary, 
1995). This could be assessed through a single global question asking how the individual is 
satisfied with life in general (Ferrans et al., 2005). This study used a global measure with 
the question, “Looking at all parts of my life – physical, emotional, social, spiritual and 
financial in the last two weeks, the quality of my life has been?”. Possible scores range from 
0 very bad to 10, excellent; a higher score indicates better HRQL. The single global quality 
of life measure has been used extensively in literature as a subjective assessment of overall 
health (Heo et al., 2005; Ulvik et al., 2008; Carlson et al., 2014). Voruganti et al.(1998) in 
a study of schizophrenia asked the patients to appraise their quality of life on a single-item 
global quality of life measure. They reported that patients’ self-reports were highly 
consistent over the past four weeks and therefore concluded that self-report measures are 
potentially useful tools in clinical outcomes studies. Gough et al.(1983) showed that a single 
item linear analogue self-assessment which indicated the patients’ global feeling of well-
being showed excellent psychometric properties therefore a single item asking a direct 
question such as ‘how would you rate your health life today?’ is a valid and reliable indicator 
of quality of life of patients. 
4.4.6 Individual Characteristics 
Additionally, Wilson and Cleary model conceptualises the characteristics of the individual 
and of the environment as having impact on each of the five levels. Individual characteristics 
are defined to include symptom amplification, personality/motivation, and 
value/preferences. Consistent with literature, patients’ sociodemographic status, which 
included age, gender, educational status and having children (Arnold et al., 2005; Heo et al., 
2005; Phaladze et al., 2005; Carlson et al., 2014; Wan et al., 2016) were used as indicators.  
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4.4.7 Environmental Characteristics 
Environmental characteristics were made up of patients’ psychological and social economic 
supports. These were measured in this study by variables such as: living situation, having a 
confidant, marital status and income (Heo et al., 2005; Moi and Nilsen, 2012; Shiu et al., 
2014; Brunault et al., 2015). Having a confidant was a yes or no; marital status was re-coded 
into three categories to reflect current situation, they are single, married and others 
(separated, divorcees, widows/widowers). In the same vein, living situation was categorised 
into ‘living alone’ and ‘living with people’ (living with siblings, spouse, children, friends or 
other relatives). 
4.4.8 Utility measures 
Utility measures had its origin in health economics and constitute an important subgroup of 
generic measures used in cost effectiveness studies (Drummond et al., 2015) and medical 
decision-making analyses (Naglie et al., 1997).   Utility measures can be used to calculate 
quality adjusted life years (QALYs), which is useful in economic valuations (cost-utility 
analysis) and valuable because they incorporate the gained life years and quality of life years 
to guide decision making (van Litsenburg Raphaële et al., 2013). QALY also provides an 
indication of the benefits gained from a variety of medical procedures in terms of quality of 
life and survival of the patient (Gutteling et al., 2007).  A utility measure attempts to express 
the overall effect of a disease upon the patient in a single continuous scale that ranges from 
0-1 where 0 indicates dead and 1, perfect health. Utilities are value-based HRQL indicating 
patient-preferences for a certain health state which lies between 0 (death) and 1 (perfect 
health). Such a preference-based method is useful for: assessing the burden of a chronic 
condition that affects quality of life (Bramlett, Bothe and Franic, 2006); comparison of 
different therapies in comparative effectiveness research, making decisions about overall 
health impact (Hays et al., 2014) and cost-effectiveness analysis (Drummond et al., 2015). 
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Additionally, policy makers found information on utility score useful to guide in making 
informed decisions based on cost utility analysis(van Litsenburg Raphaële et al., 2013). 
Utilities are obtained by direct methods which could be by the method of Time Trade-Off 
(TTO) or Standard Gamble (SG). In SG patients are asked to choose between life with the 
health state (living with a chronic disease), and life without the health state but with 
consequences that carry a risk of immediate death, while in TTO, the consequence may be a 
reduction in total life time. However, direct measure of utilities are not always feasible in 
terms of cost, time, personnel and other socio-economic issues. Researchers have therefore 
developed algorithms to derive utilities from instruments such as the SF-36 (Brazier et al., 
1998; Nichol, Sengupta and Globe, 2001; Brazier, Roberts and Deverill, 2002; Lobo, Gross 
and Matthees, 2004; Kharroubi et al., 2007). Derived utilities have been found to be valid 
and reliable. The SF-6D was such a derivation that enables data collected with the SF-36 to 
be transformed into a measure of utility score (Brazier et al., 1998, 2012; Brazier, Roberts 
and Deverill, 2002; Kharroubi et al., 2007).   
4.5 Instruments  
In selecting instruments to use for data collection, attention was paid to their psychometric 
properties, common use in different population including SCD, brevity, ease of scoring and 
use in the Nigerian population. Five instruments were combined into one and used to collect 
data from the participants. The instruments were: (a) the Personal 
information/sociodemographic questionnaire, (b) the SF-36 health survey (c) the Patient 
Health Questionnaire, PHQ-15 for somatic symptoms, (d) PHQ-9 for depression and (e) 
Generalised Anxiety, GAD-7 for anxiety. 
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4.5.1 The Sociodemographic Questionnaire  
The questionnaire contains information on the demographic and social characteristics of the 
patients such as age, marital status, living situation, employment, income, genotype and 
education, comorbidities and other measures of disease severity such as genotype, frequency 
of pain, use of emergency department and frequency of admission to hospital. This 
instrument was used to elicit information which was grouped into physiological, 
characteristics of the individual and characteristics of the environmental in line with Wilson 
and Cleary constructs as follows: 
o Biological and physiological variables consisted of genotype, comorbidities 
and measures of disease severity. 
o Characteristics of the individual: age, gender, number of children and marital 
status 
o Characteristics of the environment: education, employment status, living 
situation, having a confidant, income   
o A single item question to measure overall quality of life. 
4.5.2 The GAD-7 Anxiety 
Generalised Anxiety Disorder (GAD) has been reported as one of the most common mental 
disorders in outpatients (Spitzer et al., 2006). (GAD-7) measure is a 7-item scale developed 
for screening generalised anxiety disorder in line with the Diagnostic and Statistical Manual 
of Mental Disorders Fourth Edition (DSM-IV) (American Psychiatric Association, APA, 
2000) diagnoses. The items reflect most of the DSM-IV symptom criteria for generalised 
anxiety disorder and has been used in screening other forms of anxiety disorder (Spitzer et 
al., 2006). Respondents were asked to rate their experience in the last two weeks with respect 
to how they were bothered by these symptoms. Rating options were ‘not at all’, ‘several 
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days’, ‘more than half the days’, ‘nearly every day’. The ratings were allocated scores of 
0,1,2,3 respectively. The GAD-7 total score ranges from 0 to 21. Cut points of 5, 10, and 15 
were interpreted as representing mild, moderate and severe level of anxiety (Kroenke et al., 
2010). In other words, 0-4 = minimal anxiety, 5-9=mild anxiety, 10-14 = moderate anxiety 
and ≥15 = severe anxiety. 
The instrument has good internal, and test-retest reliability as well as convergent, construct 
and criterion validity (Spitzer et al., 2006). The measure has also been found to have good 
sensitivity and specificity as a screener for panic, social anxiety and post-traumatic stress 
disorder (Spitzer et al., 2000; Löwe et al., 2008; Kroenke et al., 2010). GAD-7 has been 
used to measure anxiety in an SCD population in Brazil (Mastandréa et al., 2015) and the 
USA (Treadwell et al., 2015). 
4.5.3 The PHQ-9 Depression 
The Patient Health Questionnaire (PHQ) is a self-administered version of the Primary 
Evaluation and Mental Disorders (PRIME-ED). The PHQ-9 is a subscale of the PHQ 
designed to assess depression in patients and focuses on the 9-diagnostic criteria for the 
DSM-IV major depressive disorders. The instrument has been established to be reliable and 
valid instrument for screening depressive disorder according to the DSM-IV diagnoses in 
primary care (Kroenke, Spitzer and Williams, 2001). 
Patients were asked to rate how often they have been bothered by each of the depressive 
symptoms in the last two weeks. Experiences were rated from 0, ‘not at all’ to 3, ‘nearly 
every day’. The total scores range from 0 to 27. Depression symptoms level of severity were 
categorised based on scores cut points of 5,10 and 15. Thus the symptom for depression was 
assumed to be minimal for score < 5, mild = 5-9, moderate = 10-14, and severe, ≥15 
(Kroenke et al., 2010).  
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The psychometric properties of PHQ-9 have been well documented (Kroenke et al., 2010). 
In a systematic review of 38 studies involving 16 case-finding measures, in over 32,000 
patients, PHQ-9 was shown to be equal or superior to other measures of depression 
(Williams et al., 2002; Henkel et al., 2004; Löwe et al., 2004). The PHQ-9 performed 
similarly across age, sex (Klapow et al., 2002; Löwe et al., 2004) and racial ethnic groups 
(Löwe et al., 2004; Chen et al., 2006) and found sensitive to change (Löwe et al., 2004; 
Williams et al., 2007). PHQ-9 also serves as a dual-purpose instrument for making diagnoses 
and measuring severity of depressive disorder, the operating characteristics compared 
favourably with nine other case-finding instruments for depression in primary care, and takes 
less time to complete (Kroenke et al., 2010).  
The PHQ-9 is reputed to be the most commonly used depression measure in the UK National 
Health Service (Kendrick et al., 2009) and has been tested for validity and reliability in many 
languages and disease populations such as HIV/AIDs, diabetes, systemic sclerosis (Kroenke, 
Spitzer and Williams, 2001; Monahan et al., 2009; Milette et al., 2010) and in sickle cell 
(Mastandréa et al., 2015; Treadwell et al., 2015; Lucchesi et al., 2016; Ola, Yates and Dyson, 
2016). A study has also established the validity of the instrument in a Nigerian population 
(Adewuya, Ola and Afolabi, 2006). The study was conducted among university students to 
evaluate the psychometric properties of PHQ-9 in a Nigerian population and yielded high 
reliability (Cronbach alpha, 0.85) with excellent specificity and sensitivity (Adewuya, Ola 
and Afolabi, 2006).The PHQ-9 was chosen for this work because of its brevity, good 
psychometric properties, wide use in clinical practice and research, validation in Nigeria, 
prior use in an SCD population and ease of scoring. 
Items left blank (missing data) were filled with the means of the completed items provided 
missing items were less than 20% otherwise the item is treated as completely missing for the 
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individual (Kroenke et al., 2010). This approach was considered to have a lower risk of 
missing persons with depression, anxiety or somatisation (Kroenke et al., 2010).  
4.5.4 The PHQ-15 Somatic Symptoms 
The Patient Health Questionnaire (PHQ-15) is a subscale of the Patient Health Questionnaire 
(Kroenke, Spitzer and Williams, 2002) designed as a continuous measure of somatic 
symptoms burden in patients over the last four weeks. The PHQ-15 screens for 15 somatic 
symptoms (e.g. headaches, back pain, dizziness) that account for more than 90% of the 
physical complaints reported in outpatient settings (apart from self-limited upper respiratory 
symptoms such as cough, nasal symptoms, and sore throat) (Kroenke, Spitzer and Williams, 
2002; Kocalevent, Hinz and Brähler, 2013). Patients were asked to rate how much they have 
been bothered during the past month on a three-point Likert scale that ranges from “0” (not 
bothered at all) to “2” (bothered a lot) scale. The total raw score of the instrument ranges 
from 0 to 30 and is categorised as, ‘minimal somatic symptoms, 0-4’; ‘mild somatic 
symptoms, 5-9’; ‘moderate somatic symptoms, 10-14’; and severe somatic symptoms, ≥15’. 
(Kroenke et al., 2010). The instrument has been reported to be sensitive to change both in 
longitudinal studies and large randomised trials where depression is a primary(Andrews et 
al., 2008; Dimsdale, Creed and Disorders, 2009) outcome measure or a secondary(Kroenke 
et al., 2010) outcomes measure. PHQ-15 has been recommended as an excellent measure of 
somatic symptom burden and potential somatisation (Kroenke, 2006, 2007) because of the 
association between scores on the PHQ-15 and functional impairment, disability and health 
cost use (Kroenke et al., 2010). In addition, items on PHQ-15 were found to overlap better 
with other validated instruments for measuring somatisation than any other two measuring 
instruments do with one another while total self-reported PHQ-15 somatic symptom score 
has been reported to be highly associated with clinic-rated somatoform disorder symptom 
counts (Kroenke, Spitzer and Swindle, 1998; Kroenke et al., 2010).   
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In scoring the instrument, attention was paid to items left unanswered. A prorated score was 
obtained by multiplying the total score of answered question by 15 and dividing by the 
number of answered items and rounded to the nearest whole number as specified in the 
manual. For instance, if 12 questions are answered and the scores add up to 20, the prorated 
score will be 20*15/12 = 25. This is acceptable provided the items left unanswered are not 
more than 20% (Kroenke et al., 2010).  
The validity and reliability of the instrument has been established in over 40 studies, and in 
different health care settings (Kroenke et al., 2010), as a measure of somatic symptoms in 
primary care, research and general population (Kocalevent, Hinz and Brähler, 2013). 
Moreover, the reliability and validity of PHQ-15 in SCD has been established (Sogutlu et 
al., 2011; McClish et al., 2017).   
4.5.6 The Medical Outcomes Study SF-36 Health Survey Questionnaire 
The Medical Outcomes Study short form 36 (SF-36v1) health survey is a generic 
multidimensional measure derived from the original 245 RAND MOS questionnaire and 
designed to measure various component of HRQL (Ware Jr, 1995) for self-administration 
by persons of 14 years of age or older (Ware Jr and Sherbourne, 1992).  
The instrument cannot be summed up as a single instrument but is made up of eight subscales 
from 35 of the 36 items, each subscale represents a health dimension. They are Physical 
Functioning (PF), Role Physical (RP), Role Emotional (RE), Bodily Pain (BP), Vitality 
(VT), Mental Health (MH), General Health (GH), and Social Function (SF) and the one item 
on health transition or changes in health. All the eight subscales are independent of each 
other. Table 3-2 summarises the basic element of SF 36 and the meaning of low and high 
scores presented by the instrument. 
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Table 4-2: The Contents of the SF 36 
Health concepts/ 
Domain 
Number 
of items 
Meaning of low scores Meaning of high scores 
Physical 
Functioning (PF) 
10 Limited a lot in performing all 
physical activities including 
bathing or dressing due to 
health 
Performs all types of physical 
activities including the most 
vigorous without limitations 
due to health 
Role Emotional 
(RP) 
4 Problems with work or other 
daily activities as a result of 
physical health 
No problems with work or 
other daily activities as a 
result of physical health 
Bodily Pain (BP) 2 Very severe and extremely 
limiting pain 
No pain or limitations due to 
pain 
General health 
(GH) 
5 Evaluates personal health as 
poor and believes it is likely to 
get worse  
Evaluates personal health as 
excellent 
Vitality (VT) 4 Feels tired and worn out all the 
time 
Feels full of pep and energy 
all the time 
Social 
Functioning (SF) 
2 Extreme and frequent 
interference with normal social 
activities due to physical or 
emotional problems 
Performs normal social 
activities without interference 
due to physical or emotional 
problems 
Role Emotional 
(RE) 
3 Problems with work or other 
daily activities as a result of 
emotional problems 
No problems with work or 
other daily activities as a 
result of emotional problems 
Mental Health 
(MH) 
5 Feelings of nervousness and 
depression all of the time 
Feels peaceful, happy and 
calm all of the time 
Reported health 
transition (HT) 
1 Believes general health is 
much worse now than one year 
ago 
Believes general health is 
much better now than one 
year ago 
Source: Ware et al. (1999) pp 3:5) 
Component analysis showed that the instrument measures two distinct constructs of the 
HRQL, the physical health dimension referred to as the Physical Component Summary 
(PCS) or ‘physical health’, and the psychological or mental health dimension referred to as 
the Mental Component Summary (MCS) or ‘mental health’ (McHorney, Ware Jr and 
Raczek, 1993). Exploratory factor analysi has been used to determine the factor structure of 
the instrument in 10 different populations (Ware and Gandek, 1998). Heo et al.(2005) 
suggested that using SF-36 had advantages above the sickness impact profile (SIP) because 
of its more robust validity and test-retest reliability. 
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The instrument uses a four-week recall, to measure the different dimensions of HRQL. One 
of the items assesses overall well-being. Subjects are asked to rate their health on a 5-point 
Likert scale from excellent =1, to poor=5 with lower scores indicating better health. 
The SF-36 is a common quality of life measurement and is one of the most widely used 
general HRQL measures, and has been reported in over 1000 publications (Ware Jr, 2000). 
The instrument has been validated across a wide variety of age, race, disease populations 
including many chronic diseases (Ware Jr and Sherbourne, 1992) and as outcomes of clinical 
trials and with different population.  
The instrument is very popular for evaluating HRQL (Lins and Carvalho, 2016). The 
instrument has been used to measure various aspect of HRQL in diabetes, cancer, HIV/IDs, 
SCD with acceptable psychometric properties (Bullinger, 1995; Phaladze et al., 2005; 
Asnani, Lipps and Reid, 2007, 2009; Dampier et al., 2011; Shiu et al., 2014). The SF-36 is 
well preferred because of its brevity, ease of use, and applicability across a range of health 
states and cultures (Garratt et al., 1993; Gandek et al., 1998). The validity and reliability of 
the instrument has been established (Ware Jr and Sherbourne, 1992)., The SF-36 is the most 
frequent measure used to study quality of life in SCD (Asnani, Lipps and Reid, 2007, 2009). 
SF-36 has been translated and adapted in more than 40 countries, including Nigeria (Mbada 
et al., 2015).  
The instrument has also been translated to Yoruba and tested in the Nigerian population. 
Based on the protocol of the International Quality of Life Assessment (IQOLA) Project, 
Mbada et al.(2015) conducted a study that translated and adapted the instrument into Yoruba. 
The translated version was tested in a population of 1087 participants made up of 95.8% 
native Yoruba speakers. They established satisfactory psychometric properties, a concurrent 
validity score of between 0.749 and 0.902 for the scales and domains, convergent validity 
score of between 0.421 to 0.907 and discriminant validity was also found satisfactory except 
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for item ‘1’. They reported a reliability score of between 0.636 and 0.843 for scales and 
range of 0.783 to 0.851 for domains that the Yoruba SF-36 showed excellent psychometric 
properties comparable to the original American and other versions and indicated that the 
Yoruba version is a valid tool to assess HRQL among the Yoruba population. Asnani, Lipps 
and Reid,(2009) have established psychometric properties of the instrument in the SCD 
population. They reported acceptable degree of internal consistency, reliability and 
discriminant validity in the Jamaican SCD population. 
The instrument was coded on a scale of 0-100 as recommended in the manual (Ware and 
Kosinski, 2001) and transformed so that higher values reflect better quality of health. Each 
dimension (subscale) was obtained by adding all the items in the subscale and dividing by 
the number of items. For example, the physical functioning (PF) subscale was obtained by 
adding all the 10 items PF01 – PF10 and dividing by 10.  
Norm-based scoring has been introduced by the developer to facilitate comparison and 
interpretation (www.qualitymetric.com). The norm-based scoring was based on the USA 
1988 general population each scale was scored to have mean 50 and standard deviation, 10. 
This implies that all scores above 50 were interpreted as having a more positive response set 
to whatever the domain measures. A scoring software license was obtained from Quality 
Metric Inc. (Appendix 8) to score the data and to facilitate the comparison of the HRQL 
scores of Nigerians with SCD with the norm-based value.  
In treating missing values for the instrument, The designer of the instrument recommended 
that missing data could be substituted with the mean value of valid responses up to 50% of 
items in the subscale (Ware et al., 2000). If any respondent has more than 50% of the items 
missing in a subscale, the subscale score for the individual was considered missing. The 
developers of the scale however hinted at a more sophisticated method of handling the 
missing values. In this study, a more robust method of treating missing value, the full 
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information maximum likelihood (FIML) or simply called maximum likelihood imputation 
technique, was used to reduce bias due to mean values. This method produces unbiased 
estimates of parameters as well as good estimates of the standard errors (see 3.8.2). In a 
comparison of methods for dealing with missing items in SF-36, A study reported that 
multiple imputation and full information maximum likelihood appeared superior to the 
personal mean score in terms of accuracy and precision (Peyre, Leplège and Coste, 2011). 
The IBM SPSS AMOS 25 maximum likelihood imputation was used, the pattern analysis 
showed that no items has more than 20% missing value. The before and after imputation 
characteristics of the data is shown in Table 3-3. The table shows that no bias was introduced 
by the imputation whereas more power has been made available through the larger sample 
size.  
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Table 4-3: Comparison of Items of SF-36 Before and After Imputation of Missing Values 
 Before imputation After imputation Test Statistic 
Items N Mean SD N Mean SD Mean diff. 
(Absolute) 
p-
value 
Equal 
Variance 
test 
PF1 194 38.920 38.838 200 39.00 38.227 0.080 0.984 0.412 
PF2 190 62.368 38.036 200 61.75 37.836 0.618 0.872 0.470 
PF3 190 53.684 38.656 200 53.50 38.342 0.184 0.962 0.454 
PF4 190 51.842 39.296 200 52.00 39.098 0.158 0.968 0.471 
PF5 187 63.102 38.479 200 63.00 37.923 0.102 0.979 0.419 
PF6 190 55.526 36.493 200 55.75 36.208 0.224 0.952 0.456 
PF7 170 55.588 36.259 200 55.5 35.370 0.088 0.981 0.377 
PF8 171 60.234 37.148 200 60.75 37.113 0.516 0.894 0.496 
PF9 169 68.935 38.142 200 70.25 37.207 1.315 0.738 0.367 
PF10 176 74.716 39.640 200 73.25 39.110 1.466 0.719 0.426 
RP1 191 59.162 49.283 200 60.00 49.113 0.836 0.866 0.480 
RP2 188 53.723 49.994 200 53.50 50.003 0.223 0.965 0.499 
RP3 188 45.745 49.952 200 46.00 49.965 0.255 0.960 0.499 
RP4 191 56.021 49.767 200 55.50 49.821 0.521 0.918 0.494 
RE1 190 60.00 49.119 200 60.00 49.113 0.000 1.000 0.499 
RE2 187 59.358 49.248 200 60.00 49.113 0.642 0.898 0.484 
RE3 191 64.398 48.008 200 64.50 47.971 0.102 0.983 0.495 
BP1 192 72.083 22.415 200 72.20 22.308 0.117 0.954 0.470 
BP2 190 67.50 29.317 200 67.37 29.034 0.126 0.966 0.465 
SF1 188 68.351 30.955 200 68.62 30.593 0.274 0.930 0.435 
SF2 185 59.865 30.629 200 59.75 30.571 0.115 0.971 0.459 
VT1 175 62.171 31.548 200 61.50 31.122 0.671 0.836 0.425 
VT2 197 64.586 29.092 200 64.60 29.035 0.014 0.996 0.488 
VT3 191 65.655 30.253 200 65.20 30.687 0.455 0.883 0.422 
VT4 196 60.816 23.693 200 60.90 23.494 0.084 0.972 0.452 
GH1 190 64.211 27.132 200 64.88 27.005 0.664 0.809 0.473 
GH2 196 51.020 37.791 200 50.50 35.881 0.520 0.888 0.233 
GH3 197 65.228 34.112 200 65.50 34.048 0.272 0.937 0.489 
GH4 196 80.740 29.562 200 80.38 29.642 0.365 0.902 0.485 
GH5 195 74.359 31.134 200 74.38 30.842 0.016 0.996 0.447 
MH1 186 64.086 30.922 200 62.70 31.170 1.386 0.661 0.457 
MH2 197 72.893 33.047 200 72.40 33.283 0.493 0.882 0.460 
MH3 195 74.154 26.877 200 74.00 26.900 0.154 0.955 0.496 
MH4 193 67.565 31.865 200 67.50 31.856 0.065 0.984 0.498 
MH5 193 80.622 24.144 200 80.20 24.309 0.422 0.863 0.462 
HT 185 89.730 20.587 200 89.88 20.221 0.145 0.995 0.333 
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4.5.7 Derived Utility measure (SF-6D) 
The SF-6D is a six-dimensional health classification (Brazier et al., 1998) derived from the 
SF-36 which estimated utility or preference-based measures from SF-36 score (Brazier et 
al., 2012). SF-6D was developed in the UK general population from 11 questions of the SF-
36. The questions were extracted from the six health dimensions of physical function, role 
limitations, social functioning, pain, mental health and vitality. SF-6D ranges from 0.30 to 
1.0 (full health). The derived measure of utility has been used in many studies to obtain 
utility scores for patients in general and disease populations (Thein et al., 2005; Walters and 
Brazier, 2005; Sullivan and Ghushchyan, 2006; Wyld et al., 2012). A license was obtained 
from the University of Sheffield for the scoring algorithm. 
4.6 Analysis of instruments  
Though the psychometric properties of these instruments have been established in different 
studies, populations and countries, researchers have suggested that investigators should not 
rely on published reliability estimates because alpha is a property obtained from a specific 
sample of the population being tested (Streiner, 2003; Tavakol and Dennick, 2011). These 
instruments were therefore examined for validity and reliability in the study population as 
required in quality of life measurements (Bowling, 1991; Fitzpatrick, 2000). 
The reliability, measured by Cronbach alpha (Cronbach, 1951), was for all the scales above 
the recommended 0.70. The means and standard deviations (SD) of scores were also 
calculated. 
The mean and standard deviation of each item of the SF-36 instruments were computed. The 
ceiling and the floor effects were also examined, and the reliability was obtained for each 
domain or subscale. These were all found acceptable. Further psychometric properties 
beyond the Cronbach alpha were examined for the SF-36. To establish item validity, the 
correlations between items and the hypothesised scale (item internal consistency) was 
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expected to be at least 0.40 (Streiner, Norman and Cairney, 2015) and the correlation 
between each item and its hypothesised scale (corrected for overlap) should be higher than 
the correlation between that item and the other scales (item discriminant validity). A scaling 
success rate was tallied for each item whenever it correlated higher with its hypothesised 
scale than with all the other scales (Prieto, Alonso & Ferrer, 1997). Construct validity was 
based on sociodemographic variables (Jenkinson, Coulter and Wright, 1993; Prieto et al., 
1997). It has been hypothesised that HRQL will be inversely associated with patients’ age, 
with lower socioeconomic level and relatively worse HRQL results for female patients 
(Hemingway et al., 1997). Percentages were obtained for patients with worst possible scores 
(floor effect) and best possible score (ceiling effect).  
According to the developers of the SF-36, the 35 items were expected to produce an 8-facror 
structure representing the domains of the instruments (Ware Jr and Sherbourne, 1992; Ware 
and Gandek, 1998) . Factor analysis was therefore carried out to determine the structure of 
SF-36 in the Nigerian population of SCD patients whether it conformed to the expected 8-
factor structure Principal component analysis followed with varimax rotation was conducted 
on the 35 items. A factor was assumed relevant if its eigenvalue is greater than one.  
4.7 Structural Equation Modelling (SEM) 
Structural equation modelling (SEM) is a statistical technique that encompasses factor 
analysis, path analysis and regression which has been established as an ideal method to test 
a priori hypothesis concerning relationships among latent (theoretical constructs) and 
measured (observed) variables (Schumacker and Lomax, 2004; Kline, 2011; Mayo et al., 
2015). A powerful tool that allows researchers to test simultaneously the underlying 
relationship between several variables within the framework of a model, SEM allows for 
confirmatory testing of complex relationships (Byrne, 2001) as well as confirming factor 
structure of an instrument (Tomarken and Waller, 2005). Some advantages of SEM 
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according to Chan et al.(2007) include the ability of constructs in SEM to perform both as 
predictor and as criterion construct and also enable a set of measured variables to represent 
a latent theoretical construct more realistically than a single variable. SEM procedures may 
be used to compute reliability of both measurement instruments and estimated latent 
constructs. In addition, SEM enables evaluation of the general compatibility (i.e., the 
goodness of fit) of the model as well as the strength of relationship among constructs and 
useful to compare competing theoretical models. The technique has the capacity for 
assessing and modifying theoretical models (Anderson and Gerbing, 1988) and because it is 
covariance-based, provide better coefficient estimates and more accurate model analyses 
(Bollen, 1989).  
SEM is made up of two distinct models or sub-models. The first part is the measurement 
model, in which relationships of the observed indicators to their hypothesised constructs are 
specified and the constructs are allowed to freely correlate with each other, the second part 
is the structural model which specifies the causal pathways of the constructs as they relate 
to one another based on theory (Anderson and Gerbing, 1982; Jöreskog and Sörbom, 1984). 
Researchers often use the measurement model to examine the extent of interrelationships 
and the presence or absence of correlation among the latent constructs. SEM has been widely 
used in HRQL models due to its capability to test such complex models which sets a priori 
hypothesised relationships among multiple correlated variables (Musil, Jones and Warner, 
1998; Kline, 2011), researchers are increasingly using it in HRQL studies. This is because 
SEM allows simultaneous investigation of a set of measurement paths and a structural path 
proposed by HRQL models. Researchers have used SEM to evaluate the goodness of fit of 
HRQL model to better understand the relationships of the physiological and psychosocial 
factors to each other and to HRQL in many disease conditions including epilepsy (Bishop et 
al., 2002), HIV/AIDs (Sousa and Kwok, 2006), diabetes (Shiu et al., 2014), heart failure 
(Mayo et al., 2015), Coronary artery disease (Hofer et al., 2005).  
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The use of SEM has been predicted to increase in research as a means of confirming 
measurement structures of instruments and to assess appropriateness of theoretical 
constructs. The ability of SEM to compare a hypothesised model’s covariance with that of 
observed data allows a more ‘causal’ explanation of findings (Hofer et al., 2005) and is also 
suitable for investigating mediator effects (Baron and Kenny, 1986; Holmbeck, 1997; Cole 
and Maxwell, 2003). SEM has been rated better than standard regression models because of 
its theory-driven approach and the evidences that the resulting prediction equation more 
accurately represent the true causes of variation in the dependent variable (Anderson and 
Gerbing, 1988; Hofer et al., 2005). The basic steps for SEM analysis are briefly discussed 
as follows:  
4.7.1 Specification 
The generally recommended approach to model specification is the two-phase approach 
(Anderson and Gerbing, 1988; Mueller and Hancock, 2008) with the measurement and 
structural models specified separately. This method ensures assessment and earlier detection 
of possible misspecification error in the measurement which could be addressed before the 
assessment of the hypothesised causal relationships (Mueller and Hancock, 2008). In this 
study the measurement model and the structural model were constructed following the 
theoretical framework of Wilson and Cleary (1995). A multiple-indicator approach (Kline, 
2011) was employed so that at least two observed variables were used to measure a construct 
except the overall QOL which has one indicator variable. Kline (2011) has suggested that 
scores from multiple indicators measuring the same constructs should be positively 
correlated. This was ensured by reversing the score of some indicators before analysis in 
SEM such that all indicators that measure the same construct are in the same direction. For 
example, since the SF-36 was scored such that high score indicated better health (Ware et 
al., 2000; Ware, 2007), the BP and MH were reversed so that higher scores indicated worse 
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health to ensure that for example, bodily pain did not correlate negatively with depression 
as they were in the same cluster that measures symptoms status. In the initial step, the 
measurement model stage, the indicators were loaded on the latent constructs and the 
constructs were allowed to freely intercorrelate. No indicator was allowed to load on more 
than one latent construct (McDonald and Ho, 2002). In the second part, the latent variables 
were connected as posited by Wilson and Cleary (1995) to form the structural path of the 
model. The relationship between the latent variable or between a single predictor and a latent 
variable were specified as path coefficients or regression coefficients (Hofer et al., 2005; 
Mueller and Hancock, 2008).  
4.7.2 Identification 
Identification is an important issue in SEM as it relates to whether there is a unique set of 
parameters consistent with the data. A structural model has three possible state of 
identification (Byrne, 2001); under-identified, just-identified and overidentified. An under-
identified model has insufficient information to estimate the parameters because the number 
of parameters to be estimated is more that the data points. A just-identified model has the 
number of parameters equal to the number of data points which returns a zero degree of 
freedom, such model is not scientifically useful because the model to be tested cannot be 
rejected (Chan et al., 2007). The over-identified model has more data points than the number 
of parameters to be estimated returning a positive degree of freedom to obtain a determinant 
solution that can lead to rejecting or confirming the hypothesised model (Chan et al., 2007). 
A simple method for establishing identifiability is to subtract the number of parameters to 
be estimated form the number of data points. The number of data points is obtained from the 
formula s(s+1) where s is the number of indicator variables. The number of parameters is 
based on the sum of the number of regression coefficients, variances and covariances. A 
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sufficient condition for a parameters of measurement model to be identified required that 
each latent variable should have at least two indicators (Kline, 2011). 
4.7.3 Estimation  
The estimation stage of SEM centres on the evaluation of the fit between the hypothesised 
model and the observed data, and the interpretation of parameter estimates  
Parameter estimation 
Two commonly used methods for parameter estimation in SEM are the ML (maximum 
likelihood) and the WLS (weighted least squares). The ML was used in this study because it 
has been the predominant method (Anderson and Gerbing, 1988) and the most widely used 
fitting function for SEM (Schermelleh-Engel, Moosbrugger and Müller, 2003). In addition, 
most available softwares use ML as the default estimator. For a correctly specified model 
and adequate sample size, the ML produces parameter estimates that are asymptotically 
unbiased, consistent and efficient (Schermelleh-Engel, Moosbrugger and Müller, 2003). 
Moreover, the ML allows for a statistical test of overall model fit for overidentified models, 
in addition, the ML estimates are scale invariant (Bollen, 1989) which means that the values 
of the fit function do not depend on whether correlation or covariance matrices are analysed, 
and whether original or transformed data are analysed. Though the ML assumes multivariate 
normality of data which could be a limitation, research has however shown that ML is robust 
against violation of the normality assumption (Browne, 1984; Chou and Bentler, 1995; 
McDonald and Ho, 2002; Muthén and Muthén, 2002). Simulation studies have further shown 
that under conditions of severe non-normality, ML parameter estimates are still consistent 
though not necessarily efficient (Schermelleh-Engel, Moosbrugger and Müller, 2003). 
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4.7.4 Model fit  
Model fit in SEM is evaluated by examining various statistics. The purpose is to determine 
whether the results provide empirical evidence that the model fits the data (Aroian and 
Norris, 2005). The inferential Chi-square (χ2) likelihood ratio statistic is used to assess the 
magnitude of the discrepancy between the sample and fitted matrices. A non-significant Chi-
square is expected to confirm model fit. A significant Chi-square indicates a poor fit. 
However, χ2 is sensitive to sample size as it increases with increase in sample size (Gerbing 
and Anderson, 1985) which makes χ2 always significant with large samples and thus return 
poor fit to SEM models leading to a rejection of the model even though the model may be 
well-fitted to the data. Because of this sensitivity, a modified test is the χ2 divided by its 
degree of freedom (df). If χ2/df does not exceed 3.0 the model should be considered a good 
fit to the data (Schermelleh-Engel, Moosbrugger and Müller, 2003). Researchers have also 
recommended additional indices to assess the fit of the model. These descriptive fit indices 
have also been accepted in literature as confirmatory tests. These fit indices have been 
broadly categorised into three classes (Mueller and Hancock, 2008) as absolute, 
parsimonious and incremental or comparative indices (Schermelleh-Engel, Moosbrugger 
and Müller, 2003; Schumacker, Lomax and Group, 2010).  
Absolute fit indices include the global chi-square (χ2) test (already mentioned above as 
inferential statistic), the root mean square error of approximation (RMSEA) and the 
standardised root mean residual (SRMR) assess the overall discrepancy between the 
observed and the expected covariance matrices. The RMSEA (Steiger, 1990) is a measure 
of discrepancy between the observed and model implied covariance matrices per degree of 
freedom. Browne and Cudeck (1993) has suggested that RMSEA values between 0.05 and 
0.08 indicate an adequate fit. The SRMR (Hu and Bentler, 1998) is a measure of the average 
179 
 
of the fitted residuals and ranges from 0.00 to 1.00, SRMR value less than 0.05 represents 
an adequate fit (Schermelleh-Engel, Moosbrugger and Müller, 2003).  
Parsimonious indices in evaluating overall discrepancy between observed and implied 
covariance matrices take into account the model’s complexity, they include the Parsimony 
goodness of fit index (PGFI), parsimony normed fit index (PNFI), the Akaike information 
criterion (AIC) to compare fit across non-nested models and the expected cross validation 
index (ECVI).  
Incremental or comparison indices focus on model comparisons, they evaluate absolute or 
parsimonious fit relative to a baseline model (a model that specifies no relationship among 
measured variables), they include the comparative fit index (CFI) the normed fit index (NFI) 
and the non-normed fit index (NNFI), the goodness of fit index (GFI) and the adjusted 
goodness of fit (AGFI). The CFI (Bentler, 1990) which is the most popularly used in this 
group, provides a measure of complete covariation in the data. CFI value greater than  0.95 
indicates acceptable fit to the data.  
Most commonly used indices in current publications and their threshold for making 
statements on the model being evaluated are stated on Table 4-4.  
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Table 4-4: Fit Indices and Threshhold Values 
Fit Index Good fit Acceptable fit 
χ2 
p value 
χ2 / df 
0 ≤ χ2 ≤ 2df 
0.05 < p ≤ 1.00 
0 ≤ χ2/ df ≤ 2 
2df ≤ χ2 ≤ 3df 
0.05 ≤ p ≤ 0.10 
2 < χ2/ df ≤ 3 
RMSEA 
P value for test of close 
fit (RMSEA < 0.05) 
Confidence interval (CI) 
 
SRMR 
0 ≤ RMSEA ≤ 0.05 
0.10 < p ≤1.00 
Close to RMSEA,  
left boundary of CI = .00 
 
0 ≤ SRMR ≤ 0.05 
.05 < RMSEA ≤ 0.08 
.05 ≤ p ≤ 0.10 
Close to RMSEA 
 
 
.05 < SRMR ≤ .10 
NFI 
NNFI 
CFI 
GFI 
AGFI 
.95 ≤ NFI ≤ 1.00 
.97 ≤ NNFI ≤ 1.00 
 97 ≤ CFI ≤ 1.00 
95 ≤ GFI ≤ 1.00 
90 ≤ AGFI ≤ 1.00, 
Close to GFI 
.90 ≤ NFI < .95 
.95 ≤ NNFI < .97 
.95 ≤ CFI < .97 
.90 ≤ GFI < .95 
.85 ≤ AGFI < .90, 
Close to GFI 
AIC 
CAIC 
ECVI 
Smaller than AIC for comparison model 
Smaller than CAIC for comparison model 
Smaller than ECVI for comparison model 
Source: ‘Evaluating the fit of structural equation models: Tests of significance and descriptive goodness-of-fit 
measures’, Methods of psychological research online, 8(2) (Schermelleh-Engel, Moosbrugger and Müller, 
2003, p. 52). 
4.7.5 Modification 
Model modification, where necessary, was expected to be in line with theory such that 
inferences will be based on established theory and not on data variability. 
4.8 Data management  
Two computer statistical packages were used in this study. They are the Statistical Package 
for the Social Sciences (SPSS) version 24 (IBM SPSSv24) and the Analysis of Moment 
Structures (AMOS) version 25 (IBM SPSS AMOS 25, 2018).  
4.8.1 Data Screening procedures 
Screening procedures were performed on the raw data to ensure that they were suitable for 
analysis in SEM. Some of the problems that arise in SEM stem from the violation of its 
assumptions. SEM assumes among others, multivariate normality, positive definiteness, 
homoscedasticity and acceptable psychometric properties of instruments (Schumacker, 
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Lomax and Group, 2010; Kline, 2011). The presence of multicollinearity, outliers and 
missing data could render data unfit for use in SEM. Data were screened as outlined below 
to check and ensure the fitness of data for SEM analysis.  
Multivariate normality. According to Kline (2011), assumption of multivariate normality 
implies that all individual univariate distributions are normal, the joint distribution of any 
pair of variable is normal, all bivariate scatter plots are normal and the distribution of 
residuals is homoscedastic. He argued that instances of multivariate normality can be 
detected by examining the univariate distributions. Detecting non-normality in variables can 
be accomplished by inspecting the skewness (the degree of symmetry around the mean) and 
kurtosis (the degree of peakedness or flatness of the distribution). Studies suggested that the 
absolute value of the skew index and kurtosis index should not exceed 3 and 10 respectively 
(Kline, 2011). DeCarlo (1997) however argued that the lack of univariate skewness and 
kurtosis are necessary but not sufficient conditions for multivariate skewness, kurtosis and 
normality, thus the Mardia’s multivariate skewness and kurtosis coefficient (Mardia, 1970) 
was employed to inspect the multivariate property of the data. 
Multicollinearity. A collinearity diagnostic check was conducted. Three methods were used 
to check for multicollinearity in the predictors. 
1. Correlation matrix: the presence of multicollinearity is suspected between two 
predictor variables if the coefficient of correlation between them is almost unity or 
the squared multiple correlation, R2 > 0.90. 
2. Tolerance and the variance inflation factor (VIF): the rule is that tolerance statistic 
should not be less than 0.1 and the VIF should not be greater than 10 (Kline, 2011). 
3. Eigenvalues: an eigenvalue close to zero with a corresponding large condition will 
indicate the presence of multicollinearity.  
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Homoscedasticity. To confirm homoscedasticity, the variances of predictor variables were 
examined. The ratio of the largest variance to the smallest variance was expected not to be 
greater than 10 otherwise the assumption was considered violated. 
Outliers. A linear regression on the predictor variables was performed. The Mahalonobis 
distance (D) statistic was used to check for the presence of outliers. In a large, normally 
distributed sample, D2 follows a central chi-square (χ2) distribution statistic with the number 
of variables as degrees of freedom. 
Positive definiteness: This was examined through the determinant of the correlation matrix 
which was expected to be greater than zero. 
Sample size: Sufficiency of sample size was examined through the Kaiser-Meyer-Olkin 
KMO test of sample size adequacy (Williams, Onsman and Brown, 2010). A KMO greater 
than 0.5 could confirm the adequacy of the sample size. 
4.8.2 Missing Data 
Missing data is a common occurrence in research. Problems that emanate from using 
inappropriate methods to deal with missing data include bias in parameter estimates (Jones, 
1996), standard errors and test statistics (Glasser, 1964; Little and Rubin, 1987) and 
inefficient use of the data (Afifi and Elashoff, 1966). Many statistical methods have been 
recommended to deal with missing data to avoid biased conclusion on the result of analysis. 
Missing patterns have been categorised in literature to be missing completely at random 
(MCAR), or missing at random (MAR) Data are said to be MCAR if given two variables 
X,Y, the probability that data are missing on Y does not depend on X or Y while data are 
MAR if the probability that the data are missing on Y does not depend on Y but may depend 
on the value of X holding X constant (Rubin, 1976; Kline, 2011). This implies that in MAR, 
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missingness depends on things observed but not on things that are not observed (Allison, 
2003). Invariably, if data is MCAR, they are also MAR. 
In SEM, conventional methods such as the pairwise deletion and the listwise deletion have 
been reported inappropriate under the assumption of MAR because they produce biased 
estimates and are also not amenable to estimating standard errors (SEs) or testing 
hypotheses. The mean imputation technique which involves substituting missing cases with 
the overall sample mean also yields biased estimates of parameters (Little and Rubin, 1987). 
Furthermore, the conditional mean imputation method, estimated by regressing variable with 
missing data on other variables in the data set for cases with complete data, was reported to 
have a “general tendency” to produce underestimates of variances and overestimate of 
correlations (Little and Rubin, 1987). 
In view of the weaknesses of these highlighted methods, a maximum likelihood (ML) 
approach was used in this study. Researchers have recognised the ML method as the most 
widely used method for estimating SEM under the assumption of multivariate normality and 
has been shown to produce estimates that are consistent (estimates converge in probability 
to the true parameter value as the sample size increases, i.e. bias shrinks to zero with 
increasing sample size), asymptotically efficient (sampling variance of estimate is as small 
or smaller than that of any other estimator, and improves with increasing sample size), and 
asymptotically normal(Arbuckle, 1996) and can handle missing data under the weaker 
assumption of MAR as well as under variety of distributional assumptions (Allison, 2003). 
Under conditions of missing data, there are three major methods of ML estimators of 
parameters; they are one, the method of factoring of the likelihood (Marini, Olsen and Rubin, 
1980), two, the EM (Expectation-Maximisation) algorithm (McLachlan and Krishnan, no 
date; Dempster, Laird and Rubin, 1977) and three, the direct ML otherwise called the full 
information ML (FIML) ((Allison, 1987; Muthén, Kaplan and Hollis, 1987). Comparing 
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these three approaches Allison (2003) reported that direct ML overcomes the weakness of 
EM algorithm, Arbuckle (1996) also proposed the use of direct ML for general missing data 
patterns and implemented same in AMOS. In addition, Duncan, Duncan and Li (1998) 
suggested that direct ML appears to be the best method for handling missing data in SEM. 
The multiple imputation (MI) technique was also considered in the search for the best means 
of handling missing data in SEM. Though the MI has statistical properties similar to the 
optimality of direct ML and can be used in almost any situation, the method lacks the ability 
to produce determinate results and overestimates the correlation coefficient (Allison, 2003). 
Also, the parameters estimates are less efficient and the standard error estimates are 
considered too low because additional variability are not accounted for. Moreover, the need 
to obtain combined estimates for the various imputations has introduced computational 
problems which currently can only be handled by the “MINIALIZE” procedure in SAS 
unlike the direct ML which is available in most statistical packages. Schafer and Olsen 
(1998) further suggested that the direct ML may be more efficient than the MI because they 
do not rely on simulation. In view of the robustness of direct ML in handling missing data 
in SEM including its ability to produce reliable estimates even when multivariate normality 
assumptions are violated(Allison, 2003), and the recommendation of its use to structural 
equation modelers (Allison, 1987), the ML approach was employed in handling missing data 
in this study.  
4.9. Psychometric properties of the instruments  
The psychometric properties of the SF-36 are displayed on Table 4-5. The reliabilities were 
acceptable ranging from 0.70 to 0.87. the item internal consistency and the item-discriminant 
validity were appropriate. The scaling test recorded 100% in all the domains except the GH 
domain where GH05 ‘my health is excellent’ correlated higher with MH (r = 0.68) compared 
with its hypothesised scale (r = 0.58). The ceiling (the proportion of patients with best 
possible scores) was high for RP and RE domains 30 and 42.5 respectively. Both domains 
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also recorded high floor (proportion of patients with worst possible score) 22.5 and 20 
respectively.  
 Table 4-5: Test of Reliability and Scaling Parameters of SF-36 in the Sample. 
Scale 
No of 
items 
Reliability 
Cronbach 
(α) 
item 
internal 
consistency a 
Item 
discriminant 
validity b 
Ceiling / 
floor c 
Success 
/ totals 
d 
Scaling 
success 
(%) 
PF 10 0.866 0.422 - 0.783 0.00-0.37 5.0 / 2.5 80/80 100 
RP 4 0.771 0.731 - 0.796 0.17-0.51 30 / 22.5 32/32 100 
RE 3 0.731 0.796 - 0.817 0.09-0.62 42.5 / 20 24/24 100 
SF 2 0.774 0.9-0.906 0.15-0.47 
18.0 / 
1.0 16/16 100 
BP 2 0.702 0.873-0.883 0.08-0.50 
17.5 / 
0.0 16/16 100 
VT 4 0.715 0.688 - 0.805 0.02-0.51 1.5 / 0.0 32/32 100 
MH 5 0.712 0.529 - 0.819 0.08-0.49 6.0 / 0.0 40/40 100 
GH 5 0.716 0.575 - 0.775 0.07-0.68 5.0 / 0.0 39/40 98 
Note: a Correlation between items and hypothesised scale  b Correlation between items and other scales c 
Proportion of patients with best possible score (ceiling) and worst possible score (floor) d Number of 
hypothesised correlation higher /total number of correlations. PF=Physical Functioning, RP=Role 
Physical, RE=Role Emotional, SF=Social Functioning, BP=Bodily Pain, VT=Vitality, MH=Mental 
Health, GH=General Health. 
 
The reliabilities of the measures of anxiety, depression and somatic symptoms are shown in 
Table 4-6. The measures showed acceptable reliabilities which ranged between 0.80 and 
0.90.  
Table 4-6: Reliability of the Measures of Anxiety, Depression and Somatic Symptoms. 
Measure Range Mean SD Reliability 
Genarlised Anxiety Disorder 
(GAD-7) 
0-16 3.86 3.91 0.802 
Patient Health Questionnaire for 
depression (PHQ-9) 
0-25 5.14 4.70 0.824 
Patient Health Questionnaire for 
somatic symptoms (PHQ-15) 
0-30 7.475 6.48 0.902 
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4.10 Statistical analysis 
Both descriptive and inferential statistical analyses were performed on the data in line with 
the specific objectives and research questions of this study. The P- value was set at 0.05 to 
be able to make specific statements on statistical properties of results. 
4.10.1 Descriptive statistics 
The sample characteristics of the population used proportion and percentages to summarise 
qualitative variables and result presented in frequency tables. Appropriate measures of 
central tendency were used to summarise and present quantitative variables. These were 
calculated using SPSS version 24 (IBM SPSS 24). 
4.10.2 Inferential statistics 
Data were analysed in line with the specific objectives of the study. Statistical tools used 
included t-test, chi-square and correlations. The student independent t-test was used to 
measure differences between two groups while the one-way analysis of variance (ANOVA) 
was used where there were more than two groups. The Turkey’s HSD post-hoc test was 
performed for pairwise comparison of groups among groups. For the second objective, the 
relationship among biophysiological variables, symptoms status, functional status, general 
health perceptions and overall quality of life were investigated. Factors that associated with 
HRQL were also investigated. Correlations for continuous and Chi-square (χ2) statistic for 
discrete variables were used to investigate hypothesised relationships. 
Hierarchical regression modelling was used to test predictors. Hierarchical regression was 
preferred to simple linear or stepwise regression because this study is based on a theoretical 
model that signifies order of relationship hence groups of variables were entered into the 
regression model based on the Wilson and Cleary model of health-related quality of life. 
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4.10.3 Structural equation modelling 
Structural equation modelling is a powerful statistical tool that allows for the simultaneous 
testing of complex interrelationships between variables specified within a priori models 
(Kline, 2011), and currently regarded as the best technique for assessing and modifying 
theoretical models (Baker, 2007). SEM has been described as “the preeminent multivariate 
method of data analysis” (Hershberger, 2003, pp. 43–44; Mueller and Hancock, 2008). The 
technique is a confirmatory method (Jöreskog, 1978; Bentler, 1985) which allows 
researchers to assess and modify theoretical models (Anderson and Gerbing, 1988). Also 
SEM is useful to express complicated variable relationships through hierarchical or non-
hierarchical, recursive or non-recursive structural equations, and to present a more complete 
picture of the entire model (Hanushek and Jackson, no date; Bullock, Harlow and Mulaik, 
1994). The step by step application of SEM to the data is detailed as follows. 
Model specification 
An exploratory factor analysis was first carried out on the data. The analysis yielded a 7-
factor model with 59.11% cumulative percentage of variance explained. The determinant of 
the correlation matrix was greater than zero satisfying the condition of positive definiteness. 
The Kaiser-Meyer-Olkin (KMO) test (Williams, Onsman and Brown, 2010) returned by 
SPSS was 0.75 confirming that the sample size of 200 was adequate to run the 7-factor 
model. 
A two-step procedure recommended by Anderson and Gerbing (1988) was implemented. 
The model building procedure was viewed as the analysis of two distinct models; 
measurement and structural (Anderson and Gerbing, 1982, 1988). The initial step was to 
develop models to represent each of the constructs. A confirmatory factor analysis (CFA) 
was carried out on each of the model separately, individual measured variables for each 
construct were allowed to load on a single factor or latent construct it was hypothesised to 
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measure. For example, the scales of role emotional (RE), social function (SF), physical 
functioning (PF) and role physical (RP) were allowed to load on the latent construct, function 
status (FS). This was to ensure that indicator variables reflect the latent construct they were 
hypothesised to measure. Next, a first-order CFA was implemented to assess the adequacy 
of the measurement model of the latent variables. This process allowed all the constructs to 
intercorrelate freely with each other. Applying the second step of Anderson and Gerbing, the 
structural model was specified as hypothesised by Wilson and Cleary (1995). Relationship 
among the dependent and independent latent variables were estimated. Fit indices (see Table 
4-4) were examined. All analyses were conducted with the Analysis of Moment Structures 
(AMOS) software version 25 (IBM AMOS 25). 
Model identification 
The identification property of the model was checked based on the counting rule which 
requires the model’s degree of freedom dfM > 0 based on the difference between number of 
free parameters and observations (Kline, 2011). A dfM < 0 means that the model is 
unidentified and is unusable, a dfM = 0 implies the model is just identified and one cannot 
test any hypothesis since degree of freedom is zero while a dfM > 0 implies an overidentified 
model and suitable for statistical test.  
In the current study, number of distinct single moments = 153 
Number of parameters to be estimated = 50. 
Degree of freedom, dfM = 153 – 50 = 103. As this is greater than zero, the model is 
overidentified. 
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Evaluation of model assumptions  
The assumptions of the model include that of linearity of relationship, normality of 
distribution, independence/homogeneity of variances, homoscedasticity and 
multicollinearity. They were examined as follows:  
Normality. The distribution properties of the variables were examined by checking the 
skewness and kurtosis of each variable to establish the deviation or otherwise of such 
variable from normality. Skewness and kurtosis close to zero implies symmetrical and 
mesokurtic distribution. The rule of thumb for interpreting kurtosis and skewness in a large 
sample is that the absolute value of kurtosis greater than 10 may indicate problem and greater 
than 20 evidence a very serious problem while variable with absolute skewness greater than 
3.0 may be considered extremely skewed (Kline, 2011). Table 4-7 shows that none of the 
variables have a value of skewness greater than 3.0 and none of the kurtosis was greater than 
10. Hence, the univariate normality assumption was not violated.  
Multicollinearity. Multicollinearity is the problem of high correlations between two 
independent variables in the model, this disturbance may affect SEM procedure and make 
statistical inference about the data unreliable 
(http://www.statisticssolutions.com/multicollinearity/). To check for multicollinearity, 
collinearity diagnostics was carried out in SPSS (See Table 4-7. The values of variance 
inflation factor (VIF) and tolerance were examined. Multicollinearity is indicated if 
tolerance is less than 0.01 and if VIF is greater than 10. Table 4-7 shows that VIF ranged 
from 1.11 to 3.14 while tolerance ranged from 0.318 to 0.898. Thus, the assumptions of 
absence of multicollinearity was not violated by the data for the current study.  
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 Table 4-7: Skewness and Kurtosis and Collinearity Diagnostics 
 
 N = 200 N = 200    
Minimu
m 
Maximu
m Skewness Kurtosis 
Collinearit
y Statistics 
Statistic Statistic 
Statist
ic 
Std. 
Error Statistic 
Std. 
Error 
Tol
era
nce VIF 
Gender 1 2 -.348 .172 -1.898 .342 .772 1.296 
Age 1.00 3.00 1.601 .172 1.476 .342 .589 1.697 
Marital status 1.00 3.00 1.728 .172 2.106 .342 .548 1.826 
N. children 1.00 3.00 2.157 .172 3.916 .342 .500 2.000 
Level of Education 1.00 3.00 -.417 .172 -.687 .342 .699 1.431 
Employment status 1 3 .916 .172 -.897 .342 .542 1.847 
Living situation 1 2 -2.887 .172 6.399 .342 .783 1.277 
Confidant 1 2 -2.032 .172 2.149 .342 .833 1.201 
Genotype 1 2 1.975 .172 1.921 .342 .857 1.167 
N. Comorbidities .00 2.00 1.315 .172 .568 .342 .520 1.921 
HT 25.00 100.00 -2.010 .172 3.077 .342 .661 1.513 
PF .00 100.00 -.320 .172 -.496 .342 .672 1.487 
RP .00 100.00 -.129 .172 -1.440 .342 .365 2.739 
RE .00 100.00 -.449 .172 -1.274 .342 .383 2.608 
SF .00 100.00 -.317 .172 -1.041 .342 .496 2.018 
GH 5.00 100.00 -.579 .172 -.464 .342 .528 1.894 
PHQ9 .00 25.00 1.062 .172 .927 .342 .339 2.952 
GAD7 .00 16.00 .992 .172 .150 .342 .318 3.144 
PHQ15 .00 26.00 1.168 .172 1.266 .342   
Overall Qol 1 7 -.781 .172 .146 .342 .776 1.289 
BPR .00 80.00 .289 .172 -.936 .342 .549 1.821 
MHR .00 92.00 .629 .172 -.380 .342 .517 1.936 
Income status 1.00 2.00 1.819 .172 1.321 .342 .549 1.823 
VTR .00 95.00 .551 .172 .180 .342 .898 1.114 
DSEI       .710 1.408 
Notes: PF=Physical Functioning; RP=Role Physical; RE=Role Emotional; SF= Social Functioning; 
GH=General Health; HT= Health Transition; PHQ9=Patient Health Questionaire-9; GAD7=Generalised 
anxiety Disorde-7; PHQ15=Patient Health Questionnaire-15; BPR=reversed score of Bodily Pain; 
MHR=reversed score of Mental; VTR= reveserd score of Vitality; Health; DSEI=Disease sveverity index.  
 
Homoscedasticity. The possible presence of homoscedasticity was checked by using the 
principle of relative variance, that is comparing the variances of all the variables entered to 
detect if there is any variance that is 10 times the other. A relative variance greater than 10 
is ill-scaled. SEM procedure is iterative (initial estimates are derived by the computer and 
then modified through subsequent cycles of iteration). The analysis of a covariance that is 
ill-scaled will be problematic. No variance was 10 times greater than the variance of any 
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other variable hence the assumption of absence of homoscedasticity was satisfied (See Table 
3-8).  
Outliers. Both univariate and multivariate outliers were assessed both by graphical and 
statistical methods. Data were inspected to ensure they were accurately entered. Kline (2011) 
opined that there is no single definition of an extreme outlier. Univariate outliers could be 
detected by examining the frequency distribution of the z-score. Absolute value of Z greater 
than 3 standard deviations from the mean (‖Z‖ ≤ 3.29, p < 0.001) may indicate an outlier 
(Kline 2011). This rule of thumb was applied, the boxplots were also examined. Extreme 
outliers were observed in 10 cases from 3 variables namely number of children, 7 cases, 
PHQ-9, 1 case and PHQ-15, 3 cases. The boxplot of each variable was also examined. A 
transformation was applied to correct for the outliers (see Table 3-8.). 
A method based on the Mahalanobis distance (D) was computed to evaluate possible 
presence of multivariate outliers. The Mahalanobis distance is the distance of a case from 
the centroid of all cases where the centroid is calculated as the intersection of the mean of 
the variables being assessed. The Mahalanobis distance squared (D2) is distributed as chi-
square (χ2) statistic with degree of freedom equal to the number of variables. A value of D2 
with a low p-value (P < 0.001) indicates multivariate outliers. The SPSS returned a 
Mahalanobis distance value of 57.544, the Chi-square value was obtained using Microsoft 
Excel. None of the variables had a p < 0.001, the assumption of absence of multivariate 
outliers was therefore satisfied. 
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Table 4-8: Skewness, Kurtosis and Collinearity Diagnostics after Transformation 
Variable 
(N = 200) 
Before transformation After transformation  
Skewness Kurtosis 
Skewne
ss 
Kurtosi
s 
Variance 
statistic 
Statist
ic 
Std. 
Error Statistic 
Std. 
Error 
   
Gender -.348 .172 -1.898 .342 -.348 .172 .244 
Age 1.601 .172 1.476 .342 1.24 -.113 .248 
Marital status 1.728 .172 2.106 .342 1.402 .394 .113 
N. children 2.157 .172 3.916 .342 1.64 .793 .172 
Level of Education -.417 .172 -.687 .342 -.417 -.687  
Employment status .916 .172 -.897 .342 .916 .897 .677 
Living situation -2.887 .172 6.399 .342 -2.887 6.399 .082 
Confidant -2.032 .172 2.149 .342 -2.032 2.149 .125 
Genotype 1.975 .172 1.921 .342 1.975 1.921 .128 
N. Comorbidities 1.315 .172 .568 .342 .997 -.616 .149 
HT -2.010 .172 3.077 .342 -1.443 .391 .434 
PF -.320 .172 -.496 .342 -.320 -.496 .253 
RP -.129 .172 -1.440 .342 -.743 -.912 .568 
RE -.449 .172 -1.274 .342 .041 -1.711 .177 
SF -.317 .172 -1.041 .342 -.317 -1.041 .304 
GH -.579 .172 -.464 .342 .041 -1.121 .337 
PHQ9 1.062 .172 .927 .342 -.316 -.924 .767 
GAD7 .992 .172 .150 .342 .390 -.967 .171 
PHQ15 1.168 .172 1.266 .342 -.072 -.271 .350 
Overall Qol -.781 .172 .146 .342 -.205 -1.006 .498 
BPR .289 .172 -.936 .342 .289 -.936 .802 
MHR .629 .172 -.380 .342 .198 -.180 .420 
Income status 1.819 .172 1.321 .342 .874 -.901 .297 
VTR .551 .172 .180 .342 .551 .180 .688 
DSEI     .130 -.146 .363 
Notes: PF=Physical Functioning; RP=Role Physical; RE=Role Emotional; SF= Social Functioning; 
GH=General Health; HT= Health Transition; PHQ9=Patient Health Questionaire-9; GAD7=Generalised 
anxiety Disorde-7; PHQ15=Patient Health Questionnaire-15; BPR=reversed score of Bodily Pain; 
MHR=reversed score of Mental; VTR= reveserd score of Vitality; Health; DSEI=Disease sveverity index.  
 
Linearity assumption. Figure 4-2 below shows that most of the variables are linearly related 
with one another. 
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Figure 4-2: Linearity Test 
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Model Estimation 
SEM with maximum likelihood (ML) estimation was implemented in AMOS 25 (IBM SPSS 
AMOS 25) to estimate the parameters of the model. The main a priori hypotheses were that 
bio-physiological factors would predict symptoms status which in turn would predict 
functional status and functional status would predict general health perception which in turn 
would predict overall quality of life. Additionally, both characteristics of the individual and 
characteristics of the environment would predict symptom status, functional status, general 
health perception and overall quality of life. AMOS provides estimates for the total effects, 
made up of both the direct effects (a path direct from one variable to another e.g. symptoms 
status → functional status) and the indirect effects (a path mediated through other variables 
e.g. symptom status → general health perceptions via functional status). Mediation was 
investigated using the bootstrap method.  
SEM Bootstrapping 
The bootstrap framework has been recommended as the best approach to test both direct and 
indirect effects in mediation models (MacKinnon et al., 2002; Shrout and Bolger, 2002; 
Baker, 2007) even when sample sizes are small to moderate, 20-80 (Tibshirani and Efron, 
1993). The presence of mediation was therefore assessed by testing the significance of the 
indirect effects using bias-corrected bootstrap confidence intervals.  
Following Strout and Bolger techniques (Shrout and Bolger, 2002), 2000 bootstrap sampling 
was created (resampled from the original dataset) in order to derive less biased standard 
errors and 95% confidence interval (95% CI) bootstrap percentiles. The bias corrected 95% 
CI (BC95%CI) is reported. These have been shown to be more accurate even with small 
sample sizes (Tibshirani, 1984; Tibshirani and Efron, 1993). 
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Model Fit 
The adequacy of the fit of the model was assessed by the Chi-square test statistic, together 
with the chi-square divided by its degree of freedom, the comparative fit index (CFI), the 
root-mean-square error of approximation (RMSEA) with 90% confidence interval (90% CI) 
and the standardised root mean residual (SRMR). Statements of the fitness of the model were 
based on the recommended threshold values of these indices (see Table 3.4). 
4.11 The Pratt Index 
The Pratt relative index was used to create the hierarchy of importance of the predictors. 
Several indices have been proposed for determining relative importance of predictor 
variables in regression models. Such indices include the Beta coefficients β, t-values, partial 
correlation and relative Pratt index. Pedhazur (1982) and Darlington (1990) has argued that 
beta weights and partial correlations lack proportionality and additive properties and hence 
should not be used to determine relative importance but recommended the use of partial 
correlations.  
Pratt relative index because of its good additive properties and simplicity in interpretation 
has been shown to have advantage over the semi-partial correlation and has been 
recommended as the better index to use in determining relative importance and ordering of 
variables (Thomas, Hughes and Zumbo, 1998).  
The relative Pratt index (Pratt, 1987) dj in a regression equation is determined by the 
proportion of the variance in the criterion variable Y accounted for by Xj (a predictor 
variable). The value is computed from the product of the sample correlation and beta 
coefficient of a variable Xj from the standardized regression equation of the form: 
Y = β1X1 + β2X2+… βjXj + βpXp 
The relative Pratt index dj is obtained as 
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  dj = β *│r │/R2.  
dj is the proportion of variance R
2 in the criterion variable accounted for by the predictor 
variable Xj.  The relative Pratt index of the predictors sum up to one. 
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CHAPTER FIVE 
 RESULTS 
 
5.0 Introduction 
This chapter presents the findings of the study. The results are presented in line with the 
specific objectives and research questions of the study. 
5.1  Characteristics of the sample 
The socio-demographic characteristics of the participants are displayed in Table 5-1(a). 
Participants were made up of 41.5% male and 58.5% female. Seventy-three percent (73%) 
of participants were between 18 and 30 years of age and only 5 (2.5%) were above 50 years 
of age. About 3 out of 4 (75.5%) of the participants had never been married, 20.5% were 
married and 4% were either divorced, separated or widowed. Eighty-one percent (81%) had 
no child, 13% had one child while the remaining 6% had 5 (2.5%) and 7 (3.5%) children 
respectively. The HbSS genotype was found in 85% of the participants compared to 15% 
HbSC, there was no Hb thalassemia in the study population. The educational profile of the 
sample population was high with only 9.5% having below secondary education, while 48% 
had secondary education and 42.2% had tertiary education. However, only 36% indicated 
that they had full time or part time employment, and few, 16.5% were earning above the 
national minimum wage, 20% were earning below the minimum wage while 63.5% did not 
report having any income. Majority of the participants, 91%, were either living with relatives 
or friends. Most of the participants reported that they have confidants (85.5%). Most of the 
participants 87.5% were from the states in the south west, 7% from North central, 3% from 
south-south, 1.5% from south East and 1 % were non-Nigerians. The participants were 
distributed along religious groups with 52.5% Christians, 47% Muslims and 0.5% traditional 
worshippers.  
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Table 5-1: Characteristics of Study Participants 
 
Demographic Variables 
All (N=200) Male (N = 83) Female  
(N= 117)  
n (percent) n (percent) n (percent) 
Age (Years) 
18-30 
31-40 
41-50 
Above 50 
 
146 (73%) 
41 (20.5%) 
8 (4%) 
5 (2.5%) 
 
56 (67.5%) 
22 (26.5%) 
4 (4.8%) 
1(1.2%) 
 
90 (76.9%) 
19 (16.2%) 
4 (3.4%) 
4 (3.4%) 
Genotype 
HbSS 
HbSC 
 
170 (85%) 
30 (15%) 
 
71(85.5%) 
12 (14.5%) 
 
99 (84.6%) 
18 (15.4%) 
Marital Status 
Never Married 
Married 
Others (separated, divorced, 
widowed) 
 
151 (75.5%) 
41 (20.5%) 
8 (4%) 
 
66 (79.5%) 
13 (15.7%) 
4 (4.8%) 
 
85 (72.6%) 
28 (23.9%) 
4 (3.4%) 
Education 
Primary 
Secondary 
Post-secondary 
 
19 (9.5%) 
97 (48.5%) 
84 (42%) 
 
3(3.6%) 
43 (51.8%) 
37 (44.6%) 
 
16 (13.7%) 
54 (46.2%) 
47 (40.2%) 
Employment status 
Not employed  
Part-time employment 
Full employment 
 
127 (63.5%) 
30 (15%) 
43 (21.5%) 
 
57 (68.7%) 
12 (14.5%) 
14 (16.9%) 
 
70 (59.8%) 
18 (15.4%) 
29 (24.8%) 
Income level 
No income 
Below minimum wage 
≥ Minimum wage 
 
127 (63.5%) 
40 (20%) 
33 (16.5%) 
 
57 (68.7%) 
16 (19.3%) 
10 (12%) 
 
70 (59.8%) 
24 (20.5%) 
23 (19.7%) 
Have Children 
No 
Yes 
 
182 (81%) 
38 (17%) 
 
70 (84.3%) 
13 (15.7%) 
 
92 (78.6%) 
25 (21.4%) 
Number of children 
0 
1-2 
≥ 3 
 
162 (81%) 
31 (15.5%) 
7 (3.5%) 
 
70 (84.3%) 
10 (12.1%) 
3 (3.6%) 
 
92 (78.6%) 
21 (17.9%) 
4 (3.4%) 
Living situation 
Living alone 
Living with others 
 
18 (9%) 
182 (91%) 
 
6 (7.2%) 
77 (92.8%) 
 
12 (10.3%) 
105 (89.7%) 
Have confidants 
No  
Yes 
 
29 (14.5%) 
171 (84.5%) 
 
15 (18.1%) 
68 (81.9%) 
 
14 (12%) 
103 (88%) 
Religion 
Christianity 
Islam 
Traditional 
 
105 (52.5%) 
94 (47%) 
1 (0.5%) 
 
38 (45.8%) 
45 (54.8%) 
 
67 (57.3%) 
49 (41.9%) 
1 (0.95) 
Comorbidity 
No  
Yes 
 
135 (67.5%) 
65 (32.5%) 
 
55 (66.3%) 
28 (33.7%) 
 
80 (68.4%) 
37 (31.6%) 
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One out of three participants (32.5%) indicated that they have been diagnosed to have 
comorbidities, the number of comorbidities ranged from 0 to 5 in the sample; the most 
prevalent comorbidity in the sample was leg ulcers (12.5%) followed by priapism (8.5%) 
and high blood pressure (8%). Other identified comorbidities were mostly pain-related, 
rheumatism, chest pain and back pain (See Table 5-2). 
Table 5-2: Comorbidity by Type 
Comorbid disease  Frequency Percent 
Asthma 
Arthritis 
Diabetes 
Epilepsy 
Heart disease 
High blood pressure 
Leg ulcers 
Lung disease 
Pneumonia  
Priapism  
Stroke  
Others 
8 
11 
6  
3  
3  
16 
25 
9  
13 
17 
3  
5 
4% 
5.5% 
3% 
1.5% 
1.5% 
8% 
12.5% 
4.5% 
6.5% 
8.5% 
1.5% 
2.5% 
 
5.1.1 Healthcare resources utilisation 
In the 6 months preceding the data collection, 12.5% of the participants had visited 
emergency department 3 or more times, 15.5% twice, 55% once and 17% not at all. Eighty-
five percent (85%) had been admitted into hospital at least once in the last six months while 
97% reported experiencing pain at least once in the last six months, 35% had pain episode 3 
or more times in the last six months. Also, 87% had SCD-related health issues at least once 
in the last six months and about 20% had blood transfusion more than once (see Table 5-3). 
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Table 5-3: Disease Severity/Healthcare Resources Utilisation in Adults with Sickle Cell 
Disease 
 All (N=200) Male (N = 83) Female ( N= 117)  
n (percent) n (percent) n (percent) 
In the last 6 months: 
1. Visited emergency dept 
     None 
      Once 
      Twice 
      3 times 
      More than 3 times 
2. Admitted to hospital 
      None 
      Once 
      Twice 
      3 times 
      More than 3 times 
3. Have pain episodes 
      None 
      Once 
      Twice 
      3 times 
      More than 3 times 
4. Have other SCD-related 
crisis 
      None 
      Once 
      Twice 
      3 times 
      More than 3 times 
5. Have blood transfusion 
      None 
      Once 
      Twice 
      3 times 
      More than 3 times 
 
 
34 (17%) 
110 (55%) 
31 (15.5%) 
13 (6.5%) 
12 (6%) 
 
30 (15%) 
98 (49%) 
34 (17%) 
19 (9.5%) 
19 (9.5%) 
 
6 (3%) 
50 (25%) 
59 (29.5%) 
35 (17.5%) 
50 (25%) 
 
26 (13%) 
101 (50.5%) 
30 (15%) 
20 (10%) 
23 (11.5%) 
 
34 (17%) 
105 (52.5%) 
42 (21%) 
15 (7.5%) 
4 (2%) 
 
 
18 (21.7%) 
38 (45.8%) 
14 (16.9%) 
10 (12%) 
3 (3.6%) 
 
15 (18.1%) 
44 (53%) 
13 (15.7%) 
4 (4.8%) 
7 (8.4%) 
 
4 (4.8%) 
20 (24.1%) 
30 (36.1%) 
16 (19.3%) 
13 (15.7%) 
 
11 (13.3%) 
42 (50.6%) 
14 (16.9%) 
7 (8.4%) 
9 (10.8%) 
 
13 (15.7%) 
49 (59%) 
14 (16.9%) 
6 (7.2%) 
1 (1.2%) 
 
 
 
16 (13.7%) 
72 (61.5%) 
17 (14.5%) 
3 (2.6%) 
9 (7.7%) 
 
15 (12.8%) 
54 (46.2%) 
21 (17.9%) 
15 (12.8%) 
12 (10.3%) 
 
2 (1.7%) 
30 (25.6%) 
29 (24.8%) 
19 (16.2%) 
37 (31.6%) 
 
15 (12.8%) 
59 (50.4%) 
16 (13.7%) 
13 (11.1%) 
14 (12%) 
 
21 (17.9%) 
56 (47.9%) 
28 (23.9%) 
9 (7.7%) 
3 (2.6%) 
5.1.2  Psychosocial status of study participants 
Table 5-4 reveals that a significant number 131 (66.5%) of the participants indicated minimal 
or no anxiety (GAD7 < 5), 22.5% had mild anxiety, 11.5% had moderate anxiety and one 
person, reported severe anxiety. Signs of depression were found in 42.5% of the participants 
(PHQ9 ≥ 5); 23.5% was mild, 13.5% moderate and 5.5% were moderately severe or severe 
while 115 (57.5%) reported minimal or no depression. Forty percent of the participants 
indicated minimal or no somatic symptoms, 30.5% had low somatic symptoms, 16% 
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medium and 13.5% had high somatic symptoms, 19 (70.4%) of the 27 people with somatic 
symptoms were women.  
Table 5-4: Level of Anxiety, Depression and Somatic Symptoms in Adults with Sickle Cell 
 All (N=200) Male (N = 83) Female  
(N= 117)  
n (percent) n (percent) n (percent) 
Anxiety (GAD-7) 
None/minimal anxiety 
Mild anxiety 
Moderate anxiety 
Severe anxiety 
 
131 (65.5%) 
45 (22.5%) 
23 (11.5%) 
1 (0.5%) 
 
59 (71.1%) 
14 (16.9%) 
10 (12%) 
 - 
 
72 (61.5%) 
31 (26.5%) 
13 (11.1%) 
1 (0.9%) 
Depression (PHQ-9) 
None/minimal depression 
Mild depression 
Moderate depression 
Moderately severe depression 
Severe depression 
 
115 (57.5%) 
47 (23.5%) 
27 (13.5%) 
10 (5%) 
1 (0.5%) 
 
50 (60.2%) 
20 (24.1%) 
10 (12%) 
3 (3.6%) 
 - 
 
65 (55.6%) 
27 (23.1%) 
17 (14.5%) 
7 (6%) 
1 (0.9%) 
Somatic symptoms (PHQ-15) 
None/minimal somatic 
symptoms 
Low somatic symptoms 
Medium somatic symptoms 
High somatic symptoms 
 
80 (40%) 
61 (30.5%) 
32 (16%) 
27 (13.5%) 
 
44 (53%) 
21 (25.3%) 
10 (12%) 
8 (9.6%) 
 
36 (30.8%) 
40 (34.2%) 
22 (18.8%) 
19 (16.2%) 
 
From Table 5-5, the mean age of participants was 27.9 (SD = 6.95). Although female 
participants appeared slightly older there was no statistical difference in age between genders 
(p > 0.05).  
The means and standard deviations of the SF-36 domains in the SCD population are also 
displayed in Table 5-5. Higher scores represented better health. The best score was in Mental 
Health (above 70) while the worst scores were in the Role Physical and Physical Functioning 
(below 60). All the other domains; Bodily Pain, Vitality, General Health Role Emotional 
and Social Functioning had means scores between 60 and 70.  
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Table 5-5: Means and Standard Deviations of SF-36 and other Measure Instruments in 
the Sample. 
 All Male Female   
 Mean (SD) Mean (SD) Mean (SD) T-test P value 
Age 27.88 (6.95) 28.40 (6.85) 27.51 (7.03) 0.892 0.374 
SF-36 domains      
Physical Functioning 
(PF) 
58.48 
(25.14) 
62.59 
(23.55) 
55.56 
(25.92) 
1.96  0.051 
Bodily Pain (BP) 69.79 
(22.39) 
76.69 
(19.23) 
64.89 
(23.24) 
3.79  0.000 
Vitality (VT) 63.05) 
20.73) 
64.28 
(20.66) 
62.18 
(20.83) 
0.70 0.462 
General Health (GH) 67.13 
(23.51) 
63.61 
(22.19) 
69.62 
(24.20 
1.79 0.075 
Role Physical (RP) 53.75 
(38.40) 
54.52 
(36.03) 
53.21 
(40.14) 
0.24 0.812 
Role Emotional (RE) 61.5  
(38.41) 
64.26 
(35.61) 
59.54 
(40.31) 
0.85 0.394 
Social Functioning 
(SF) 
64.19 
(27.59) 
69.43 
(26.28) 
60.47 
(27.99) 
2.29 0.023 
Mental Health (MH) 71.36 
(20.85) 
70.99 
(19.32) 
71.62 
(21.95) 
0.21 0.832 
Physical Health 
Component Summary 
(PCS) 
67.66 
(13.18) 
69.63 
(12.82) 
66.26 
(13.27) 
1.79  0.075 
Mental Health 
Component Summary 
(MCS) 
68.77 
(15.91) 
69.30 
(15.08) 
68.40 
(16.52) 
0.39 0.697 
Health Transition 
(HT)  
89.88 
(20.22) 
89.16 
(19.98) 
90.38 
 (20.4) 
0.42 0.673 
Others      
Global measure of 
QOL 
5.44 (1.42) 5.55 (1.27) 5.36 (1.52) 0.96  0.339 
Anxiety (GAD-7) 3.86 (3.91) 3.47 (3.92) 4.14 (3.89) 1.189 0.236 
Depression (PHQ-9) 5.14 (4.70) 4.48 (4.35) 5.61 (4.89) 1.677 0.095 
Somatic symptoms 
(PHQ-15) 
7.48 (6.48) 5.88 (6.13) 8.61 (6.51) 2.989 0.003 
Body Mass Index 
(BMI) 
19.25(3.86) 18.81 (3.67) 19.56 (3.98) 1.1382 0.169 
No of comorbidities 0.40 (0.63) 0.42 (0.65) 0.39 (0.63) 0.312 0.755 
Disease Severity 
Index (DSEI) 
7.97 (3.41) 7.52 (3.01) 8.29 (3.64) 1.587 0.114 
Emergency dept visit 1.30 (1.02) 1.30 (1.05) 1.29 (1.00) 0.072 0.943 
Admitted to hospital 1.495 (1.15) 1.33 (1.09) 1.62 (1.17 1.771 0.078 
Frequency of pain 2.37 (1.19) 2.17 (1.11) 2.50 (1.23) 1.978 0.005 
SCD-related crisis 1.57 (1.18) 1.53 (1.16) 1.59 (1.21) 0.350 0.727 
Blood transfusion 1.25 (0.83) 1.19 (0.83) 1.29 (0.94) 0.761 0.448 
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The summary scores, Physical Component Scores (PCS) and Mental Health Scores (MCS) 
had means between 65 and 70 with no statistical significance difference between males and 
females. The mean global measure of quality of life was 5.44 (SD = 1.42).  
The mean anxiety score was 3.86 (SD=3.91), depression 5.14 (SD=4.70) and somatic 
symptoms (PHQ15) was 7.48 (SD=6.48). Females reported worse anxiety, depression and 
somatic symptoms, these differences however were not significant except in somatic 
symptoms (p< 0.05). The female participants reported significantly higher frequency of pain 
than the male participants (p < 0.05).  
The results of the study with respect to the objectives are outlined below. 
5.2 Objective one. 
To Describe the HRQL profile of adult living with sickle cell disease 
5.2.1 Research Question 1: 
What is the profile of Health-related quality of life in adults with sickle cell disease in the 
study area? 
Norm-based scores of SF-36 in the study population 
The norm-based scores of SF-36 were also compared with the conventional percentile score. 
(Table 5-6). The norm-based scores facilitated comparison with other populations based on 
1988 US general population with mean 50, and standard deviation, 10 (Ware et al., 2000; 
Ware, 2007). One subscale, Physical Functioning was below 40, three subscales; Social 
Functioning, Role Physical and Role Emotional were between 40 and 45. Furthermore, three 
subscales; General Health, Bodily pain and Mental health were between 45 and 50. The 
norm-based scores confirmed that the HRQL of SCD patients in Nigeria was significantly 
reduced compared to the norms in all the domains (all p < 0.01) except in vitality which was 
similar to the scores in the general population (mean = 50.96, SD=9.93, p = 0.176). 
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Table 5-6: Quality ofLlife Domain Scores of SF-36 in Adults with Sickle Cell Disease: 
Norm-based Scores versus Conventional Scores. 
 
Conventional 
score* 
Norm-based 
score**  
Scale Mean 
Std. 
Deviatio
n Mean 
Std. 
Deviatio
n  
Physical Functioning (PF) 58.475 25.14 38.62 10.98  
Role Physical (RP) 53.750 38.40 41.88 11.36  
Role Emotional (RE) 61.50 38.41 44.01 11.63  
Social Functioning (SF) 64.188 27.59 41.33 12.33  
Bodily Pain (BP) 69.788 22.39 47.58 9.50  
Vitality (VT) 63.05 20.73 50.96 9.93  
Mental Health (MH) 71.36 20.85 48.07 11.58  
General Health (GH) 67.125 23.51 47.48 11.66  
Physical Component 
Summary (PCS) 
67.66 13.18 42.61 8.07  
Mental Component 
Summary (MCS) 
68.77 15.91 48.25 10.07  
* Score based on the 0-100 transformation  
**Score based on US 1988 general population with mean 50 and SD 10. 
Comparison of Southwest SCD patients and other reference groups on SF-36 Measure  
Table 5-7 shows the comparison of the result in the current study with the hypertensive 
patients group in Southwest Nigeria. Sickle cell disease patients reported better health score 
in Physical Function, and Role Emotional, similar scores in Role Physical and Mental Health 
and lower scores in Social Functioning, Bodily Pain and Vitality than hypertensive patients 
in southwest Nigeria.  
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Table 5-7: Comparison of SF-36 HRQL Domains Scores between  SCD Patients and 
Hypertension Patients in Southwest Nigeria.  
SF-36 domains Hypertensive patients 
Southwest Nigeria1 
(N = 265) 
SCD Southwest 
Nigeria 
N =200) 
 
P 
 Mean SD Mean SD  
Physical Functioning (PF) 33.53 29.65 58.48 25.14 0.000 
Role Physical (RP) 54.66 40.36 53.75 38.40 0.806 
Role Emotional (RE) 51.14 40.58 61.5  38.41 0.006 
Social Functioning (SF) 75.19 22.97 64.19 27.59 0.000 
Bodily Pain (BP) 76.28 30.17 69.79 22.39 0.000 
Vitality (VT) 79.85 14.57 63.05 20.73 0.000 
Mental Health (MH) 70.65 17.87 71.36 20.85 0.693 
General Health (GH) n/a n/a 67.13 23.51  
Source: 1Ogunlana et al., 2009 
Sociodemographic variables and Health-related quality of life 
The profile of HRQL in adults with SCD with respect to sociodemographic variables are 
displayed in Table 5-8 
Age: Younger participants reported better health in 4 of the 8 domains of the SF-36 measure 
of HRQL namely, Role Physical, Role Emotional, General Health and Mental Health as well 
as in the mental health summary. Similar scores were reported in other domains by the 
different age groups.  
Gender: Poorer health-related quality of life was observed for women in Bodily pain (t = 
3.806, p < 0.01) and Social functioning (t = 2.112, p < 0.05). Though women recorded lower 
net scores in the other domains, they were not significant.  
Marital Status: The result was similar for the group in all the domains except in Role 
Emotional where those never married reported better health (p < 0.05) than those married, 
separated, divorced or widowed 
Education: Participants with higher education reported worse quality of life in Role Physical 
and General Health, no differences were observed in other domains of SF-36.  
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Employment: Participants in full-employment or part-time employment reported higher net 
scores in five domains which included Role physical, Social functioning, Bodily Pain, 
General Health and Vitality along with PCS and MCS but no statistical difference. 
Living situation: In the Social Functioning domain, adults with SCD living with others 
reported better health (p < 0.01), while the HRQL appeared similar between those living 
alone and those living with others in the other domains. People living with others also 
reported better health in the mental health component summary score (p < 0.01).  
Confidants: Participants who reported having confidants had better health scores in General 
Health and Mental health while the scores are similar in other domains of the SF-36.  
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Table 5-8: The Sociodemographic Profile of HRQL in Adults with Sickle Cell Disease 
Variables N PF 
Mean ± SD 
RP 
Mean ± SD 
RE 
Mean ± SD 
SF 
Mean ± SD 
BP 
Mean ± SD 
VT   
Mean ± SD 
GH 
Mean ± SD 
MH 
Mean ± SD 
PCS 
Mean ± SD 
MCS 
Mean ± SD 
Age  
18-30 
Above 30 
T-test, P 
Cohen’s d 
(ES) 
 
146 
54 
 
59.35±26.29 
56.11±21.79 
0.81, 0.42 
0.1 
 
60.27±36.75 
36.11±37.51 
4.11, 0.00 
0.7 
 
68.95±36.23 
41.36±37.16 
4.75, 0.00 
0.8 
 
66.10±27.23 
59.03±28.15 
1.62, 0.11 
0.3 
 
70.53±22.86 
67.78±21.13 
0.77, 0.44 
0.1 
 
62.57±21.63 
64.35±18.20 
0.54, 0.59 
0.1 
 
69.66±23.17 
60.28±23.28 
2.54, 0.012 
0.4 
 
73.78±20.42 
54.81±20.77 
2.74, 0.013 
0.4 
 
68.49±13.0
0 
65.42±13.5
2 
1.47, 0.14 
0.2 
 
71.03±15.9
6 
62.66±14.1
8 
3.39, 0.00 
0.5 
Gender  
Male  
Female  
T-test (T), P 
Cohen’s d 
(ES) 
 
83 
117 
 
62.59±23.55 
55.56±25.92 
1.96, 0.051 
0.3 
 
54.52±36.03 
53.21±40.14 
0.24, 0.812 
0.3 
 
64.26±35.61 
59.54±40.31 
0.85, 0.394 
0.1 
 
69.43±26.28 
60.47±27.99 
2.29, 0.023 
0.3 
 
76.69±19.23 
64.89±23.24 
3.79, 0.000 
0.6 
 
64.28±20.66 
62.18±20.83 
0.70, 0.462 
0.1 
 
63.61±22.19 
69.62±24.20 
1.79, 0.075 
0.3 
 
70.99±19.32 
71.62±21.95 
0.21, 0.832 
0.03 
 
69.63±12.8
2 
66.26±13.2
7 
1.79, 0.075 
0.3 
 
69.30±15.0
8 
68.40±16.5
2 
0.39, 0.697 
0.1 
Marital 
Status 
Never 
married 
Married 
Others  
Anova (F), P 
 
151 
41 
8 
 
60.07±25.35 
54.87±24.76 
46.87±20.34 
1.58, 0.208 
 
57.28±38.69 
43.90±37.82 
37.5±23.15 
2.75, 0.066 
 
65.34±37.49 
49.59±40.91 
50.00±30.86 
3.15, 0.045 
 
65.73±27.48 
58.54±28.29 
64.06±25.39 
1.09, 0.336 
 
69.32±23.38 
71.10±19.68 
71.88±17.41 
0.14, 0.872 
 
61.92±21.5 
64.88±18.52 
75.00±11.95 
1.73, 0.181 
 
67.12±24.35 
67.56±21.00 
65.00±22.04 
0.04, 0.961 
 
71.50±21.10 
72.88±17.94 
61.00±28.98 
1.10, 0.335 
 
68.21±13.4
4 
68.17±12.7
7 
64.85±10.3
5 
0.57, 0.565 
 
69.29±16.3
6 
67.25±13.7
9 
66.74±16.6
3 
0.33, 0.718 
Num of 
child. 
0 
1-2 
≥ 3 
Anova (F), P 
 
162 
31 
7 
 
59.26±25.04 
56.77±27.25 
47.86±16.55 
0.77, 0.463 
 
57.25±37.97 
45.55±35.92 
17.86±37.40 
5.02, 0.007 
 
65.23±37.59 
51.61±36.35 
19.05±37.80 
6.40, 0.002 
 
65.35±27.38 
59.68±28.08 
57.14±31.34 
0.79, 0.457 
 
69.68±22.40 
71.29±24.09 
65.71±14.91 
0.19, 0.830 
 
62.81±21.09 
65.16±20.23 
59.29±15.12 
0.29, 0.752 
 
67.41±23.56 
69.19±21.68 
51.43±27.95 
1.70, 0.185 
 
71.33±21.48 
71.10±19.59 
73.14±10.76 
0.03, 0.972 
 
68.16±13.1
4 
67.22±13.2
5 
57.94±11.7
0 
2.06, 0.130 
 
69.39±16.1
7 
66.86±14.9
3 
62.92±13.9
5 
0.82, 0.443 
Notes: PF – Physical Functioning; RP – Role Emotional; SF- Social Functioning; BP- Bodily Pain; VT- Vitality; GH- General Health; MH- Mental Health; PCS – Physical 
Health Component Summary Score; MCS – Mental Health Summary Score   
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Table 5-8 cont: The Sociodemographic Profile of HRQL in Adults with Sickle Cell Disease 
Variables  PF 
 
Mean ± SD 
RP 
 
Mean ± SD 
RE 
 
Mean ± SD 
SF 
 
Mean ± SD 
BP 
 
Mean ± SD 
VT   
 
Mean ± SD 
GH 
 
Mean ± SD 
MH 
 
Mean ± SD 
PCS 
 
Mean ± 
SD 
MCS 
 
Mean ± 
SD 
Employment 
Full-Time 
Part-time 
Not employed 
Anova (F), P 
 
43 
30 
127 
 
53.49±18.24 
57.67±23.03 
60.35±27.44 
1.22, 0.298 
 
56.98±38.70 
42.50±39.47 
55.32±37.88 
1.55, 0.214 
 
60.47±42.57 
52.22±40.76 
64.04±36.27 
1.17, 0.312 
 
68.02±26.91 
58.75±32.36 
64.17±26.60 
0.998, 0.37 
 
77.15±22.58 
67.83±21.01 
67.76±22.28 
3.02, 0.051 
 
63.60±22.07 
64.33±19.60 
62.56±20.67 
0.11, 0.898 
 
69.30±24.77 
65.50±24.01 
66.77±23.10 
0.27, 0.765 
 
70.98±20.71 
66.67±26.08 
72.60±19.50 
0.99, 0.373 
 
68.90±10.8
3 
66.64±13.0
1 
67.48±13.9
8 
0.29, 0.749 
 
69.32±16.1
5 
64.97±18.8
8 
69.49±15.0
6 
1.01, 0.365 
Living 
situation 
Alone 
With others 
T-test (T), P 
Cohen’s d 
(ES) 
 
18 
182 
 
54.44±26.17 
58.87±25.08 
0.72, 0.477 
0.2 
 
54.17±38.59 
53.71±38.49 
0.05, 0.962 
0.0 
 
50.00±44.65 
62.64±37.68 
1.33, 0.184 
0.3 
 
44.44±23.18 
66.14±27.27 
3.26, 0.001 
0.8 
 
65.56±17.83 
70.21±22.79 
0.84, 0.402 
0.2 
 
61.39±19.69 
63.21±20.88 
0.36, 0.723 
0.1 
 
67.50±19.87 
67.09±23.89 
0.07, 0.944 
0.0 
 
62.44±22.88 
72.24±20.50 
1.91, 0.057 
0.5 
 
68.62±11.2
1 
67.57±13.3
8 
0.32, 0.747 
0.1 
 
59.43±15.2
2 
69.70±15.7
1 
2.65, 0.009 
0.7 
Confidants 
Yes 
No 
T-test (T), P 
Cohen’s d 
(ES) 
 
171 
29 
 
 
59.24±25.14 
53.97±25.16 
0.84, 0.297 
0.2 
 
54.82±38.194
7.41±39.72 
0.86, 0.338 
0.2 
 
62.18±38.08 
57.47±40.72 
0.42, 0.543 
0.1 
 
65.42±27.135
6.90±29.62 
0.48, 0.124 
0.3 
 
68.86±22.037
5.26±24.09 
0.64, 0.155 
0.3 
 
63.45±20.376
0.69±23.02 
0.66, 0.509 
0.1 
 
68.83±22.32 
57.07±27.95 
2.52, 0.012 
0.5 
 
72.75±20.136
3.17±23.41 
2.31, 0.022 
0.5 
 
67.88±13.0
0 
66.38±14.3
6 
0.57, 0.573 
0.1 
 
69.67±15.8
5 
63.49±15.4
7 
1.95, 0.053 
0.4 
Notes: PF – Physical Functioning; RP – Role Emotional; SF- Social Functioning; BP- Bodily Pain; VT- Vitality; GH- General Health; MH- Mental Health; PCS – Physical 
Health Component Summary Score; MCS – Mental Health Summary Score.Effects sizes were calculated using a website calculator www.psychometrica.de/effect_size.htm 
assessed 17/05/2018  
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Clinical and Psychosocial variables and Health-related quality of life 
Table 5-9 displays the profile of HRQL in adults with SCD with respect to the clinical and 
psychosocial variables. 
Genotype: There was no significant difference between the genotypes though net scores 
were higher in participants with the HbSC genotype in all the domains apart from Bodily 
Pain.  
Comorbidity: Participants who reported to have a comorbid disease expressed worse scores 
in 6 HRQL domains; Role physical, Role Emotional Social Functioning, Bodily Pain, 
General Health, Mental Health (all p < 0.01) and in the Physical health Component Summary 
scores and the Mental Health component Summary scores (p < 0.01) 
Anxiety: Twelve percent of the participants had high symptoms of anxiety (GAD7 ≥10). 
They expressed worse (p < 0.01) health in 7 of the 8 HRQL domains and the summary scores 
PCS and MCS. Only in Physical Functioning was the score similar.  
Depression: Moderate to severe symptoms of depression (PHQ9 ≥ 10) was reported in 19% 
of the participants. High depressive symptoms reduced the HRQL in 7 of the domains of 
HRQL and towards low HRQL in Physical Functioning (P=0.055) 
 Somatic Symptoms: High somatic symptoms (PHQ15 ≥15) was reported in 13.5% of the 
patients. Participants with somatic symptoms reported worse health in all the HRQL 
domains, the summary scores PCS and MCS except physical Functioning and Role 
Emotional.  
Healthcare Utilisation: Utilisation of healthcare facilities also reflected a deteriorating 
quality of life; high emergency department utilizers had lower quality of life in Functioning, 
General Health and Mental Health. In addition, high rate of hospital admission associated 
with worse quality of life in Role Physical, Role Emotional, Social Functioning, Bodily Pain, 
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General Health, Mental Health and the summary scores but similar in Physical Functioning 
and Vitality (p > 0.05). 
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Table 5-9: Clinical and Psychosocial Profile of HRQL in Adults with Sickle Cell Disease. 
Variables N PF 
Mean ± SD 
RP 
Mean ± SD 
RE 
Mean ± SD 
SF 
Mean ± SD 
BP 
Mean ± SD 
VT   
Mean ± SD 
GH 
Mean ± SD 
MH 
Mean ± SD 
PCS 
Mean ± SD 
MCS 
Mean ± SD 
Genotype 
SS 
SC 
T-test (T), P 
 
170 
30 
 
57.32±24.85 
65.00±26.23 
1.55, 0.123 
 
52.94±37.77 
58.33±42.21 
0.71, 0.480 
 
61.37±38.61 
62.22±37.89 
0.11, 0.911 
 
63.31±28.04 
69.17±24.73 
1.07, 0.285 
 
70.90±21.92 
63.5±24.31 
1.68, 0.095 
 
62.24±21.35 
67.67±16.33 
1.32, 0.187 
 
67.00±24.14 
67.83±19.90 
0.18, 0.858 
 
70.92±21.55 
73.87±16.43 
0.71, 0.476 
 
67.48±13.01 
68.70±14.29 
0.47, 0.640 
 
68.40±16.54 
70.86±11.72 
0.78, 0.437 
Comorbidity 
No 
Yes 
T-test (T), P 
 
135 
65 
 
59.74±25.67 
55.85±23.99 
1.03, 0.306 
 
62.59±36.63 
35.38±35.60 
4.96, 0.000 
 
68.89±37.37 
46.15±36.18 
4.07, 0.000 
 
68.43±27.27 
55.38±26.33 
3.20, 0.00 
 
73.50±21.82 
62.08±21.72 
3.47, 0.001 
 
64.89±22.30 
59.23±16.54 
1.82, 0.071 
 
72.89±22.10 
55.15±21.92 
5.33, 0.000 
 
76.18±19.95 
61.35±19.19 
4.98, 0.000 
 
69.86±12.61 
63.09±13.26 
3.5, 0.001 
 
72.47±15.25 
61.10±14.54 
5.01, 0.000 
Anxiety 
Low 
High 
T-test (T), P 
 
176 
24 
 
59.46±25.67 
51.25±19.90 
1.51, 0.134 
 
56.68±37.91 
32.29±35.72 
2.98, 0.003 
 
64.29±37.88 
41.67±37.11 
2.74, 0.007 
 
66.83±27.15 
44.79±22.99 
3.79, 0.000 
 
71.34±22.30 
58.44±19.97 
2.69, 0.008 
 
64.38±20.82 
53.33±17.55 
2.48, 0.014 
 
68.52±22.47 
49.58±24.04 
4.04, 0.000 
 
73.14±20.62 
58.33±18.00 
3.35, 0.001 
 
68.67±12.93 
60.22±12.89 
3.01, 0.003 
 
70.37±15.60 
57.03±13.24 
4.00, 0.000 
Depression 
Low 
High 
T-test (T), P 
 
162 
38 
 
60.12±25.51 
51.45±22.51 
1.92, 0.055 
 
56.64±37.67 
41.45±39.54 
2.22, 0.026 
 
64.61±37.09 
48.25±41.51 
2.39, 0.018 
 
69.98±26.61 
48.03±26.08 
4.18, 0.000 
 
71.59±21.98 
62.11±22.78 
2.38, 0.018 
 
65.59±20.74 
52.24±17.07 
3.68, 0.000 
 
69.78±22.49 
55.79±24.70 
3.39, 0.001 
 
73.60±20.77 
61.79±18.57 
3.22, 0.002 
 
68.87±13.08 
62.52±12.50 
2.72, 0.007 
 
70.97±15.37 
59.41±14.91 
4.19, 0.000 
Somatic 
symptoms 
Low 
High 
T-test (T), P 
 
 
173 
27 
 
 
59.71±25.68 
50.56±20.02 
1.77, 0.078 
 
 
57.37±37.45 
30.56±36.91 
3.47, 0.000 
 
 
63.20±38.39 
50.62±37.41 
1.56, 0.114 
 
 
67.05±26.93 
45.83±25.00 
3.84, 0.000 
 
 
72.73±21.43 
50.93±19.24 
4.98, 0.000 
 
 
65.09±20.58 
50.00±16.87 
3.62, 0.000 
 
 
70.49±21.72 
45.56±23.47 
5.49, 0.000 
 
 
74.17±19.84 
53.33±18.23 
5.13, 0.000 
 
 
69.27±12.66 
57.35±11.95 
4.59, 0.000 
 
 
70.59±15.41 
57.11±14.27 
4.27, 0.000 
Emergency 
Dept 
Utilisation 
Low 
High 
T-test (T), P 
 
 
175 
25 
 
 
59.14±25.45 
53.80±22.79 
0.99, 0.324 
 
 
55.43±42.00 
42.00±37.31 
1.64, 0.102 
 
 
63.43±38.27 
48.00±37.37 
1.89, 0.06 
 
 
66.21±27.67 
50.00±22.82 
2.80, 0.006 
 
 
70.70±22.16 
63.40±23.38 
1.53, 0.128 
 
 
63.17±20.90 
62.20±19.90 
0.22, 0.827 
 
 
68.43±23.25 
58.00±23.76 
2.09, 0.038 
 
 
73.30±20.33 
57.76±19.67 
3.59, 0.000 
 
 
68.03±13.21 
65.09±12.91 
1.04, 0.299 
 
 
70.13±15.93 
59.28±12.30 
3.27, 0.001 
Hosp 
Admission 
Low 
High 
T-test (T), P 
 
162 
38 
 
59.35±25.07 
54.74±25.44 
1.02, 0.310 
 
57.87±37.12 
36.18±39.29 
3.21, 0.002 
 
65.23±37.224
5.61±39.84 
2.89, 0.004 
 
66.36±27.91 
54.93±24.41 
2.32, 0.021 
 
72.84±22.295
6.78±17.88 
4.14, 0.000 
 
63.67±21.62 
60.39±16.41 
0.88, 0.382 
 
69.04±23.12 
58.95±23.71 
2.41, 0.017 
 
74.17±20.16 
59.37±16.70 
4.09, 0.000 
 
68.76±12.78 
62.99±13.98 
2.46, 0.015 
 
70.67±15.70 
60.69±14.33 
3.58, 0.000 
Notes: PF – Physical Functioning; RP – Role Emotional; SF- Social Functioning; BP- Bodily Pain; VT- Vitality; GH- General Health; MH- Mental Health; PCS – Physical 
Health Component Summary Score; MCS – Mental Health Summary Score
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Clinical, psychosocial land HRQL profile in the study population 
Table 5-10 presents the impact of the comorbid diseases on HRQL of adults with SCD. Sickle cell 
patients who also had arthritis reported limitations in Role Physical, Role Emotional, Bodily Pain, 
Mental Health and Mental Health Summary compared to those who did not have arthritis. Participants 
who had asthma reported similar health status with those who did not have asthma. Participants with 
diabetes had worse General Health compared with those who did not have diabetes. Epilepsy was 
associated with worse mental Health in the population. Patients who had hypertension had worse 
scores in Role Physical, Bodily Pain, Vitality, General Health, Mental health and in both the Physical 
and Mental health Summary scores. Leg ulcers was associated with reduced quality of life in all the 
domains including the summary scores except in vitality where the health status appeared similar. 
Participants who had pneumonia reported worse scores in Physical Functioning, Social Functioning, 
Bodily Pain, Vitality, General health, Mental Health and the Summary scores. Priapism was 
responsible for worse Mental Health and Mental Component Summary Score. Stroke associated with 
reduced Physical Functioning.  
Figure 5-1 (a – j) show the HRQL profile of the participants with respect to reported comorbid 
diseases. Participants with leg ulcers reported the lowest mean quality of life scores in role physical, 
role emotional and bodily pain and consistently low in other HRQL domains. In addition, participants 
with epilepsy, pneumonia, arthritis, high blood pressure and stroke reported low scores in most of the 
HRQL domains. Participants with epilepsy reported lowest scores in social functioning and mental 
health. 
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Table 5-10: Comorbid Diseases and HRQL Domains in the Study Population. 
Disease  N PF 
 
Mean ± SD 
RP 
 
Mean ± SD 
RE 
 
Mean ± SD 
SF 
 
Mean ± SD 
BP 
 
Mean ± SD 
VT   
 
Mean ± SD 
GH 
 
Mean ± SD 
MH 
 
Mean ± 
SD 
PCS 
 
Mean ± 
SD 
MCS 
 
Mean ± 
SD 
Arthritis No 
Yes 
189 
11 
58.84±25.65 
52.27±12.92 
0.84, 0.401 
55.56±38.45 
22.73±20.78 
2.80, 0.006 
62.79±38.70 
39.39±25.03 
1.98, 0.049 
65.08±27.67 
48.86±21.98 
1.91, 0.058 
70.58±22.59 
56.14±12.96 
2.10, 0.037 
63.28±21.06 
59.09±14.11 
0.65, 0.516 
67.51±24.00 
60.45±11.06 
0.97, 0.334 
72.32±20.905 
4.91±11.18 
2.74, 0.007 
68.01±13.3
4 
61.61±8.39 
1.57, 0.118 
69.44±16.0
8 
57.30±4.42 
2.36, 0.034 
Asthma No 
Yes 
 
192 
8 
58.33±25.52 
61.88±13.87 
0.39, 0.697 
53.91±38.60 
50.00±35.36 
0.28, 0.779 
61.11±38.79 
70.83±27.82 
0.70, 0.484 
64.39±27.625
9.38±28.15 
0.50, 0.616 
70.04±22.396
3.75±22.95 
0.78, 0.438 
62.94±21.046
5.63±11.48 
0.36, 0.721 
67.53±23.575
7.50±21.04 
1.18, 0.238 
71.77±20.9
2 
61.50±17.2
3 
1.37, 0.173 
67.73±13.2
265.97±13.
03 
0.37, 0.713 
68.88±16.0
466.24±12.
96 
0.46, 0.647 
Diabetes No 
Yes 
194 
6 
 
58.07±25.31 
71.67±14.72 
1.31, 0.193 
54.51±38.54 
29.17±24.58 
1.60, 0.112 
61.86±38.39 
50.00±40.82 
0.74, 0.458 
64.11±27.90 
66.67±15.14 
0.22, 0.824 
69.83±22.67 
68.33±10.57 
0.16, 0.872 
63.17±20.76 
59.17±21.31 
0.47, 0.642 
68.07±22.92 
36.67±24.01 
3.30, 0.001 
71.71±20.9
1 
60.00±16.2
0 
1.36, 0.176 
67.76±13.2
764.28±10.
35 
0.64, 0.524 
69.01±15.9
4 
61.12±13.7
7 
1.20, 0.232 
Epilepsy No 
Yes 
197 
3 
58.53±25.33 
55.00±0.00 
0.24, 0.810 
53.81±38.69 
50.00±0.00 
0.17, 0.865 
61.42±38.69 
66.67±0.00 
0.23, 0.815 
64.59±27.60 
37.50±0.00 
1.70, 0.091 
69.82±22.56 
67.50±0.00 
0.18, 0.859 
63.07±20.89 
61.68±2.89 
0.12, 0.908 
67.08±23.68 
70.00±5.00 
0.21, 0.832 
71.72±20.8
1 
48.00±0.00 
1.97, 0.05 
67.62±13.2
8 
70.36±1.01 
0.36, 0.722 
68.98±15.9
455.46±0.5
2 
1.46, 0.145 
Hyperten
sion 
No 
Yes 
184 
16 
58.78±25.44 
55.00±21.83 
0.58, 0.566 
55.84±38.36 
29.69±30.58 
2.65, 0.009 
62.14±38.77 
54.17±34.16 
0.80, 0.427 
64.88±28.18 
56.25±18.26 
1.20, 0.231 
71.02±22.27 
55.63±19.14 
2.68, 0.008 
64.35±20.87 
48.13±11.53 
3.07, 0.002 
69.35±22.76 
41.56±15.99 
4.78, 0.000 
73.15±20.3
0 
50.75±15.7
8 
4.30, 0.000 
68.43±13.0
8 
58.83±11.2
4 
2.84, 0.005 
69.76±15.8
4 
57.48±12.2
4 
3.02, 0.003 
Heart 
disease 
No 
Yes 
197 
3 
58.53±25.29 
55.00±15.00 
0.24,0.810 
53.68±38.50 
58.33±38.19 
0.21, 0.836 
61.42±38.55 
66.67±33.33 
0.23, 0.815 
64.59±27.57 
37.50±12.50 
1.70, 0.091 
69.99±22.47 
56.67±11.27 
1.02, 0.308 
62.99±20.82 
66.67±16.07 
0.30, 0.762 
67.18±23.38 
63.33±37.53 
0.28, 0.779 
71.49±20.8
6 
62.67±22.0
3 
.073, 0.468 
67.70±13.2
0 
65.26±13.9
1 
0.32, 0.752 
68.86±15.9
7 
62.91±11.5
8 
0.64, 0.522 
Leg 
ulcers 
 
No 
Yes 
175 
25 
59.97±24.37 
48.00±28.36 
2.25, 0.026 
58.29±36.98 
22.00±33.32 
4.64, 0.000 
65.91±37.13 
30.67±33.22 
4.49, 0.000 
66.71±26.52 
45.50±28.98 
3.52, 0.001 
72.51±21.27 
50.70±21.04 
4.80, 0.000 
63.37±21.06 
60.80±18.52 
0.58, 0.563 
68.37±23.10 
58.40±25.03 
2.00, 0.047 
73.44±19.9
6 
56.80±21.5
4 
3.86, 0.000 
68.88±12.4
8 
59.11±14.9
9 
3.57, 0.000 
70.42±15.3
2 
57.25±15.4
4 
4.01, 0.000 
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Lung 
disease 
No 
Yes 
191 
9 
58.27±25.57 
62.78±13.250
.52, 0.601 
53.66±38.56 
55.56±37.03 
0.14, 0.886 
61.08±38.59 
70.37±35.14 
0.71, 0.480 
64.40±27.60 
59.72±28.49 
0.50, 0.620 
69.92±22.70 
66.94±14.99 
0.39, 0.698 
63.06±21.09 
62.78±11.49 
0.04, 0.968 
67.43±23.37 
60.56±27.09 
0.86, 0.392 
71.75±20.8
8 
63.11±19.4
7 
1.22, 0.225 
67.64±13.2
9 
68.15±11.2
2 
0.11, 0.909 
68.92±16.0
0 
65.68±14.1
7 
0.60, 0.552 
Pneumon
ia 
No 
Yes 
187 
13 
59.41±25.21 
45.00±20.62 
2.01, 0.045 
55.08±38.29 
34.62±36.14 
1.87, 0.063 
62.57±38.66 
46.15±32.03 
1.49, 0.137 
65.71±27.64 
42.31±14.91 
3.01, 0.003 
71.03±22.30 
51.92±15.28 
3.04, 0.003 
63.96±20.86 
50.00±13.69 
2.37, 0.019 
68.96±22.56 
40.77±21.78 
4.37, 0.000 
72.56±20.4
9 
53.85±18.6
6 
3.20, 0.002 
68.47±12.9
6 
55.94±10.9
1 
3.40, 0.001 
69.63±15.8
8 
56.38±10.4
0 
2.96, 0.003 
Priapism No 
Yes 
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57.79±25.60 
65.88±18.56 
1.27, 0.205 
55.19±38.70 
38.24±32.01 
1.75, 0.082 
62.30±39.29 
52.94±26.51 
0.96, 0.338 
64.48±27.96 
61.03±23.75 
0.49, 0.623 
70.11±22.27 
66.32±24.03 
0.67, 0.506 
63.22±21.19 
61.18±15.26 
0.39, 0.698 
67.54±24.26 
62.65±12.64 
0.80, 0.413 
72.48±21.0
6 
59.29±13.9
5 
2.53, 0.012 
67.55±13.2
9 
68.82±12.2
4 
0.38, 0.706 
69.50±16.1
8 
60.92±9.83 
2.15, 0.033 
Stroke No 
Yes 
197 
3 
58.91±24.84 
30±34.64 
.99, 0.048 
53.68±38.50 
58.33±38.19 
0.21, 0.836 
61.42±38.55 
66.67±33.3 
0.23, 0.8153 
64.28±27.61 
58.33±31.46 
0.37, 0.712 
69.59±22.39 
82.50±22.22 
0.99, 0.323 
62.89±20.82 
73.33±10.41 
0.87, 0.388 
67.34±23.25 
53.33±41.63 
1.02, 0.307 
71.11±20.8
7 
88.00±12.0
0 
1.40, 0.164 
67.83±13.0
8 
56.23±17.9
81.52, 
0.131 
68.58±15.9
0 
81.26±12.4
5 
1.37, 0.172 
Notes: PF – Physical Functioning; RP – Role Emotional; SF- Social Functioning; BP- Bodily Pain; VT- Vitality; GH- General Health; MH- Mental Health; PCS – Physical 
Health Component Summary Score; MCS – Mental Health Summary Score
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Figure 5-1: Profile of Domains Related to Disease
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Charcteristics of  psychsoscial factors in the study population 
Participants reported their anxiety, depression and somatic symptoms (Table 5-11). Younger 
participants showed less anxiety and depression, but similar somatic symptoms compared to 
those between ages 31 and 50 years (Table 5-11). While depression increases with age from 
18 years to 50 years (F = 5.98, P < 0.01). Participants above 50 years reported less anxiety 
and depression with similar somatic symptoms compared with those in ages between 31 and 
50 years. Participants with comorbidities experience significantly worse anxiety, depression 
and somatic symptoms compared to those who reported no comorbidities (P < 0.001). The 
worst expression of somatic symptoms was found among those with comorbidities (mean = 
11.65, SD=7.81). 
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Table 5-11: Anxiety, Depression and Somatic Symptoms in the Study Population 
 
 
  
 N GAD-7 
Mean ± SD 
PHQ-9 
Mean ± SD 
PHQ-15 
Mean ± SD 
Age  
18-30 
31-40 
41-50 
Above 50 
Anova, P 
 
146 
41 
8 
5 
 
3.35±3.64 
5.34±4.03 
7.25±5.37 
1.20±1.79 
5.98, 0.001 
 
4.61±4.53 
7.05±4.22 
6.13±8.18 
3.4±2.41 
3.34, 0.020 
 
7.04±6.65 
9.37±6.25 
7.75±3.99 
4.20±3.27 
1.83, 0.142 
Gender  
Male  
Female  
T-test (T), P 
 
83 
117 
 
3.47±3.92 
4.14±3.89 
1.19, 0.236 
 
4.48±4.35 
5.61±4.89 
1.68, 0.095 
 
5.88±6.13 
8.61±6.51 
2.99, 0.003 
Marital Status 
Never married 
Married 
Others (divorced, 
separated, widowed) 
Anova (F), P 
 
151 
41 
8 
 
3.72±3.87 
4.20±3.81 
4.88±5.33 
 
0.52, 0.595 
 
4.87±4.75 
5.98±4.77 
6.00±2.45 
 
1.04, 0.356 
 
7.66±6.71 
7.14±6.12 
5.75±3.49 
 
0.39, 0.676 
Number of children 
0 
1-2 
≥ 3 
Anova (F), P 
 
162 
31 
7 
 
3.79±3.91 
3.13±3.10 
8.71±4.46 
6.27, 0.002 
 
4.98±4.74 
5.12±4.33 
9.00±4.24 
2.50, 0.085 
 
7.43±6.45 
7.87±7.12 
6.71±4.57 
0.11, 0.897 
Education 
≤ Primary 
Secondary 
Post-secondary 
Anova (F), P 
 
19 
97 
84 
 
6.00±4.06 
2.65±3.26 
4.77±4.15 
10.73, 0.000 
 
7.84±6.17 
3.61±3.64 
6.30±4.85 
12.07, 0.000 
 
10.58±7.21 
5.07±4.03 
9.55±6.48 
14.98, 0.000 
Employment 
Full-Time 
Part-time 
Not employed 
Anova (F), P 
 
43 
30 
127 
 
3.67±4.03 
4.23±4.42 
3.83±3.77 
0.19, 0.830 
 
5.14±4.95 
5.47±5.13 
5.06±4.54 
0.09, 0.915 
 
7.33±1.12 
7.03±1.28 
6.07±0.54 
0.31, 0.732 
Living situation 
Alone 
With others 
T-test (T), P 
 
18 
182 
 
4.94±4.58 
3.75±3.84 
1.23, 0.219 
 
8.39±5.77 
4.82±4.47 
3.15, 0.002 
 
7.94±5.66 
7.43±6.57 
0.32, 0.748 
Confidants 
Yes 
No 
T-test (T), P 
 
171 
29 
 
 
3.76±3.79 
4.45±4.62 
0.88, 0.383 
 
4.94±4.45 
6.31±5.88 
1.46, 0.147 
 
7.68±6.72 
6.28±4.79 
1.08, 0.282 
Genotype 
HbSS 
HbSC 
T-test (T), P 
 
170 
30 
 
3.91±3.93 
3.60±3.86 
0.39, 0.694 
 
5.20±4.83 
4.80±3.93 
0.43, 0.668 
 
7.45±6.39 
7.53±7.12 
0.05, 0.958 
Comorbidity 
No 
Yes 
T-test (T), P 
 
135 
65 
 
2.44±2.86 
6.82±4.16 
8.69, 0.000 
 
3.59±3.59 
8.37±5.09 
7.67, 0.00 
 
5.46±4.55 
11.66±7.81 
7.08, 0.000 
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5.3 Objective two. 
To Characterize predictors of HRQL in adults with sickle cell disease 
5.3.1 Research Question 2: 
What are the factors that associate with the measures of HRQL?  
Table 5-12 shows the correlation of hypothesised predictor variables with the domains of 
HRQL and the summary scores (PCS and MCS). The direction of relationship with each 
HRQL domain and significance are stated as follows. 
Physical Functioning: The correlations sign of all the variables were as expected however 
only depression associated significantly with Physical Functioning (r = 0.22, p < 0.05). 
Role Physical: Age, anxiety, depression, somatic symptoms number of comorbidity and 
diseases severity associated significantly with Role Physical (p < 0.01) and they were in the 
expected direction. Also, number of children associated inversely with Role Physical (r = -
0.20, p < 0.01).  
Role Emotional: All the variables associated significantly with Role Emotional and 
followed the expected direction. The value of r ranged from -0.19 to -0.43. Number of 
children also associated negatively with Role Emotional (r = -0.20, p < 0.01). Table 4-7 also 
shows that marital status associated with role emotional (p < 0.05).  
Social Functioning: Reduced Social Functioning was associated with increased anxiety, 
depression, somatic symptoms, number of comorbidities and disease severity (p < 0.05), age 
did not significantly associate with Social functioning (r = -0.11, p > 0.05). Reduced Social 
Functioning also associated with the female gender and living alone (Table 5-8). 
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Table 5-2: Correlations between Health-related Quality of Llife and Hypothesised Determinants in Adult Sickle Cell population 
Variable
s 
PF RP RE SF BP VT GH MH PCS MCS 
Age -0.068 -0.281** -0.305** -0.106 -0.044 0.030 -0.154* -0.191** -0.095 -0.224** 
GAD7 -0.128 -0.411** -0.430** -0.342** -0.340** -0.324** -0.446** -0.413** -0.318** -0.513** 
PHQ9 -0.218** -0.384** -0.346** -0.297** -0.294** -0.364** -0.373** -0.363** -0.357** -0.413** 
PHQ15 -0.106 -0.361** -0.223** -0.237** -0.438** -0.409** -0.407** -384** -0.362** -0.379** 
Comorbi
dity 
-0.078 -0.322** -0.226** -0.219** -0.270** -0.196** -0.352** -0.361** -0.253** -0.343** 
DSEI -0.123 -0.206** -0.192** -0.226** -0.280** -0.169* -0.154* -0.210** -0.205** -0.241** 
N. 
children 
-0.071 -0.204** -0.213** -0.088 0.006 0.006 -0.038 0.004 -0.091 -0.084 
Notes: PF – Physical Functioning; RP – Role Emotional; SF- Social Functioning; BP- Bodily Pain; VT- Vitality; GH- General Health; MH- Mental Health; PCS – Physical 
Health Component Summary Score; MCS – Mental Health Summary Score  *Correlation significant at 0.05 level (2 tailed); **Correlation significant at 0.01 level (2 tailed). 
221 
 
Bodily Pain: Age did not associate significantly with Bodily Pain (p > 0.05), but anxiety, 
depression, somatic symptoms, number of comorbidities and disease severity associated 
with bodily pain (p < 0.01). In addition, female gender was also associated with worse health 
of bodily pain (p < 0.01). 
Vitality: Variables that associated with vitality included anxiety (r = -0.32, p < 0.01), 
depression (r = -0.36, p < 0.01), somatic symptoms (r = -0.41, p < 0.01), number of 
comorbidities (r = -0.20, p < 0.01) and disease severity (r = -0.17, p < 0.05). 
General health: A worse expression of General Health was associated with increasing age, 
anxiety, depression, somatic symptoms, number of comorbidities and disease severity. The 
correlation coefficient ranged from r = -0.15 to r = -0.45. Being without a confidant also 
contributed to reduced reported general health (p < 0.05, see Table 5-8).  
Mental Hhealth: Reduced Mental Health was associated with increasing age, anxiety, 
depression, somatic symptoms, number of comorbidities and disease severity; r ranged from 
-0.19 to -0.41 (all p < 0.01) as well as with being without a confidant (p < 0.05). 
Physical Component Summary: Low physical health summary score associated with more 
anxiety, depression, somatic symptoms, number of comorbidities and disease severity.  
Mental Component Summary: The mental component summary score associated with age 
(r = -0.22, p < 0.01), anxiety (r = -0.51, p < 0.01), depression (r = -0.41, p < 0.05), somatic 
symptoms (r = -0.38, p < 0.01), number of comorbidity (r = -0.34, p < -0.01), disease severity 
(r = -0.24, p < .01) and living alone (t = 2.65, p < 0.01; see Table 5-8). 
Further analysis was carried out on the variables with significant associations to examine 
which variables predicted a domain of HRQL. A hierarchical regression was used. Based on 
the Wilson and Cleary’s (1995) model of HRQL, the biological-physiological variables 
DSEI and number of comorbidities were entered first as possible predictors of the respective 
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HRQL domain (Block 1), these were followed by psychosocial variables of anxiety, 
depression and somatic symptoms (Block 2) and finally, the relevant sociodemographic 
variables were entered (Block 3). The results are displayed on Table 5-13. 
The biological-physiological factor, measured by number of comorbidities and disease 
severity, predicted all the HRQL domains including the Physical Component Summary score 
and the Mental Component Summary scores except Physical Functioning (F = 1.7, p > 0.05). 
The biological-physiological factor accounted for variation in the model ranging from 5.2% 
to 14.2 %. The number of comorbidities was a significant predictor of all the domains while 
disease severity predicted Social Functioning, Bodily Pain and MCS. The psychosocial 
factors; anxiety, depression and somatic symptoms explained additional 3.9% (lowest) in 
Physical Functioning, and 17.4% (highest) in Social Functioning. Anxiety was a significant 
predictor of Role Physical, Role Emotional, Social Functioning, General Health, Mental 
Health, Physical Component Score and Mental Health score. Depression was a significant 
predictor of Physical Functioning and Vitality while somatic symptoms was a significant 
predictor of Bodily Pain, Vitality) and General Health. All the signs were negative as 
expected. The sociodemographic variable, age, was a significant predictor of Role Physical 
and Role Emotional; the negative direction of prediction implies that each of Role Physical 
and Role Emotional reduced with advancing age. Gender significantly predicted Bodily Pain 
with female gender experiencing worse health in Bodily Pain. Having confidant predicted 
General Health and Mental Health; participants who had confidants experienced better 
Mental Health and General Health. Living situation was a significant predictor of the Mental 
Component Summary scores; participants living with others reported better mental health 
than participants living alone.  
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Table 5-33: Hierarchical Regression Modelling of Predictors of Health-related Quality of Life 
  Physical Functioning Role Physical 
Block Variables B  SE(B) *Std. β P R2 F (p) B  SE(B) *Std. β p R2 F (p) 
1 Constant 2.872 0.337   0.017 1.71 
(0.19) 
1.823 0.239    
0.117 
 
13.05  
(< 0.001) 
 DSEI -0.182 0.123 -0.109 0.14 -0.152 0.088 -0.122 0.08 
 Comorbidity -0.121 0.193 -0.046 0.53 -0.559 0.137 -0.286 0.000 
2 Constant 3.123 0.554    
 
0.056 
2.31  
(0.046) 
2.631 0.379    
 
 
0.214 
 
 
10.53 
(< 0.001) 
 DSEI -0.159 0.128 -0.095 0.22 -0.093 0.088 -0.074 0.29 
 Comorbidity 0.099 0.229 0.038 0.67 -0.149 0.156 -0.076 0.34 
 GAD7 -0.011 0.246 -0.004 0.97 -0..393 0.168 -0.215  
0.021 
 PHQ9 -0.274 0.111 -0.239  0.014 -0.125 0.076 -0.145 0.10 
 PHQ15 0.078 0.153 0.050 0.61 -0.096 0.104 -0.082 0.36 
3 Constant 3.141 0.555     2.752 0.373    
 
 
 
0.259 
 
 
 
 
9.58 
(< 0.001) 
 DSEI -0.167 0.129    -0.122 0.086 -0.097 0.16 
 Comorbidity 0.134 0.235    0.024 0.162 0.012 0.88 
 GAD7 0.001 0.247    -0.375 0.165 -0.205 0.024 
 PHQ9 -0.271 0.111    -0.112 0.074 -0.130 0.13 
 PHQ15 0.070 0.153    -0.136 0.103 -0.117 0.19 
 Age -0.029 0.062    -0.099 0.046 -0.158 0.033 
 N. children      -0.193 0.134 -0.106 0.15 
Notes: DSEI=Disease Severity Index;GAD7= Geneeralised Anxiety disorder-7; PHQ9=Patient Health Questionnaire-9; PHQ15=Patient Health Questionnaire-15.  
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Table 5-13 cont.:  Hierarchical Regression Modelling of Predictors of Health-related Quality of Life 
  Role Emotional Social Functioning 
Block Variables B  SE(B) *Std. β P R2 F (p) B  SE(B) *Std. β p R2 F (p) 
1 Constant 4.949 0.134    
0.06
8 
7.239 
0.001 
10.033     
0.077 
8.195 
(< 0.001)  DSEI -0.094 0.049 -0.137 0.058 -0.142  -0.177 0.014 
 Comorbidity -0.198 0.077 -0.186  0.01 -0.209  -0.167 0.021 
2 Constant 5.775 0.207    
 
0.21
4 
 
 
10.55 
(< 0.001) 
 
10.666     
 
0.151 
 
 
6.891 
(< 0.001) 
 DSEI -0.096 0.048 -0.141 0.045 -0.133  -0.17 0.023 
 Comorbidity 0.019 0.085 0.018 0.82 -0.009  -0.007 0.94 
 GAD7 -0.404 0.092 -0.406 < 0.001 -0.308  -0.264  0.006 
 PHQ9 -0.065 0.041 -0.138 0.12 -0.062  -0.113 0.22 
 PHQ15 0.090 0.057 0.141 0.117 0.040  0.053 0.57 
3 Constant 5.852 0.201    
 
 
0.27
8 
 
 
 
9.19 
(< 0.001) 
10.245     
 
 
 
 
0.197 
 
 
 
 
 
 
5.846 
(< 0.001) 
 DSEI -0.116 0.046 -0.170 < 0.013 -0.134  -0.168 0.020 
 Comorbidity 0.131 0.088 0.123 0.136 -0.025  -0.020 0.81 
 GAD7 -0.392 0.089 -0.394 < 0.001 -0.315  -0.271 0.004 
 PHQ9 -0.059 0.040 -0.126 0.145 -0.025  -0.045 0.63 
 PHQ15 0.067 0.056 0.106 0.231 0.042  0.057 0.54 
 Age -0.067 0.025 -0.196 0.009 -0.013  -0.032 0.65 
 Nom Child -0.138 0.082 -0.139 0.094     
 Marital status 0.043 0.097 0.035 0.66     
 Gender       0.113  -0.116 0.09 
 Living 
situation 
      0.300  0.179  0.009 
Notes: DSEI=Disease Severity Index;GAD7= Geneeralised Anxiety disorder-7; PHQ9=Patient Health Questionnaire-9; PHQ15=Patient Health Questionnaire-15.  
 
  
225 
 
Table 5-13 cont.:  Hierarchical Regression Modelling of Predictors of Health-related Quality of Life 
  Bodily Pain Vitality 
Block Variables B  SE(B) *Std. β P R2 F (p)  B  SE(B) *Std. 
β 
P R2 F (p) 
1 Constant 3.816 0.284    
0.117 
 
13.059 
(< 0.001) 
1.207 0.161    
0.052 
5.413 
(0.005)  DSEI -0.327 0.104 -0.220  
0.002 
-0.099 0.059 -0.122 0.09 
 Comorbidity -0.477 0.163 -0.205 0.004 -0.204 0.092 -0.160  
0.028 
2 Constant 4.257 0.449    
 
0.217 
 
 
10.754 
(< 0.001) 
1.390 0.249    
 
0.199 
 
 
9.667 
(< 0.001) 
 DSEI -0.197 0.104 -0.132 0.06 -0.014 0.058 -0.018 0.80 
 Comorbidity 0.003 0.185 0.001 0.99 0.118 0.103 0.093 0.25 
 GAD7 -0.287 0.199 -0.133 0.15 -0.084 0.110 -0.071 0.45 
 PHQ9 -0.003 0.090 -0.003 0.97 -0.103 0.050 -0.185 0.039 
 PHQ15 -0.423 0.124 -0.306  
0.001 
-0.230 0.069 -0.305 0.001 
3 Constant 4.708 0.472    
 
 
0.248 
 
 
9.051 
(< 0.001) 
1.374 0.248    
 
 
0.207 
 
 
8.380 
(< 0.001) 
 DSEI -0.185 0.103 -0.125 0.07 -0.007 0.058 -0.009 0.91 
 Comorbidity -0.082 0.190 -0.035 0.67 0.086 0.105 0.068 0.42 
 GAD7 -0.289 0.197 -0.13 0.14 -0.095 0.110 -0.080 0.39 
 PHQ9 0.012 0.089 0.012 0.89 -0.107 0.050 -0.191 0.033 
 PHQ15 -0.359 0.124 -0.260 0.004 -0.223 0.069 -0.294 0.001 
 Age -0.003 0.049 -0.004 0.96 0.037 0.028 0.090 0.19 
 Gender -0.332 0.118 -0.118 0.006      
Notes: DSEI=Disease Severity Index;GAD7= Geneeralised Anxiety disorder-7; PHQ9=Patient Health Questionnaire-9; PHQ15=Patient Health Questionnaire-15.  
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Table 5-13 cont.:  Hierarchical Regression Modelling of Predictors of Health-related Quality of Life 
  General Health Mental Health 
Block Variables B SE(B) *Std. 
β 
P R2 F (p) B SE(B) *Std. 
β 
P R2 F (p) 
1 Constant 3.172    0.126 14.251 
(< 0.001) 
3.470 0.261    
0.142 
16.345 
(< 0.001)  DSEI -0.086 0.109 -0.055 0.43 -0.157 0.096 -0.113 0.10 
 Comorbidity -0.819 0.170 -0.335 0.000 -0.710 0.149 -0.328 0.000 
2 Constant 4.229 0.464    
 
 
0.241 
 
 
12.316 
(< 0.001) 
4.272 0.417    
 
0.223 
 
 
11.111 
(< 0.001) 
 DSEI 0.015 0.108 0.010 0.89 -0.087 0.097 -0.063 0.37 
 Comorbidity -0.247 0.192 -0.101 0.20 -0.287 0.172 -0.133 0.097 
 GAD7 -0.565 0.206 -0.248 0.007 -0.416 0.185 -0.206 0.026 
 PHQ9 -0.075 0.093 -0.070 0.42 -0.080 0.084 -0.084 0.34 
 PHQ15 -0.249 0.128 -0.17 0.053 -0.155 0.115 -0.120 0.18 
3 Constant 3.276 0.572    
 
 
0.273 
 
 
10.318 
(< 0.001) 
3.545 0.514    
 
 
 
0.254 
 
 
9.352 
(< 0.001) 
 DSEI 0.013 0.106 0.009 0.90 -0.095 0.095 -0.069 0.32 
 Comorbidity -0.251 0.194 -0.103 0.20 -0.257 0.175 -0.119 0.14 
 GAD7 -0.523 0.203 -0.230 0.011 -0.372 0.183 -0.184 0.043 
 PHQ9 -0.047 0.092 -0.044 0.61 -0.055 0.083 -0.058 0.51 
 PHQ15 -0.301 0.127 -0.208 0.019 -0.203 0.114 -0.158 0.078 
 Age -0.019 0.051 -0.024 0.71 -0.051 0.046 -0.074 0.27 
 Confidant 0.474 0.168 0.178 0.005 0.370 0.151 0.157 0.015 
Notes: DSEI=Disease Severity Index;GAD7= Geneeralised Anxiety disorder-7; PHQ9=Patient Health Questionnaire-9; PHQ15=Patient Health Questionnaire-15.  
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Table 5-13 cont.:  Hierarchical Regression Modelling of Predictors of Health-related Quality of Life 
  Physical Component Summary  Mental Component Summary 
Block Variables B  
SE(B) 
*Std. β P R2 F (p)  B  SE(B) *Std. 
β 
P R2 F (p) 
1 Constant 3.126 0.170    
0.083 
8.895 
(< 0.001) 
3.125 0.199    
0.139 
15.933 
(< 0.001)  DSEI -0.125 0.062 -0.143  0.047 -0.162 0.073 -0.154  
0.027 
 Comorbidity -0.289 0.098 -0.211 0.003 -0.492 0.114 -0.298  
0.000 
2 Constant 3.347 0.272    
 
 
0.172 
 
 
8.050 
(< 0.001) 
4.482 0.303    
 
 
0.293 
 
16.079 
(< 0.001) 
 DSEI -0.062 0.063 -0.071 0.32 -0.126 0.070 -0.119 0.07 
 Comorbidity -0.019 0.112 -0.014 0.87 -0.077 0.125 -0.047 0.54 
 GAD7 -0.090 0.121 -0.071 0.46 -0.597 0.134 -0.388 0.000 
 PHQ9 -0.112 0.055 -0.187 <0.041 -0.072 0.061 -0.099 0.24 
 PHQ15 -0.145 0.075 -0.178 0.054 -0.022 0.084 -0.022 0.79 
3 Constant 3.353 0.273    
0.173 
6.715 
(< 0.001) 
3.981 0.400    
 
 
0.322 
 
 
 
13.019 
(< 0.001) 
 DSEI -0.065 0.063 -0.075 0.31 -0.140 0.069 -0.133 0.045 
 Comorbidity -0.007 0.116 -0.005 0.95 -0.023 0.127 -0.014 0.86 
 GAD7 -0.086 0.121 -0.067 0.48 -0.589 0.133 0.382  
0.000 
 PHQ9 -0.111 0.055 -0.185 0.044 -0.038 0.061 -0.052 0.54 
 PHQ15 -0.148 0.075 -0.182 0.051 -0.050 0.083 -0.051 0.55 
 Age -0.014 0.030 -0.031 0.65 -0.059 0.033 -0.112 0.077 
 Living 
situation 
    0.278 0.137 -0.125 0.043 
Notes: DSEI=Disease Severity Index;GAD7= Geneeralised Anxiety disorder-7; PHQ9=Patient Health Questionnaire-9; PHQ15=Patient Health Questionnaire-15.  
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5.4 Objective three 
To Test the Wilson-Cleary HRQL model in the population of adults with sickle cell disease 
5.4.1 Research Question 3:  
How does the Wilson and Cleary model fit the HRQL data of the study population? 
Latent factors and indicator variables 
A 2-step procedure recommended by Anderson and Anderson and Gerbing (1988) was 
implemented. The first step was implemented in two stages. The first stage of the first step 
was carried out to examine the fit of the indicator variables to the construct they were 
hypothesised to measure. The results are displayed in Table 5-14 . 
 
Table 5-14: The Fit Indices for Each Factor in the Construct (N=200) 
Latent constructs CMIN 
(χ2) 
χ2 / df  
SRMR 
CFI RMSEA 
Biological-Physiological 
Factors (BPF) 
0.888 0.444 0.02 1.00 0.00 
Symptoms Status (SS) 15.163* 3.033 0.05 0.97 0.12 
Functional Status (FS) 9.602** 4.801 0.05 0.96 0.10 
General Health Perception 
(GHP) 
32.825** 32.825 0.03 1.00 0.40 
Characteristics of 
Individual (COI) 
5.656 2.828 0.04 0.98 0.09 
Characteristics of the 
Environment (COE) 
  0.00 1.00 0.06 
Notes: CMIN=chi-square value, χ2 / df=relative chi-square, SRMR=Standardised Root Mean 
Square Residual, CFI=Comparative Fit Index, RMSEA=Root Mean Square Error of 
Approximation, CI=Confidence Interval, df=degree of freedom. *p<0.05, **p<0.01  
 
In determining the fit of the model, the chi-square was considered. A non-significant chi-
square where the p-value associated with the chi-square is larger than 0.05 can indicate that 
the model adequately represents the relations among the variables (Schermelleh-Engel, 
Moosbrugger and Müller, 2003). However, a weakness of chi-square is its sensitivity to large 
samples such that in most cases, the chi-square will return significant values. Other fit 
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indices were thus considered (see Table 4-4). The biological/physiological construct had a 
non-significant chi-square while other fit indices also indicated good fit. The three indicator 
variables for this construct were genotype, a measure of disease severity index and number 
of comorbidities. Apart from genotype (p > 0.05) all the variables associated with the 
construct (p < 0.01). Symptom status was measured with five indicators; though the chi-
squared was significant (p < 0.05), the CFI and SRMR were within acceptable limits. All the 
five indicators; bodily pain, mental health, anxiety, depression and somatic symptoms 
associated with the symptoms status construct (p < 0.01). All the four indicators of functional 
status; physical functioning, role emotional, role physical and social functioning associated 
with the construct (p < 0.01) and have acceptable CFI and SRMR but the chi-square was 
significant and the RMSEA was outside acceptable limit. Three of the four indicators of the 
characteristics of the individual: age, number of children and marital status associated with 
the construct (p < 0.05) but gender did not (p > 0.05). The chi-square was not significant (p 
> 0.05) and all the other fit indices were acceptable except RMSEA which was outside the 
acceptable limit at 0.096.    
The Full Measurement model 
The second stage of the first step was implemented to examine the full measurement model. 
The measurement model is a 7-factor model made up of 22 variables (see Figure 5-2). Table 
5.15 displays the measurement model and the modification steps. Model1, was the full 7-
factor measurement model with 22 variables. 
The model converged within 9 iterations and was admissible. The chi-square (χ2) was large 
and significant (χ2(189) = 387.098, p < 0.01). However, the fit indices χ2/DF = 2.048 (≤ 3), 
SRMR = 0.076 (≤ 0.08), RMSEA = 0.073 (≤ 0.08) were all within acceptable limits but CFI 
= 0.83 (≥ 0.9) was outside the acceptable limits.  
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Notes: PF=Physical Functioning, RP= Role Emotional, SF=Social Functioning, BPR=Bodily Pain reversed, 
VT=Vitality, GH=General Health, MHR=Mental Health reversed, NOCHD=Number of children, 
DSEI=Disease severity index, LIVSTN=living situation, CNFDT=confidant, HRQL=Health-related quality of 
life, BPF=bio-physiological factor, GHP=General health perception, FS=Function status, SS=symptoms status, 
IndCh=Characteristics of the individual, EnvCh=Charateristics of the environment.  
 
An attempt was made to improve the fit of the model. The modification indices suggested 
by AMOS were examined in line with theory. A path was constructed to correlate the 
residual (e8) of Social functioning with the residual (e12) of bodily pain. This correlation 
Figure 5-2: The 7-Factor, 22-Variable Basic Model 
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was considered reasonable because bodily pain could limit social functioning and a 
heightened social activity on the part of the patient could trigger bodily pain. The model 
containing this additional path was re-tested (Model 2 in Table 5-15). The chi-square 
difference test showed that the model improved significantly over the original model (χ2(1) = 
387.098 – 360.109 = 26.99, p < 0.01). all the other fit indices also improved. The 90% CI of 
RMSEA was 0.057-0.078 (acceptable limit: 0.00-0.08). A further effort was attempted to 
improve the fit; to further reduce the chi-square and improve the CFI which was still outside 
the acceptable limit. Model 3 was developed by removing the gender variable which 
contributed almost nothing to the measurement model (R2 = 0.002) or 0.2%. The model was 
retested. A significant improvement in Model 3 over Model 2 was observed ((χ2(20) = 58.00, 
p < 0.01), all the fit indices also improved. A further attempt was made to improve the model 
(Model 4) by drawing a path from e8 (Social functioning) to e22(living situation). It was felt 
reasonable to correlate these residuals because social functioning could be expected to be 
affected by living situation; participants living with people are more likely to enjoy better 
social relationship and functioning than participants who leave alone. The chi-square 
reduced by 10.57 though the change in chi-square was not significant (p > 0.05), there were 
improvements in the other fit parameters (Model 4, Table 5-15). 
Model 5 correlated the residual, e15 of Disease severity and the residual, e13 of somatic 
symptoms. This is also reasonable because somatic symptoms could be aggravated with 
worsen disease condition. Model 6 modified model 5 by drawing a path to relate the error 
terms of the Physical functioning and Social functioning, again this was reasonable as both 
indicators measured function status. Other fit modifications applied included drawing a path 
to link residuals of living situation and depression as well as linking the residual of Role 
emotional and anxiety, a path was also drawn to link the residuals of anxiety and depression. 
Finally, the variables, genotype and confidant were removed as indicator variables because 
they had no significant contributions to the model, genotype (R2 = 0.002) and having 
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confidant (R2 = 0.015). This gave rise to the final model (Figure 4.3). The fit indices were 
acceptable χ2/df = 1.391 (close to 1), SRMR = 0.06 (< 0.08), CFI = 0.957 (> 0.95) and 
RMSEA = 0.04 (< 0.08), 90% CI for RMSEA = 0.0027-0.060. The measurement model was 
therefore an acceptable fit.  
Table 5-15: Full Measurement Model and Modification Summary 
Model CMIN 
(χ2) 
DF P χ2/DF SRMR CFI RMSE
A 
90% CI 
for 
RMSEA 
Differen
ce in  
χ2, (p) 
1.Full Model, 7-factor 
CFA 23 variables  
387.098 189 0.00 2.048 0.076 
 
0.831 0.073 0.062-
0.083 
 
2. Path was added from 
e8(SF) to e12(BP)  
360.109 188 0.00 1.915 0.073 0.853 0.068 0.057-
0.078 
26.99 
(0.00) 
3. The indicator 
variable, gender was 
removed 
302.108 168 0.00 1.798 0.069 0.88 0.063 0.052-
0.075  
58.00 
(0.00) 
4. Path from e22 
(Living situation) to 
e8(SF) 
291.536 167 0.00 1.746 0.068 0.89 0.061 0.049-
0.073 
10. 57 
(0.11) 
5. Path from e13 
PHQ15) to e15 (DSEI)  
280.476 166 0.00 1.690 0.08 0.90 0.059 0.047-
0.071 
11.06 
(0.12) 
6. Path e5 (PF) to e8 
(SF) 
272.172 165 0.00 1.650 0.067 0.91 0.057 0.045-
0.069 
8.30 
(0.36) 
7. e22 (living situation) 
to e9 (PHQ9) 
263.170 164 0.00 1.605 0.067 0.91 0.055 0.042-
0.067 
9.00 
(0.26) 
8. Path e7(RE) to 
e10(GAD7) 
254.555 163 0.00 1.562 0.067 0.92 0.053 0.040-
0.063 
8.62 
(0.33) 
9. Path e9(PHQ9) to 
e10(GAD7) 
246.364 162 0.00 1.521 0.067 0.93 0.051 0.038-
0.064 
8.2 
(0.42) 
10. Removed confidant 
and genotype 
169.730 122 0.00 1.391 0.06 0.957 0.044 0.027-
0.060 
76.63 
(0.04) 
Notes: CMIN=chi-square value, χ2 / df=relative chi-square, SRMR=Standardised Root Mean 
Square Residual, CFI=Comparative Fit Index, RMSEA=Root Mean Square Error of 
Approximation, CI=Confidence Interval, df=degree of freedom.  
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χ2/df = 1.391, SRMR = 0.06; CFI = 0.957, RMSEA = 0.04 
  
Notes: PF=Physical Functioning, RP= Role Emotional, SF=Social Functioning, BPR=Bodily Pain reversed, 
VT=Vitality, GH=General Health, MHR=Mental Health reversed, NOCHD=Number of children, 
DSEI=Disease severity index, LIVSTN=living situation, CNFDT=confidant, HRQL=Health-related quality of 
life, BPF=bio-physiological factor, GHP=General health perception, FS=Function status, SS=symptoms status, 
IndCh=Characteristics of the individual, EnvCh=Charateristics of the environment.  
 
Figure 5-3: The 7-Factor, 19-Variable Measurement Model 
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The correlation matrix of the 19 variables is displayed on Table 5-16. All the composites 
were significantly correlated with each other (p < 0.01) except the characteristic of the 
environment (p > 0.05). The range of correlations were functional status 0.305-0.718, 
general health perception 0.265-0.390, symptom status 0.340-0.647, biophysiological 
construct 0.294 and characteristics of the individual 0.444-0.588. 
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Table 5-16: Correlation Matrix for Variables in the Measurement Model 
Constr
ucts 
Variables 1 2 3 4 5 6 7 8 9 10 11 12 
HRQL 1. QOL 1            
 
GHP 
2. GH 0.254** 1           
3. HT 0.215** 0.390** 1          
 
FS 
4. PF 0.124 0.307** 0.160* 1         
5. RE 0.156* 0.333** 0.195** 0.305** 1        
6. RP 0.185** 0.397** 0.321** 0.347** 0.718** 1       
7. SF -0.042 0.244** 0.172* 0.354** 0.353** 0.386** 1      
 
 
SS 
8. BPR 0.023 -0.265** -0.123 -0.168* -0.261** -0.313** -0.487** 1     
9. GAD7 -0.183** -0.446** -0.267** -0.128 -0.430** -0.411** -0.342** 0.340** 1    
10. PHQ9 -0.118 -0.373** -0.251** -0.218** -0.346** -0.384** -0.297** 0.294** 0.647** 1   
11. PHQ15 -0.161* -0.407** -0.185* -0.106 -0.223** -0.361** -0.237** 0.438** 0.589** 0.568** 1  
12. MHR -0.190** -0.427** -0.296** -0.174* -0.413** -0.449** -0.399** 0.362** 0.416** 0.368** 0.391** 1 
 
BPF 
13. Comorbidity -0.173* -0.352** -0.253** -0.078 -0.226** -0.322** -0.219** 0.270**.. 0.523** 0.470** 0.526** 0.363** 
14. DSEI 0.072 -0.154* 0.051 -0.123 -0.192** -0.206** -0.226** -0.280** 0.194** 0.241** 0.397** 0.208** 
 
CoI 
15. Age -0.137 -0.154* -0.210** -0.068 -0.305** -0.281** -0.106 0.044 -0.209** 0.178* 0.095 0.188** 
16. Mar_status -0.034 -0.004 -0.071 -0.122 -0.163* -0.131 -0.083 -0.037 0.071 0.135 -0.057 0.029 
17. No_ childr -0.084 -0.038 -0.183* -0.071 -0.213** -0.204** -0.088 -0.006 0.067 0.082 0.010 0.022 
18. Employment -0.048 0.020 -0.009 -0.099 -0.106 -0.062 -0.009 -0.120 -0.007 0.008 0.001 0.062 
19. Livingsitu 0.013 -0.005 -0.018 0.051 0.107 -0.005 0.222** -0.060 -0.081 -0.212** -0.023 -0.137 
**Correlation significant at 0.01 level (2tailed) *Correlation significant at 0.05 level (2 tailed); BPR and MHR are reversed scores of BP and MH respectively so that higher values represented 
worse scores, they were reversed to have same direction with measured variables of the constructs. 
Table5-16 cont: Correlation Matrix for Variables in the Measurement Model 
Constructs Variables 13 14 15 16 17 18 19 
 
BPF 
13. Comorbidity 1       
14. DSEI 0.294** 1      
 
CoI 
 
 
COE 
15. Age -0.281** -0.026 1     
16. Mar_status 0.165* -0.009 0.444** 1    
17. No_ childr 0.289** -0.015 0.491** 0.588** 1   
18. Emploment 0.063 0.033 0.092 0.295** 0.233** 1  
19. Livingsitu -0.060 -0.003 -0.135 -0.193** -0.071 0.124 1 
**Correlation significant at 0.01 level (2tailed) *Correlation significant at 0.05 level (2 tailed); BPR and MHR are reversed scores of BP and MH respectively so that higher 
values represented worse scores, they were reversed to have same direction with measured variables of the constructs. 
236 
 
5.4.2 Research Question 4:  
Are there relationships among the bio-physiological variables, symptoms, functional 
status, general health perceptions, individual characteristics and the overall quality of 
life as hypothesized by Wilson and Cleary? 
Table 5-17 was obtained from the measurement model. The biological-physiological 
construct associated positively with the symptom status construct. This was as expected as 
worse biological conditions were associated with increased symptoms (p < 0.01). The 
association between biological-physiological construct and general health perception was 
negative indicating that worse disease conditions reduced general health perception. 
Similarly, worse disease condition was associated with reduced HRQL. An increase in 
symptoms was associated with reduced functional status, reduced general health perception 
and reduced HRQL. Better functional status was associated with better general health 
perception and better HRQL. General health perception was also associated positively with 
HRQL. The characteristics of the environment and the characteristics of the individual were 
negatively associated. The characteristics of the individual followed the same direction as 
biological-physiological and symptom status constructs. 
Table 5-17: Intercorrelations among the Constructs of the Wilson and Cleary model 
 BPF SS FS GHP HRQL COI COE 
BPF -       
SS 0.764** -      
FS -0.396 -0.649** -     
GHP -0.533** -0.769** 0.587** -    
HRQL -0.191 -0.251 0.213 0.357** -   
COI 0.363 0.130 -0.318 -0.152 -0.113 -  
COE -0.143 -0.050 0.196 -0.064 0.126 -0.605** - 
Notes: BPF = Biological-physiological, SS = symptoms status, FS = functional status, GHP = general health 
perception, COI = characteristics of the individual. 
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5.4.3 Research Question 5:  
What are the patterns and paths of the relationship of the HRQL determinants? 
The second step for conducting structural equation modelling recommended by Anderson 
and Gerbing, (1988) was implemented here. To test whether the hypothesized structural 
relationship proposed by Wilson and Cleary (1995) was consistent with observations in the 
sickle cell disease population. The causal relationship is depicted in Figure 5-4.  
 
Figure 5-4: The Structural Model 
 
The path coefficients representing the strength of relationship between the concepts were 
assessed and tested for statistical significance at 5% level of significance. The magnitudes 
of the path coefficients were also evaluated using the thresholds of 0.10, 0.30 and 0.50 to 
identify small, moderate and strong effect sizes (Cohen, 1988). 
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The paths of relationship are shown in figure 5-5. From SEM analysis, it was observed that 
the Wilson and Cleary model fits well the data of people with sickle cell disease in Southwest 
Nigeria (χ2 == 200.760, df=152, p > 0.05, χ2/df = 1.321, SRMR = 0.06, CFI = 0.959, RMSEA 
= 0.04 (90% CI = 0.023-0.054), pclose = 0.864).  
 
Notes: PF=Physical Functioning, RP= Role Emotional, SF=Social Functioning, BPR=Bodily Pain reversed, 
VT=Vitality, GH=General Health, MHR=Mental Health reversed, NOCHD=Number of children, 
DSEI=Disease severity index, LIVSTN=living situation, CNFDT=confidant, HRQL=Health-related quality of 
life, BPF=bio-physiological factor, GHP=General health perception, FS=Function status, SS=symptoms status, 
COI=Characteristics of the individual, COE=Charateristics of the environment.  
 
Figure 5-5: Un-standardised Beta (Initial Model) 
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However, the latent factor, characteristics of the environment (COE) did not show any direct 
or indirect effect on any of the other latent factors, (Figure 5-5), it was therefore removed to 
achieve optimal fit and parsimony (Arnold et al., 2005). The model was then re-tested. The 
model converged in 8 iterations and was admissible (Figure 5-6). A bootstrap procedure was 
implemented with 2000 bootstraps samples. Nevitt and Hancock (2001) recommended 2000 
samples to assure the stability of the standard deviation. Bollen-Sline bootstrap method 
(Bollen and Stine, 1992) was used to further examine whether the model was correctly 
specified. According to Bollen and Sline the null hypothesis tests that the model is correct, 
a Bollen and Sline (B-S) p-value less than 0.05 indicates that the model is not correct. The 
bootstrap procedure returned a B-S p-value of 0.152, hence it was established that the data 
used in this study confirmed that the model was correct.  
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Figure 5-6: Standardised Beta (Final Model) 
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Fit indices 
The fit indices are first presented in Table 5-18. The exact fit test, chi-square was significant 
(p < 0.05), but χ2 /df = 1.3 (close to 1, the closer χ2 /df is to 1 the better the model fit). The 
SRMR = 0.04 <0.08, and CFI = 0.98. all the fit indices showed good fit of the model to the 
data. The standardised residual covariances were also examined; only 3.2% had an absolute 
value greater than 2 thus the model was considered a good fit to the data. The interpretation 
of the fit indices was guided by the criteria recommended in the overview by Schermelleh-
Engel, Moosbrugger and Müller (2003)(Engel et al., 2014), some studies, for example, Höfer 
et al. (2005) used less stringent criteria. 
Table 5-18: Model Fit Indices 
Fit indices Criteria Value Conclusion 
 χ2 103( p) 130.392, (p < 0.05) 0.035  
χ2 /df < 3  1.27 Good fit 
SRMR ≤ 0.08  0.06 Good fit 
CFI ≥ 0.95  0.975 Good fit 
RMSEA ≤ 0.08  0.04 Good fit 
90% CI for 
RMSEA 
0.00-0.08 0.010 – 0.054  Good fit 
PClose    > 0.05 0.884 Good fit 
Bollen-Sline (B-S) 
bootstrap p-value 
Reject if p < 0.05 0.152 Model was accepted 
as correct 
Notes: SRMR=Standardised Root Mean Square Residual, CFI=Comparative Fit Index, 
RMSEA=Root Mean Square Eerror of Approximation, CI=Confidence Interval, df=degree 
of freedom. 
Direct Effects 
Results of the structural equation modelling of the Wilson and Cleary model are presented 
in Table 5-19. The path analysis showed that: 
1. The Biological factors had a statistically significant direct effect on the symptom 
status of the participants (β =0.67, p < 0.001), the direction of influence was as 
expected indicating that a worsening health condition as a result of the disease was 
associated with more symptoms of illness in the patients. This path explained 44.3% 
of the variance in symptom status. 
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2. Symptoms status affected functional status (β = -0.53, p < 0.001), the negative sign 
indicated that as symptoms increased, functional health declined in the patient. 
Symptoms status and the characteristics of the individual explained 38.8% of the 
variance of functional status. 
3. Functional status directly affected general health perceptions (β = 0.30, p < 0.001), 
the direction of influence is positive as expected which implies that patient who had 
better functional health had better perception of their health. This path and the direct 
path from symptoms status explained 54.7% of the variance in general health 
perception. 
4. General health perception directly affected overall quality of life (β = 0.37, p < 
0.001), quality of life improved with better perception of health. Fourteen percent of 
variance in global quality of life was explained by general health perception. 
5. Symptoms status had a direct negative effect on general health perception (β = -0.52, 
p < 0.001); patients with more disease symptoms had a low perception of their 
general health.  
6. Characteristics of the individual (age, marital status and number of children) had a 
negative effect on functional status (β = -0.22, p < 0.001) of the patient, this was as 
expected for example functional status declined with increasing age.  
Items 1 to 4 satisfied the basic structural model of Wilson and Cleary (1995), Item five also 
confirm their observation that direct relationship was possible between non-adjacent 
constructs.  
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Table 5-19: Direct Effects for the Wilson and Cleary HRQL Model in the SCD Population 
Sample 
Path Unstand
ardized 
B 
SE (B) CR  
Standar
dised β 
Explained 
variance 
  R2 
Total effects 
Standardise
d β 
BPF → SS 1.180** 0.278 4.250 0.666 0.443 0.666 
SS → FS -0.539** 0.084 -6.438 -0.534 0.388 -0.534 
SS → GHP -0.563** 0.120 -4.679 -0.525 0.547 -0.684 
FS → GHP 0.316** 0.114 2.769 0.298 0.547 -0.298 
GHP → QOL 0.452** 0.102 4.429 0.374 0.14 0.374 
COI → FS -0.198** 0.067 -2.951 -0.223 0.388 -0.223 
*P < 0.05, **p < 0.01, SE = standard error, B = regression coefficient, β = standardised estimate, BPF = 
Biological-physiological, SS = symptoms status, FS = functional status, GHP = general health perception, COI 
= characteristics of the individual. 
Indirect effects 
There were several significant indirect effects between non-adjacent levels of the model. 
These paths are presented in Table 5-20. The bootstrap bias-corrected confidence intervals 
are reported in this study as they have been established to be more accurate for testing the 
significance of indirect effects (MacKinnon et al., 2002; Shrout and Bolger, 2002).  
1. The biological-physiological construct had significant indirect effect on functional 
status through symptom status (β = -0.36, BC95%CI = -0.536 – -0.184, p < 0.01). 
The negative sign of effect was as expected as patients with worsened biological 
markers of health and more symptoms had reduced functional health.  
2. Biological-physiological construct affected general health perception through 
symptom status and through functional status (BPF → SS → FS → GHP). The 
direction of effect was negative in line with expectations and significant (β = -0.46, 
BC95%CI = -0.661 – -0.265, p < 0.01). Patients who experienced worsening health, 
more symptoms and reduced functional status had low perception of their general 
health. 
3. Biological-physiological construct affected overall quality of life through symptom 
status, through functional status and through general health perception (BPF → SS 
→ FS → GHP → QOL). The effect was negative and significant (β = -0.17, 
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BC95%CI = -0.268 – -0.086, p < 0.01). Patients who experienced declining health 
due to the disease, more symptoms, reduced functional status and low health 
perception had reduced quality of life. 
4. Symptoms status had indirect effect on general health perception through functional 
status (SS → FS → GHP). The direction of effect was negative ((β = -0.16, 
BC95%CI = -0.305 – -0.027, p < 0.05). Patients who had more symptoms and 
reduced functional health had low perceptions of their general health. 
5. Symptoms status had indirect effect on overall quality of life through function status 
and through general health perception (SS → FS → GHP → QOL). The direction of 
effect was negative (β = -0.26, BC95%CI = -0.363 – -0.152, p < 0.01). Patients who 
had more symptoms, reduced functional health and low general health perception 
had reduced overall quality of life. 
6. The indirect effect of functional status on overall quality of life through general 
health perception (FS → GHP → QOL) was positive, and the bias-corrected 95% 
confidence interval was significant (β = 0.11, BC95%CI = 0.014 – 0.236, p < 0.05). 
Patients who had better functional health and high general health perception had 
better overall quality of life.  
7. Characteristics of the individual had indirect effect on general health perception 
through functioning status (COI → FS → GHP). The direction was negative and 
statistically significant (β = -0.07, BC95%CI = -0.168 – -0.012, p < 0.05).  
8. Characteristics of the individual had indirect effect on overall quality of life through 
functioning status through general health perception (COI → FS → GHP → QOL). 
The direction was negative and statistically significant (β = -0.03, BC95%CI = -0.073 
– -0.004, p < 0.05). 
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Table 5-20: Total Iindirect Effects for the Wilson and Cleary HRQL Model in the SCD 
Population Sample 
Path Unstandardised 
β 
SE 
(B)1 
Standardised 
β 
BC 95% 
CI 
BPF → SS → FS -0.636 0.297 -0.355 -0.536 – 
 -0.184** 
BPF → SS → FS → GHP -0.865 0.381 -0.456 -0.661– 
 -0.265** 
BPF → SS → FS → GHP 
→ QOL 
-0.391 0.173 -0.170 -0.268 –  
-0.086** 
SS → FS → GHP -0.170 0.077 -0.159 -0.305 –  
-0.027* 
SS → FS → GHP → QOL -0.331 0.077 -0.256 -0.363 –  
-0.152** 
FS → GHP → QOL 0.143 0.073 0.111 0.014 – 
0.236* 
COI → FS → GHP -0.063 0.036 -0.066 -0.168 –  
-0.012* 
COI → FS → GHP → 
QOL 
-0.028 0.019 -0.025 -0.073 –  
-0.004* 
1Notes: Bootstrap standard error*P < 0.05, **p < 0.01 BC95%CI = bias-corrected 95% confidence interval, BPF 
= Biological-physiological, SS = symptoms status, FS = functional status, GHP = general health perception, 
COI = characteristics of the individual. 
 
In summary, this study identified six determinants of HRQL in sickle cell disease.  
a) One direct determinant, the general health perception which explained 14% 
(95%BCI: 10% - 26%) of the variance; 
b) two indirect determinants through general health perception, functional status and 
symptom status which explained 55% (95% BCI: 39% - 74%) of the variance; 
c) two indirect determinants through functional status namely, symptom status and 
characteristics of the individual which explained 39% (95%BCI: 24% - 53%); and 
d) one indirect determinant through symptoms status namely biological-physiological 
factor which explained 44% of the variance. 
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5.5 Objective four. 
To Create a hierarchy of importance of the determinants as targets for potential 
intervention. 
5.5.1 Research Question 6:  
What is the relative importance of each construct? 
Effect size 
Effect sizes were obtained from the absolute value of the standardised path coefficients. 
From Table 5-20, large effect size was observed in the biological-physiological → symptoms 
status path (β = 0.67), the biological factor did not have any further direct effect on other 
factors. Symptoms status had direct effect on both functional status and general health 
perception. These effects were large (SS → FS, β = 0.53; SS→GHP, β = 0.53). The effect 
of functional status → general health perception path was of medium size (β = 0.3). Also, 
the effect size of the general health perception → overall quality of life path was medium (β 
= 0.37). characteristics of the individual only had direct path to functional status and the size 
was small (β = 0.22). Effect sizes of indirect paths ranged from small in 
COI→FS→GHP→QOL (β = 0.030 to medium in BPF→SS→SS→GHP (β = 0.46). 
Total effect and percentage contribution of constructs 
The total effects of the latent factors are displayed on Table 5-21. Symptoms had the highest 
impact on functional health and general health perception while general health perception 
had the highest impact on overall quality of life followed by symptom status.  
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Table 5-21: Total Effects 
Factor BPF SS FS COI GHP 
SS 0.666     
FS -0.355 -0.534  -0.223  
GHP -0.456 -0.684 0.298 -0.066  
QOL -0.17 -0.256 0.111 -0.025 0.374 
Notes: BPF = Biological-physiological, SS = symptoms status, FS = functional status, GHP = general health 
perception, COI = characteristics of the individual., QOL=Quality of Life 
 
Tables 5-22 to 5-24 show the contribution of the latent factors as we move through the HRQL 
model continuum, from the initial end of the model, the biological function, to the end of the 
model, the overall quality of life. The Pratt index shows that biological-physiological factor 
contributed 28.2% of variance explained in functional status, 24.5% of variance explained 
in general health perception and 11.5% of total variance explained in the overall quality of 
life. Symptoms status contributed 57.7% to the variance explained in functional health, 
53.7% of the variance explained in general health perception and 25.3% of the variance 
explained in overall quality of life. General health perception contributed 52.9% of the 
variance explained in the overall quality of life while the characteristics of the individual 
contributed 14.1% to the variance explained in functional status, 1.6% to variance explained 
in general health perceptions and less than 1% to variance explained in overall quality of 
life. 
 
Table 5-22: Contributions to Functional Status 
 BPF SS COI R2 BC 95% CI 
for R2 
Std Beta -0.355 -0.534 -0.223  
0.39 
 
0.24-0.53 Correlation -0.430 -0.584 -0.342 
Pratt index % 28.2 57.7 14.1 
Notes: BPF = Biological-physiological, SS = symptoms status, COI = characteristics of the individual. 
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Table 5-23: Contributions to General Health Perception 
 BPF SS FS COI R2 BC95%CI 
for R2 
Std Beta -0.456 -0.684 0.298 -0.066  
0.55 
 
0.39-0.74 Correlation -0.478 -0.699 0.604 -0.219 
Pratt index % 24.5 53.7 20.2 1.6 
Notes: BPF = Biological-physiological, SS = symptoms status, FS = functional status, GHP = general health 
perception, COI = characteristics of the individual. 
 
 
Table 5-24: Contributions to Global quality of life. 
 BPF SS FS COI GHP R2 BC95%CI 
for R2 
Std Beta -0.170 -0.256 0.111 -0.025 0.374  
0.14 
 
0.1-0.26 Correlation -0.179 -0.261 0.226 -0.082 0.374 
Pratt index % 11.5 25.3 9.5 0.8 52.9 
  Notes: BPF = Biological-physiological, SS = symptoms status, FS = functional status, GHP = general health 
perception, COI = characteristics of the individual. 
 
5.6 Objective five 
To Determine the health utility score and its associated factors in people with sickle cell disease 
5.6.1 Research Question 7:  
What is the health utility score and its determinants in the population? 
The mean utility score in the population was 0.65 (SD: 0.12; Range: 0.310-0.965). The utility score 
was lower for participants who had co-morbidities than participants who did not (see Table 5-23). 
This difference was statistically significant (p < 0.01) with an effect size of 0.63. Women also had 
lower but not statistically significant utility score. The utility scores between patients with SS and 
SC genotypes was similar. Participants living alone and participants living with others also 
reported similar health utilities. 
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Table 5-25: Group Differences and Effects sizes 
 
 
The mean utility score for the 65 (32.5%) participants having comorbidities was 0.60 (SD = 
0.10). Figure 5-7 shows that participants who had epilepsy, arthritis and leg ulcers reported 
lower utility scores. The score was below the mean for 8 out of the 11 comorbid diseases. 
Participants having epilepsy as comorbid condition reported the minimum quality of life. 
 
 
 N Mean SD 95% CI P-value Cohen’s d 
Gender 
Male 
Female 
 
83 
117 
 
0.66 
0.64 
 
0.11 
0.12 
 
0.64 – 0.69 
0.62 – 0.66 
 
0.179 
 
0.17 
Marital Status 
Never married 
Married 
Others (divorced, 
separated, widowed) 
 
151 
41 
8 
 
0.66 
0.63 
0.61 
 
 
 
0.12 
0.09 
0.12 
 
0.64 – 0.68 
0.61 – 0.66 
0.53 – 0.69 
 
 
0.322 
 
0.12 
Education 
≤ Primary 
Secondary 
Post-secondary 
 
19 
97 
84 
 
0.60 
0.65 
0.66 
 
0.12 
0.11 
0.12 
 
0.55 – 0.65 
0.63 – 0.67 
0.64 – 0.67 
 
 
0.092 
 
 
0.16 
Employment 
Full-Time 
Part-time 
Not employed 
 
43 
30 
127 
 
0.66 
0.64 
0.65 
 
0.11 
0.10 
0.12 
 
0.63 – 0.67 
0.60 – 0.68 
0.63 – 0.70 
 
0.732 
 
0.06 
Living situation 
Alone 
With others 
 
18 
182 
 
0.62 
0.65 
 
0.08 
0.12 
 
0.58 – 0.65 
0.64 – 0.67 
 
0.227 
 
0.30 
Confidants 
Yes 
No 
 
171 
29 
 
0.651 
0.647 
 
0.11 
0.13 
 
0.60 – 0.70 
0.63 – 0.67 
 
0.891 
 
0.02 
Genotype 
HbSS 
HbSC 
 
170 
30 
 
0.651 
0.648 
 
0.12 
0.12 
 
0.63 – 0.67 
0.61 – 0.69 
 
0.894 
 
0.03 
Co-morbidity 
No 
Yes 
 
135 
65 
 
0.67 
0.60 
 
0.12 
0.10 
 
0.65 – 0.69 
0.58 – 0.63 
 
0.000 
 
0.63 
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Utility score decreased with an increase in number of co-morbidities (r = -0.32, p < 0.01), 
depression (r = -0.35, p < 0.01), anxiety (r = -0.41, p < 0.01), somatic symptoms (r = -0.39, 
p < 0.01), DSEI (r= -0.26, p < 0.01) but exhibited a positive relationship with level of 
education (r = 0.14, p < 0.05). The association with age was also negative as expected but 
not statistically significant (r = -0.13, p > 0.05).  
All the independent variables explained 27.9% of the variation (see Table 5-24). The bio-
physiological variables were responsible for 13.2% with both measures, disease severity and 
number of comorbidities as predictors of health utility. The psychosocial variables were 
responsible for 9.4% variation in the model with anxiety as a major predictor of health utility 
in the patients. The sociodemographic factors of age and level of education added 5.3% 
percent variation. Thus, increased anxiety, disease severity and number of co-morbidities 
predicted reduced utility score while higher level of education predicted better utility score.  
 
  
Figure 5-7:  Mean Utility Score of Participants by Comorbid Disease 
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Table 5-246: Predictors of Health Utility Score 
Variables B SE (B) Stand. 
   β 
Statistic 
 (t) 
 
P 
R2 95% CI for β 
L             U 
Block 1 
Constant 
Disease Severity Index 
Number of comorbidities 
 
0.768 
-0.035 
-0.080 
 
0.037 
0.013 
-0.021 
 
 
-0.182 
-0.266 
 
 
-2.618 
3.830 
 
 
< 0.05 
< 0.01 
 
0.132 
 
0.696      0.840 
-0.062   -0.009 
-0.122   -0.039 
Block 2 
Constant 
Disease Severity Index 
Number of comorbidities 
Anxiety 
Depression 
Somatic Symptoms 
 
0.894 
-0.025 
-0.017 
-0.067 
-0.008 
-0.025 
 
0.058 
0.013 
0.024 
0.026 
0.012 
0.016 
 
 
-0.127 
-0.055 
-0.237 
-0.063 
-0.139 
 
 
-1.830 
-0.696 
-2.592 
-0.724 
-1.558 
 
 
0.069 
0.487 
< 0.05 
0.470 
0.121 
 
 
 
0.226 
 
0.779     1.00 
-0.051    0.002 
-0.064    0.031 
-0.118    -0.016 
-0.031    0.015 
-0.057    0.007 
Block 3 
Constant 
Disease Severity Index 
Number of comorbidities 
Anxiety 
Depression 
Somatic Symptoms 
Age 
Level of Education 
 
0.969 
-0.028 
-0.025 
-0.059 
-0.008 
-0.029 
-0.009 
-0.043 
 
0.060 
0.013 
0.024 
0.025 
0.011 
0.016 
0.006 
0.012 
 
 
-0.144 
-0.083 
-0.209 
-0.056 
-0.162 
-0.091 
-0.237 
 
16.190 
-2.125 
-1.044 
2.352 
-0.664 
-1.859 
-1.380 
-3.694 
 
 
< 0.05 
0.298 
< 0.05 
0.508 
0.065 
0.169 
< 0.01 
 
 
 
0.279 
 
0.673    0.920 
-0.054   -0.002 
-0.073    0.022 
-0.109    -0.010 
-0.030    0.015 
-0.060    0.002 
-0.021    0.004 
0.02       0.066   
*P < 0.05, ** P < 0.01, ***=F statistic 
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CHAPTER SIX 
DISCUSSION 
6.0 Introduction 
This study was undertaken to understand health-related quality of life and its predictors 
among adults with sickle cell disease in Nigeria. Some studies have been carried out in some 
high income nations to analyse predictors of HRQL in chronic diseases (Halvorsrud et al., 
2010; Taylor et al., 2011; Carlson et al., 2014; Kumar, Kroon and Lalloo, 2014; Vilhena et 
al., 2014; Grove et al., 2016; Yeng, Gallagher and Elliott, 2016) including SCD (Edwards 
et al., 2001; Panepinto, 2012; Ivo and Pinto, 2013; Beverung et al., 2015; Mastandréa et al., 
2015). However, in view of the different healthcare systems, cultural differences and other 
socioeconomic realities, such studies are unable to reflect the prevailing situation from a 
lower-middle income country like Nigeria because of the differences in weightings attached 
to the various factors (Curtis, 2000) which makes measuring quality of life a challenging 
task (Szabo, Orley and Saxena, 1997). This chapter discusses the findings of this study as 
related to the objectives of the study.  
6.1 Characteristics  
The mean age of participants in the current study was 27.9 which was comparable to similar 
studies in Nigeria, Cameroun 28.2 (Chemegni et al., 2018), Saudi Arabia (Ahmed et al., 
2015) but younger when compared to about 30 years in UK (Anie, Steptoe and Bevan, 2002) 
and between 31-34 years in in US (Schaeffer et al., 1999; Jenerette, Funk and Murdaugh, 
2005; McClish et al., 2006; Levenson et al., 2008; Dampier et al., 2011). This age difference 
could be related to the substantial difference between developed and developing nations in 
general life expectancies both in the SCD population as well as in the general population. In 
the SCD population, life expectancy in UK was 67 (Gardner et al., 2016) compared with 21 
in Nigeria (Chijioke and Kolo, 2009). Furthermore, while life expectancy in UK was 80 for 
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males and 83 for females, in Nigeria it was 55 for males and 56 for females (WHO global 
health observatory data, 2016). The low mean age in Nigeria reflected the low life 
expectancy common to people with SCD. SF-36 has been known to decrease with age of 
patients, the fact that people with SCD are younger and yet with substantially poorer scores 
in the subscales of SF-36 is quite revealing and of great concern that calls for effective 
intervention from healthcare providers and healthcare policy-makers.  
Females were more in number than the male participants similar to reports of other studies  
(Kotila and Shokunbi, 2001; Jenerette, Funk and Murdaugh, 2005; Anie et al., 2012). SCD 
is not a gender selective disease therefore the higher number of women could be explained 
in terms of health-seeking behaviour; women have been reported to be a more frequent 
seeker of information and healthcare services than men (Tudiver and Talbot, 1999; 
Courtenay, 2000a; Galdas, Cheater and Marshall, 2005). For example, Friedman (1989) has 
argued that the symptoms of weakness or fainting may be interpreted differently based on 
sex. Nathanson (1975) has suggested that women are more likely to use health services more 
than men because it is more socially acceptable for women to disclose information about 
their health status and to admit weakness while men are reluctant to engage in healthcare 
seeking (Jewkes and Morrell, 2010). Studies have shown that men show poorer health 
maintenance and fewer health-seeking behaviours than women (Schofield et al., 2000). This 
behaviour is a product of gender constructions of masculinity, which affects self-
management of chronic conditions (Courtenay, 2000b; Oliffe, 2004). These constructions of 
masculinity seem to be stronger among men of African origin as reported in African 
American men compared with European American men (Levant, Majors and Kelley, 1998; 
Levant et al., 2003). In African culture, males are expected to show strength and endurance 
during times of crisis, to be the bread winners and leaders in their family and to endure pain 
(Ampofo and Boateng, 2007). Furthermore, studies of self-reported health status have shown 
that women have poorer health profiles than men across a range of chronic conditions 
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(Waldron, 1983) and they report or complain more than males when they are suffering from 
different types of illnesses (Ilesanmi, 2013). This result is therefore in line with findings in 
literature. 
The HbSS genotypes which is the more severe type (Platt et al., 1994) outnumbered the less 
severe HbSC. This is consistent with findings in other studies where the more severe HbSS 
was always reported to be more than HbSC in any sample (McClish et al., 2006; Adams‐
Graves et al., 2008; Mann‐Jiles and Morris, 2009; Anie, Egunjobi and Akinyanju, 2010; 
Mastandréa et al., 2015; Anim, Osafo and Yirdong, 2016). 
A fifth of participants were married, similar to the findings in previous studies (Levenson et 
al., 2008; Santos and Gomes Neto, 2013; McClish et al., 2016). The low percentage of 
people with SCD who are married could be due to fear of being a burden on their spouse, or 
giving birth to a child with SCD (Adzika et al., 2017), or inability to find a partner due to 
stigma (Jenerette, Funk and Murdaugh, 2005; Adeyemo et al., 2015) or to consummate a 
relationship. A study conducted in Saudi Arabia found that more than 60% of adults with 
SCD were likely to cancel an at risk marriage, that is, marriage likely to produce an offering 
with haemoglobinopathy (Al Sulaiman et al., 2008). Only 17% of participants in this study 
had a child compared with another study which reported 26%. Further study may be required 
to establish wheather this is due to financial and psychological implications of child rearing 
in their condition and associated burden. Chemengi et al, (2018) reported that having a child 
negatively affected their finances and could be a factor for anxiety and depression. 
Eighty-nine percent of the participants had secondary education and beyond similar to other 
studies in literature. In a study of 78 adults with sickle cell in Cameroun 87.2% were reported 
to have level of education of secondary school and beyond (Chemegni et al., 2018). Also, 
86.5% of the 232 subjects in the US Pain in Sickle Cell Epidemiology Study (PiSCES) 
Cohort had secondary education and beyond (Levenson et al., 2008). On the contrary, some 
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studies found low level of education among sickle cell patients (Santos and Gomes Neto, 
2013). The reason for the high percentage of participants with higher education in the current 
study may be because this was a hospital-based survey and those attending hospital were 
those educated and are likely to be better informed about the disease and its management 
outcomes (Adzika et al., 2017). Also, like the study in Cameroun, the University College 
Hospital, Ibadan is located in an area populated with University students, lecturers and top 
civil servants. Moreover Ibadan, where the study was carried out, is one of the most 
educationally more advantaged states in Nigeria (States in Nigeria were categorised as 
educationally advantaged and educationally less advantaged). About 36.5% had either full-
time or part-time employment compared with Nigeria’s unemployment rate 0f 18.8% and 
21.2% underemployment rate (National Bureau of Statistics, 2017) . This is comparable to 
the findings of Belgrave et al (1991), Santos and Neto (2013) and Chemegni et al (2018) 
who reported 32%, 31.2% and 30.8.%, respectively. These low rates of employment reflect 
the impact of the disease. Another study in Brazil however reported that 88% of their 
participants were employed, although this high rate could be attributed to the low sample 
size of 25 enrolled in the study due to limited facility at their centre (Vilela et al., 2012). 
6.2 Objective one. 
To Describe the HRQL profile of adult living with sickle cell disease 
Chronic diseases have been widely reported to affect health-related quality of life with age, 
type of pathology, family support, values, beliefs and socio-economic level indicated to 
affect the perception of HRQL (Moreno et al., 1996; Santos and Gomes Neto, 2013). This 
section of the study examined the health-related quality of life profile in a population of 
sickle cell disease. The findings of this study reveal a low quality of life in the SF-36 domains 
compared with the standardised norm scores. Using the norm-based score for comparability 
with the general population and other diseases, all the SF-36 domains were below the general 
population score except vitality which was similar to the general population mean. This is 
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consistent with other studies (Dampier et al., 2011; McClish et al., 2016) which reported 
decrement in SF-36 domains. In a study of 408 SCD patients in the PiSCES cohort, patients 
with SCD experienced worse HRQL compared to the general population and similar to 
patients undergoing haemodialysis (McClish et al., 2016).  
Compared with the norm, very low scores were observed in functioning, Physical 
Functioning (below 40) and Role Physical (below 45) were similar to findings in previous 
studies (Santos and Gomes Neto, 2013). This underscores the limitations experienced by 
people with SCD in daily activities due to the effects of the disease on physical health 
resulting in reduced quality of life. McClish et al (McClish et al., 2016) compared their 
results in thePiSCES cohort with three cohorts’ studies of other chronic diseases; asthma, 
cystic fibrosis and haemodialysis. They found that SCD patients had significantly lower 
scores than the general population in all domains of SF-36 except Mental Health. Compared 
with cystic fibrosis, SCD patients reported significantly lower scores in all the domains 
except Mental Health. In addition, when compared with asthma, scores were similar in 
physical functioning, Role Physical, Role Emotional and Mental Health but significantly 
worse in Bodily Pain, General Health, Vitality and Social Functioning. When compared with 
haemodialysis patients, sickle cell patients scored significantly worse in Bodily Pain, 
General Health and Vitality but similar in Role Physical, Social Functioning, Role Emotional 
and Mental Health. SCD patients were however significantly better in Physical Functioning; 
this may be due to the coping strategy of the sickle cell patients. According to Anie et al, 
(Anie, Steptoe and Bevan, 2002) coping mechanisms differ between people such that 
functional ability may not reflect the level of disease severity. Another study in the UK which 
compared SF-36 subscales with the general population and people with haemochromatosis 
reported that adults with sickle cell had poorer quality of life on all eight subscales of SF-36 
compared to the general population (Anie, Steptoe and Bevan, 2002). The authors also 
showed that the quality of life in adults with sickle cell was similar to the quality of life in 
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people with hemochromatosis but worse in Role Emotional. HRQL domain scores of 
participants in the current study were compared with scores of hypertensive patients in 
southwest Nigeria, the same geographical location where this study took place. The scores 
were similar in Role Physical, and Mental Health. Sickle cell patients had higher scores in 
Physical Functioning but worse scores in Bodily Pain, Social Functioning, Vitality and Role 
Emotional. 
The highest mean score was observed in Vitality, this was similar to the result obtained in 
Brazil in a study of 32 SCD patients (Santos and Gomes Neto, 2013) and the study of 1046 
US adults with sickle cell from the Comprehensive Sickle Cell Centres Consortium 
(Dampier et al., 2011). Better Vitality reflects the tendency of patients with SCD to seek 
better coping strategies against feelings of tiredness and exhaustion due to pain, fatigue and 
depressive symptoms that they often experience (Santos and Gomes Neto, 2013). Also, 
spirituality, belief system and optimism may have offered some support (Adegbola, 2011) 
According to Anie et al (2010), coping responses, acquisition of new skills to deal with the 
sickness, and modification of daily lifestyle are likely to reduce the effect of the disease on 
the individual. Recourse to spiritual healing (prayer) has also been reported among Africans 
as an alternative approach to or in addition to medical treatment (Omonzejele, 2008). In a 
study, Mann-Jilles and Morris (2009) reported that African-Americans tend to use 
religious/spiritual practices as a primary means of coping. People of Africa origin are highly 
spiritual by nature and culture (Adegbola, 2011). Santos and Neto (2013) also opined that 
health conditions improve when optimism is part of the individual’s psychological condition. 
Mental Health had the next highest mean score after Vitality, in fact the non-normed score 
was highest for Mental Health in the present study. Similarly, McClish and colleagues 
reported that SCD patients in their study did not report poorer Mental Health than the general 
US population (McClish et al., 2016). Studies have shown that though chronically ill people 
may report worse health than the general population, they appear to have comparable 
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wellbeing (Schlenk et al., 1997; Alonso et al., 2004; Rijken et al., 2005). Such reports of 
good psychological wellbeing despite a chronic disease condition, has been attributed to 
increased social support, lack of other stressors or a ‘response shift’ (changes in one’s 
internal standards which affects changes in one’s values, priorities and evaluation of a 
construct) connected with managing their chronic disease (Schlenk et al., 1997). Such 
‘response shift’ could be associated with scale recalibration which implies change in the 
patients’ values, or reconceptualization of their mental health and wellbeing (Rapkin et al., 
2004; Sprangers et al., 2010) over time to accommodate their disease condition. However, 
in a study of haemodialysis patients, Ris et al (2005) disagreed with the concept of scale 
recalibration but rather argued that people have only adapted to their condition. In contrast, 
a study of 27 adults with sickle cell in Brazil reported mental health as the most affected, the 
authors (Ohara et al., 2012) suggested that pain crises, and frequent hospitalisation may 
cause anxiety, depression, aggressive behaviour and fear (Ohaeri et al., 1995; Ohaeri and 
Shokunbi, 2002; Adegoke et al., 2012). Also, limitations in achieving some tasks due to pain 
may trigger feelings of inferiority and low self-esteem which affect mental health (Ohara et 
al., 2012).  
Mean bodily pain in this study was comparable to findings found elsewhere (Ahmed et al., 
2015; Mastandréa et al., 2015; McClish et al., 2016). Female participants reported 
significantly worse scores in bodily pain and social functioning than their male counterparts, 
similarly to previous studies (McClish et al., 2006). Other studies have also shown that 
women reported worse bodily pain not only in sickle cell (Cleeland et al., 1994; Fillingim et 
al., 2003) which may be attributed to physiological gender difference rather than response 
bias factors (McClish et al., 2006). Laboratory studies have shown that women have a 
heightened neurophysiological response to heat and physiological response to noxious 
stimuli (Fillingim and Maixner, 1995; Fillingim, Edwards and Powell, 1999), higher pain 
intensity and pupil dilation has also been reported in women at high heat pressure levels 
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(Ellermeier and Westphal, 1995), Some have also suggested that differences may be due to 
men’s tendency to ignore pain or at least avoid public expression of pain (McClish et al., 
2006). 
Forty-two percent of participants in this study had a pain frequency equal or greater than 3 
times within 6 months before the study. In a study of 6-month pain diary of adults with SCD, 
29% reported sickle cell pain everyday (Smith et al., 2008). Pain in SCD is both acute and 
chronic, with acute pain having the potential to develop into a chronic sickle cell pain (Smith 
et al., 2008). The mean number of pains reported in this study was 2.37 in the last six months 
with women reporting significant higher mean number of pain than their male counterpart 
(P < 0.05) similar to results of previous studies (McClish et al., 2006; Chemegni et al., 2018). 
Pain has a negative impact on the financial, emotional, functional, physical, social, 
occupational dimension of life (Ferrell, Wisdom and Wenzl, 1989).  
High utilisation of healthcare resources as measured by emergency department visits ≥ 3 
(Aisiku et al., 2009) was reported by 12% of the participants in this study. In a study of 232 
adults with sickle cell enrolled in the PiSCES project, high emergency department utilisation 
was estimated at 35% (Aisiku et al., 2009) which was much higher than in this study. This 
could be because the PiSCES participants had better medical facilities, access and financial 
support for healthcare usage than the population in the current study. Due to government 
low spending on health, Nigerian hospitals lack medical facilities for quality care, 
additionally, the out of pocket heath financing system makes good healthcare inaccessible 
and unaffordable to the majority (Ogunbekun, Ogunbekun and Orobaton, 1999; Asuzu, 
2004; Galadanci et al., 2013; Obansa and Orimisan, 2013). Aisiku and colleagues reported 
that higher emergency department users reported higher mean pain and distress level than 
other sickle cell patients (Aisiku et al., 2009). Three or more emergency admissions is a 
likely marker of disease severity (Aisiku et al., 2009) and severe enough to require 
hydroxyurea therapy (Samuel Charache et al., 1995). High emergency department utilisation 
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was associated with worse Social Functioning, General Health, and Mental Health similar 
to the result of Chemegni and colleagues (2018). Also, a high frequency of hospital 
admissions was associated with limitations in Role Physical, Role Emotional, worse Bodily 
Pain, reduced General health and Mental health in agreement with previous study (Chemegni 
et al., 2018).   
In the current study, 83% had history of blood transfusion similar to the study in Saudi 
Arabia where 85.9% of the 629 participants reported history of blood transfusion (Ahmed et 
al., 2015). According to Ugwu et al (2011), the higher frequency of blood transfusion may 
be associated with higher frequency of sickle cell related complications including chronic 
leg ulcers. 
Sickle cell is a debilitating genetic disease in which the number of complications increases 
significantly with advancing age (Dampier et al., 2011). The presence of other comorbid 
conditions was therefore expected in the population. Thirty-two percent (32%) of 
participants reported at least one comorbid disease. Similar studies have reported 
comparable high prevalence of comorbid conditions in SCD. For example, in the study of 
adults with sickle cell in Cameroun, a comorbidity prevalence of 23% was reported 
(Chemegni et al., 2018). Number of comorbidities in the present study correlated positively 
with age, in agreement with previous studies (Dampier et al., 2011). The prevalence and 
effect of different comorbid diseases in this study was found in most cases to be comparable 
to existing literature on the subject.  
Leg ulcers had the highest prevalence in this study estimated at 12.5%. Leg ulcers are the 
most common cutaneous manifestation associated with sickle cell disease and responsible 
for impaired quality of life (Minniti et al., 2010; Umeh et al., 2017). Leg ulcers have been 
reported to cause pain, negatively affect physical and emotional function and with the 
potential to impact on multiple dimensions of an individual’s daily life in chronic diseases 
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(Phillips et al., 1994). The prevalence of leg ulcers in this study was similar to the findings 
in related studies. Ugwu et al (2017) reported 12% in their study carried out in the South 
Eastern part of Nigeria. In a cohort study of 505 adults with SCD in US, a prevalence of 18% 
was reported (Minniti et al., 2010). In the data of Comprehensive Sickle Cell Centres 
Clinical Trial Consortium (CSCCTC), a prevalence of 12% was reported (Dampier et al., 
2011). Another study in Nigeria (Kotila and Shokunbi, 2001) however reported 8% 
prevalence, this low percentage could be attributed to the sample used as most of the subjects 
in their study were much younger with expected fewer complications. Leg ulcers were 
associated with reduced scores in seven domains of SF-36 as well as in Physical and Mental 
component summary except in Vitality where they appeared to have no significant impact. 
Percentage of patients with priapism in this study was 8.5% which was lower than the 16 % 
in the CSCCTC study (Dampier et al., 2011). A similar result was obtained for hypertension; 
8% in this study compared with 12% in the CSCCTC study. The CSCCTC study had a larger 
sample and wider coverage and could be considered more representative of the population. 
Also, the data were from different countries and cultures with different medical orientations, 
significant differences in health experience and behaviour (Marks et al., 2005), access to 
health facilities and affordability of healthcare. Priapism was associated with worse health 
in Mental Health and the Mental component summary score. Hypertension was associated 
with limitations in Role Physical, Bodily Pain, Vitality, General Health and Mental Health 
and the Physical and Mental Health summary scores. The prevalence of arthritis was 5.5% 
and arthritis was associated with limitations in Role Physical, Role Emotional, Bodily pain, 
Mental Health and MCS. This is in line with previous studies which suggested that people 
with arthritis were more likely to report lower scores on physical functioning-related 
measures, suggested to be related to pain (Maddigan, Feeny and Johnson, 2005). Asthma in 
this study did not associate with HRQL contrary to the findings of CSCCTC study (Dampier 
et al., 2011). Diabetes, and Epilepsy associated with reduced General Health and reduced 
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Mental health respectively. Pneumonia was associated with all domains of SF-36 except 
Role Physical and Role Emotional while stroke was associated with limitations in Physical 
Functioning. A study of US Medical Expenditure Panel Survey data also showed that 
emphysema, heart disease, stroke, high BP, diabetes and asthma associated with lower scores 
of EQ5D, a measure of quality of life (Lubetkin et al., 2005; Singh et al., 2017). 
Older participants reported worse scores in Role Physical, Role Emotional, General Health 
and Mental Health but reported similar scores in the other subscales. This was supported by 
related previous studies. In a study of 256 adults with SCD in Jamaica, increasing age was 
associated with Physical Health Summary score (Asnani et al., 2008). Also, a US study by 
Dampier et al (2011) reported that age was associated with impaired health. Another study 
reported that older patients had worse Physical Health, Social Functioning and Mental 
Health (Woods et al, 1997). Participants who were married reported limitations in Role 
Emotional (p < 0.05) than those who were single, divorced, separated or widowed. In the 
current study, participants living alone had worse score in Social Functioning, a similar study 
reported that unsatisfactory social support associated with worse quality of life in adults with 
SCD (Chemegni et al., 2018). Participants in this study who had confidants reported better 
health in General Health and Mental Health domains of SF-36 than participants without 
confidants.  
The prevalence of anxiety symptoms (GAD7 ≥ 10) in this study was 12%. This was 
comparable to 14% in Cameroun (Chemegni et al., 2018) but higher than reported by some 
other authors (Levenson et al., 2008; Sogutlu et al., 2011) where 6.5 % of participants 
reported anxiety. There was no gender difference in anxiety. 
Asnani et al (2010), showed that complications in sickle cell tend to increase psychiatric 
complications in the patients especially depression. Nineteen percent of participants in the 
current study presented depressive symptoms (PHQ9 ≥ 10). This is in the range reported 
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from previous studies of patients with SCD which ranged from 13.2% to 27% (Ohaeri et al., 
1995; Schaeffer et al., 1999; Hasan et al., 2003; Levenson et al., 2008; Asnani et al., 2010; 
Sogutlu et al., 2011; Gibson et al., 2013) and similar to results obtained for other chronic 
illnesses such as coronary artery disease and diabetes mellitus. However, because different 
measures were used, the result of the comparison is interpreted with caution.  
Depression has been reported to be more among people with SCD compared with healthy 
controls (Molock and Belgrave, 1994) and also among people with other chronic diseases 
with consequent negative influence on general quality of life ratings (Skevington, 1998). 
Causes of depression in adults with SCD could be due to disease progression or reaction to 
stigma (Jenerette, Funk and Murdaugh, 2005), or repeated hospitalisation (Comer, 1998). 
Studies have shown that SCD patients are being stigmatised (Smith et al., 2006; Adeyemo 
et al., 2015) by healthcare providers, who sometimes see them as people addicted to opiates 
(Jenerette, Funk and Murdaugh, 2005; Jenerette and Brewer, 2010; Haywood Jr, 2013) as 
well as by society and peers (Jenerette, Funk and Murdaugh, 2005; Adeyemo et al., 2015). 
According to Hasan et al, (2003) factors that associated with depression include increase in 
blood transfusion, low level of pain control, low income, female gender and medication with 
hydroxyurea. Levenson et al (2008) identified increasing age and low income as factors that 
associated with depression symptoms. The display of anxiety and depressive symptoms by 
a substantial proportion of patients in this study requires that attention be given by healthcare 
personnel to them. For example, patients could be screened for symptoms of anxiety and 
depression and strategies be evolved to improve their psychological well-being in addition 
to use of medications to manage physical symptoms (Wan et al., 2016).  
High somatic symptoms (PHQ15≥ 15) was 13.5% comparable to 18.3% in Sogutlu et al 
(2011). Worse somatic symptoms was observed in female participants similar to findings in 
the PiSCES cohort (Sogutlu et al., 2011). There is a high correlation among somatic 
symptoms anxiety and depression. This result is similar to findings in studies of sickle cell 
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patients (Sogutlu et al., 2011). Low anxiety and depression were observed among patients 
who were aged above 50 years compared to younger participants in the present study. There 
is need for further study to investigate whether this was due to their been able to live beyond 
their expectation especially since the average age at death was 21.3 years (Ogun, Ebili and 
Kotila, 2014) in Nigeria and life expectancy at birth in the general population was around 
five decades. (WHO, 2015). Further study is also required to find out whether living above 
the average lifespan was responsible for less expression of anxiety or depression at this age 
especially since they are aware from early age that they have shortened lifespan (Thomas 
and Taylor, 2002). Moreover, at this age, they might have learnt some coping strategies that 
has enabled them to live better while the fear of early death associated with younger age 
(Anie, Egunjobi and Akinyanju, 2010) would have been overcome. Worthy of note is that 
quality of life is a dynamic construct which implies that people may redefine their internal 
standards of what constitutes health and change their idea of quality of life as they grow 
older (Schwartz et al., 2004). This response shift may influence them to lower their 
expectations about what they value as good quality of life (Camacho et al., 2002). Gibson 
and colleagues also found higher depressive symptoms among younger individuals with 
SCD and suggested that this was a pointer to emotional maturity resulting in greater ability 
to cope with the disease as patients grow older (Gibson et al., 2013)  
6.3 Objective two. 
To Characterize predictors of HRQL in adults with sickle cell disease 
The current study examined the relationship between bio-physiological, psychosocial and 
sociodemographic variables and health-related quality of life measured by the SF-36.  
SCD Genotype did not associate with any of the subscales of SF-36. Therefore, this study 
has shown that the more severe genotype HbSS was not responsible for worse quality of life 
in the patients. Conflicting results have been reported in literature as to the effect of genotype 
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on quality of life of sickle cell patients. For example, in the study of both the CSCCTC and 
PiSCES cohorts of sickle cell patients in US, genotype did not associate with quality of life 
domains (Dampier et al., 2011; McClish et al., 2016). Additionally, a study of 256 patients 
(Asnani et al., 2008) and another independent study of 277 sickle cell patients and 65 
controls (Asnani et al., 2010) both in Jamaica did not show any correlation between genotype 
and quality of life. Furthermore, van Tujin et al (2010) in a study of 94 adults with sickle 
cell in Amsterdam, reported that genotype and the presence of chronic injury in organs were 
unrelated to quality of life while pain rate and social circumstances did. However, Panepinto 
(2012), reported that laboratory markers for sickle cell such as genotype, foetal haemoglobin 
(HbF) and dehydrogenase were associated with diminished quality of life Mastandrea and 
colleagues also reported that more severe genotype decreased role physical and general 
health in adult sickle cell patients in Brazil (Mastandréa et al., 2015). Different methods of 
treatment, patients’ adherence to treatment regime and affordability of treatment medications 
might be responsible for these differences. According to Mastandrea et al, results from 
studies on genotype and quality of life may be related to the quality of treatment given to the 
patients, whether treatment was well managed by the physician and adhered to by patients 
and whether the patient can afford to buy medication (Mastandréa et al., 2015). Anie et al 
has argued that how patients cope with the disease rather than its severity may be responsible 
for differences in psychosocial functioning(Anie, Steptoe and Bevan, 2002; Anie, 2005). 
In this study, the presence of comorbidity resulted in lower scores in all the domains of SF-
36 and statistical significance was observed in all, except in physical functioning and vitality 
where the difference was not significant. A negative correlation was observed between 
increase in number of comorbidities and all the domains of SF-36 (p < 0.01) with non-
significance only in Physical Functioning. This association is consistent with previous 
studies. In a type-2 diabetic population, number of comorbidities was significantly 
negatively correlated with six domains of the SF-36 (Anderson et al., 1997). A study in the 
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Saudi Arabian population of adults with sickle cell disease revealed that other chronic 
diseases significantly associated with Vitality, Mental Health and Social Functioning 
(Ahmed et al., 2015). Increase in the number of comorbidities predicted worse health in 
seven domains of the SF-36 and the physical and mental summary scores of SF-36 but did 
not predict Physical Functioning. A one-point increase in comorbidities will lead to between 
0.20 to 0.82 decrease in scores on the subscales. For example, a unit increase in number of 
comorbidities will lead to a12.2 points (conventional score) or 8.7 points (normed score) 
reduction in Role Emotional. This result is consistent with findings in literature. Ahmed et 
al., (2015) reported that other diseases in SCD predicted worse health in Vitality, social 
functioning and Mental Health. In a population of 331 diabetic veterans, increase in diabetic 
complications was associated with significant decrease in six of the domains of SF-36 
namely Physical Functioning, Role Physical, Social Functioning, Bodily Pain, Vitality and 
General Health). Disease severity predicted worse Role Emotional, Social Functioning, 
Bodily Pain, Physical Health Summary and Mental Health Summary.  
Anxiety symptoms was correlated with all the SF-36 domains except Physical Functioning 
and predicted limitations in Role Physical, Role Emotional, Social Functioning, worse 
General Health, Mental Health and Mental component summary scores. This is consistent 
with previous findings (McClish et al., 2006). A similar result was reported in 
haemodialysis, where anxiety symptoms predicted worse Social Functioning, Mental Health, 
and Mental component score (Birmelé et al., 2012) and in coronary artery disease (Höfer et 
al., 2005) 
More depressive symptoms predicted worse Physical Functioning, Vitality, and Physical 
component summary in this study. In a related study of 77 adults wiSCD in Brazil, 
depression associated with both the Physical and Mental components of quality of life 
(Treadwell et al., 2005). Another study reported that depression and anxiety predicted more 
daily pain and poorer Physical and Mental quality of life in adults with sickle cell (Levenson 
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et al., 2008). In the PiSCES cohort, depression predicted Physical and Mental Health. In 
other chronic diseases, depression was a strong predictor of domains of HRQL. For example, 
in chronic coronary artery disease, depression was associated with more Physical limitations 
and worse quality of life. Depression also predicted reduced quality of life in other chronic 
diseases including hepatitis C (Olson et al., 2005) and diabetes mellitus (Egede, 2004). 
Studies have shown that depression had similar or higher impact on quality of life than 
objective bio-physiological factors (Bair et al., 2003; Katon, Lin and Kroenke, 2007). 
Depressed patients are more likely to entertain a negative perception of their health status 
which affects their HRQL (Sullivan et al., 2000). Depressive symptoms in patients with 
sickle cell disease also appear to be a function not only of demographics but also disease 
severity (Hasan et al., 2003). The impact of depression on the quality of life of sickle cell 
patients is important; Molock and Belgrave (1994) has suggested that when there is evidence 
of poor psychological adjustment in patients with sickle cell disease, the role of 
socioeconomic status needs to be explored, as factors such as financial difficulties, racial 
discrimination, and lack of social support are known to contribute to depression in physically 
healthy African Americans. However, Hilton et al (1997) did not find any significant 
relationship between depression and sickle cell in adults. Alao and Cooley (2001) suggested 
that small sizes, retrospective design and self-report may be responsible for the conflicting 
results. 
Somatic symptoms were found to be significantly negatively correlated with all the subscales 
of SF-36. This was similar to findings in the PiSCES project where somatic symptoms 
burden significantly associated with all subscales of SF-36 (Sogutlu et al., 2011). Earlier 
studies of primary care patients have shown that people with high somatic symptoms 
reported poorer quality of life (Kroenke, Spitzer and Williams, 2002; Kroenke et al., 2010). 
In this study, somatic symptoms also predicted Bodily Pain, Vitality and General Health. A 
similar study also showed that subjects with more somatic symptoms reported higher pain 
268 
 
and that high somatic symptoms predicted increased sickle cell disease related healthcare 
utilisation including hospitalisation, and frequency of visits to physicians (Sogutlu et al., 
2011).  
Sociodemographic variables that predicted quality of life domains in this study include older 
age predicted limitations in Role Physical similar to results of Treadwell et al (2015), female 
gender predicted worse Bodily Pain, being married predicted worse Role Emotional and 
Social Functioning similar to findings of Ahmed et al., (2015) which showed that being 
married predicted worse Role Emotional, Vitality, Social Functioning and Mental Health; 
and having confidants predicted better General Health and Mental Health. This contrasts 
with a study of people with heart failure where having a confidant or marital status were not 
associated with quality of life (Heo et al., 2005). Furthermore, living with others predicted 
better Social Functioning and Mental Health component Summary. 
6.4 Objective three. 
To Test the Wilson-Cleary HRQL model in the population of adults with sickle cell disease.  
This section examined the determinants of quality of life in SCD using the Wilson and Cleary 
(1995) model. The aim was to test the structural paths of relationship between 
biophysiological factors, symptoms status, functioning, general health perception and 
overall health-related quality of life as hypothesised by Wilson and Cleary. The effect of 
characteristics of the individual and of the environment on the main factors were also 
examined as suggested by the authors. Structural equation modelling (SEM) was used to 
evaluate the model because the structural modelling techniques permits simultaneous 
estimation of a set of measurement models and structural paths coefficients (Höfer et al., 
2005), and has been recommended for development of models in HRQL research (Smith, 
Avis and Assmann, 1999). Several studies that empirically evaluated Wilson and Cleary 
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model in chronic diseases have also used SEM techniques (Höfer et al., 2005; Baker, 
Pankhurst and Robinson, 2007; Shiu et al., 2014; Mayo et al., 2015; Santos et al., 2015b) 
The findings of the current study supported the usefulness of the Wilson and Cleary model 
as a theoretical framework to understand relationships among clinical and psychosocial 
factors in chronic diseases and offers insight to enhance quality of life in patients with sickle 
cell disease. The result supported the main structural relationships as hypothesised in the 
model. Bio-physiological factors predicted symptoms, symptoms predicted functioning, 
functional status predicted general health perception and general health perception predicted 
overall quality of life. The data also supported the hypothesis that characteristics of the 
individual influenced functional status but did not support paths between the characteristics 
of the environment to symptoms, health perception and overall quality of life. The data did 
not support the influence of the characteristics of the environment on any of the main factors 
as well. 
The study established a significant path between bio-physiological factors and symptoms 
status. Worsening health conditions indicated by increased disease severity and increased 
number of comorbidities or complications predicted more symptoms in the patients. Forty-
four percent of variance in symptoms status was explained by bio-physiological factors. 
Furthermore, bio-physiological factors had an indirect effect on functioning through 
symptom status as hypothesised by Wilson and Cleary. Similar results have been reported 
for xerostomia (Baker, Pankhurst and Robinson, 2007), coronary artery disease (Höfer et al., 
2005) and stroke (Mayo et al., 2015). The effect size of the present study was fairly large 
(Cohen, 1988) indicating a strong impact. The large effect may be as a result that SCD is a 
debilitating life-threatening disease which is often accompanied with, and /or is responsible 
for triggering symptoms in patients. However, some studies failed to support such 
relationships between bio-physiological factors and symptoms (Arnold et al., 2005; Shiu et 
al., 2014); Shiu et al (2014) who studied community-dwelling older Chinese with diabetes 
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explained that the failure to support relationship between bio-physiological factor and 
symptom status may be due to their sample which consisted of older adults with stable 
diabetes control, moreover, Wilson and Cleary also stated that bio-physiological factors may 
be unrelated to symptoms status in some disorders. 
Symptoms status (anxiety, depression, bodily pain, mental health, somatic symptoms) had a 
direct significant link with functional status demonstrating that more symptoms significantly 
predicted reduced daily functioning. About 39% of variance in function status was explained 
by symptom status and characteristics of the individual. In addition, symptoms had a 
significant indirect pathway through functional status to general health perception indicating 
that more symptoms led to limitations in functioning and reduced general health perception 
leading to impaired quality of life. Furthermore, symptoms had a direct link to general health 
perception leading to a low health perception and reduction in quality of life. Wilson and 
Cleary did not draw a direct link between symptoms and health perception but suggested 
that such non-adjacent pathways are possible (Wilson and Cleary, 1995). This result is 
therefore consistent with the intent of the model. Several studies including those on oral 
health, HIV/IDS and coronary artery disease (Höfer et al., 2005; Sousa and Kwok, 2006; 
Baker, Pankhurst and Robinson, 2007) supported the direct pathway between symptoms 
status and functioning and an indirect link to general health perception mediated by 
functional status. Some studies also supported the direct pathway between non-adjacent 
latent constructs. In a study of people recovering from stroke (Mayo et al., 2015), a non-
adjacent link between symptoms and general health perception was supported. Similarly in 
a study of people with xerostomia (Baker, Pankhurst and Robinson, 2007), the non-adjacent 
link between symptoms and general health perceptions, between symptoms status and 
overall quality of life and between functional status and quality of life were supported. 
Furthermore, study of chronic obstructive pulmonary disease and chronic heart failure 
supported non-adjacent relationships (Arnold et al., 2005). 
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The direct effect of functional status on general health perception and the indirect effect of 
functional status on overall quality of life mediated by general health perceptions as revealed 
in this study is consistent with the Wilson and Cleary model. Patients who experienced 
limitations in daily functioning had lower health perception and impaired quality of life. 
Related studies reported similar findings, for example, in HIV (Sousa and Kwok, 2006). On 
the contrary, Mayo and colleagues did not find a direct link between functional status and 
general health perception in people with stroke. They suggested that this might be due to 
their sample which consisted of older persons in a community dwelling and only functional 
older persons with stroke could return and remain at home (Mayo et al., 2015).in the current 
study,  55% of variance in general health perception was explained by the direct pathway 
from functional status and the non-adjacent direct pathway from symptom status.  
The path from general health perception to overall quality of life was positive and significant 
in agreement with the model indicating that a positive general health perception predicted 
better overall quality of life. Comparable results have been obtained from several studies in 
diabetes (Shiu et al., 2014), heart failure (Heo et al., 2005; Krethong et al., 2008) oral health 
(Santos et al., 2015b), generalised anxiety disorder (Wyrwich et al., 2011) and coronary 
artery disease (Höfer et al., 2005). 
Although Wilson and Cleary did not draw any path to connect the characteristics of the 
individual and the characteristics of the environment to the main concepts in their diagram, 
they however indicated that these two concepts (characteristics of the individual and the 
characteristics of the environment) would influence symptom status, function status, general 
health perception and the overall quality of life (Wilson and Cleary, 1995). The data in this 
study were only able to support a significant path between the characteristics of the 
individual and function status but did not support significant path between the characteristics 
of the environment and any of the main concepts. This is similar to the result in coronary 
artery disease where a path from the characteristics of the individual to functioning status 
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was supported (Höfer et al., 2005). However, several previous studies did not investigate the 
influence of the characteristics of the individual and of the environment (Sousa and Kwok, 
2006; Baker, Pankhurst and Robinson, 2007). 
These findings provide insight into the predictors of health-related quality of life in people 
with sickle cell disease and highlight the importance of assessing subjective symptoms 
alongside biological factors both in research and clinical practice geared towards the 
management of the disease. The model has depicted health-related quality of life in sickle 
cell disease as grossly impaired and influenced by a combination of bio-physiological, 
sociodemographic and psychosocial factors suggesting the necessity for a multidisciplinary 
approach to the management of the disease because physiological treatment is insufficient 
to help improve the quality of life of patients. Furthermore, the model is useful to direct 
choice of study design, research instruments and intervention and rehabilitation programmes 
(Wettergren, Björkholm, Axdorph, Langius-Ekiöf, et al., 2004). 
 
6.5 Objective four. 
To Create a hierarchy of importance of the determinants as targets for potential 
intervention. 
Evidence from this study shows that symptoms was the most important predictor of general 
health status and quality of life in SCD. Symptoms monitoring, and management are 
important to the improved quality of life of the patients. Symptom status in this study were 
measured by anxiety, depression, bodily pain, somatic symptoms and mental health. Hofer 
et al (2005), in their prospective study of 432 people with coronary artery disease reported 
that depression was the most important indirect influence on the course of HRQL in coronary 
artery disease followed by anxiety symptoms. Additionally, in a study of 422 Thai patients 
with heart failure, symptom status had the most significant impact on HRQL both directly 
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and indirectly through functional status and general health perception (Krethong et al., 
2008). According to Heo et al (2005), general health perceptions and symptom status are the 
strongest and most consistent factors associated with HRQL in heart failure. In sickle cell 
disease, pain and depression are the most common symptoms that reflect patients’ subjective 
perception of presence and severity of abnormal physical and physiological sensations (Heo 
et al., 2005). 
6.6 Objective five. 
To determine the health utility score and its associated factors in people with sickle cell 
disease. 
This study also investigated the preference-based measure or utility scores of HRQL in sickle 
cell disease. Preference-based measures or health utilities are designed to investigate across 
domains of health to provide a single score that incorporates how patients (or the general 
population) value experiencing a given health state that is defined by level of functioning 
and well-being in those domains. Such scores are important to measure the burden of 
diseases. The mean utility score for SCD patients, in the present study, (0.65±0.12) compares 
with the utility score (0.66±0.14) reported for people with age-related macular degeneration 
(Espallargues et al., 2005) and those with chronic kidney disease (0.67±0.13) (Davison, 
Jhangri and Feeny, 2009) but lower than the utility score of (0.745±0.137) reported in adults 
with type 1 diabetes (Peasgood et al., 2016), and that for overweight and obese women with 
urinary continence (0.75±0.10 ) (Pinto et al., 2011). Anie et al,(Anie et al., 2012) reported a 
utility score of 0.39±0.40 for SCD patients on admission for pain which improved to 
0.65±0.29 after treatment which is similar to our result. Lower utility values indicate that 
SCD can substantially diminish the HRQL of the affected individual.  
The lower utility scores in women than men found in this study might not be statistically 
significant, but this difference and its 95% CI could be of clinical importance and requires 
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further study. The same conclusion goes for the difference between those living alone and 
those living with others, because a difference of 0.03 could be clinically important (Walters 
and Brazier, 2003; Khanna et al., 2007). The finding of a significant difference between 
those who had at least one co-morbidity compared to those who had none deserves some 
comments. SCD patients are a vulnerable, chronically ill population with a high prevalence 
of co-morbidities which contributes to reduced quality of life in chronic diseases (Rijken et 
al., 2005). 
Age was negatively associated with utility, as expected, because SCD patients are exposed 
to increased clinical complications as they age. This supports findings from a general UK 
population where utility score was reported to decrease as age increases (Berg, 2012) as a 
result of age-dependent end-organ dysfunction associated with the disease. The negative 
associations of anxiety and depression with health utility found in this study, support 
previous studies where these variables were reported to associate negatively with HRQL in 
SCD (Edwards et al., 2001; McClish et al., 2006; El-Shinnawy et al., 2013; Mastandréa et 
al., 2015). The regression modelling showed that disease severity, anxiety, number of co-
morbidities and education were strong predictors of health utility score. In terms of the 
direction of effects, these impacts were as expected. This result also has implications for new 
therapy and healthcare costs. For example, if a new treatment or service, at a cost of £100 
produces a difference of 0.02 on the utility scale compared to existing treatment this would 
be cost effective as it translates to £5,000 (£100/0.02) per QALY (Hays et al., 2014). Such 
a saving would be substantial in sub-Saharan Africa which are generally low-income 
countries. 
The beta coefficients ranged between -0.01 and 0.04 on the 0-1 health utility score. These 
have the minimally clinically important difference (Walters and Brazier, 2003; Khanna et 
al., 2007). The predictors all had the unstandardized beta coefficients with absolute values 
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equal or greater than 0.03 indicating that beyond statistical significance, they are of clinical 
importance in the management of SCD.  
6.7 Implications 
This study has implications for the healthcare professionals, sickle cell patients and the 
policymakers. These are discussed in the following sections.  
6.7.1 Healthcare providers 
Due to better medical attention and treatment leading to increased survival rates of SCD 
patients, better education and awareness, healthcare providers will increasingly encounter 
adults with SCD. It is therefore important for these professionals to understand both the 
clinical complications of the disease and the subjective psychological impacts of the disease 
on patients.  
Health-related quality of life research in SCD has been limited by a lack of a theoretical 
framework. The WCM  is useful to healthcare professionals and researchers who want to 
explore how changes in specific clinical characteristics may affect a patient’s overall health 
outcomes.  The results indicate the importance of including HRQL along with clinical 
indicators, symptom measures and subjective well-being. 
This study has shown that individuals with more comorbidities and worse symptoms have 
reduced GHP and HRQL. This may lead to reduced capacity of the patient to cope with SCD 
resulting in adverse effects on their daily lives. If healthcare providers are in possession of 
such information, they may be able to easily identify ‘high risk’ individuals, design the most 
effective treatment management for them and educate them on stress management and how 
to develop effective coping strategies. 
The findings show that objective health relates to functioning through symptoms status (see 
Table 5-20). This suggests that rather than the physical disorder often emphasised by 
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clinicians, it is the resultant limitations in physical functioning that are important 
determinants of the HRQL of the patients. The findings that symptoms status is the most 
important relative predictor of HRQL in SCD (see 5.5.1) means that measures of symptoms 
burden are important to capture the full effect of the disease on HRQL. These suggest the 
need for healthcare providers to know the symptoms expressed and the physical limitations 
experienced and their HRQL because these factors are directly related to GHP which 
determine HRQL and therefore may inform treatment protocol of patients. Effective 
interventions to control symptoms are also desirable.  
Number of comorbidities was significant predictor of reduced HRQL, pointing to the need 
for healthcare professionals to be sensitive to cumulative burden of additional comorbidities 
in the management of SCD patients.  
Based on the systematic reviews (Chapters 2 and 3) and the present findings, it is essential 
that healthcare providers adopt a comprehensive care protocol that can optimise both the 
physiological and the psychological well-being of the patients. Several researchers have also 
proposed that psychological interventions should be a standard part of care in the routine 
management of sickle cell disease in addition to treatment (Anie, 2005). Combining medical 
treatment with regular assessment of daily psychosocial experience and the long-term effects 
of both psychological and medical therapies in the management protocol would allow 
patients to cope better, perform activities and enjoy better quality of life.  
HRQL is a distinct health entity (Höfer et al., 2005) and should routinely be examined as 
part of standard care. Physicians should pay more attention to the quality of life 
characteristics of the patients. For example, physicians could monitor patients by asking 
them about their ability to work and their involvement in leisure activities. This routine 
challenge of the functionality of the patients could assist in helping physicians understand 
the extent of the effect of the diseases on patients’ daily activities (Mastandréa et al., 2015). 
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Similar to the published principles to improve quality of life in multiple sclerosis 
(https://www.msif.org/), sickle cell patients should be empowered and allowed to fully 
participate in decisions about their treatment, care and lifestyle in harmony with their 
personal beliefs and values. Additionally, healthcare providers should listen to individual 
needs and respect the knowledge that comes from lived experience which only the patient 
can provide, this implies that clinicians must rely on and believe the patient’s self-report of 
pain rather than assuming that they are addicted to their pain medications or being disparaged 
as ‘sicklers’ (Haywood Jr, 2013). It has been argued that not having sufficient participation 
in their care, or having a problematic relationship with clinicians can lead to harmful clinical 
and behavioural outcomes for the patient (Haywood et al., 2010). On the other hand, when 
patients were allowed self-assessment of mood, pain health and quality of life at three 
instances: upon admission to hospital, prior to discharge and a week after discharge, better 
self-assessment of health, general mood and quality of life led to significant improvement in 
pain reduction for these patients upon hospital admission, prior to discharge and after one 
week of follow up (Anie et al., 2012). 
There is need for training and re-orientation of healthcare providers to relate appropriately 
and effectively with individuals who have sickle cell disease in order for them to be able to 
discuss the problems experienced by patients and to provide necessary care (Alao and 
Cooley, 2001). Inappropriate assumptions or attitudes from caregivers could contribute to 
depressive thoughts in patients with a consequent effect on their health status. There is the 
need to properly understand the nature of the disease especially the unremitting pain nature 
of the disease which are yet to be properly understood by the physicians. Pack-Mabien et 
al., (2001) has suggested that nurses for example, would benefit fom training that focus on 
attitudes toward pain and drug addiction in SCD.  Suspecting drug dependence, may lead to 
patients being undertreated (McClish et al., 2016) making them reluctant to seek medical 
attention (Maxwell, Streetly and Bevan, 1999; Elander et al., 2003).  
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This thesis has shown that depression significantly affects HRQL in SCD (see section 6.2-
6.4); therefore, integrating routine depression screening for individual patients as part of 
management strategies so that patients at risk can be adequately treated on time should be 
taken as a priority. This is to reduce further suffering, morbidity and suicidal thoughts which 
according to  Jenerette, Funk and Murdaugh, (2005) are associated with depression. 
Moreover, depression may also adversely affect the ability to cope with the disease, reduce 
active care seeking resulting in increased practice of self-care management activities 
(Cooper, 2004) and diminished quality of life (Whitter, 2001). Healthcare professionals 
should strive to follow and improve on recommended standards of care for patients with 
SCD (Health, 2002).  
 
6.7.2 People with SCD 
In line with evidence in literature on the effectiveness of self-management interventions, 
there is need to provide counselling or psychoeducation which could help to mediate 
psychosocial outcome (e.g depression) by enhancing self-efficacy as well as deliberate 
empowerment to engage in proactive coping. Educating sickle cell patients on methods of 
selfcare is important to help the patients take control of their own health (see 1.8.2, pp.1) for 
better quality of life. For example, previous study showed that older patients aged 48-73 
associated their longevity with learning how to take care of themselves (Jenerette, Leak and 
Sandelowski, 2011). They referred to this method as “listening to their bodies” which was 
responsible for selfcare practices that reduced the effect of the disease on the daily living of 
the participants. Patients should be encouraged to practice early health-seeking, be aware of 
their right to health resources and disabuse their minds of the stigma attached to frequent 
hospital visits (Galloway-Blake et al., 2014). Sickle cell patients should also be encouraged 
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to organise social activities among themselves and to participate in educational forums that 
will further enlighten them on the high possibility of a better quality of life if they adhere to 
good self-health-management practices. 
The systematic reviews (see 2.4 and 3.13) show that depression is an important symptom 
responsible for reduced HRQL in SCD, it may therefore be beneficial to engage in 
therapeutic communication about depression with SCD patients during their visit to the 
hospital. Living with others (social support) was associated with increased HRQL, this 
should be encouraged through public education, to reduce stigma and promote social support 
for SCD patients.  
 
6.7.3 Policymakers 
The model is useful for policy makers who are expected to take a comprehensive look at 
various issues when making decisions about treatment for SCD as it provides insight into 
understanding the mechanisms that drive changes in health that may occur during natural 
course of the disease or treatment of patients. This could guide policymakers to evolve 
strategies for how healthcare is delivered, design appropriate training to raise awareness 
about symptoms management in sickle cell disease. 
One important step would be the creation of a national record of all patients with sickle cell 
disease, newborns affected, and haemoglobinopathy-related deaths such as that developed 
in Greece (Voskaridou et al., 2012) and neonatal clinics like in Midwest Brazil where sickle 
cell screening for children helped to significantly reduce child mortality (Ivo and Pinto, 
2013). A register of all patients with sickle cell disease at local government level should be 
established with adequate budgetary provisions made for them. Also, government should be 
responsible for the medical expenses of people with sickle cell as currently applies to people 
with HIV/AIDS to ensure patients have access to good and free healthcare services, 
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furthermore, rehabilitating centre should be created to cater for patients already disabled due 
to the disease (Olaniyi, 2008). Currently, unlike the high-income countries, Nigeria lacks a 
national programme of health insurance or a social welfare system, what is currently 
available is restricted to employees of the Federal government. The current out-of-pocket 
system of healthcare financing has made it difficult for sickle cell disease patients to have 
acces to medical facilities or to receive quality healthcare. Some patients have to depend on 
families, relatives, and friends for financial assistance to get minimal healthcare. Th e 
financial burden could further worsen the poverty level, increase anxiety and depression due 
to the burden of the disease and the barriers at securing healthcare. Inaugurating a social 
welfare programme for people with sickle cell might go a long way to relieve the patients 
and their caregivers of the financial burden that often translates to the neglect of other 
members of the family (Adegoke and Kuteyi, 2012). 
Hospital management should establish, in their emergency departments, a comprehensive 
programme specific to sickle cell patients and aimed at timely delivery of compassionate, 
pain-management services to better the patients’ quality of life (Aisiku et al., 2009). Free 
genotype counselling should be available in community health centres for people with sickle 
cell traits especially those yet to be married to possibly educate on possible consequences 
when two people with sickle cell tratis are married as this will predispose the couple to a 
25% risk of giving birth to a child with sickle cell disease.   
SCD, like other chronic illness is expensive to treat, creates disability and requires life 
changes. Policymakers should therefore address the welfare, income generation and 
education for people with SCD. There is a need for policies to assist patients financially and 
to make healthcare accessible and affordable for them to help reduce the burden of the 
disease. Such assistance will protect patients from stress and potentially a lack of treatment. 
In addition, having a guaranteed source of income will protect against barriers to self-care 
created by low financial capacity. In addressing their education, one method is the Brazil 
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model. Brazil operates a policy that guarantees continuity of studies to compensate for 
classes missed due to the illness (Ivo and Pinto, 2013). It will also be necessary to organise 
vocational and professional training tailored to their specific condition and aimed at 
providing them with better integration in the job market. Additionally, education policies 
should recognise open and distance education that gives better opportunities to people with 
sickle cell disease and enables them to study at their own pace. Furthermore, governments 
should develop policies to insulate sickle cell patients from being discriminated against 
either overtly or covertly in the job market and to protect those who have jobs from being 
relieved of their jobs because of frequent absences due to illness. 
The activities of social groups such as the Nigerian Sickle Cell Association and the Sickle 
Cell Disease Clubs have been reported to be at present of little community impact (Ohaeri 
and Shokunbi, 2002). Religious organisations should also be enlisted to raise awareness and 
provide proper counsel to their yet to be married adherents to know the genotype of their 
partner as part of measures of compatibility before going into the union. A premarital genetic 
screening project should be instituted by the government following the example of Saudi 
Arabia where premarital screening has helped to reduce instances of marriages likely to 
produce sickle cell child (Al Sulaiman et al., 2008).  
6.8  Limitations  
This is a cross sectional study. One of the conditions to make a causal inference is that there 
must be temporal precedence which implies that the independent variable, X must precede 
the dependent variable, Y in time. A cross sectional study violates this principle; hence it is 
not possible to infer causal relationship from this study. A longitudinal analysis which 
combines autoregressive and latent curve models (Curran and Bollen, 2001) is required to 
further support the causal relationship suggested by the Wilson and Cleary model. However, 
the analysis has shown that the relationships depicted were supported by the data and could 
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lead to a more comprehensive testing of the Wilson and Cleary conceptual model (Sousa and 
Kwok, 2006).  
The clinic setting for the data collection also posed some limitations to the study. All the 
participants were SCD patients who attended hospital on a clinic day either for an 
appointment or for specific complaints. The views of patients not receiving medical 
treatment or without access to conventional medical care could be different if study was 
carried out in a community setting (Anie, Egunjobi and Akinyanju, 2010). In addition, data 
were collected from only one state, this may not be representative of the wider SCD 
population in the country. A population-based study with appropriately designed sampling 
techniques may yield more objective results and generalisable conclusions. It is difficult to 
determine if the findings are representative of the wider SCD population group in Nigeria 
because of the lack of population-based SCD cohorts with which to compare. 
This study relied on self-reported co-morbid conditions which could be subject to bias. 
However, evidence have shown good agreement between self-report and clinical measures 
of conditions (Bush et al., 1989; Heliövaara et al., 1993; Macintyre, Ford and Hunt, 1999; 
Bombard et al., 2005) and high agreement between self-reported co-morbidities and medical 
records abstractions (Van Den Bos, 1995; Kriegsman et al., 1996; Penninx et al., 1996; 
Bayliss, Ellis and Steiner, 2005; Miller et al., 2008).  
The SF-36 is a generic instrument which measures HRQL as patients’ perception of their 
health status in broad areas of physical, social and psychological functioning and being not 
diseases specific, does not measure patients’ HRQL from their SCD peculiar experience. A 
disease-specific measure would have been more sensitive to detect specific quality of life 
issues in the patients. The available quality of life instrument for sickle cell, the Adult Sickle 
Cell Quality of Life Measurement System, ASCQ-Me (Keller et al., 2014; Treadwell et al., 
2014) is still being validated. The SF-36 has however been used widely in sickle cell and 
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chronic diseases and has been reported to be valid for use in patients with SCD (Asnani, 
Lipps and Reid, 2007, 2009).  
The Wilson and Cleary model has significantly contributed to our understanding of the 
predictors of quality of life by proposing a conceptual model that integrate the objective and 
subjective health concepts. Currently, guidelines for selecting indicator variables for the 
model is at best flexible. For example, Wilson and Cleary have suggested that depression or 
any other psychological factor could be considered as a bio-physiological variable, as a 
symptom status variable or as a functioning status variable. Many studies have arbitrarily 
selected indicator variables for the latent factors based on their own understanding of the 
model or simply using what has been used in previous studies. Such situations may lead to 
the choice of inappropriate indicator variables or inconsistent conclusions in literature. For 
example, Höfer et al. (2005) used depression as indicator for individual characteristics in 
coronary artery disease, Saensgisri et al (2014), also for coronary artery disease, used 
depression as indicator of symptoms. The choice of variables in this study was constrained 
by the available data. The guidelines of Wilson and Cleary were followed in the choice of 
the variables. However, such variables may not be the most ideal to measure the constructs. 
This may be responsible for the non-significance of, for example, the characteristics of the 
environment in the model. Furthermore, to obtain a good fit for the model, errors of non-
adjacent variables were correlated as suggested by the modification index in AMOS, this 
suggests the need for future work to investigate possible partial mediation of latent variables 
identified in Wilson and Cleary as well as the use of alternative indicators of the latent factors 
in the model.  
SF-6D was used to obtain a utility score for the study. SF-6D may have a floor effect and 
different derivations of utility measures have been reported to yield different results (Feeny 
et al., 2012; Peasgood et al., 2016), although SF-6D is relatively better in discriminating 
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between health states than other measures of utility such as EQ-5D and EQ-VAS 
(Richardson, Iezzi and Khan, 2015; Peasgood et al., 2016).  
6.9 Further work 
In the absence of national record of sickle cell disease in Nigeria, regional and state and 
community studies of sociodemographic aspects and quality of life of people with SCD will 
be necessary to provide current and continuing information on the dynamics of the illness to 
help understand their quality of life. Such studies will also shed light on the urban-rural 
dynamics and the role of cultural practices in the study of quality of life. Furthermore, quality 
of life is a multidimensional construct with wide variations in its measures, therefore 
qualitative data to inform quality of life dimensions in the specific illness (Skevington, 1999) 
of sickle cell is important to add to knowledge on the impact of the disease on patients’ 
quality of life. A qualitative study will also be necessary to help understand some of the 
cultural practices and health decisions and to further clarify factors affecting quality of life 
in the population. 
As mentioned in section 6.8, there is need to establish the direction of relationship and 
causality. A longitudinal study is therefore required both for this and also to compare the use 
of disease-specific and generic instruments for measuring quality of life in SCD. A 
longitudinal study using disease-specific instrument like the ASCQ-Me (Treadwell et al., 
2014) may be necessary to establish causality and its direction in adults with sickle cell 
disease.  
Furthermore, a longitudinal study of utility in people with SCD using both direct and derived 
methods is also required to broaden our knowledge of preference-based quality of life status 
in sickle cell patients. 
285 
 
6.10.  Recommendations 
This study has identified determinants of quality of life in people with sickle cell disease and 
has established the appropriateness of using the Wilson and Cleary model to guide further 
studies. A comprehensive model for managing a patient with SCD is imperative to help 
improve his or her quality of life. Symptoms status indicated by pain, depression, anxiety 
and somatic symptoms in patients have a significant impact on their quality of life. Similar 
to the published principles to improve quality of life in multiple sclerosis 
(https://www.msif.org/), sickle cell patients should be empowered and allowed to fully 
participate in decisions about their treatment, care and lifestyle in harmony with their 
personal beliefs and values. Routine investigation of patients’ psychiatric status should be 
integrated into the disease management protocol to be targeted for immediate attention once 
SCD is diagnosed. Healthcare providers should design a more effective management 
programme for persistent pain and depression while policymakers should, ensure the passage 
of the national policy on SCD by the national assembly, embark on education of the patients 
on self-care and habits that could help reduce the frequency of pain occurrence. Furthermore, 
in line with the WHO African region SCD strategy, general individual and community 
awareness about the disease should be promoted. Also, specific periodic education for 
families and caregivers on disease management at home and routine practices to prevent 
crisis should be implemented.  
6.11 Conclusion 
The paradigm shift in healthcare demands a holistic definition of health and consequently 
points of care with emphasis now on health, functioning, quality of life and focus on health 
care instead. This shift comes with a challenge of how to identify and appropriately measure 
patient outcomes for the purpose of improving the quality of patient care; the Wilson and 
Cleary model can be used to help tackle these challenges, as supported by empirical analysis 
in this study. The insight gained by examining the relationship between subjective and 
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objective health outcomes in SCD can be used by clinicians to understand how changes in 
specific clinical characteristics affect a patient’s overall health outcomes.  
The effects of symptoms especially pain, depression and anxiety on functioning and overall 
quality of life should be considered when designing or redesigning protocols for the 
management of the disease. For interventions to be fully effective, patients’ experiences of 
their symptoms must be taken into consideration along with the bio-physiological variables 
because two patients with identical health status or clinical characteristics may have a very 
different quality of life experience, as well as expectations and perceptions regarding their 
health. Factors like living conditions, disease severity, socioeconomic status and nationality 
are also determinants of clinically important differences in the SCD population. 
This study provides insight into the predictors of health-related quality of life in people with 
sickle cell disease and highlights the importance of assessing subjective symptoms alongside 
biological factors both in research and clinical practice geared towards the management of 
the disease. Additionally, health utilities are important values necessary to understand the 
preferences of an individual for different health outcomes and when combined with survival 
estimates can be employed in cost utility analysis of medical treatment. The predictors of 
preference-based measures also have clinical importance in the management of sickle cell 
disease. 
 
  
287 
 
REFERENCES 
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, 
A., Flechtner, H., Fleishman, S. B. and de Haes, J. C. J. M. (1993) ‘The European 
Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument 
for use in international clinical trials in oncology’, JNCI: Journal of the National Cancer 
Institute. Oxford University Press, 85(5), pp. 365–376. 
Adams‐Graves, P., Lamar, K., Johnson, C. and Corley, P. (2008) ‘Development and 
validation of SIMS: An instrument for measuring quality of life of adults with sickle cell 
disease’, American journal of hematology. Wiley Online Library, 83(7), pp. 558–562. 
Ade-Oshifogun, J. B. (2012) ‘Model of Functional Performance in Obese Elderly People 
With Chronic Obstructive Pulmonary Disease’, Journal of Nursing Scholarship, 44(3), pp. 
232–241. doi: 10.1111/j.1547-5069.2012.01457.x. 
Adegbola, M. (2011) ‘Spirituality, Self-Efficacy, and Quality of Life among Adults with 
Sickle Cell Disease’, Southern online journal of nursing research, 11(1), p. 5. 
Adegoke, S. A., Abioye-Kuteyi, E. A. and Orji, E. O. (2014) ‘The rate and cost of 
hospitalisation in children with sickle cell anaemia and its implications in a developing 
economy’, African Health Sciences, 14(2), pp. 475–480. doi: 10.4314/ahs.v14i2.27. 
Adegoke, S. A. and Kuteyi, E. A. (2012) ‘Psychosocial burden of sickle cell disease on the 
family, Nigeria’, African Journal of Primary Health Care and Family Medicine. AOSIS, 
4(1), pp. 1–6. 
Adegoke, S. A., Kuteyi, E. A., Ohaeri, J. U., Shokunbi, W. A., Olaniyi, J. A., Alagbe, A. E., 
Olutoogun, T. A., Busari, O. E., Smith, W. R., Penberthy, L. T., Bovbjerg, V. E., McClish, 
D. K., Roberts, J. D., Dahman, B., Aisiku, I. P., Levenson, J. L. and Roseff, S. D. (2012) 
‘Psychosocial burden of sickle cell disease on caregivers in a Nigerian setting.’, Annals of 
internal medicine. National Medical Association, 4(1), pp. 94–101. 
Adewoyin, A. S. (2015) ‘Management of sickle cell disease: a review for physician 
education in Nigeria (sub-saharan Africa)’, Anemia. Hindawi, 2015. 
Adewuya, A. O., Ola, B. A. and Afolabi, O. O. (2006) ‘Validity of the patient health 
questionnaire (PHQ-9) as a screening tool for depression amongst Nigerian university 
students’, Journal of Affective Disorders, 96(1–2), pp. 89–93. doi: 
10.1016/j.jad.2006.05.021. 
Adeyemo, T. A., Ojewunmi, O. O., Diaku-Akinwumi, I. N., Ayinde, O. C. and Akanmu, A. 
S. (2015) ‘Health related quality of life and perception of stigmatisation in adolescents living 
with sickle cell disease in {Nigeria}: {A} cross sectional study’, Pediatric Blood & Cancer, 
62(7), pp. 1245–1251. doi: 10.1002/pbc.25503. 
Adzika, V. A., Glozah, F. N., Ayim-Aboagye, D. and Ahorlu, C. S. K. (2017) ‘Socio-
demographic characteristics and psychosocial consequences of sickle cell disease: the case 
of patients in a public hospital in Ghana’, Journal of Health, Population and Nutrition. 
BioMed Central, 36(1), p. 4. 
Afifi, A. A. and Elashoff, R. M. (1966) ‘Missing observations in multivariate statistics I. 
Review of the literature’, Journal of the American Statistical Association. Taylor & Francis, 
61(315), pp. 595–604. 
Ahmed, A. E., Alaskar, A. S., Al-Suliman, A. M., Jazieh, A.-R., McClish, D. K., Al Salamah, 
M., Ali, Y. Z., Malhan, H., Mendoza, M. A., Gorashi, A. O., El-Toum, M. E. and El-Toum, 
288 
 
W. E. (2015) ‘Health-related quality of life in patients with sickle cell disease in Saudi 
Arabia.’, Health and quality of life outcomes. Health and Quality of Life Outcomes, 13(1), 
p. 183. doi: 10.1186/s12955-015-0380-8. 
Ahmed, A. E., Alaskar, A. S., McClish, D. K., Ali, Y. Z., Aldughither, M. H., Al-Suliman, 
A. M. and Malhan, H. M. (2016) ‘Saudi SCD patients’ symptoms and quality of life relative 
to the number of ED visits’, BMC Emerg Med. BMC Emergency Medicine, 16(1), p. 30. doi: 
10.1186/s12873-016-0096-z. 
Aisiku, I. P., Smith, W. R., McClish, D. K., Levenson, J. L., Penberthy, L. T., Roseff, S. D., 
Bovbjerg, V. E. and Roberts, J. D. (2009) ‘Comparisons of High Versus Low Emergency 
Department Utilizers in Sickle Cell Disease’, Annals of Emergency Medicine. American 
College of Emergency Physicians, 53(5), pp. 587–593. doi: 
10.1016/j.annemergmed.2008.07.050. 
Akinyanju, O. O. (1989) ‘A profile of sickle cell disease in {Nigeria}’, Annals of the New 
York Academy of Sciences, 565(1 Sickle Cell D), pp. 126–136. doi: 10.1111/j.1749-
6632.1989.tb24159.x. 
Alao, A. O. and Cooley, E. (2001) ‘Depression and sickle cell disease’, Harvard Review of 
Psychiatry. Taylor & Francis, 9(4), pp. 169–177. 
Aliyu, Z. Y., Gordeuk, V., Sachdev, V., Babadoko, A., Mamman, A. I., Akpanpe, P., Attah, 
E., Suleiman, Y., Aliyu, N., Yusuf, J., Mendelsohn, L., Kato, G. J. and Gladwin, M. T. (2008) 
‘Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell 
disease patients in Nigeria’, American Journal of Hematology, (January), pp. 485–490. doi: 
10.1002/ajh.21162. 
AlJuburi, G., Laverty, A. A., Green, S. A., Phekoo, K. J., Banarsee, R., Okoye, N. V. O., 
Bell, D. and Majeed, A. (2012) ‘Trends in hospital admissions for sickle cell disease in 
England, 2001/02-2009/10’, Journal of Public Health, 34(4), pp. 570–576. doi: 
10.1093/pubmed/fds035. 
Allison, A. C. (1960) ‘Turnovers of erythrocytes and plasma proteins in mammals’, Nature. 
Nature Publishing Group, 188(4744), p. 37. 
Allison, P. D. (1987) ‘Estimation of linear models with incomplete data’, Sociological 
methodology. JSTOR, pp. 71–103. 
Allison, P. D. (2003) ‘Missing data techniques for structural equation modeling.’, Journal 
of abnormal psychology. American Psychological Association, 112(4), p. 545. doi: 
10.1037/0021-843X.112.4.545. 
Alonso, J., Ferrer, M., Gandek, B., Ware, J. E., Aaronson, N. K., Mosconi, P., Rasmussen, 
N. K., Bullinger, M., Fukuhara, S. and Kaasa, S. (2004) ‘Health-related quality of life 
associated with chronic conditions in eight countries: results from the International Quality 
of Life Assessment (IQOLA) Project’, Quality of life research. Springer, 13(2), pp. 283–
298. 
Ampofo, A. A. and Boateng, J. (2007) ‘Multiple meanings of manhood among boys in 
Ghana’, From boys to men: Social constructions of masculinity in contemporary society. 
UCT Press Cape Town, pp. 50–74. 
Amr, M. A. M., Amin, T. T. and Al-Omair, O. A. (2011) ‘Health related quality of life 
among adolescents with sickle cell disease in {Saudi} {Arabia}’, Pan African Medical 
Journal, 8(1). doi: 10.4314/pamj.v8i1.71057. 
289 
 
Anderson, J. C. and Gerbing, D. W. (1982) ‘Some methods for respecifying measurement 
models to obtain unidimensional construct measurement’, Journal of marketing research. 
JSTOR, pp. 453–460. 
Anderson, J. C. and Gerbing, D. W. (1984) ‘The effect of sampling error on convergence, 
improper solutions, and goodness-of-fit indices for maximum likelihood confirmatory factor 
analysis’, Psychometrika, 49(2), pp. 155–173. 
Anderson, J. and Gerbing, D. (1988) ‘Structural Equation Modeling in Practice: A Review 
and Recommended Two-Step Approach’, Psychological Bulletin, 103(3), pp. 411–423. doi: 
10.1037/0033-2909.103.3.411. 
Anderson, K. L. and Burckhardt, C. S. (1999) ‘Conceptualization and measurement of 
quality of life as an outcome variable for health care intervention and research.’, Journal of 
advanced nursing, 29(2), pp. 298–306. doi: 10.1046/j.1365-2648.1999.00889.x. 
Anderson, R. M., Fitzgerald, J. T., Wisdom, K., Davis, W. K. and Hiss, R. G. (1997) ‘A 
comparison of global versus disease-specific quality-of-life measures in patients with 
NIDDM’, Diabetes care. Am Diabetes Assoc, 20(3), pp. 299–305. 
Andrews, G., Anderson, T. M., Slade, T. and Sunderland, M. (2008) ‘Classification of 
anxiety and depressive disorders: problems and solutions’, Depression and anxiety. Wiley 
Online Library, 25(4), pp. 274–281. 
Anie, K. A. (2005) ‘Psychological complications in sickle cell disease’, British journal of 
haematology. Wiley Online Library, 129(6), pp. 723–729. 
Anie, K. A., Egunjobi, F. E. and Akinyanju, O. O. (2010) ‘Psychosocial impact of sickle cell 
disorder: perspectives from a Nigerian setting.’, Globalization and health, 6, p. 2. doi: 
10.1186/1744-8603-6-2. 
Anie, K. A. and Green, J. (2000) ‘Psychological therapies for sickle cell disease and pain.’, 
The Cochrane database of systematic reviews, (3), pp. CD001916-CD001916. 
Anie, K. A., Grocott, H., White, L., Dzingina, M., Rogers, G. and Cho, G. (2012) ‘Patient 
self-assessment of hospital pain, mood and health-related quality of life in adults with sickle 
cell disease’, BMJ Open, 2(4), pp. e001274–e001274. doi: 10.1136/bmjopen-2012-001274. 
Anie, K. A., Steptoe, A. and Bevan, D. H. (2002) ‘Sickle cell disease: Pain, coping and 
quality of life in a study of adults in the UK’, British Journal of Health Psychology, 7(3), 
pp. 331–344. 
Anim, M. T., Osafo, J. and Yirdong, F. (2016) ‘Prevalence of psychological symptoms 
among adults with sickle cell disease in Korle-Bu Teaching Hospital, Ghana’, BMC 
Psychology. London: BioMed Central, 4, p. 53. doi: 10.1186/s40359-016-0162-z. 
Antonovsky, A. (1979) ‘Health, stress, and coping’. Jossey-Bass San Francisco. 
Antonovsky, A. (1987) Unraveling the mystery of health: How people manage stress and 
stay well. Jossey-bass. 
Arbuckle, J. L. (1996) ‘Full information estimation in the presence of incomplete data’, 
Advanced structural equation modeling: Issues and techniques. Mahwah, NJ: Erlbaum, 243, 
p. 277. 
Aregbeyen, J. B. O. (1992) ‘Dimension of Policy and Institutional Reforms in the Health 
Sector’, Lecture Delivered at Training Programme on Sectoral Policy Analysis and 
Management organized by NCEMA. 
290 
 
Arnold, R., Ranchor, A. V, Koëter, G. H., de Jongste, M. J. L. and Sanderman, R. (2005) 
‘Consequences of chronic obstructive pulmonary disease and chronic heart failure: the 
relationship between objective and subjective health.’, Social science {&} medicine (1982), 
61(10), pp. 2144–2154. doi: 10.1016/j.socscimed.2005.04.025. 
Aroian, K. J. and Norris, A. E. (2005) ‘Confirmatory factor analysis’, Statistical methods for 
health care research. Lippincott Williams & Wilkins Philadelphia, 5, pp. 351–375. 
Ashcroft, M. T. and Serjeant, G. R. (1981) ‘Growth, morbidity, and mortality in a cohort of 
Jamaican adolescents with homozygous sickle cell disease.’, West Indian Medical Journal, 
30(4), pp. 197–201. 
Ashley-Koch, A., Yang, Q. and Olney, R. S. (2000) ‘Sickle Hemoglobin (Hb S) Allele and 
Sickle Cell Disease: A HuGE Review’, American Journal of Epidemiology Huge Genome 
Epidemiology (HuGE) Reviews, 151(9), pp. 839–845. 
Ashley-Koch, A., Yang, Q. and Olney, R. S. (2000) ‘Sickle hemoglobin (Hb S) allele and 
sickle cell disease: a HuGE review’, American Journal of Epidemiology. Oxford University 
Press, 151(9), pp. 839–845. 
Asnani, M., Lipps, G. and Reid, M. (2007) ‘Component structure of the SF-36 in Jamaicans 
with sickle cell disease’, West Indian Medical Journal. The University of the West Indies, 
56(6), pp. 491–497. 
Asnani, M. R., Fraser, R., Lewis, N. A. and Reid, M. E. (2010) ‘Depression and loneliness 
in Jamaicans with sickle cell disease.’, BMC psychiatry, 10(1997), p. 40. doi: 10.1186/1471-
244X-10-40. 
Asnani, M. R., Lipps, G. E. and Reid, M. E. (2009) ‘Validation of the SF-36 in Jamaicans 
with sickle-cell disease’, Psychology, health & medicine. Taylor & Francis, 14(5), pp. 606–
618. 
Asnani, M. R., Reid, M. E., Ali, S. B., Lipps, G. and Williams-Green, P. (2008) ‘Quality of 
life in patients with sickle cell disease in Jamaica: rural-urban differences’, Rural Remote 
Health, 8(2), p. 890. 
Asuzu, M. C. (2004) ‘Commentary: The necessity for a health systems reform in Nigeria’, 
Journal of community medicine and primary health care. Association of Community 
Physicians of Nigeria, 16(1), pp. 1–3. 
Bair, M. J., Robinson, R. L., Katon, W. and Kroenke, K. (2003) ‘Depression and pain 
comorbidity: a literature review’, Archives of internal medicine. American Medical 
Association, 163(20), pp. 2433–2445. 
Bakas, T., McLennon, S. M., Carpenter, J. S., Buelow, J. M., Otte, J. L., Hanna, K. M., Ellett, 
M. L., Hadler, K. A. and Welch, J. L. (2012) ‘Systematic review of health-related quality of 
life models’, Health & Quality of Life Outcomes, 10(1), p. 134. 
Baker, F. and Intagliata, J. (1982) ‘Quality of life in the evaluation of community support 
systems’, Evaluation and program planning. Elsevier, 5(1), pp. 69–79. 
Baker, S. R. (2007) ‘Testing a conceptual model of oral health: a structural equation 
modeling approach’, Journal of dental research. SAGE Publications, 86(8), pp. 708–712. 
Baker, S. R., Pankhurst, C. L. and Robinson, P. G. (2007) ‘Testing relationships between 
clinical and non-clinical variables in xerostomia: A structural equation model of oral health-
related quality of life’, Quality of Life Research, 16(2), pp. 297–308. doi: 10.1007/s11136-
006-9108-x. 
291 
 
Balkin, R. S. (2014) ‘Principles of quantitative research in counseling: A humanistic 
perspective’, The Journal of Humanistic Counseling, 53(3), pp. 240–248. 
Ballas, S. K. (2009) ‘The cost of health care for patients with sickle cell disease’, American 
Journal of Hematology, 84(6), pp. 320–322. doi: 10.1002/ajh.21443. 
Ballas, S. K., Barton, F. B., Waclawiw, M. A., Swerdlow, P., Eckman, J. R., Pegelow, C. 
H., Koshy, M., Barton, B. A. and Bonds, D. R. (2006) ‘Hydroxyurea and sickle cell anemia: 
effect on quality of life’, Health and Quality of Life Outcomes. BioMed Central, 4(1), p. 59. 
Ballas, S. K., Lewis, C. N., Noone, A. M., Krasnow, S. H., Kamarulzaman, E. and Burka, E. 
R. (1982) ‘Clinical, hematological, and biochemical features of Hb SC disease’, American 
journal of hematology. Wiley Online Library, 13(1), pp. 37–51. 
Balog, J. E. (1979) ‘AN HISTORICAL REVIEW AND PHILOSOPHICAL ANALYSIS OF 
ALTERNATIVE CONCEPTS OF HEALTH AND THEIR RELATIONSHIP TO HEALTH 
EDUCATION.’ 
Balogun, R. A., Obalum, D. C., Giwa, S. O., Adekoya-Cole, T. O., Ogo, C. N. and Enweluzo, 
G. O. (2010) ‘Spectrum of musculo-skeletal disorders in sickle cell disease in Lagos, 
Nigeria’, Journal of orthopaedic surgery and research. BioMed Central, 5(1), p. 2. 
Banerjee, S., Gurland, B. and Graham, N. (no date) ‘Improving quality of life for people 
with dementia : the ADI-Stroud symposia Understanding quality of life’. 
Banyard, P. (1996) Applying psychology to health. Hodder and Stoughton. 
Barakat, L. P., Lutz, M., Smith-Whitley, K. and Ohene-Frempong, K. (2005) ‘Is treatment 
adherence associated with better quality of life in children with sickle cell disease?’, Quality 
of Life Research, 14(2), pp. 407–414. doi: 10.1007/s11136-004-5328-0. 
Barakat, L. P., Patterson, C. A., Daniel, L. C. and Dampier, C. (2008) ‘Quality of life among 
adolescents with sickle cell disease: {Mediation} of pain by internalizing symptoms and 
parenting stress’, Health and Quality of Life Outcomes, 6(1), p. 60. doi: 10.1186/1477-7525-
6-60. 
Barbarin, O. A. and Christian, M. (1999) ‘The social and cultural context of coping with 
sickle cell disease: I. A review of biomedical and psychosocial issues’, Journal of Black 
Psychology. Sage Publications Sage CA: Thousand Oaks, CA, 25(3), pp. 277–293. 
Barenthin, I. (1975) ‘The concept of health in community dentistry’, Journal of public health 
dentistry. Wiley Online Library, 35(3), pp. 177–184. 
Baron, R. M. and Kenny, D. A. (1986) ‘The moderator–mediator variable distinction in 
social psychological research: Conceptual, strategic, and statistical considerations.’, Journal 
of personality and social psychology. American Psychological Association, 51(6), p. 1173. 
Barrett-connor, E. (1971) ‘Bacterial infection and sickle cell anemia: an analysis of 250 
infections in 166 patients and a review of the literature’, Medicine. LWW, 50(2), pp. 97–
112. 
Barsky, A. J., Cleary, P. D., Sarnie, M. K. and Klerman, G. L. (1993) ‘The course of transient 
hypochondriasis’, The American journal of psychiatry. American Psychiatric Association, 
150(3), p. 484. 
Basch, E., Iasonos, A., Barz, A., Culkin, A., Kris, M. G., Artz, D., Fearn, P., Speakman, J., 
Farquhar, R. and Scher, H. I. (2007) ‘Long-term toxicity monitoring via electronic patient-
reported outcomes in patients receiving chemotherapy’, Journal of Clinical Oncology. 
292 
 
American Society of Clinical Oncology, 25(34), pp. 5374–5380. 
Bayliss, E. A., Ellis, J. L. and Steiner, J. F. (2005) ‘Subjective assessments of comorbidity 
correlate with quality of life health outcomes: initial validation of a comorbidity assessment 
instrument’, Health and Quality of life Outcomes, 3(1), p. 51. 
Bazuaye, G. N., Nwannadi, A. I. and Olayemi, E. E. (2010) ‘Leg Ulcers in Adult sickle cell 
disease patients in Benin City, Nigeria’, Gomal Journal of Medical Sciences, 8(2). 
Beck, A. T. and Steer, R. A. (1984) ‘Internal consistencies of the original and revised Beck 
Depression Inventory’, Journal of clinical psychology. Wiley Online Library, 40(6), pp. 
1365–1367. 
Beddhu, S., Bruns, F. J., Saul, M., Seddon, P. and Zeidel, M. L. (2000) ‘A simple 
comorbidity scale predicts clinical outcomes and costs in dialysis patients’, The American 
journal of medicine. Elsevier, 108(8), pp. 609–613. 
Belgrave, F. Z. and Molock, S. D. (1991) ‘The role of depression in hospital admissions and 
emergency treatment of patients with sickle cell disease.’, Journal of the National Medical 
Association. National Medical Association, 83(9), p. 777. 
Bentler, P. M. (1985) Theory and implementation of EQS: A structural equations program. 
BMDP Statistical Software. 
Bentler, P. M. (1990) ‘Comparative fit indexes in structural models.’, Psychological bulletin. 
American Psychological Association, 107(2), p. 238. 
Bentler, P. M. and Chou, C.-P. (1987) ‘Practical issues in structural modeling’, Sociological 
Methods & Research, 16(1), pp. 78–117. 
Berg, B. (2012) ‘Sf‐6d Population Norms’, Health economics. Wiley Online Library, 21(12), 
pp. 1508–1512. 
Berlim, M. T. and Fleck, M. P. A. (2003) ‘“{Quality} of life”: {A} brand new concept for 
research and practice in psychiatry’, Revista Brasileira de Psiquiatria, 25(4), pp. 249–252. 
doi: 10.1590/s1516-44462003000400013. 
Beverung, L. M., Strouse, J. J., Hulbert, M. L., Neville, K., Liem, R. I., Inusa, B., Fuh, B., 
King, A., Meier, E. R., Casella, J., Debaun, M. R. and Panepinto, J. A. (2015) ‘Health-related 
quality of life in children with sickle cell anemia: Impact of blood transfusion therapy’, 
American Journal of Hematology, 90(2), pp. 139–143. doi: 10.1002/ajh.23877. 
Bhagat, V., Baviskar, S., Mudey, A. and Goyal, R. (2014) ‘Poor health related quality of life 
among patients of sickle cell disease’, Indian Journal of Palliative Care, 20(2), p. 107. doi: 
10.4103/0973-1075.132622. 
Bhatia, M., Kolva, E., Cimini, L., Jin, Z., Satwani, P., Savone, M., George, D., Garvin, J., 
Paz, M. L., Briamonte, C., Cruz-Arrieta, E. and Sands, S. (2015) ‘Health-related quality of 
life after {Allogeneic} {Hematopoietic} stem cell transplantation for sickle cell disease’, 
Biology of Blood and Marrow Transplantation, 21(4), pp. 666–672. doi: 
10.1016/j.bbmt.2014.12.007. 
Birmelé, B., Le Gall, A., Sautenet, B., Aguerre, C. and Camus, V. (2012) ‘Clinical, 
sociodemographic, and psychological correlates of health-related quality of life in chronic 
hemodialysis patients’, Psychosomatics. Elsevier, 53(1), pp. 30–37. 
Bishop, M., Berven, N. L., Hermann, B. P. and Chan, F. (2002) ‘Quality of life among adults 
with epilepsy: an exploratory model’, Rehabilitation Counseling Bulletin. Sage Publications 
293 
 
Sage CA: Thousand Oaks, CA, 45(2), pp. 87–95. 
Blaxter, M. (2010) ‘Health (2. uppl.)’, Cambridge: Polity. 
Bollen, K. A. (1989) ‘A new incremental fit index for general structural equation models’, 
Sociological Methods & Research. Sage Publications, 17(3), pp. 303–316. 
Bollen, K. A. and Stine, R. A. (1992) ‘Bootstrapping goodness-of-fit measures in structural 
equation models’, Sociological Methods & Research. SAGE PERIODICALS PRESS, 21(2), 
pp. 205–229. 
Bombard, J. M., Powell, K. E., Martin, L. M., Helmick, C. G. and Wilson, W. H. (2005) 
‘Validity and reliability of self-reported arthritis: Georgia senior centers, 2000–2001’, 
American journal of preventive medicine. Elsevier, 28(3), pp. 251–258. 
Boomsma, A. (1983) ‘On the robustness of LISREL (maximum likelihood estimation) 
against small sample size and non-normality’. Rijksuniversiteit Groningen. 
Booth, C., Inusa, B. and Obaro, S. K. (2010) ‘Infection in sickle cell disease: a review’, 
International Journal of Infectious Diseases. Elsevier, 14(1), pp. e2–e12. 
Boruchovitch, E. and Mednick, B. R. (1997) ‘Cross-cultural differences in children’s 
concepts of health and illness’, Revista de Saúde Pública. SciELO Public Health, 31, pp. 
448–456. 
Boruchovitch, E. and Mednick, B. R. (2002) ‘The meaning of health and illness: some 
considerations for health psychology’, Psico-USF. SciELO Brasil, 7(2), pp. 175–183. 
Van Den Bos, G. A. M. (1995) ‘The burden of chronic diseases in terms of disability, use of 
health care and healthy life expectancies’, The European Journal of Public Health, 5(1), pp. 
29–34. 
Bowling, A. (1991) Measuring health: a review of quality of life measurement scales. Open 
University Press Milton Keynes. 
Bowling, A. (1995a) ‘Health-related quality of life: a discussion of the concept, its use and 
measurement’, Measuring disease. Open University Press Buckingham, pp. 1–19. 
Bowling, A. (1995b) ‘What things are important in people’s lives? A survey of the public’s 
judgements to inform scales of health related quality of life’, Social science & medicine. 
Elsevier, 41(10), pp. 1447–1462. 
Bowling, A. (2001) ‘Measuring disease. A review of disease-specific quality of life 
measurement scales’, Open University Press, p. 390. doi: 
10.1001/jama.1994.03520080061045. 
Bowling, A. (2014) Research methods in health: investigating health and health services. 
McGraw-Hill Education (UK). 
Bowling, A. and Ebrahim, S. (2005) Handbook of health research methods: investigation, 
measurement and analysis. McGraw-Hill Education (UK). 
Bradley, C. (2006) ‘Feedback on the FDA’s February 2006 draft guidance on Patient 
Reported Outcome (PRO) measures from a developer of PRO measures’, Health and Quality 
of life outcomes. BioMed Central, 4(1), p. 78. 
Bramlett, R. E., Bothe, A. K. and Franic, D. M. (2006) ‘Using preference-based measures to 
assess quality of life in stuttering’, Journal of Speech, Language, and Hearing Research. 
ASHA, 49(2), pp. 381–394. 
294 
 
Brandow, A. M., Brousseau, D. C., Pajewski, N. M. and Panepinto, J. A. (2010) ‘Vaso‐
occlusive painful events in sickle cell disease: Impact on child well‐being’, Pediatric blood 
& cancer. Wiley Online Library, 54(1), pp. 92–97. 
Brazier, J. E., Rowen, D., Mavranezouli, I., Tsuchiya, A., Young, T., Yang, Y., Barkham, 
M. and Ibbotson, R. (2012) ‘Developing and testing methods for deriving preference-based 
measures of health from condition-specific measures (and other patient-based measures of 
outcome).’ NIHR Journals Library. 
Brazier, J., Roberts, J. and Deverill, M. (2002) ‘The estimation of a preference-based 
measure of health from the SF-36’, Journal of health economics. Elsevier, 21(2), pp. 271–
292. doi: 10.1016/S0167-6296(01)00130-8. 
Brazier, J., Usherwood, T., Harper, R. and Thomas, K. (1998) ‘Deriving a preference-based 
single index from the UK SF-36 Health Survey’, Journal of Clinical Epidemiology, 51(11), 
pp. 1115–1128. doi: 10.1016/S0895-4356(98)00103-6. 
Brousse, V., Makani, J. and Rees, D. C. (2014) ‘Management of sickle cell disease in the 
community’, BMJ, 348(mar10 11), pp. g1765--g1765. doi: 10.1136/bmj.g1765. 
Brousseau, D. C., A Panepinto, J., Nimmer, M. and Hoffmann, R. G. (2010) ‘The number 
of people with sickle‐cell disease in the United States: national and state estimates’, 
American journal of hematology. Wiley Online Library, 85(1), pp. 77–78. 
Brown, M. (2012) ‘Managing the acutely ill adult with sickle cell disease’, British Journal 
of Nursing. MA Healthcare London, 21(2), pp. 90–96. 
Brown, R. T., Armstrong, F. D. and Eckman, J. R. (1993) ‘Neurocognitive aspects of 
pediatric sickle cell disease’, Journal of Learning Disabilities. Sage Publications Sage UK: 
London, England, 26(1), pp. 33–45. 
Browne, M. W. (1984) ‘Asymptotically distribution‐free methods for the analysis of 
covariance structures’, British Journal of Mathematical and Statistical Psychology. Wiley 
Online Library, 37(1), pp. 62–83. 
Browne, M. W. and Cudeck, R. (1993) ‘Alternative ways of assessing model fit’, Sage focus 
editions. Sage publications, 154, p. 136. 
Brunault, P., Battini, J., Potard, C., Jonas, C., Zagala-Bouquillon, B., Chabut, A., Mercier, 
J.-M., Bedhet, N., Réveillère, C., Goga, D. and Courtois, R. (2016) ‘Clinical {Paper}: 
{Orthognathic} surgery improves quality of life and depression, but not anxiety, and patients 
with higher preoperative depression scores improve less’, International Journal of Oral & 
Maxillofacial Surgery, 45, pp. 26–34. doi: 10.1016/j.ijom.2015.07.020. 
Brunault, P., Frammery, J., Couet, C., Delbachian, I., Bourbao-Tournois, C., Objois, M., 
Cosson, P., Réveillère, C. and Ballon, N. (2015) ‘Predictors of changes in physical, 
psychosocial, sexual quality of life, and comfort with food after obesity surgery: a 12-month 
follow-up study’, Quality of Life Research. Springer, 24(2), pp. 493–501. 
Bullinger, M. (1995) ‘German translation and psychometric testing of the SF-36 health 
survey: preliminary results from the IQOLA project’, Social science & medicine. Elsevier, 
41(10), pp. 1359–1366. 
Bullock, H. E., Harlow, L. L. and Mulaik, S. A. (1994) ‘Causation issues in structural 
equation modeling research’, Structural Equation Modeling: A Multidisciplinary Journal. 
Taylor & Francis, 1(3), pp. 253–267. 
Bush, T. L., Miller, S. R., Golden, A. L. and Hale, W. E. (1989) ‘Self-report and medical 
295 
 
record report agreement of selected medical conditions in the elderly.’, American journal of 
public health. American Public Health Association, 79(11), pp. 1554–1556. 
Byrne, B. M. (1998) ‘Structural equation modeling with LISREL’, Prelis, and Simplis, pp. 
196–199. 
Byrne, B. M. (2001) ‘Structural equation modeling: Perspectives on the present and the 
future’, International Journal of Testing. Taylor & Francis, 1(3–4), pp. 327–334. 
Caird, H., Camic, P. M. and Thomas, V. (2011) ‘The lives of adults over 30 living with 
sickle cell disorder’, British journal of health psychology. Wiley Online Library, 16(3), pp. 
542–558. 
Calman, K. C. (1984) ‘Quality of life in cancer patients--an hypothesis.’, Journal of medical 
ethics. Institute of Medical Ethics, 10(3), pp. 124–127. 
Campbell, A., Converse, P. E. and Rodgers, W. L. (1976) The quality of American life: 
Perceptions, evaluations, and satisfactions. Russell Sage Foundation. 
Carey, P. J. (2014) ‘Addressing the global health burden of sickle cell disease’, International 
Health, 6(4), pp. 269–270. doi: 10.1093/inthealth/ihu045. 
Carlson, B., Pozehl, B., Hertzog, M., Zimmerman, L. and Riegel, B. (2014) ‘Predictors of 
overall perceived health in patients with heart failure.’, The Journal of cardiovascular 
nursing, 28(3), pp. 206–15. doi: 10.1097/JCN.0b013e31824987a8. 
Carr, A. J., Gibson, B. and Robinson, P. G. (2001) ‘Is quality of life determined by 
expectations or experience?’, Bmj. British Medical Journal Publishing Group, 322(7296), 
pp. 1240–1243. 
Carson, A. J., Ringbauer, B., Stone, J., McKenzie, L., Warlow, C. and Sharpe, M. (2000) 
‘Do medically unexplained symptoms matter? A prospective cohort study of 300 new 
referrals to neurology outpatient clinics’, Journal of Neurology, Neurosurgery & Psychiatry. 
BMJ Publishing Group Ltd, 68(2), pp. 207–210. 
Castro, O., Brambilla, D. J., Thorington, B., Reindorf, C. A., Scott, R. B., Gillette, P., Vera, 
J. C. and Levy, P. S. (1994) ‘The acute chest syndrome in sickle cell disease: incidence and 
risk factors. The Cooperative Study of Sickle Cell Disease’, Blood. Am Soc Hematology, 
84(2), pp. 643–649. 
Castro, O., Brambilla, D. J., Thorington, B., Reindorf, C. A., Scott, R. B., Gillette, P., Vera, 
J. C., Levy, P. S. and Disease, T. C. S. of S. C. (1994) ‘The Acute Chest Syndrome in Sickle 
Cell Disease: Incidence and Risk Factors’, Blood, 84(2), pp. 643–649. 
Cella, D. and Stone, A. A. (2015) ‘Health-related quality of life measurement in oncology: 
Advances and opportunities.’, American Psychologist. Cella, David, Department of Medical 
Social Sciences, Northwestern University Feinberg School of Medicine, 633 N. St. Clair - 
19th Floor, Chicago, IL, US, 60611: American Psychological Association (Cancer and 
Psychology), 70(2), pp. 175–185. doi: 10.1037/a0037821. 
Center for Disease Control and Prevention. (2016) ‘Sickle Cell Disease (SCD). 2011’, 
Retreived from http://www. cdc. gov/NCBDDD/sicklecell/data. html on March, 3. 
Cepeda, M. L., Yang, Y., Price, C. C. and Shah, A. (1997) ‘Mental disorders in children and 
adolescents with sickle cell disease.’, Southern medical journal, 90(3), pp. 284–287. 
Chan, F., Lee, G. K., Lee, E.-J., Kubota, C. and Allen, C. A. (2007) ‘Structural equation 
modeling in rehabilitation counseling research’, Rehabilitation Counseling Bulletin. Sage 
296 
 
Publications Sage CA: Los Angeles, CA, 51(1), pp. 44–57. 
Chang, Y.-P. C., Maier‐Redelsperger, Mi., Smith, K. D., Contu, L., Ducrocq, R., De 
Montalembert, M., Belloy, M., Elion, J., J. DOVER, G. and Girot, R. (1997) ‘The relative 
importance of the X‐linked FCP locus and β‐globin haplotypes in determining haemoglobin 
F levels: a study of SS patients homozygous for βS haplotypes’, British journal of 
haematology. Wiley Online Library, 96(4), pp. 806–814. 
Charache, S. (1991) ‘Hydroxyurea as treatment for sickle cell anemia’, 
Hematology/Oncology Clinics. Elsevier, 5(3), pp. 571–583. 
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V, 
McMahon, R. P. and Bonds, D. R. (1995) ‘Investigators of the Multicenter Study of 
Hydroxyurea in Sickle Cell Anemia Effect of hydroxyurea on the frequency of painful crises 
in sickle cell anemia’, N Engl J Med, 332(20), pp. 1317–1322. 
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V, 
McMahon, R. P., Bonds, D. R. and Anemia, I. of the M. S. of H. in S. C. (1995) ‘Effect of 
hydroxyurea on the frequency of painful crises in sickle cell anemia’, New England Journal 
of Medicine. Mass Medical Soc, 332(20), pp. 1317–1322. 
Chase, D. M., Huang, H. Q., Wenzel, L., Cella, D., McQuellon, R., Long, H. J., Moore, D. 
H. and Monk, B. J. (2012) ‘Quality of life and survival in advanced cervical cancer: a 
Gynecologic Oncology Group study’, Gynecologic oncology. Elsevier, 125(2), pp. 315–319. 
Chaturvedi, S. and DeBaun, M. R. (2016) ‘Evolution of sickle cell disease from a life‐
threatening disease of children to a chronic disease of adults: The last 40 years’, American 
journal of hematology. Wiley Online Library, 91(1), pp. 5–14. 
Chemegni, C., Jpo, K. O., Lj, U. N., F, N. E. and Mbanya, D. (2018) ‘iMedPub Journals 
Anxiety , Depression and Quality of Life in Adults with Sickle Cell Disease Keywords ’:, 
pp. 1–7. doi: 10.21767/1989-5216.1000259. 
Chen, T. M., Huang, F. Y., Chang, C. and Chung, H. (2006) ‘Using the PHQ-9 for depression 
screening and treatment monitoring for Chinese Americans in primary care’, Psychiatric 
services. Am Psychiatric Assoc, 57(7), pp. 976–981. 
Chijioke, A. and Kolo, P. M. (2009) ‘Mortality pattern at the adult medical wards of a 
teaching hospital in sub-Saharan Africa’, Int J Trop Med, 4(1), pp. 27–31. 
Chou, C.-P. and Bentler, P. M. (1995) ‘Estimates and tests in structural equation modeling.’ 
Sage Publications, Inc. 
Chrischilles, E. A., Rubenstein, L. M., Voelker, M. D., Wallace, R. B. and Rodnitzky, R. L. 
(2002) ‘Linking clinical variables to health-related quality of life in Parkinson’s disease’, 
Parkinsonism & Related Disorders. Elsevier, 8(3), pp. 199–209. 
Cieza, A. and Stucki, G. (2008) ‘The International Classification of Functioning Disability 
and Health: its development process and content validity’, Eur J Phys Rehabil Med, 44(3), 
pp. 303–313. 
Cleary, P. D., Greenfield, S. and McNeil, B. J. (1991) ‘Assessing quality of life after 
surgery’, Controlled clinical trials. Elsevier, 12(4), pp. S189–S203. 
Cleeland, C. S., Gonin, R., Hatfield, A. K., Edmonson, J. H., Blum, R. H., Stewart, J. A. and 
Pandya, K. J. (1994) ‘Pain and its treatment in outpatients with metastatic cancer’, New 
England Journal of Medicine. Mass Medical Soc, 330(9), pp. 592–596. 
297 
 
Cober, M. P. and Phelps, S. J. (2010) ‘Penicillin prophylaxis in children with sickle cell 
disease’, The Journal of Pediatric Pharmacology and Therapeutics. Pediatric Pharmacy 
Advocacy Group, 15(3), pp. 152–159. 
Cohen, J. (1988) ‘Statistical power analysis for the behavioral sciences 2nd edn’. Erlbaum 
Associates, Hillsdale. 
Cole, D. A. and Maxwell, S. E. (2003) ‘Testing mediational models with longitudinal data: 
questions and tips in the use of structural equation modeling.’, Journal of abnormal 
psychology. American Psychological Association, 112(4), p. 558. 
Coleman, B., Ellis-Caird, H., McGowan, J. and Benjamin, M. J. (2016) ‘How sickle cell 
disease patients experience, understand and explain their pain: An Interpretative 
Phenomenological Analysis study’, British Journal of Health Psychology, 21(1), pp. 190–
203. doi: 10.1111/bjhp.12157. 
Comer, E. W. (1998) ‘Effects of a cognitive behavioral group intervention on the reduction 
of depressive symptoms in individuals with sickle cell disease’. University of North Carolina 
at Chapel Hill. 
Connelly, J. E., Philbrick, J. T., Smith Jr, G. R., Kaiser, D. L. and Wymer, A. (1989) ‘Health 
perceptions of primary care patients and the influence on health care utilization’, Medical 
care. JSTOR, pp. S99–S109. 
Cope, A. and Darbyshire, P. J. (2013) ‘Sickle cell disease, update on management’, 
Paediatrics and Child Health. Elsevier, 23(11), pp. 480–485. 
Cosby, C., Holzemer, W. L., Henry, S. B. and Portillo, C. J. (2000) ‘Hematological 
complications and quality of life in hospitalized AIDS patients’, AIDS patient care and 
STDs, 14(5), pp. 269–279. doi: 10.1089/108729100317731. 
Couque, N., Girard, D., Ducrocq, R., Boizeau, P., Haouari, Z., Missud, F., Holvoet, L., Ithier, 
G., Belloy, M. and Odièvre, M. (2016) ‘Improvement of medical care in a cohort of 
newborns with sickle‐cell disease in North Paris: impact of national guidelines’, British 
journal of haematology. Wiley Online Library, 173(6), pp. 927–937. 
Courtenay, W. H. (2000a) ‘Behavioral factors associated with disease, injury, and death 
among men: Evidence and implications for prevention’, The Journal of Men’s studies. 
SAGE Publications Sage CA: Los Angeles, CA, 9(1), pp. 81–142. 
Courtenay, W. H. (2000b) ‘Constructions of masculinity and their influence on men’s well-
being: a theory of gender and health’, Social science & medicine. Elsevier, 50(10), pp. 1385–
1401. 
Cronbach, L. J. (1951) ‘Coefficient alpha and the internal structure of tests’, psychometrika. 
Springer, 16(3), pp. 297–334. 
Cummins, R. A. and Lau, A. L. D. (2006) ‘Using health and subjective well-being for quality 
of life measurement: A review’, SOCIAL POLICY REVIEW-HARLOW-, 18, p. 165. 
Curran, P. J. and Bollen, K. A. (2001) ‘The best of both worlds: Combining autoregressive 
and latent curve models.’ American Psychological Association. 
Curtis, A. J. (2000) Health psychology. Psychology Press. 
Dacie, J. V. (1960) The haemolytic anaemias: congenital and acquired. Grune & Stratton. 
Dale, J. C., Cochran, C. J., Roy, L., Jernigan, E. and Buchanan, G. R. (2011) ‘Health-related 
quality of life in children and adolescents with sickle cell disease’, Journal of Pediatric 
298 
 
Health Care, 25(4), pp. 208–215. doi: 10.1016/j.pedhc.2009.12.006. 
Dampier, C., LeBeau, P., Rhee, S., Lieff, S., Kesler, K., Ballas, S., Rogers, Z. and Wang, W. 
(2011) ‘Health-related quality of life in adults with sickle cell disease (SCD): A report from 
the comprehensive sickle cell centers clinical trial consortium’, American Journal of 
Hematology, 86(2), pp. 203–205. doi: 10.1002/ajh.21905. 
Dampier, C., Lieff, S., LeBeau, P., Rhee, S., McMurray, M., Rogers, Z., Smith-Whitley, K. 
and Wang, W. (2010) ‘Health-related quality of life in children with sickle cell disease: {A} 
report from the comprehensive sickle cell centers clinical trial consortium’, Pediatric Blood 
& Cancer, 55(3), pp. 485–494. doi: 10.1002/pbc.22497. 
Darlington, R. B. (no date) ‘Regression and linear models. 1990’. McGraw-Hill, New York. 
Davis, H., Moore Jr, R. M. and Gergen, P. J. (1997) ‘Cost of hospitalizations associated with 
sickle cell disease in the United States.’, Public health reports. SAGE Publications, 112(1), 
p. 40. 
Davis, K., Yount, S., Del Ciello, K., Whalen, M., Khan, S., Bass, M., Du, H., Eton, D., 
Masters, G. and Hensing, T. (2007) ‘An innovative symptom monitoring tool for people with 
advanced lung cancer: a pilot demonstration’, J Support Oncol, 5(8), pp. 381–387. 
Davison, S. N., Jhangri, G. S. and Feeny, D. H. (2009) ‘Comparing the Health Utilities Index 
Mark 3 (HUI3) with the Short Form‐36 Preference‐Based SF‐6D in Chronic Kidney 
Disease’, Value in Health. Wiley Online Library, 12(2), pp. 340–345. 
De, D. (2005) ‘Sickle cell anaemia 1: background, causes and incidence in the UK’, British 
journal of nursing. MA Healthcare London, 14(8), pp. 447–450. 
DeBaun, M. R. (2014) ‘Perspective: Thinking beyond survival’, Nature. Nature Research, 
515(7526), pp. S16–S16. 
DeBaun, M. R., Armstrong, F. D., McKinstry, R. C., Ware, R. E., Vichinsky, E. and 
Kirkham, F. J. (2012) ‘Silent cerebral infarcts: a review on a prevalent and progressive cause 
of neurologic injury in sickle cell anemia’, Blood. Am Soc Hematology, 119(20), pp. 4587–
4596. 
DeCarlo, L. T. (1997) ‘On the meaning and use of kurtosis.’, Psychological methods. 
American Psychological Association, 2(3), p. 292. 
Dempster, A. P., Laird, N. M. and Rubin, D. B. (1977) ‘Maximum likelihood from 
incomplete data via the EM algorithm’, Journal of the royal statistical society. Series B 
(methodological). JSTOR, pp. 1–38. 
Dennis-Antwi, J. A., Dyson, S. and Frempong, K. O. (2008) ‘Healthcare provision for sickle 
cell disease in Ghana: challenges for the African context’, Diversity & Equality in Health 
and Care. iMedPub, 5(4). 
Denzin, N. K. and Lincoln, Y. S. (2011) The Sage handbook of qualitative research. Sage. 
DeSalvo, K. B., Bloser, N., Reynolds, K., He, J. and Muntner, P. (2006) ‘Mortality prediction 
with a single general self-rated health question’, Journal of general internal medicine. 
Springer, 21(3), p. 267. 
Diener, E. (1984) ‘Subjective well-being.’, Psychological bulletin. American Psychological 
Association, 95(3), p. 542. 
Diggs, L. M. (1973) ‘Anatomic lesions in sickle cell disease’, Sickle cell disease: Diagnosis, 
management, education, and research. CV Mosby, St. Louis, pp. 189–229. 
299 
 
Dimsdale, J., Creed, F. and Disorders, D.-V. W. on S. S. (2009) ‘The proposed diagnosis of 
somatic symptom disorders in DSM-V to replace somatoform disorders in DSM-IV—a 
preliminary report’. Elsevier. 
Ding, L., Velicer, W. F. and Harlow, L. L. (1995) ‘Effects of estimation methods, number 
of indicators per factor, and improper solutions on structural equation modeling fit indices’, 
Structural Equation Modeling: A Multidisciplinary Journal, 2(2), pp. 119–143. 
Dominick, K. L., Ahern, F. M., Gold, C. H. and Heller, D. A. (2002) ‘Relationship of health-
related quality of life to health care utilization and mortality among older adults’, Aging 
clinical and experimental research. Springer, 14(6), pp. 499–508. 
Dosunmu, A. O., Akinola, R. A., Onakoya, J. A., Balogunt, T. M., Adeyeye, O. O., 
Akinbami, A. A., Arogundade, O. M. and Brodie-Mends, A. T. (2013) ‘Pattern of chronic 
lung lesions in adults with sickle cell disease in Lagos, Nigeria’, Caspian journal of internal 
medicine. Babol University of Medical Sciences, 4(4), p. 754. 
Downie, R. S., Fyfe, C. and Tannahill, A. (1990) ‘Health promotion: models and values’. 
Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L. and Torrance, G. W. (2015) 
Methods for the economic evaluation of health care programmes. Oxford university press. 
Duncan, T. E., Duncan, S. C. and Li, F. (1998) ‘A comparison of model‐and multiple 
imputation‐based approaches to longitudinal analyses with partial missingness’, Structural 
Equation Modeling: A Multidisciplinary Journal. Taylor & Francis, 5(1), pp. 1–21. 
Eberst, R. M. (1984) ‘Defining health: A multidimensional model’, Journal of School 
Health. Wiley Online Library, 54(3), pp. 99–104. 
Ebong, W. W. (1986) ‘Acute osteomyelitis in Nigerians with sickle cell disease.’, Annals of 
the rheumatic diseases. BMJ Publishing Group, 45(11), p. 911. 
Edelmann, R. J. (2000) Psychosocial aspects of the health care process. Pearson Education 
Harlow. 
Edwards, C. L., Scales, M. T., Loughlin, C., Bennett, G. G., Harris-Peterson, S., De Castro, 
L. M., Whitworth, E., Abrams, M., Feliu, M. and Johnson, S. (2005) ‘A brief review of the 
pathophysiology, associated pain, and psychosocial issues in sickle cell disease’, 
International Journal of Behavioral Medicine. Springer, 12(3), pp. 171–179. 
Edwards, R., Telfair, J., Cecil, H. and Lenoci, J. (2001) ‘Self-efficacy as a predictor of adult 
adjustment to sickle cell disease: One-year outcomes’, Psychosomatic Medicine. LWW, 
63(5), pp. 850–858. 
Effective Public Health Practice Project (2010) ‘Quality assessment tool for quantitative 
studies’, Effective Public Health Practice Project., pp. 2–5. 
Egede, L. E. (2004) ‘Effects of depression on work loss and disability bed days in individuals 
with diabetes’, Diabetes care. Am Diabetes Assoc, 27(7), pp. 1751–1753. 
Eichner, E. R. (2010) ‘Sickle cell trait in sports’, Current sports medicine reports. LWW, 
9(6), pp. 347–351. 
Eilayyan, O., Gogovor, A., Mayo, N., Ernst, P. and Ahmed, S. (2015) ‘Predictors of 
perceived asthma control among patients managed in primary care clinics’, Quality of Life 
Research, 24(1), pp. 55–65. doi: 10.1007/s11136-014-0700-1. 
El-Shinnawy, H., Goueli, T., Nasreldin, M. and Meshref,  a. (2013) ‘Anxiety, depressive 
disorders, and quality of life in adults with sickle cell disease’, Middle East Current 
300 
 
Psychiatry, 20(2), pp. 80–86. doi: 10.1097/01.XME.0000426319.48898.03. 
Elander, J., Lusher, J., Bevan, D. and Telfer, P. (2003) ‘Pain management and symptoms of 
substance dependence among patients with sickle cell disease’, Social Science and Medicine, 
57(9), pp. 1683–1696. doi: 10.1016/S0277-9536(02)00553-1. 
Ellermeier, W. and Westphal, W. (1995) ‘Gender differences in pain ratings and pupil 
reactions to painful pressure stimuli’, Pain. Elsevier, 61(3), pp. 435–439. 
Ellison, A. M., Ota, K. V, McGowan, K. L. and Smith-Whitley, K. (2012) ‘Pneumococcal 
bacteremia in a vaccinated pediatric sickle cell disease population’, The Pediatric infectious 
disease journal. LWW, 31(5), pp. 534–536. 
Ellison, A. M. and Shaw, K. (2007) ‘Management of vasoocclusive pain events in sickle cell 
disease’, Pediatric emergency care. LWW, 23(11), pp. 832–841. 
Elmariah, H., Garrett, M. E., De Castro, L. M., Jonassaint, J., Ataga, K. I., Eckman, J., 
Ashley-Koch, A. E. and Telen, M. J. (2014) ‘Factors Associated with Survival in a 
Contemporary Adult Sickle Cell Disease Cohort’, Am J Hematol, 89(5), pp. 530–535. doi: 
10.1002/ajh.23683. 
Engel, G. L. (1977) ‘The need for a new medical model: a challenge for biomedicine’, 
Science. American Association for the Advancement of Science, 196(4286), pp. 129–136. 
Engel, G. L. (1980) ‘The clinical application of the biopsychosocial model’, American 
journal of Psychiatry. Citeseer, 137, pp. 535–544. 
Engel, G. L. (1997) ‘From biomedical to biopsychosocial: Being scientific in the human 
domain’, Psychosomatics. Elsevier, 38(6), pp. 521–528. 
Engel, L., Bryan, S., Evers, S. M. A. A., Dirksen, C. D., Noonan, V. K. and Whitehurst, D. 
G. T. (2014) ‘Exploring psychometric properties of the SF-6D, a preference-based health-
related quality of life measure, in the context of spinal cord injury.’, Quality of life research : 
an international journal of quality of life aspects of treatment, care and rehabilitation, 23(8), 
pp. 2383–2393. doi: 10.1007/s11136-014-0677-9. 
Espallargues, M., Czoski-Murray, C. J., Bansback, N. J., Carlton, J., Lewis, G. M., Hughes, 
L. A., Brand, C. S. and Brazier, J. E. (2005) ‘The impact of age-related macular degeneration 
on health status utility values’, Investigative ophthalmology & visual science. The 
Association for Research in Vision and Ophthalmology, 46(11), pp. 4016–4023. 
Eton, D. T., Fairclough, D. L., Cella, D., Yount, S. E., Bonomi, P. and Johnson, D. H. (2003) 
‘Early change in patient-reported health during lung cancer chemotherapy predicts clinical 
outcomes beyond those predicted by baseline report: results from Eastern Cooperative 
Oncology Group Study 5592’, Journal of Clinical Oncology. American Society of Clinical 
Oncology, 21(8), pp. 1536–1543. 
Fayers, P. M. and Machin, D. (2000) ‘Multi‐Item Scales’, Quality of life: assessment, 
analysis and interpretation. Wiley Online Library, pp. 72–90. 
Fayers, P. M. and Machin, D. (2013) Quality of life: the assessment, analysis and 
interpretation of patient-reported outcomes. John Wiley & Sons. 
Feeny, D., Spritzer, K., Hays, R. D., Liu, H., Ganiats, T. G., Kaplan, R. M., Palta, M. and 
Fryback, D. G. (2012) ‘Agreement about identifying patients who change over time: 
cautionary results in cataract and heart failure patients’, Medical Decision Making. Sage 
Publications Sage CA: Los Angeles, CA, 32(2), pp. 273–286. 
301 
 
Feinstein, A. R. (1987) ‘Clinimetric perspectives’, Journal of chronic diseases. Elsevier, 
40(6), pp. 635–640. 
Felce, D. and Perry, J. (1995) ‘Quality of life: Its definition and measurement’, Research in 
developmental disabilities. Elsevier, 16(1), pp. 51–74. 
Ferrans, C. E. and Powers, M. J. (1985) ‘Quality of life index: development and 
psychometric properties.’, Advances in nursing science. Lippincott Williams & Wilkins. 
Ferrans, C. E. and Powers, M. J. (1992) ‘Psychometric assessment of the Quality of Life 
Index’, Research in nursing & health. Wiley Online Library, 15(1), pp. 29–38. 
Ferrans, C. E., Zerwic, J. J., Wilbur, J. E. and Larson, J. L. (2005) ‘Conceptual model of 
health-related quality of life.’, Journal of nursing scholarship : an official publication of 
Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau, 37(4), pp. 336–
342. doi: http://dx.doi.org/10.1111/j.1547-5069.2005.00058.x. 
Ferrell, B. R., Wisdom, C. and Wenzl, C. (1989) ‘Quality of life as an outcome variable in 
the management of cancer pain’, Cancer. Wiley Online Library, 63(11), pp. 2321–2327. 
Fillingim, R. B., Doleys, D. M., Edwards, R. R. and Lowery, D. (2003) ‘Clinical 
characteristics of chronic back pain as a function of gender and oral opioid use’, Spine. 
LWW, 28(2), pp. 143–150. 
Fillingim, R. B., Edwards, R. R. and Powell, T. (1999) ‘The relationship of sex and clinical 
pain to experimental pain responses’, PAIN®. Elsevier, 83(3), pp. 419–425. 
Fillingim, R. B. and Maixner, W. (1995) ‘Gender differences in the responses to noxious 
stimuli’, in Pain forum. Elsevier, pp. 209–221. 
Fisak, B., Belkin, M. H., von Lehe, A. C. and Bansal, M. M. (2011) ‘The relation between 
health-related quality of life, treatment adherence and disease severity in a paediatric sickle 
cell disease sample’, Child: Care, Health and Development, 38(2), pp. 204–210. doi: 
10.1111/j.1365-2214.2011.01223.x. 
Fitzpatrick, R. (2000) ‘Measurement issues in health-related quality of life: Challenges for 
health psychology’, Psychology and Health. Taylor & Francis, 15(1), pp. 99–108. 
Fitzpatrick, R., Davey, C., Buxton, M. J. and Jones, D. R. (1998) ‘Evaluating patient-based 
outcome measures for use in clinical trials’, Health Technology Assessment. NHS R&D 
HTA Programme, 2(14). 
Fleming, A. F., Storey, J., Molineaux, L., Iroko, E. A. and Attai, E. D. E. (1979) ‘Abnormal 
haemoglobins in the Sudan savanna of Nigeria: I. Prevalence of haemoglobins and 
relationships between sickle cell trait, malaria and survival’, Annals of Tropical Medicine & 
Parasitology. Taylor & Francis, 73(2), pp. 161–172. 
Friedman, H. S. and DiMatteo, M. R. (1989) Health psychology. Prentice-Hall, Inc. 
Gagne, P. and Hancock, G. R. (2006) ‘Measurement model quality, sample size, and solution 
propriety in confirmatory factor models’, Multivariate Behavioral Research. Taylor & 
Francis, 41(1), pp. 65–83. 
Galadanci, N., Wudil, B. J., Balogun, T. M., Ogunrinde, G. O., Akinsulie, A., Hasan-Hanga, 
F., Mohammed, A. S., Kehinde, M. O., Olaniyi, J. A. and Diaku-Akinwumi, I. N. (2013) 
‘Current sickle cell disease management practices in Nigeria’, International health. Oxford 
University Press, 6(1), pp. 23–28. 
Galdas, P. M., Cheater, F. and Marshall, P. (2005) ‘Men and health help‐seeking behaviour: 
302 
 
literature review’, Journal of advanced nursing. Wiley Online Library, 49(6), pp. 616–623. 
Galloway-Blake, K., Reid, M., Walters, C., Jaggon, J. and Lee, M. G. (2014) ‘Clinical 
Factors Associated with Morbidity and Mortality in Patients Admitted with Sickle Cell 
Disease.’, The West Indian medical journal, 63(7), pp. 711–6. doi: 10.7727/wimj.2014.012. 
Galloway, S., Bell, D., Hamilton, C. and Scullion, A. (2006) ‘Quality of life and well-being: 
measuring the benefits of culture and sport. A literature review’, Quality of Life and Well-
being: Measuring the Benefits of Culture and Sport: Literature Review and Thinkpiece, pp. 
4–97. doi: 0 7559 2907 1. 
Gandek, B., Ware, J. E., Aaronson, N. K., Alonso, J., Apolone, G., Bjorner, J., Brazier, J., 
Bullinger, M., Fukuhara, S. and Kaasa, S. (1998) ‘Tests of data quality, scaling assumptions, 
and reliability of the SF-36 in eleven countries: results from the IQOLA Project’, Journal of 
clinical epidemiology. Elsevier, 51(11), pp. 1149–1158. 
Gardner, K., Douiri, A., Drasar, E., Allman, M., Mwirigi, A., Awogbade, M. and Thein, S. 
L. (2016) ‘Letters to Blood To the editor : Survival in adults with sickle cell disease in a 
high-income setting’, 128(10), pp. 3–5. 
Garratt, A. M., Ruta, D. A., Abdalla, M. I., Buckingham, J. K. and Russell, I. T. (1993) ‘The 
SF36 health survey questionnaire: an outcome measure suitable for routine use within the 
NHS?’, Bmj. British Medical Journal Publishing Group, 306(6890), pp. 1440–1444. 
Gaston, M. H., Verter, J. I., Woods, G., Pegelow, C., Kelleher, J., Presbury, G., Zarkowsky, 
H., Vichinsky, E., Iyer, R. and Lobel, J. S. (1986) ‘Prophylaxis with oral penicillin in 
children with sickle cell anemia’, New England Journal of Medicine. Mass Medical Soc, 
314(25), pp. 1593–1599. 
De Geest, S. and Moons, P. (2000) ‘The patient’s appraisal of side-effects: the blind spot in 
quality-of-life assessments in transplant recipients’, Nephrology Dialysis Transplantation. 
Oxford University Press, 15(4), pp. 457–459. 
George, I. O. and Frank-Briggs, A. I. (2011) ‘Stroke in Nigerian children with sickle cell 
anaemia’, Journal of Public health and Epidemiology. Academic Journals, 3(9), pp. 407–
409. 
Gerbing, D. W. and Anderson, J. C. (1985) ‘The effects of sampling error and model 
characteristics on parameter estimation for maximum likelihood confirmatory factor 
analysis’, Multivariate Behavioral Research. Taylor & Francis, 20(3), pp. 255–271. 
Gibson, R. C., Morgan, K. A. D., Abel, W. D., Sewell, C. A., Martin, J. S., Lowe, G. A., 
Haye, W. D. La, Edwards, C. L., O’Garo, K. N. and Reid, M. E. (2013) ‘Locus of control, 
depression and quality of life among persons with sickle cell disease in Jamaica’, 
Psychology, health & medicine. Taylor & Francis, 18(4), pp. 451–460. 
Gill, F. M., Sleeper, L. A., Weiner, S. J., Brown, A. K., Bellevue, R., Grover, R., Pegelow, 
C. H. and Vichinsky, E. (1995) ‘Clinical events in the first decade in a cohort of infants with 
sickle cell disease. Cooperative Study of Sickle Cell Disease [see comments]’, Blood. Am 
Soc Hematology, 86(2), pp. 776–783. 
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, 
B., Coles, W. A., Nichols, J. S. and Ernst, I. (2004) ‘Pulmonary hypertension as a risk factor 
for death in patients with sickle cell disease’, New England Journal of Medicine. Mass 
Medical Soc, 350(9), pp. 886–895. 
Glasser, M. (1964) ‘Linear regression analysis with missing observations among the 
303 
 
independent variables’, Journal of the American Statistical Association. Taylor & Francis, 
59(307), pp. 834–844. 
Goldberg, M. F., Charache, S. and Acacio, I. (1971) ‘Ophthalmologic manifestations of 
sickle cell thalassemia’, Archives of internal medicine. American Medical Association, 
128(1), pp. 33–39. 
Gordon, J. and Fadiman, J. (1984) ‘Toward an Integral Medicine’’, Mind, Body, and Health: 
Toward an Integral Medicine, Human Sciences Press, New York, NY. Google Scholar. 
Gotay, C. C., Kawamoto, C. T., Bottomley, A. and Efficace, F. (2008) ‘The prognostic 
significance of patient-reported outcomes in cancer clinical trials’, Journal of Clinical 
Oncology. American Society of Clinical Oncology, 26(8), pp. 1355–1363. 
Gotay, C. C. and Moore, T. D. (1992) ‘Assessing quality of life in head and neck cancer’, 
Quality of Life Research. Springer, 1(1), pp. 5–17. 
Gough, I. R., Furnival, C. M., Schilder, L. and Grove, W. (1983) ‘Assessment of the quality 
of life of patients with advanced cancer’, European Journal of Cancer and Clinical 
Oncology. Elsevier, 19(8), pp. 1161–1165. 
Grabowski, H. G. and Hansen, R. W. (1990) ‘Economic scales and tests’, Quality of life 
assessments in clinical trials. New York, Raven Press, pp. 61–70. 
Granda, H., Gispert, S., Dorticos, A., Martin, M., Zayas, M. A., Heredero, L., Cuadras, Y., 
Martinez, G., Calvo, M. and Oliva, J. A. (1991) ‘Cuban programme for prevention of sickle 
cell disease’, The Lancet. Elsevier, 337(8734), pp. 152–153. 
Grant, A. M., Parker, C. S., Jordan, L. B., Hulihan, M. M., Creary, M. S., Lloyd-Puryear, M. 
A., Goldsmith, J. C. and Atrash, H. K. (2011) ‘Public health implications of sickle cell trait: 
A report of the CDC meeting’, American Journal of Preventive Medicine. Elsevier Inc., 41(6 
SUPPL.4), pp. S435–S439. doi: 10.1016/j.amepre.2011.09.012. 
Grant, M. M. and Dean, G. E. (2003) ‘in Oncology and Oncology Nursing’, Quality of Life: 
From Nursing and Patient Perspectives: Theory, Research, Practice. Jones & Bartlett 
Publishers, p. 3. 
Grosse, S. D., Schechter, M. S., Kulkarni, R., Lloyd-Puryear, M. A., Strickland, B. and 
Trevathan, E. (2009) ‘Models of comprehensive multidisciplinary care for individuals in the 
United States with genetic disorders’, Pediatrics. Am Acad Pediatrics, 123(1), pp. 407–412. 
groSSe Schlarmann, J., Metzing-Blau, S. and Schnepp, W. (2008) ‘The use of health-related 
quality of life (HRQOL) in children and adolescents as an outcome criterion to evaluate 
family oriented support for young carers in Germany: an integrative review of the literature’, 
BMC Public Health. BioMed Central, 8(1), p. 414. 
Grove, T. B., Tso, I. F., Chun, J., Mueller, S. A., Taylor, S. F., Ellingrod, V. L., McInnis, M. 
G. and Deldin, P. J. (2016) ‘Negative affect predicts social functioning across schizophrenia 
and bipolar disorder: {Findings} from an integrated data analysis’, Psychiatry Research, 
243, pp. 198–206. doi: 10.1016/j.psychres.2016.06.031. 
Gurková, E. (2011) ‘Issues in the definitions of HRQoL’, J Nurs Soc Stud Public Health 
Rehabilit, 3, pp. 190–197. 
Gutteling, J. J., De Man, R. A., Busschbach, J. J. and Darlington, A. S. (2007) ‘Overview of 
research on health-related quality of life in patients with chronic liver disease’, Neth J Med, 
65(7), pp. 227–234. 
304 
 
Haas, B. K. (1999) ‘A multidisciplinary concept analysis of quality of life’, Western journal 
of nursing research. Sage Publications Sage CA: Thousand Oaks, CA, 21(6), pp. 728–742. 
Haase, J. E. and Braden, C. J. (1998) ‘Guidelines for achieving clarity of concepts related to 
quality of life’, Quality of life: From nursing to patient perspectives, theory, research, 
practice, pp. 13–54. 
Halvorsrud, L., Kirkevold, M., Diseth, A. and Kalfoss, M. (2010) ‘Quality of Life Model: 
Predictors of Quality of Life Among Sick Older Adults’, Research and Theory for Nursing 
Practice, 24(4), pp. 241–259. doi: 10.1891/1541-6577.24.4.241. 
Hanel, G., Henningsen, P., Herzog, W., Sauer, N., Schaefert, R., Szecsenyi, J. and Löwe, B. 
(2009) ‘Depression, anxiety, and somatoform disorders: vague or distinct categories in 
primary care? Results from a large cross-sectional study’, Journal of psychosomatic 
research. Elsevier, 67(3), pp. 189–197. 
Hanushek, E. A. and Jackson, J. E. (no date) ‘1977Statistical methods for social scientists’, 
New York: Academic. 
Hardie, R., King, L., Fraser, R. and Reid, M. (2009) ‘Prevalence of pneumococcal 
polysaccharide vaccine administration and incidence of invasive pneumococcal disease in 
children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn 
screening’, Annals of tropical paediatrics. Taylor & Francis, 29(3), pp. 197–202. 
Harris, K. M., Haas, T. S., Eichner, E. R. and Maron, B. J. (2012) ‘Sickle cell trait associated 
with sudden death in competitive athletes’, American Journal of Cardiology. Elsevier Inc., 
110(8), pp. 1185–1188. doi: 10.1016/j.amjcard.2012.06.004. 
Harrison, M. O., Edwards, C. L., Koenig, H. G., Bosworth, H. B., Decastro, L. and Wood, 
M. (2005) ‘Religiosity/spirituality and pain in patients with sickle cell disease’, The Journal 
of nervous and mental disease. LWW, 193(4), pp. 250–257. 
Hasan, S. P., Hashmi, S., Alhassen, M., Lawson, W. and Castro, O. (2003) ‘Depression in 
sickle cell disease.’, Journal of the National Medical Association, 95(7), pp. 533–7. 
Hawthorne, G., Richardson, J. and Day, N. A. (2001) ‘A comparison of the Assessment of 
Quality of Life (AQoL) with four other generic utility instruments’, Annals of medicine. 
Taylor & Francis, 33(5), pp. 358–370. 
Hays, R. D., Reeve, B. B., Smith, A. W. and Clauser, S. B. (2014) ‘Associations of cancer 
and other chronic medical conditions with SF-6D preference-based scores in Medicare 
beneficiaries’, Quality of Life Research. Springer, 23(2), pp. 385–391. 
Haywood, C., Lanzkron, S., Ratanawongsa, N., Bediako, S. M., Lattimer‐Nelson, L. and 
Beach, M. C. (2010) ‘Hospital self‐discharge among adults with sickle‐cell disease (SCD): 
Associations with trust and interpersonal experiences with care’, Journal of hospital 
medicine. Wiley Online Library, 5(5), pp. 289–294. 
Haywood Jr, C. (2013) ‘Disrespectful care in the treatment of sickle cell disease requires 
more than ethics consultation’, The American Journal of Bioethics. Taylor & Francis, 13(4), 
pp. 12–14. 
Health, N. I. of (2002) ‘The management of sickle cell disease’, NIH publication, 2117. 
Heeney, M. M. and Ware, R. E. (2010) ‘Hydroxyurea for children with sickle cell disease’, 
Hematology/oncology clinics of North America. Elsevier, 24(1), pp. 199–214. 
Heliövaara, M., Aromaa, A., Klaukka, T., Knekt, P., Joukamaa, M. and Impivaara, O. (1993) 
305 
 
‘Reliability and validity of interview data on chronic diseases The mini-Finland health 
survey’, Journal of clinical epidemiology. Elsevier, 46(2), pp. 181–191. 
Hemingway, H., Nicholson, A., Stafford, M., Roberts, R. and Marmot, M. (1997) ‘The 
impact of socioeconomic status on health functioning as assessed by the SF-36 
questionnaire: the Whitehall II Study.’, American Journal of Public Health. American Public 
Health Association, 87(9), pp. 1484–1490. 
Henkel, V., Mergl, R., Kohnen, R., Allgaier, A.-K., Möller, H.-J. and Hegerl, U. (2004) ‘Use 
of brief depression screening tools in primary care: consideration of heterogeneity in 
performance in different patient groups’, General hospital psychiatry, 26(3), pp. 190–198. 
Heo, S., Moser, D. K., Riegel, B., Hall, L. A. and Christman, N. (2005) ‘Clinical 
Investigation: Testing a Published Model of Health-Related Quality of Life in Heart Failure’, 
Journal of Cardiac Failure, 11, pp. 372–379. doi: 10.1016/j.cardfail.2004.12.001. 
Hernigou, P., Galacteros, F., Bachir, D. and Goutallier, D. (1991) ‘Deformities of the hip in 
adults who have sickle-cell disease and had avascular necrosis in childhood. A natural 
history of fifty-two patients.’, The Journal of bone and joint surgery. American volume, 
73(1), pp. 81–92. 
Hershberger, S. L. (2003) ‘The growth of structural equation modeling: 1994-2001’, 
Structural Equation Modeling. Taylor & Francis, 10(1), pp. 35–46. 
Hijmans, C. T., Fijnvandraat, K., Oosterlaan, J., Heijboer, H., Peters, M. and Grootenhuis, 
M. A. (2010) ‘Double disadvantage: {A} case control study on health-related quality of life 
in children with sickle cell disease’, Health and Quality of Life Outcomes, 8(1), p. 121. doi: 
10.1186/1477-7525-8-121. 
Hilton, C., Osborn, M., Knight, S., Singhal, A. and Serjeant, G. (1997) ‘Psychiatric 
complications of homozygous sickle cell disease among young adults in the Jamaican Cohort 
Study’, The British Journal of Psychiatry. Cambridge University Press, 170(1), pp. 69–76. 
Hofer, S., Benzer, W., Alber, H., Ruttmann, E., Kopp, M., Sch Ssler, G. and Doering, S. 
(2005) ‘Determinants of Health-Related Quality of Life in Coronary Artery Disease Patients: 
A Prospective Study Generating a Structural Equation Model’, Psychosomatics, 46(46), pp. 
212–223. doi: 10.1176/appi.psy.46.3.212. 
Höfer, S., Benzer, W., Alber, H., Ruttmann, E., Kopp, M., Schussler, G. and Doering, S. 
(2005) ‘Determinants of {Health}-{Related} {Quality} of {Life} in {Coronary} {Artery} 
{Disease} {Patients}: {A} {Prospective} {Study} {Generating} a {Structural} {Equation} 
{Model}’, Psychosomatics, 46, pp. 212–223. doi: 10.1176/appi.psy.46.3.212. 
Holmbeck, G. N. (1997) ‘Toward terminological, conceptual, and statistical clarity in the 
study of mediators and moderators: examples from the child-clinical and pediatric 
psychology literatures.’, Journal of consulting and clinical psychology. American 
Psychological Association, 65(4), p. 599. 
Holmes, C. A. (1989) ‘Health care and the quality of life: a review’, Journal of advanced 
nursing. Wiley Online Library, 14(10), pp. 833–839. 
Hoyle, R. H. and Kenny, D. A. (1999) ‘Statistical power and tests of mediation’, Statistical 
strategies for small sample research, pp. 195–222. 
Hoyman, H. S. (1962) ‘Our modern concept of health’, Journal of School Health. Wiley 
Online Library, 32(7), pp. 253–264. 
Hu, L. and Bentler, P. M. (1998) ‘Fit indices in covariance structure modeling: Sensitivity 
306 
 
to underparameterized model misspecification.’, Psychological methods. American 
Psychological Association, 3(4), p. 424. 
Huber, M., Knottnerus, J. A., Green, L., van der Horst, H., Jadad, A. R., Kromhout, D., 
Leonard, B., Lorig, K., Loureiro, M. I. and van der Meer, J. W. M. (2011) ‘How should we 
define health?’, BMJ: British Medical Journal (Online). BMJ Publishing Group LTD, 343. 
Iacobucci, D. (2010) ‘Structural equations modeling: Fit indices, sample size, and advanced 
topics’, Sample Size, and Advanced Topics. 
Idler, E. L. and Kasl, S. (1991) ‘Health perceptions and survival: Do global evaluations of 
health status really predict mortality?’, Journal of gerontology. The Gerontological Society 
of America, 46(2), pp. S55–S65. 
Ilesanmi, O. O. (2013) ‘Gender differences in sickle cell crises: implications for genetic 
counselling and psychotherapy’, J Psychol Psychother, 3(10.4172), pp. 487–2161. 
Illich, I. (1976) ‘Medical nemesis: The expropriation of health’. New York: Pantheon. 
Inati, A. (2009) ‘Recent advances in improving the management of sickle cell disease’, 
Blood reviews. Elsevier, 23, pp. S9–S13. 
Isgro, A., Paciaroni, K., Gaziev, J., Sodani, P., Gallucci, C., Marziali, M., De Angelis, G., 
Alfieri, C., Ribersani, M. and Roveda, A. (2015) ‘Haematopoietic stem cell transplantation 
in Nigerian sickle cell anaemia children patients’, Nigerian medical journal: journal of the 
Nigeria Medical Association. Medknow Publications, 56(3), p. 175. 
Ivo, M. L. and Pinto, A. M. A. C. (2013) ‘Dynamics of sickle cell disease as one of the 
determinants of quality of life.’, Revista brasileira de hematologia e hemoterapia, 35(4), pp. 
227–8. doi: 10.5581/1516-8484.20130066. 
Jackson, D. L. (2003) ‘Revisiting sample size and number of parameter estimates: Some 
support for the N: q hypothesis’, Structural equation modeling, 10(1), pp. 128–141. 
Jadad, A. R. and O’Grady, L. (2008) ‘How should health be defined?’, BMJ: British Medical 
Journal (Online). BMJ Publishing Group LTD, 337. 
Jenerette, C., Funk, M. and Murdaugh, C. (2005) ‘Sickle cell disease: a stigmatizing 
condition that may lead to depression’, Issues in Mental Health Nursing. Taylor & Francis, 
26(10), pp. 1081–1101. 
Jenerette, C. M. (2008) ‘Relationships among types of social support and QOL in adults with 
sickle cell disease’, Southern Online Journal of Nursing Research, 8(3), pp. 1–14. 
Jenerette, C. M. and Brewer, C. (2010) ‘Health-related stigma in young adults with sickle 
cell disease’, Journal of the National Medical Association. NIH Public Access, 102(11), p. 
1050. 
Jenerette, C. M., Leak, A. N. and Sandelowski, M. (2011) ‘Life stories of older adults with 
sickle cell disease.’, The ABNF journal : official journal of the Association of Black Nursing 
Faculty in Higher Education, Inc, 22(3), pp. 58–63. 
Jenkinson, C. (1995) ‘Evaluating the efficacy of medical treatment: possibilities and 
limitations’, Social science & medicine. Elsevier, 41(10), pp. 1395–1401. 
Jenkinson, C., Coulter, A. and Wright, L. (1993) ‘Short form 36 (SF36) health survey 
questionnaire: normative data for adults of working age.’, Bmj. British Medical Journal 
Publishing Group, 306(6890), pp. 1437–1440. 
307 
 
Jenkinson, C., Peto, V., Fitzpatrick, R., Greenhall, R. and Hyman, N. (1995) ‘Self-reported 
functioning and well-being in patients with Parkinson’s disease: comparison of the short-
form health survey (SF-36) and the Parkinson’s Disease Questionnaire (PDQ-39)’, Age and 
ageing. Oxford University Press, 24(6), pp. 505–509. 
Jewkes, R. and Morrell, R. (2010) ‘Gender and sexuality: emerging perspectives from the 
heterosexual epidemic in South Africa and implications for HIV risk and prevention’, 
Journal of the International AIDS society. BioMed Central, 13(1), p. 6. 
Jones, M. P. (1996) ‘Indicator and stratification methods for missing explanatory variables 
in multiple linear regression’, Journal of the American statistical association. Taylor & 
Francis, 91(433), pp. 222–230. 
Jöreskog, K. G. (1978) ‘Structural analysis of covariance and correlation matrices’, 
Psychometrika. Springer, 43(4), pp. 443–477. 
Jöreskog, K. G. and Sörbom, D. (1984) ‘LISREL-VI user’s guide’. Mooresville, IN: 
scientific software. 
Juwah, A. I., Nlemadim, A. and Kaine, W. (2003) ‘Clinical presentation of severe anemia in 
pediatric patients with sickle cell anemia seen in Enugu, Nigeria’, American Journal of 
Hematology, 72(3), pp. 185–191. doi: 10.1002/ajh.10285. 
Kalnins, I. and Love, R. (1982) ‘Children’s concepts of health and illness—and implications 
for health education: An overview’, Health education quarterly. Sage Publications Sage CA: 
Thousand Oaks, CA, 9(2–3), pp. 8–12. 
Kanter, J. and Kruse-Jarres, R. (2013) ‘Management of sickle cell disease from childhood 
through adulthood’, Blood reviews. Elsevier, 27(6), pp. 279–287. 
Kanters, T. A., Redekop, W. K., Rutten-Van Mölken, M. P. M. H., Kruijshaar, M. E., 
Güngör, D., Van der Ploeg, A. T. and Hakkaart, L. (2015) ‘A conceptual disease model for 
adult Pompe disease’, Orphanet journal of rare diseases. BioMed Central, 10(1), p. 112. 
Kanters, T. A., Redekop, W. K., Rutten-Van Mölken, M. P. M. H., Kruijshaar, M. E., 
Güngör, D., Van Der Ploeg, A. T. and Hakkaart, L. (2012) ‘Evidence for decline in the 
incidence of cystic fibrosis: a 35-year observational study in Brittany, France’. doi: 
10.1186/s13023-015-0334-6. 
Kanungo, S., Tsuzuki, A., Deen, J. L., Lopez, A. L., Rajendran, K., Manna, B., Sur, D., Kim, 
D. R., Gupta, V. K. and Ochiai, R. L. (2010) ‘Use of verbal autopsy to determine mortality 
patterns in an urban slum in Kolkata, India’, Bulletin of the World Health Organization. 
SciELO Public Health, 88(9), pp. 667–674. 
Katon, W., Lin, E. H. B. and Kroenke, K. (2007) ‘The association of depression and anxiety 
with medical symptom burden in patients with chronic medical illness’, General hospital 
psychiatry. Elsevier, 29(2), pp. 147–155. 
Kauf, T. L., Coates, T. D., Huazhi, L., Mody‐Patel, N. and Hartzema, A. G. (2009) ‘The cost 
of health care for children and adults with sickle cell disease’, American journal of 
hematology. Wiley Online Library, 84(6), pp. 323–327. 
Kazarian, S. S. and Evans, D. R. (2001) Handbook of cultural health psychology. Elsevier. 
Keller, S. D., Yang, M., Treadwell, M. J., Werner, E. M. and Hassell, K. L. (2014) ‘Patient 
reports of health outcome for adults living with sickle cell disease: Development and testing 
of the ASCQ-Me item banks’, Health and Quality of Life Outcomes, 12(1), pp. 1–11. doi: 
10.1186/s12955-014-0125-0. 
308 
 
Kellner, R. (1985) ‘Functional somatic symptoms and hypochondriasis: a survey of 
empirical studies’, Archives of general Psychiatry. American Medical Association, 42(8), 
pp. 821–833. 
Kempen, G. I. J. M., Jelicic, M. and Ormel, J. (1997) ‘Personality, chronic medical 
morbidity, and health-related quality of life among older persons.’, Health Psychology, 
16(6), p. 539. 
Kendrick, T., Dowrick, C., McBride, A., Howe, A., Clarke, P., Maisey, S., Moore, M. and 
Smith, P. W. (2009) ‘Management of depression in UK general practice in relation to scores 
on depression severity questionnaires: analysis of medical record data’, Bmj. British Medical 
Journal Publishing Group, 338, p. b750. 
Khan, I. H. (1998) ‘Comorbidity: the major challenge for survival and quality of life in end-
stage renal disease.’, Nephrology, dialysis, transplantation: official publication of the 
European Dialysis and Transplant Association-European Renal Association, 13(suppl_1), 
pp. 76–79. 
Khanna, D., Furst, D. E., Wong, W. K., Tsevat, J., Clements, P. J., Park, G. S., Postlethwaite, 
A. E., Ahmed, M., Ginsburg, S. and Hays, R. D. (2007) ‘Reliability, validity, and minimally 
important differences of the SF-6D in systemic sclerosis’, Quality of Life Research. Springer, 
16(6), pp. 1083–1092. 
Kharroubi, S. A., Brazier, J. E., Roberts, J. and O’Hagan, A. (2007) ‘Modelling SF-6D health 
state preference data using a nonparametric Bayesian method’, Journal of health economics. 
Elsevier, 26(3), pp. 597–612. 
Klapow, J., Kroenke, K., Horton, T., Schmidt, S., Spitzer, R. and Williams, J. B. W. (2002) 
‘Psychological disorders and distress in older primary care patients: a comparison of older 
and younger samples’, Psychosomatic Medicine. LWW, 64(4), pp. 635–643. 
Kline, R. B. (2011) Principles and practice of structural equation modeling, Structural 
Equation Modeling. doi: 10.1038/156278a0. 
Knight-Madden, J. M., Forrester, T. S., Lewis, N. A. and Greenough, A. (2005) ‘Asthma in 
children with sickle cell disease and its association with acute chest syndrome’, Thorax. BMJ 
Publishing Group Ltd, 60(3), pp. 206–210. 
Kocalevent, R.-D., Hinz, A. and Brähler, E. (2013) ‘Standardization of a screening 
instrument (PHQ-15) for somatization syndromes in the general population’, BMC 
psychiatry. BioMed Central, 13(1), p. 91. 
Konotey-Ahulu, F. I. D. (1991) ‘The sickle cell disease patient.’, The sickle cell disease 
patient. Macmillan Education Ltd. 
Kotila, T. R. and Shokunbi, W. A. (2001) ‘Survival advantage in female patients with sickle 
cell anaemia’, East African medical journal. Kenya Medical Association, 78(7), pp. 373–
375. 
Krethong, P., Jirapaet, V., Jitpanya, C. and Sloan, R. (2008) ‘A causal model of health-
related quality of life in Thai patients with heart-failure’, Journal of Nursing Scholarship, 
40(3), pp. 254–260. doi: 10.1111/j.1547-5069.2008.00235.x. 
Kriegsman, D. M. W., Penninx, B. W. J. H., Van Eijk, J. T. M., Boeke, A. J. P. and Deeg, 
D. J. H. (1996) ‘Self-reports and general practitioner information on the presence of chronic 
diseases in community dwelling elderly: a study on the accuracy of patients’ self-reports and 
on determinants of inaccuracy’, Journal of clinical epidemiology, 49(12), pp. 1407–1417. 
309 
 
Kring, D. L. and Crane, P. B. (2009) ‘Factors affecting quality of life in persons on 
hemodialysis’, Nephrology Nursing Journal. Jannetti Publications, Inc., 36(1), pp. 15–27. 
Kroenke, K. (2006) ‘Physical symptom disorder: a simpler diagnostic category for 
somatization-spectrum conditions’, Journal of psychosomatic research. Elsevier, 60(4), pp. 
335–339. 
Kroenke, K. (2007) ‘Somatoform disorders and recent diagnostic controversies’, Psychiatric 
Clinics of North America. Elsevier, 30(4), pp. 593–619. 
Kroenke, K. and Spitzer, R. L. (2002) ‘The PHQ-9: a new depression diagnostic and severity 
measure’, Psychiatric annals. SLACK Incorporated, 32(9), pp. 509–515. 
Kroenke, K., Spitzer, R. L. and Swindle, R. (1998) ‘A symptom checklist to screen for 
somatoform disorders in primary care’, Psychosomatics. Elsevier, 39(3), pp. 263–272. 
Kroenke, K., Spitzer, R. L. and Williams, J. B. W. (2001) ‘The PHQ-9: Validity of a brief 
depression severity measure’, Journal of General Internal Medicine, 16(9), pp. 606–613. 
doi: 10.1046/j.1525-1497.2001.016009606.x. 
Kroenke, K., Spitzer, R. L. and Williams, J. B. W. (2002) ‘The PHQ-15: validity of a new 
measure for evaluating the severity of somatic symptoms’, Psychosomatic medicine. LWW, 
64(2), pp. 258–266. 
Kroenke, K., Spitzer, R. L., Williams, J. B. W. and Löwe, B. (2010) ‘The Patient Health 
Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: A systematic review’, 
General Hospital Psychiatry. Elsevier B.V., 32(4), pp. 345–359. doi: 
10.1016/j.genhosppsych.2010.03.006. 
Kumar, S., Kroon, J. and Lalloo, R. (2014) ‘A systematic review of the impact of parental 
socio-economic status and home environment characteristics on children’s oral health 
related quality of life’, Health and Quality of Life Outcomes, 12, pp. 1–15. doi: 
10.1186/1477-7525-12-41. 
Ladizinski, B., Bazakas, A., Mistry, N., Alavi, A., Sibbald, R. G. and Salcido, R. (2012) 
‘Sickle cell disease and leg ulcers’, Advances in skin & wound care. LWW, 25(9), pp. 420–
428. 
Laffrey, S. C. (1986) ‘Development of a health conception scale’, Research in Nursing & 
Health. Wiley Online Library, 9(2), pp. 107–113. 
Lagunju, I. A., Brown, B. J. and Sodeinde, O. O. (2013) ‘Chronic blood transfusion for 
primary and secondary stroke prevention in Nigerian children with sickle cell disease: A 5‐
year appraisal’, Pediatric blood & cancer. Wiley Online Library, 60(12), pp. 1940–1945. 
Lanzkron, S., Carroll, C. P. and Haywood Jr, C. (2013) ‘Mortality rates and age at death 
from sickle cell disease: US, 1979–2005’, Public health reports. SAGE Publications Sage 
CA: Los Angeles, CA, 128(2), pp. 110–116. 
Lanzkron, S., Haywood, C., Segal, J. B. and Dover, G. J. (2006) ‘Hospitalization rates and 
costs of care of patients with sickle‐cell anemia in the state of Maryland in the era of 
hydroxyurea’, American journal of hematology. Wiley Online Library, 81(12), pp. 927–932. 
Larson, J. S. (1999) ‘The conceptualization of health’, Medical Care Research and Review. 
Sage Publications Sage CA: Thousand Oaks, CA, 56(2), pp. 123–136. 
Lazarus, R. S. and Folkman, S. (1984) ‘Stress, coping and appraisal’. New York: Springer. 
Lee, D. and Larracoechea, U. A. (2015) ‘Statistical modelling of Health Related Quality of 
310 
 
Life measures for Colorectal Cancer with beta-binomial and quantile regression approaches 
.’, 3, pp. 23–25. 
Lee, M. T., Piomelli, S., Granger, S., Miller, S. T., Harkness, S., Brambilla, D. J. and Adams, 
R. J. (2006) ‘Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and 
final results’, Blood. Am Soc Hematology, 108(3), pp. 847–852. 
Levant, R. F., Majors, R. G. and Kelley, M. L. (1998) ‘Masculinity ideology among young 
African American and European American women and men in different regions of the 
United States.’, Cultural diversity and mental health. Educational Publishing Foundation, 
4(3), p. 227. 
Levant, R. F., Richmond, K., Majors, R. G., Inclan, J. E., Rossello, J. M., Heesacker, M., 
Rowan, G. T. and Sellers, A. (2003) ‘A multicultural investigation of masculinity ideology 
and alexithymia.’, Psychology of Men & Masculinity. Educational Publishing Foundation, 
4(2), p. 91. 
Levenson, J. L., McClish, D. K., Dahman, B. a, Bovbjerg, V. E., de A Citero, V., Penberthy, 
L. T., Aisiku, I. P., Roberts, J. D., Roseff, S. D. and Smith, W. R. (2008) ‘Depression and 
anxiety in adults with sickle cell disease: the PiSCES project.’, Psychosomatic medicine, 
70(2), pp. 192–6. doi: 10.1097/PSY.0b013e31815ff5c5. 
Lewis, A. (1953) ‘Health as a social concept’, The British Journal of Sociology. JSTOR, 
4(2), pp. 109–124. 
Lins, L. and Carvalho, F. M. (2016) ‘SF-36 total score as a single measure of health-related 
quality of life: Scoping review’, SAGE open medicine. SAGE Publications Sage UK: 
London, England, 4, p. 2050312116671725. 
van Litsenburg Raphaële R L, Huisman, J., Raat, H., Kaspers, G. J. L. and Gemke, R. J. B. 
J. (2013) ‘Health-related quality of life and utility scores in short-term survivors of pediatric 
acute lymphoblastic leukemia’, Quality of Life Research. Springer, 22(3), pp. 677–681. 
Little, R. and Rubin, D. B. (1987) ‘Statistical analysis with missing data’. New York: John 
Wiley & Sons. 
Liu, B.-C. (1976) Quality of life indicators in US metropolitan areas. Praeger. 
Lobo, F. S., Gross, C. R. and Matthees, B. J. (2004) ‘Estimation and comparison of derived 
preference scores from the SF-36 in lung transplant patients’, Quality of Life Research. 
Springer, 13(2), pp. 377–388. 
Lorenz, K. A., Cunningham, W. E., Spritzer, K. L. and Hays, R. D. (2006) ‘Changes in 
symptoms and health-related quality of life in a nationally representative sample of adults in 
treatment for HIV’, Quality of Life Research. Springer, 15(6), pp. 951–958. 
Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W. and Herzberg, P. 
Y. (2008) ‘Validation and standardization of the Generalized Anxiety Disorder Screener 
(GAD-7) in the general population’, Medical care. LWW, 46(3), pp. 266–274. 
Löwe, B., Kroenke, K., Herzog, W. and Gräfe, K. (2004) ‘Measuring depression outcome 
with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire 
(PHQ-9)’, Journal of affective disorders. Elsevier, 81(1), pp. 61–66. 
Lubetkin, E. I., Jia, H., Franks, P. and Gold, M. R. (2005) ‘Relationship among 
sociodemographic factors, clinical conditions, and health-related quality of life: examining 
the EQ-5D in the US general population’, Quality of Life Research. Springer, 14(10), pp. 
2187–2196. 
311 
 
Lucchesi, F., Figueiredo, M. S., Mastandrea, E. B., Levenson, J. L., Smith, W. R., Jacinto, 
A. F. and Citero, V. de A. (2016) ‘Physicians’ Perception of Sickle-cell Disease Pain’, 
Journal of the National Medical Association. Elsevier Inc, 108(2), pp. 113–118. doi: 
10.1016/j.jnma.2016.04.004. 
Lutz, M. J., Barakat, L. P., Smith-Whitley, K. and Ohene-Frempong, K. (2004) 
‘Psychological adjustment of children with sickle cell disease: Family functioning and 
coping’, Rehabilitation Psychology, 49(3), pp. 224–232. 
Maccallum, R. C., Browne, M. W. and Sugawara, H. M. (1996) ‘Power analysis and 
determination of sample size for covariance structure modeling of fit involving a particular 
measure of model’, Psychological Methods, 13(2), pp. 130–149. doi: 10.1037/1082-
989X.1.2.130. 
MacCallum, R. C., Widaman, K. F., Zhang, S. and Hong, S. (1999) ‘Sample size in factor 
analysis.’, Psychological methods, 4(1), p. 84. 
Macduff, C. (2000) ‘Respondent‐generated quality of life measures: useful tools for nursing 
or more fool’s gold?’, Journal of Advanced Nursing. Wiley Online Library, 32(2), pp. 375–
382. 
Macintyre, S., Ford, G. and Hunt, K. (1999) ‘Do womenover-report’morbidity? Men’s and 
women’s responses to structured prompting on a standard question on long standing illness’, 
Social science & medicine. Elsevier, 48(1), pp. 89–98. 
MacKinnon, D. P., Lockwood, C. M., Hoffman, J. M., West, S. G. and Sheets, V. (2002) ‘A 
comparison of methods to test mediation and other intervening variable effects.’, 
Psychological methods. American Psychological Association, 7(1), p. 83. 
Maddigan, S. L., Feeny, D. H. and Johnson, J. A. (2005) ‘Health-related quality of life 
deficits associated with diabetes and comorbidities in a Canadian National Population Health 
Survey’, Quality of Life Research. Springer, 14(5), pp. 1311–1320. 
Makani, J., Cox, S. E., Soka, D., Komba, A. N., Oruo, J., Mwamtemi, H., Magesa, P., 
Rwezaula, S., Meda, E. and Mgaya, J. (2011) ‘Mortality in sickle cell anemia in Africa: a 
prospective cohort study in Tanzania’, PloS one. Public Library of Science, 6(2), p. e14699. 
Malouf Jr, A. J., Hamrick-Turner, J. E., Doherty, M. C., Dhillon, G. S., Iyer, R. V and Smith, 
M. G. (2001) ‘Implementation of the STOP protocol for stroke prevention in sickle cell 
anemia by using duplex power Doppler imaging’, Radiology. Radiological Society of North 
America, 219(2), pp. 359–365. 
Mann‐Jiles, V. and Morris, D. L. (2009) ‘Quality of life of adult patients with sickle cell 
disease’, Journal of the American Association of Nurse Practitioners. Wiley Online Library, 
21(6), pp. 340–349. 
Mardia, K. V (1970) ‘Measures of multivariate skewness and kurtosis with applications’, 
Biometrika. Oxford University Press, 57(3), pp. 519–530. 
Marini, M. M., Olsen, A. R. and Rubin, D. B. (1980) ‘Maximum-likelihood estimation in 
panel studies with missing data’, Sociological methodology. JSTOR, 11, pp. 314–357. 
Marks, D. F., Murray, M., Evans, B., Willig, C., Sykes, C. M. and Woodall, C. (2005) Health 
psychology: Theory, research and practice. Sage. 
Marks James, S. (2003) ‘Commentary: Were living longer, but What about our Quality of 
Life’, Chronic Disease, Notes & Reports, Centers for Disease Control and Prevention, 
16(1), p. 2. 
312 
 
Marsh, H. W. and Hau, K.-T. (1999) ‘Confirmatory factor analysis: Strategies for small 
sample sizes’, Statistical strategies for small sample research, 1, pp. 251–284. 
Mastandréa, É. B., Lucchesi, F., Kitayama, M. M. G., Figueiredo, M. S. and Citero, V. de 
A. (2015) ‘The relationship between genotype, psychiatric symptoms and quality of life in 
adult patients with sickle cell disease in São Paulo, Brazil: a cross-sectional study.’, Sao 
Paulo medical journal = Revista paulista de medicina, 133(AHEAD), p. 00. doi: 
10.1590/1516-3180.2015.00171105. 
Mathisen, L., Andersen, M. H., Veenstra, M., Wahl, A. K., Hanestad, B. R. and Fosse, E. 
(2007) ‘Quality of life can both influence and be an outcome of general health perceptions 
after heart surgery.’, Health and quality of life outcomes, 5, p. 27. doi: 10.1186/1477-7525-
5-27. 
Maxwell, K., Streetly,  a and Bevan, D. (1999) ‘Experiences of hospital care and treatment-
seeking behavior for pain from sickle cell disease: qualitative study.’, British Medical 
Journal, 318(7198), pp. 1585–1590. 
Mayo, N. E., Scott, S. C., Bayley, M., Cheung, A., Garland, J., Jutai, J. and Wood-
Dauphinee, S. (2015) ‘Modeling health-related quality of life in people recovering from 
stroke’, Quality of Life Research, 24(1), pp. 41–53. doi: 10.1007/s11136-013-0605-4. 
Mbada, C., Adeogun, G., Ogunlana, M., Adedoyin, R., Akinsulore, A., Awotidebe, T. and 
Idowu, O. (2015) ‘Translation, cross-cultural adaptation and psychometric evaluation of 
yoruba version of the short-form 36 health survey’, Health and Quality of Life Outcomes. 
Health and Quality of Life Outcomes, 13(1), p. no pagination. doi: 10.1186/s12955-015-
0337-y. 
McAuley, C. F., Webb, C., Makani, J., Macharia, A., Uyoga, S., Opi, D. H., Ndila, C., 
Ngatia, A., Scott, J. A. G. and Marsh, K. (2010) ‘High mortality from P. falciparum malaria 
in children living with sickle cell anemia on the coast of Kenya’, Blood. Am Soc 
Hematology, p. blood-2010. 
McClish, D. K., Levenson, J. L., Penberthy, L. T., Roseff, S. D., Bovbjerg, V. E., Roberts, 
J. D., Aisiku, I. P. and Smith, W. R. (2006) ‘Gender differences in pain and healthcare 
utilization for adult sickle cell patients: The PiSCES Project’, Journal of women’s health. 
Mary Ann Liebert, Inc. 2 Madison Avenue Larchmont, NY 10538 USA, 15(2), pp. 146–154. 
McClish, D. K., Penberthy, L. T., Bovbjerg, V. E., Roberts, J. D., Aisiku, I. P., Levenson, J. 
L., Roseff, S. D. and Smith, W. R. (2005) ‘2005. {Health} related quality of life in sickle 
cell patients: the {PiSCES} project.’, Health and Quality of Life Outcomes, 3(1), p. 50. doi: 
10.1186/1477-7525-3-50. 
McClish, D. K., Penberthy, L. T., Bovbjerg, V. E., Roberts, J. D., Aisiku, I. P., Levenson, J. 
L., Roseff, S. D., Smith, W. R., Lucchesi, F., Figueiredo, M. S., Mastandrea, E. B., 
Levenson, J. L., Smith, W. R., Jacinto, A. F., Citero, V. de A., Ola, B. A., Yates, S. J., Dyson, 
S. M., Treadwell, M. J., Barreda, F., Kaur, K., Gildengorin, G. and Farmer, P. (2016) ‘2005. 
Health related quality of life in sickle cell patients: the PiSCES project.’, Health and Quality 
of Life Outcomes. Elsevier Inc, 3(1), p. 50. doi: 10.1186/1477-7525-3-50. 
McClish, D. K., Smith, W. R., Dahman, B. A., Levenson, J. L., Roberts, J. D., Penberthy, L. 
T., Aisiku, I. P., Roseff, S. D. and Bovbjerg, V. E. (2009) ‘Pain site frequency and location 
in sickle cell disease: the PiSCES project’, PAIN®, 145(1), pp. 246–251. 
McClish, D. K., Smith, W. R., Levenson, J. L., Aisiku, I. P., Roberts, J. D., Roseff, S. D. and 
Bovbjerg, V. E. (2017) ‘Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older 
313 
 
versus Younger Sickle Cell Adults: The PiSCES Project’, BioMed research international. 
Hindawi Publishing Corporation, 2017. 
McDonald, R. P. and Ho, M.-H. R. (2002) ‘Principles and practice in reporting structural 
equation analyses.’, Psychological methods. American Psychological Association, 7(1), p. 
64. 
McDowell, I. and Newell, C. (1987) ‘Pain measurements’, Measuring health. A guide to 
rating scales and questionnaires, 2, pp. 335–346. 
McHorney, C. A., Ware Jr, J. E. and Raczek, A. E. (1993) ‘The MOS 36-Item Short-Form 
Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical 
and mental health constructs’, Medical care. JSTOR, pp. 247–263. 
McLachlan, G. J. and Krishnan, T. (no date) ‘The EM algorithm and extensions. 1997’, 
Hoboken: Wiley and Sons Google Scholar. 
Mechanic, D. (1977) ‘Illness behavior, social adaptation, and the management of illness: A 
comparison of educational and medical models.’, Journal of Nervous and Mental disease. 
Lippincott Williams & Wilkins. 
Mechanic, D. (1995) ‘Sociological dimensions of illness behavior’, Social science & 
medicine. Elsevier, 41(9), pp. 1207–1216. 
Mendel, G. (1965) Experiments in plant hybridisation. Harvard University Press. 
Mendel, G., Stern, C. and Sherwood, E. (1966) ‘The origin of genetics’. WH Freeman. 
Menendez, C., Fleming, A. F. and Alonso, P. L. (2000) ‘Malaria-related anaemia’, 
Parasitology today. Elsevier, 16(11), pp. 469–476. 
Menezes, A. S. de O. da P., Len, C. A., Hilário, M. O. E., Terreri, M. T. R. A. and Braga, J. 
A. P. (2013) ‘Qualidade de vida em portadores de doença falciforme’, Revista Paulista de 
Pediatria, 31(1), pp. 24–29. doi: 10.1590/s0103-05822013000100005. 
Mewes, R., Rief, W., Brähler, E., Martin, A. and Glaesmer, H. (2008) ‘Lower decision 
threshold for doctor visits as a predictor of health care use in somatoform disorders and in 
the general population’, General hospital psychiatry. Elsevier, 30(4), pp. 349–355. 
Milette, K., Hudson, M., Baron, M., Thombs, B. D. and Group*, C. S. R. (2010) 
‘Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: internal 
consistency reliability, convergent validity and clinical correlates’, Rheumatology. Oxford 
University Press, 49(4), pp. 789–796. 
Miller, D. R., Rogers, W. H., Kazis, L. E., Spiro III, A., Ren, X. S. and Haffer, S. C. (2008) 
‘patients’ Self‐report of Diseases in the Medicare Health Outcomes Survey Based on 
Comparisons With Linked Survey and Medical Data From the Veterans Health 
Administration’, The Journal of ambulatory care management. LWW, 31(2), pp. 161–177. 
Minniti, C. P., Eckman, J., Sebastiani, P., Steinberg, M. H. and Ballas, S. K. (2010) ‘Leg 
ulcers in sickle cell disease’, American Journal of Hematology, 85(10), pp. 831–833. doi: 
10.1002/ajh.21838. 
Modell, B. and Darlison, M. (2008) ‘Global epidemiology of haemoglobin disorders and 
derived service indicators’, Bulletin of the World Health Organization. SciELO Public 
Health, 86(6), pp. 480–487. 
Modell, B., Darlison, M., Birgens, H., Cario, H., Faustino, P., Giordano, P. C., Gulbis, B., 
Hopmeier, P., Lena‐Russo, D. and Romao, L. (2007) ‘Epidemiology of haemoglobin 
314 
 
disorders in Europe: an overview’, Scandinavian journal of clinical and laboratory 
investigation. Taylor & Francis, 67(1), pp. 39–70. 
Moher, D., Liberati, A., Tetzlaff, J. and Altman, D. G. (2009) ‘Preferred reporting items for 
systematic reviews and meta-analyses: {The} {PRISMA} statement’, BMJ, 339(jul21 1), 
pp. b2535--b2535. doi: 10.1136/bmj.b2535. 
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. and Grp, P. (2009) ‘Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (Reprinted from 
Annals of Internal Medicine)’, Physical Therapy, 89(9), pp. 873–880. doi: 
10.1371/journal.pmed.1000097. 
Moi, A. L. and Nilsen, R. M. (2012) ‘Pathways leading to self-perceived general health and 
overall quality of life in burned adults’, Burns. Elsevier Ltd and International Society of 
Burns Injuries, 38(8), pp. 1157–1164. doi: 10.1016/j.burns.2012.05.004. 
Molock, S. D. and Belgrave, F. Z. (1994) ‘Depression and anxiety in patients with sickle cell 
disease: conceptual and methodological considerations’, Journal of health & social policy. 
Taylor & Francis, 5(3–4), pp. 39–53. 
Monahan, P. O., Shacham, E., Reece, M., Kroenke, K., Ong’or, W. O., Omollo, O., Yebei, 
V. N. and Ojwang, C. (2009) ‘Validity/reliability of PHQ-9 and PHQ-2 depression scales 
among adults living with HIV/AIDS in western Kenya’, Journal of General Internal 
Medicine. Springer, 24(2), p. 189. 
Moons, P., Budts, W. and De Geest, S. (2006) ‘Critique on the conceptualisation of quality 
of life: a review and evaluation of different conceptual approaches’, International journal of 
nursing studies. Elsevier, 43(7), pp. 891–901. 
Moreno, F., Gomez, J. M. L., Sanz-Guajardo, D., Jofre, R., Valderrabano, F. and Group4, S. 
C. R. P. Q. of L. S. (1996) ‘Quality of life in dialysis patients. A Spanish multicentre study’, 
Nephrology Dialysis Transplantation. Oxford University Press, 11(supp2), pp. 125–129. 
Mueller, R. O. and Hancock, G. R. (2008) ‘Best practices in structural equation modeling’, 
Best practices in quantitative methods, pp. 488–508. doi: 10.4135/9781412995627. 
Muldoon, M. F., Barger, S. D., Flory, J. D. and Manuck, S. B. (1998) ‘What are quality of 
life measurements measuring?’, Bmj, 316(7130), p. 542. doi: 10.1136/bmj.316.7130.542. 
Musil, C. M., Jones, S. L. and Warner, C. D. (1998) ‘and Its Relationship to Multiple 
Regression and Factor Analysis’, Research in Nursing & Health, 21, pp. 271–281. 
Muthén, B., Kaplan, D. and Hollis, M. (1987) ‘On structural equation modeling with data 
that are not missing completely at random’, Psychometrika. Springer, 52(3), pp. 431–462. 
Muthén, L. K. and Muthén, B. O. (2002) ‘How to use a Monte Carlo study to decide on 
sample size and determine power’, Structural equation modeling, 9(4), pp. 599–620. 
Mvundura, M., Amendah, D., Kavanagh, P. L., Sprinz, P. G. and Grosse, S. D. (2009) 
‘Health care utilization and expenditures for privately and publicly insured children with 
sickle cell disease in the United States’, Pediatric blood & cancer. Wiley Online Library, 
53(4), pp. 642–646. 
Nagel, R. L. and Ranney, H. M. (1990) ‘Genetic epidemiology of structural mutations of the 
beta-globin gene.’, in Seminars in hematology, p. 342. 
Naglie, G., Krahn, M. D., Naimark, D., Redelmeier, D. A. and Detsky, A. S. (1997) ‘Primer 
on medical decision analysis: part 3—estimating probabilities and utilities’, Medical 
315 
 
Decision Making. Sage Publications Sage CA: Thousand Oaks, CA, 17(2), pp. 136–141. 
Naidoo, J. and Wills, J. (2005) ‘Public health and health promotion: developing practice’, in 
Public health and health promotion: developing practice. 
Naidoo, J. and Wills, J. (2016) Foundations for Health Promotion-E-Book. Elsevier Health 
Sciences. 
Najman, J. M. and Levine, S. (1981) ‘Evaluating the impact of medical care and technologies 
on the quality of life: a review and critique’, Social Science & Medicine. Part F: Medical 
and Social Ethics. Elsevier, 15(2–3), pp. 107–115. 
Nathanson, C. A. (1975) ‘Illness and the feminine role: a theoretical review’, Social Science 
& Medicine (1967). Elsevier, 9(2), pp. 57–62. 
Nevitt, J. and Hancock, G. R. (2001) ‘Performance of bootstrapping approaches to model 
test statistics and parameter standard error estimation in structural equation modeling’, 
Structural equation modeling. Taylor & Francis, 8(3), pp. 353–377. 
Nichol, M. B., Sengupta, N. and Globe, D. R. (2001) ‘Evaluating quality-adjusted life years: 
estimation of the health utility index (HUI2) from the SF-36’, Medical Decision Making. 
Sage Publications Sage CA: Thousand Oaks, CA, 21(2), pp. 105–112. 
Nokes, K. M., Coleman, C. L., Hamilton, M. J., Corless, I. B., Sefcik, E., Kirksey, K. M., 
Eller, L. S., Kemppainen, J., Dole, P. J., Nicholas, P. K., Reynolds, N. R., Bunch, E. H., 
Holzemer, W. L., Wantland, D. J., Tsai, Y. F., Rivero-Mendez, M. and Canaval, G. E. (2011) 
‘Age-related effects on symptom status and health-related quality of life in persons with 
HIV/AIDS’, Applied Nursing Research. Elsevier Inc., 24(1), pp. 10–16. doi: 
10.1016/j.apnr.2009.03.002. 
Nunnally, J. C. (1967) ‘Psychometric theory.’ 
Nwogoh, B., Adewowoyin, A., Iheanacho, O. E. and Bazuaye, G. N. (2012) ‘Prevalence of 
haemoglobin variants in Benin City, Nigeria’, Annals of Biomedical Sciences. Medical and 
Dental Consultants Association of Nigeria (MDCAN) UBTH/UNIBEN Branch, 11(2), pp. 
60–64. 
Obansa, S. A. J. and Orimisan, A. (2013) ‘Health care financing in Nigeria: prospects and 
challenges’, Mediterranean Journal of social sciences, 4(1), pp. 221–236. 
Ogun, G. O., Ebili, H. and Kotila, T. R. (2014) ‘Autopsy findings and pattern of mortality in 
Nigerian sickle cell disease patients’, Pan African Medical Journal, 18, pp. 1–4. doi: 
10.11604/pamj.2014.18.30.4043. 
Ogunbekun, I., Ogunbekun, A. and Orobaton, N. (1999) ‘Private health care in Nigeria: 
walking the tightrope’, Health policy and planning. Oxford University Press, 14(2), pp. 174–
181. 
Ohaeri, J. U. and Shokunbi, W. A. (2002) ‘Psychosocial burden of sickle cell disease on 
caregivers in a Nigerian setting.’, Journal of the National Medical Association. National 
Medical Association, 94(12), p. 1058. 
Ohaeri, J. U., Shokunbi, W. A., Akinlade, K. S. and Dare, L. O. (1995) ‘The psychosocial 
problems of sickle cell disease sufferers and their methods of coping’, Social Science & 
Medicine. Elsevier, 40(7), pp. 955–960. 
Ohara, D. G., Ruas, G., Castro, S. S., Martins, P. R. J. and Walsh, I. A. P. (2012) 
‘Musculoskeletal pain, profile and quality of life of individuals with sickle cell disease.’, 
316 
 
Revista brasileira de fisioterapia (São Carlos (São Paulo, Brazil)), 16(5), pp. 431–8. doi: 
10.1590/S1413-35552012000500012. 
Ohene-Frempong, K. (2001) ‘Indications for red cell transfusion in sickle cell disease’, in 
Seminars in hematology. Elsevier, pp. 5–13. 
Ohene-Frempong, K., Weiner, S. J., Sleeper, L. A., Miller, S. T., Embury, S., Moohr, J. W., 
Wethers, D. L., Pegelow, C. H., Gill, F. M. and Disease, C. S. of S. C. (1998) 
‘Cerebrovascular accidents in sickle cell disease: rates and risk factors’, Blood. Am Soc 
Hematology, 91(1), pp. 288–294. 
Ojelabi, A. O., Graham, Y., Haighton, C. and Ling, J. (2017) ‘A systematic review of the 
application of Wilson and Cleary health-related quality of life model in chronic diseases’, 
Health and Quality of Life Outcomes, 15(1). doi: 10.1186/s12955-017-0818-2. 
Ola, B. (2016) ‘Living with Sickle Cell Disease and Depression in Lagos, Nigeria’. De 
Montfort University. 
Ola, B. A., Yates, S. J. and Dyson, S. M. (2016) ‘Living with sickle cell disease and 
depression in Lagos, Nigeria: A mixed methods study’, Social Science & Medicine. Elsevier, 
161, pp. 27–36. 
Olaniyi, J. A. (2008) ‘Multiple Complications in a Sickle Cell Disease Patient: A Case 
Report’, Clinical Medicine: Case Reports. SAGE Publications Sage UK: London, England, 
1, p. CCRep-S812. 
Oliffe, J. (2004) ‘Anglo-Australian masculinities and trans rectal ultrasound prostate biopsy 
(TRUS-Bx): Connections and collisions’, International Journal of Men’s Health, 3(1). 
Oliveira, C. C. de, Ciasca, S. M. and Moura-Ribeiro, M. (2008) ‘Stroke in patients with 
sickle cell disease: clinical and neurological aspects’, Arquivos de neuro-psiquiatria. 
SciELO Brasil, 66(1), pp. 30–33. 
Olson, S. H., Iyer, S., Scott, J., Erez, O., Samuel, S., Markovits, T., Schwartz, M., Toro, C., 
Gambarin-Gelwan, M. and Kurtz, R. C. (2005) ‘Cancer history and other personal factors 
affect quality of life in patients with hepatitis C’, Health and quality of life outcomes. 
BioMed Central, 3(1), p. 39. 
Omery, A. K. and Dean, H. (2004) ‘Multiple instruments for measuring quality of life’, 
Instruments for clinical health-care research. Jones and Bartlett, Sudbury, USA, pp. 150–
163. 
Omonzejele, P. F. (2008) ‘African Concepts of Health, Disease, and Treatment: An Ethical 
Inquiry’, Explore: The Journal of Science and Healing, 4(2), pp. 120–126. doi: 
10.1016/j.explore.2007.12.001. 
Oniyangi, O., Ahmed, P., Otuneye, O. T., Okon, J., Aikhionbare, H. A., Olatunji, O. O. and 
Akano, A. O. (2013) ‘Strokes in children with sickle cell disease at the National Hospital 
Abuja Nigeria’, Nigerian Journal of Paediatrics. Paediatric Association of Nigeria, 40(2), 
pp. 158–164. 
Oteng-Ntim, E., Chase, A. R., Howard, J., Khazaezadeh, N. and Anionwu, E. N. (2008) 
‘Sickle cell disease in pregnancy’, Obstetrics, gynaecology and reproductive medicine. 
Elsevier, 18(10), pp. 272–278. 
Pack-Mabien, A., Labbe, E., Herbert, D. and Haynes Jr, J. (2001) ‘Nurses’ attitudes and 
practices in sickle cell pain management’, Applied Nursing Research. WB Saunders, 14(4), 
pp. 187–192. 
317 
 
Padilla, G. V, Ferrell, B., Grant, M. M. and Rhiner, M. (1990) ‘Defining the content domain 
of quality of life for cancer patients with pain.’, Cancer nursing, 13(2), pp. 108–115. 
Padilla, G. V, Frank-Stromborg, M. and Koresawa, S. (2004) ‘Single instruments for 
measuring quality of life’, Instruments for clinical health-care research. Jones & Bartlett 
Learning, pp. 128–149. 
Palermo, T. M., Riley, C. A. and Mitchell, B. A. (2008) ‘Daily functioning and quality of 
life in children with sickle cell disease pain: {Relationship} with family and neighborhood 
socioeconomic distress’, The Journal of Pain, 9(9), pp. 833–840. doi: 
10.1016/j.jpain.2008.04.002. 
Palermo, T. M., Schwartz, L., Drotar, D. and McGowan, K. (2002) ‘Parental report of health-
related quality of life in children with sickle cell disease’, Journal of behavioral medicine. 
Springer, 25(3), pp. 269–283. 
Panepinto, J. A. (2008) ‘Health-related quality of life in sickle cell disease’, Pediatric Blood 
& Cancer, 51(1), pp. 5–9. doi: 10.1002/pbc.21557. 
Panepinto, J. A. (2012) ‘Health-related quality of life in patients with hemoglobinopathies.’, 
Hematology / the Education Program of the American Society of Hematology. American 
Society of Hematology. Education Program, 2012(1), pp. 284–9. doi: 10.1182/asheducation-
2012.1.284. 
Panepinto, J. A. and Bonner, M. (2012) ‘Health‐related quality of life in sickle cell disease: 
Past, present, and future’, Pediatric blood & cancer, 59(2), pp. 377–385. 
Panepinto, J. A., Hoffmann, R. G. and Pajewski, N. M. (2009) ‘A psychometric evaluation 
of the {PedsQL}TM family impact module in parents of children with sickle cell disease’, 
Health and Quality of Life Outcomes, 7(1), p. 32. doi: 10.1186/1477-7525-7-32. 
Panepinto, J. A., Pajewski, N. M., Foerster, L. M., Sabnis, S. and Hoffmann, R. G. (2008) 
‘Impact of family income and sickle cell disease on the health-related quality of life of 
children’, Quality of Life Research, 18(1), pp. 5–13. doi: 10.1007/s11136-008-9412-8. 
Parsons, T. (1958) ‘Definitions of health and illness in the light of American values and 
social structure’, Patients, physicians and illness. Free Press New York, pp. 165–187. 
Patrick, D. L. and Erickson, P. (1993) ‘Assessing health-related quality of life for clinical 
decision-making’, in Quality of life assessment: Key issues in the 1990s. Springer, pp. 11–
63. 
Paukert, A. L., Pettit, J. W., Kunik, M. E., Wilson, N., Novy, D. M., Rhoades, H. M., 
Greisinger, A. J., Wehmanen, O. A. and Stanley, M. A. (2010) ‘The roles of social support 
and self-efficacy in physical health’s impact on depressive and anxiety symptoms in older 
adults’, Journal of clinical psychology in medical settings, 17(4), pp. 387–400. 
Pauling, L., Itano, H. A., Singer, S. J. and Wells, I. C. (1949) ‘Sickle cell anemia, a molecular 
disease’, Science. JSTOR, 110(2865), pp. 543–548. 
Pearlman, R. A. and Uhlmann, R. F. (1988) ‘Quality of life in chronic diseases: perceptions 
of elderly patients’, Journal of gerontology. The Gerontological Society of America, 43(2), 
pp. M25–M30. 
Peasgood, T., Brennan, A., Mansell, P., Elliott, J., Basarir, H. and Kruger, J. (2016) ‘The 
impact of diabetes-related complications on preference-based measures of health-related 
quality of life in adults with Type I diabetes’, Medical Decision Making. SAGE Publications 
Sage CA: Los Angeles, CA, 36(8), pp. 1020–1033. 
318 
 
Pedhazur, E. J. (1982) Multiple regression in behavioral research: Explanation and 
prediction. Harcourt Brace Jovanovish College Publishers. 
Pegelow, C. H., Adams, R. J., McKie, V., Abboud, M., Berman, B., Miller, S. T., Olivieri, 
N., Vichinsky, E., Wang, W. and Brambilla, D. (1995) ‘Risk of recurrent stroke in patients 
with sickle cell disease treated with erythrocyte transfusions’, The Journal of pediatrics. 
Elsevier, 126(6), pp. 896–899. 
Penninx, B. W. J. H., Beekman, A. T. F., Ormel, J., Kriegsman, D. M. W., Boeke, A. J. P., 
Van Eijk, J. T. M. and Deeg, D. J. H. (1996) ‘Psychological status among elderly people 
with chronic diseases: does type of disease play a part?’, Journal of psychosomatic research, 
40(5), pp. 521–534. 
Peyre, H., Leplège, A. and Coste, J. (2011) ‘Missing data methods for dealing with missing 
items in quality of life questionnaires. A comparison by simulation of personal mean score, 
full information maximum likelihood, multiple imputation, and hot deck techniques applied 
to the SF-36 in the French ’, Quality of Life Research, 20(2), pp. 287–300. doi: 
10.1007/s11136-010-9740-3. 
Phaladze, N. A., Human, S., Dlamini, S. B., Hulela, E. B., Hadebe, I. M., Sukati, N. A., 
Makoae, L. N., Seboni, N. M., Moleko, M. and Holzemer, W. L. (2005) ‘Quality of Life and 
the Concept of “ Living Well ” With HIV / AIDS in Sub-Saharan Africa’, Journal of Nursing 
Schorlarship, 37(2), pp. 120–126. 
Phillips, T., Stanton, B., Provan, A. and Lew, R. (1994) ‘A study of the impact of leg ulcers 
on quality of life: financial, social, and psychologic implications’, Journal of the American 
Academy of Dermatology. Elsevier, 31(1), pp. 49–53. 
Piel, F. B., Hay, S. I., Gupta, S., Weatherall, D. J. and Williams, T. N. (2013) ‘Global burden 
of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, 
excess mortality, and interventions’, PLoS medicine. Public Library of Science, 10(7), p. 
e1001484. 
Piel, F. B., Patil, A. P., Howes, R. E., Nyangiri, O. A., Gething, P. W., Dewi, M., Temperley, 
W. H., Williams, T. N., Weatherall, D. J. and Hay, S. I. (2013) ‘Global epidemiology of 
sickle haemoglobin in neonates: {A} contemporary geostatistical model-based map and 
population estimates’, The Lancet, 381(9861), pp. 142–151. doi: 10.1016/s0140-
6736(12)61229-x. 
Piel, F. B., Patil, A. P., Howes, R. E., Nyangiri, O. A., Gething, P. W., Williams, T. N., 
Weatherall, D. J. and Hay, S. I. (2010) ‘Global distribution of the sickle cell gene and 
geographical confirmation of the malaria hypothesis’, Nature Communications, 1(8). doi: 
10.1038/ncomms1104. 
Pinto, A. M., Kuppermann, M., Nakagawa, S., Vittinghoff, E., Wing, R. R., Kusek, J. W., 
Herman, W. H. and Subak, L. L. (2011) ‘Comparison and correlates of three preference-
based health-related quality-of-life measures among overweight and obese women with 
urinary incontinence’, Quality of Life Research. Springer, 20(10), pp. 1655–1662. doi: 
10.1007/s11136-011-9896-5. 
Pizzo, E., Laverty, A. A., Phekoo, K. J., AlJuburi, G., Green, S. A., Bell, D. and Majeed, A. 
(2014) ‘A retrospective analysis of the cost of hospitalizations for sickle cell disease with 
crisis in England, 2010/11’, Journal of Public Health. Oxford University Press, 37(3), pp. 
529–539. 
Pizzo, E., Laverty, A. A., Phekoo, K. J., AlJuburi, G., Green, S. A., Bell, D. and Majeed, A. 
319 
 
(2015) ‘A retrospective analysis of the cost of hospitalizations for sickle cell disease with 
crisis in England, 2010/11’, Journal of public health (Oxford, England), 37(3), pp. 529–539. 
doi: 10.1093/pubmed/fdu026. 
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H. and 
Klug, P. P. (1994) ‘Mortality in sickle cell disease--life expectancy and risk factors for early 
death’, New England Journal of Medicine, 330(23), pp. 1639–1644. 
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E. 
and Kinney, T. R. (1991) ‘Pain in sickle cell disease: rates and risk factors’, New England 
Journal of Medicine, 325(1), pp. 11–16. 
Polit, D. F. and Beck, C. T. (2008) Nursing research: Generating and assessing evidence 
for nursing practice. Lippincott Williams & Wilkins. 
Portillo, C. J., Mendez, M. R., Holzemer, W. L., Corless, I. B., Nicholas, P. K. and Coleman, 
C. (2005) ‘Quality of Life of Ethnic Minority Persons Living with HIV/AIDS’, J Multicult 
Nurs Heal, 11, pp. 31–38. 
Post, M. (2014) ‘Definitions of Quality of Life: What Has Happened and How to Move On’, 
Topics in Spinal Cord Injury Rehabilitation, 20(3), pp. 167–180. doi: 10.1310/sci2003-167. 
Powars, D. and Hiti, A. (1993) ‘Sickle cell anemia: βS gene cluster haplotypes as genetic 
markers for severe disease expression’, American Journal of Diseases of Children. American 
Medical Association, 147(11), pp. 1197–1202. 
Powars, D. R. (1990) ‘Sickle cell anemia and major organ failure’, Hemoglobin. Taylor & 
Francis, 14(6), pp. 573–598. 
Powars, D. R., Chan, L. S., Hiti, A., Ramicone, E. and Johnson, C. (2005) ‘Outcome of 
sickle cell anemia: a 4-decade observational study of 1056 patients’, Medicine. LWW, 84(6), 
pp. 363–376. 
Powars, D., Weidman, J. A., Odom-Maryon, T., Niland, J. C. and Johnson, C. (1988) ‘Sickle 
cell chronic lung disease: prior morbidity and the risk of pulmonary failure.’, Medicine, 
67(1), pp. 66–76. 
Pratt, J. W. (1987) ‘Dividing the indivisible: Using simple symmetry to partition variance 
explained’, in Proceedings of the second international Tampere conference in statistics, 
1987. Department of Mathematical Sciences, University of Tampere, pp. 245–260. 
Prieto, L., Alonso, J., Ferrer, M., Antó, J. M. and Group, Q. of L. in C. S. (1997) ‘Are results 
of the SF-36 Health Survey and the Nottingham Health Profile similar?: A comparison in 
COPD patients’, Journal of clinical epidemiology. Elsevier, 50(4), pp. 463–473. 
Quinn, C. T., Rogers, Z. R. and Buchanan, G. R. (2004) ‘Survival of children with sickle 
cell disease’, Blood. Am Soc Hematology, 103(11), pp. 4023–4027. 
Quinn, C. T., Rogers, Z. R., Mccavit, T. L. and Buchanan, G. R. (2010) ‘Improved survival 
of children and adolescents with sickle cell disease’, Blood Journal, 115(17), pp. 3447–3452. 
doi: 10.1182/blood-2009-07-233700.The. 
Rapkin, B. D., Schwartz, C. E., Sprangers, M., Schwartz, C., Andrykowski, M., Brady, M., 
Hunt, J., Breetvelt, I., Dam, F. van, Bach, J., Tilton, M., Cassileth, B., Lusk, E., Tenaglia, 
A., Groenvold, M., Fayers, P., Sprangers, M., Bjorner, J., Klee, M., Aaronson, N., Bech, P., 
Mouridsen, H., Stensman, R., Albrecht, G., Devlieger, P., Kagawa-Singer, M., Padilla, G., 
Mishel, M., Grant, M., Wilson, I., Cleary, P., Friedland, J., Renwick, R., McColl, M., 
Sneeuw, K., Aaronson, N., Sprangers, M., Detmar, S., Wever, L., Schornagel, J., Sprangers, 
320 
 
M., Aaronson, N., Slevin, M., Stubbs, L., Plant, H., Wilson, P., Gregory, W., Armes, P., 
Downer, S., Leventhal, H., Colman, S., Schwartz, C., Sprangers, M., Campbell, A., Cantril, 
H., Stewart, A., Napoles-Springer, A., Howard, G., Ralph, K., Gulanick, N., Maxwell, S., 
Nance, S., Gerber, S., Howard, G., Dailey, P., Gulanick, N., Howard, G., Millham, J., Slaten, 
S., O, L., Howard, G., Schmeck, R., Bray, J., Howard, G., Dailey, P., Golembiewski, R., 
Billingsley, K., Yeager, S., Sprangers, M., Dam, F. van, Broersen, J., Lodder, L., Wever, L., 
Visser, M., Oosterveld, P., Smets, E., Jansen, S., Stiggelbout, A., Nooij, M., Noordijk, E., 
Kievit, J., Schwartz, C., Coulthard-Morris, L., Cole, B., Vollmer, T., Adang, E., Kootstra, 
G., Engel, G., Hooff, J. van, Merckelback, H., Ahmed, S., Mayo, N., Wood-Dauphinee, S., 
Hanley, J., Schwartz, C., Feinberg, R., Jilinskaia, E., Applegate, J., Rees, J., Waldron, D., 
O, C., Lenert, L., Treadwell, J., Schwartz, C., Cella, D., Hahn, E., Dineen, K., Lepore, S., 
Eton, D., Rapkin, B., Fischer, K., Richards, A., Folkman, S., Daltroy, L., Larson, M., Eaton, 
H., Phillips, C., Liang, M., Daltroy, L., Phillips, C., Eaton, H., Larson, M., Partridge, A., 
Logigian, M., Liang, M., Fries, J., Spitz, P., Kraines, R., Holman, H., Rapkin, B., 
Tourangeau, R., Rips, R., Rasinski, K., Jobe, J., Krause, N., Jay, G., Wilson, M., McGee, 
H., O, C., Gonzalez-Calvo, J., Gonzalez, V., Lorig, K., McGraw, S., McKinlay, J., Crawford, 
S., Costa, L., Cohen, D., Allison, P., Locker, D., Feine, J., Bernhard, J., Hürny, C., Maibach, 
R., Herrmann, R., Laffer, U., Hoeymans, N., Feskens, E., Kromhout, D., VanDenBos, G., 
Stanton, A., Danoff-Burg, S., Cameron, C., Snider, P., Kirk, S., Gruder, C., Blalock, S., 
DeVellis, B., DeVellis, R., Giorgino, K., Sauter, S., Jordan, J., Keefe, F., Mutran, E., 
Ramund, B., Stensman, R., Klinger, E., Barta, S., Maxeiner, M., Palys, T., Little, B., Rapkin, 
B., Smith, M., DuMont, K., Correa, A., Palmer, S., Cohen, S., Warnecke, R., Ferrans, C., 
Johnson, T., Chapa-Resendez, G., O, D., Suls, J., Miller, R., Schwartz, C., Mathias, S., Pasta, 
D., Colwell, H., Rapkin, B., Genderson, M., Henning, J., Sprangers, M., Hoogstraten, J., 
Norman, G. and Collins, D. (2004) ‘Toward a theoretical model of quality-of-life appraisal: 
Implications of findings from studies of response shift’, Health and Quality of Life 
Outcomes, 2(1), p. 14. doi: 10.1186/1477-7525-2-14. 
Raub, W. (1989) ‘High-fiber diet may inhibit large bowel neoplasia’, Journal of the 
American Medical Association, 262, p. 2359. 
Rees, D. C., Williams, T. N. and Gladwin, M. T. (2010) ‘Sickle-cell disease’, The Lancet. 
Elsevier, 376(9757), pp. 2018–2031. 
Richardson, J., Iezzi, A. and Khan, M. A. (2015) ‘Why do multi-attribute utility instruments 
produce different utilities: the relative importance of the descriptive systems, scale and 
“micro-utility”effects’, Quality of Life Research. Springer, 24(8), pp. 2045–2053. 
Rijken, M., van Kerkhof, M., Dekker, J. and Schellevis, F. G. (2005) ‘Comorbidity of 
chronic diseases’, Quality of Life Research. Springer, 14(1), pp. 45–55. 
Rosenberg, R. (1995) ‘Health-related quality of life between naturalism and hermeneutics’, 
Social Science & Medicine. Elsevier, 41(10), pp. 1411–1415. 
Rosenblueth, A. and Wiener, N. (1945) ‘The role of models in science’, Philosophy of 
science. Williams and Wilkins Co., 12(4), pp. 316–321. 
Rothman, K. J. (1986) ‘Objectives of epidemiologic study design’, Modern epidemiology, 
pp. 77–97. 
Rubin, D. B. (1976) ‘Inference and missing data’, Biometrika. Oxford University Press, 
63(3), pp. 581–592. 
Saban, K. L., Penckofer, S. M., Androwich, I. and Bryant, F. B. (2007a) ‘Health-related 
quality of life of patients following selected types of lumbar spinal surgery: a pilot study.’, 
Health and quality of life outcomes, 5(1), p. 71. doi: 10.1186/1477-7525-5-71. 
321 
 
Saban, K. L., Penckofer, S. M., Androwich, I. and Bryant, F. B. (2007b) ‘Health-related 
quality of life of patients following selected types oflumbar spinal surgery: {A} pilot study’, 
Health & Quality of Life Outcomes, 5, p. 71. 
Saengsiri., A.-O., Thanasilp., S., Preechawong., S., A.-O., S., S., T. and S., P. (2014) ‘Factors 
predicting quality of life for coronary artery disease patients after percutaneous coronary 
intervention’, Asian Biomedicine, 8(1), pp. 31–42. doi: 10.5372/1905-7415.0801.259. 
Samsa, G., Edelman, D., Rothman, M. L., Williams, G. R., Lipscomb, J. and Matchar, D. 
(1999) ‘Determining clinically important differences in health status measures’, 
Pharmacoeconomics. Springer, 15(2), pp. 141–155. 
Sant’Ana, P. G. dos S., Araujo, A. M., Pimenta, C. T., Bezerra, M. L. P. K., Junior, S. P. B., 
Neto, V. M., Dias, J. S., Lopes, A. de F., Rios, D. R. A. and Pinheiro, M. de B. (2017) 
‘Clinical and laboratory profile of patients with sickle cell anemia’, Revista Brasileira de 
Hematologia e Hemoterapia. Associação Brasileira de Hematologia, Hemoterapia e Terapia 
Celular, 39(1), pp. 40–45. doi: 10.1016/j.bjhh.2016.09.007. 
Santos, C. M. Dos, Celeste, R. K., Hilgert, J. B. and Hugo, F. N. (2015a) ‘Testing the 
applicability of a model of oral health-related quality of life.’, Cadernos de saúde pública, 
31(9), pp. 1871–1880. doi: 10.1590/0102-311X00119914. 
Santos, C. M. Dos, Celeste, R. K., Hilgert, J. B. and Hugo, F. N. (2015b) ‘Testing the 
applicability of a model of oral health-related quality of life.’, Cadernos de saúde pública, 
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APPENDICES 
QUESTIONNAIRE ON QUALITY OF LIFE OF ADULTS WITH SICKLE CELL 
ANAEMIA 
This questionnaire is to collect some information from you as a participant. Kindly fill 
answer the questions as they apply to you. The exercise is for research purpose and all 
information shall be treated as confidential. Thank you for completing this survey. 
SECTION A: BACKGROUND INFORMATION 
Age group (circle): (a) 18-30 (b) 31-40 (c) 41-50 (d) Above 50 
Sex (circle):    (a) Male (b) Female State of origin………………………… 
Education (circle):  (a) No education (b) Primary (c) Secondary (d) ND/NCE 
   (e) 1st degree/equivalent  (f) Higher degree 
Marital status:  (a) Single (b) Married (c) Separated/Divorced  
   (d) Widowed 
Number of children:  
Employment (circle): (a) Fully-employed (b) Employed-part-time (c) Not employed 
Employment type (circle): (a) Government (b) Private (c) Self (d)Not 
applicable 
Income (per month): (a) Below N18,000 (b) N18,000-50,000 (c) N51,000-100,000 
   (d)N101,000-200,000 (e) N201,000-300,000 (f) above N300,000  
Living situation (circle): (a) Living alone (b) Living with parent/siblings 
 (c) Living with friends  (d) Living with spouse/children 
Do you have a confidant? (a) Yes (b) No 
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Religion (circle): (a) Christianity (b) Islam (c) Traditional  (d) None 
Genotype (circle):  (a) SS (b) SC (c) Sβ  Weight (kg)………. Height (m)…… 
In the last 6 months, how many times did you do any of the following? 
(Use “✔” to indicate your answer)  
 None once 2 times 3 times More 
than 3 
times 
1.  Visited the Emergency Department      
2. Admitted to the hospital      
3. Have pain episodes/experience      
4. Have other sickle-cell related crisis       
 
Have you been diagnosed with any of the following diseases? 
 
Yes No 
Asthma   
Diabetes   
Arthritis   
Leg ulcers   
Stroke   
Epilepsy   
High blood pressure   
Heart disease   
Priapism   
Lung disease   
Pneumonia   
Others (mention)   
 
Looking at all parts of my life – physical, emotional, social, spiritual and financial in the last 
two weeks, the quality of my life has been?”.  Rate from 0, VERY BAD to 10, 
EXCELLENT. 
SECTION B: EXPERIENCES AS A RESULT OF HEALTH CONDITION 
Over the last 2 weeks, how often have you been bothered by any of the following 
problems? 
(Use “✔” to indicate your answer)  
 Not at 
all 
 
Several 
Days 
 
More than 
half the 
days 
Nearly 
Every day 
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0 1 2 3 
1. Little interest or pleasure in doing things     
2. Feeling down, depressed, or hopeless     
3.Trouble falling or staying asleep, or sleeping 
too much 
    
4. Feeling tired or having little energy     
5. Poor appetite or overeating     
6. Feeling bad about yourself — or that you 
are a failure or have let yourself or your family 
down 
    
7.Trouble concentrating on things, such as 
reading the newspaper or watching television 
    
8. Moving or speaking so slowly that other 
people could have noticed? Or the opposite — 
being so fidgety or restless that you have been 
moving around a lot more than usual  
    
9. Thoughts that you would be better off dead 
or of hurting yourself in some way 
    
 
During the last 4 weeks, how much have you been bothered by any of the following 
problems? (Use “✔” to indicate your answer)  
 Not 
bothered 
(0) 
Bothered a 
little 
(1) 
Bothered 
a lot 
(2) 
1. Stomach pain    
2. Back pain    
3. Pain in your arms, legs, or joints (knees, 
hips, etc. 
   
4. Feeling tired or having little energy    
5. Trouble falling or staying asleep, or 
sleeping too much 
   
6. Menstrual cramps or other problems 
with your periods 
   
7. Pain or problems during sexual 
intercourse 
   
8. Headaches    
9. Chest pain    
10. Dizziness    
11. Fainting spells    
12. Feeling your heart pound or race    
13. Shortness of breath    
14. Constipation, loose bowels, or 
diarrhoea 
   
15. Nausea, gas, or indigestion    
P 
Over the last 4 weeks, how often have you been bothered by any of the following 
problems? 
(Use “✔” to indicate your answer)  
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 Not at 
all 
(0) 
Several 
days 
(1) 
More than 
half 
the days 
(2) 
Nearly 
every 
day 
(3) 
1. Feeling nervous anxiety or on 
edge 
    
2. Not being able to stop or control 
worrying 
    
3. Worrying too much about 
different things 
    
4. Trouble relaxing     
5. Being so restless that it is hard to 
sit still 
    
6. Becoming easily annoyed or 
irritable 
    
7. Feeling afraid as if something 
awful might happen 
    
 
 
 
SECTION C: HEALTH STATUS 
1. In general, would you say your health is (circle): (1) Excellent  (2) Very good  
        (3) Good (4) Fair (5) Poor 
2. Compared to one year ago:   (1) Much better now than one year ago  
 (2) Somewhat better now than one year ago  
 (3) About the same       
 (4) Somewhat worse now than one year ago   
 (5) Much worse now than one year ago 
 
3. The following items are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much?  
(Circle One Number on Each Line) 
 Yes,  
Limited a  
Lot (1) 
Yes,  
Limited a  
Little (2) 
No, Not  
limited at  
All (3) 
a. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports 
1 2 3 
b. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing 
golf 
1 2 3 
c. Lifting or carrying groceries  1 2 3 
d. Climbing several flights of stairs  1 2 3 
e. Climbing one flight of stairs  1 2 3 
335 
 
f. Bending, kneeling, or stooping 1 2 3 
 
 
4. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health? (Circle One Number on 
Each Line) 
 Yes 
(1) 
No 
(2) 
a. Cut down the amount of time you spent on work or other activities 1 2 
b. Accomplished less than you would like 1 2 
c. Were limited in the kind of work or other activities 1 2 
d. Had difficulty performing the work or other activities (for 
example, it took extra effort) 
1 2 
 
5. During the past 4 weeks, have you had any of the following problems with your work 
or other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
(Circle One Number on Each Line) 
 Yes 
(1) 
No 
(2) 
a. Cut down the amount of time you spent on work or 
other activities 
1 2 
b. Accomplished less than you would like 1 2 
c. Didn't do work or other activities as carefully as usual 1 2 
6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbours, 
or groups? (1) Not at all (2) Slightly (3) Moderately (4) Quite a bit 
 (5) Extremely 
 
7. How much bodily pain have you had during the past 4 weeks?    
(1) None (2) Very mild  (3) Moderate (4) Severe (5) Very Severe 
 
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?    
  
(1) Not at all  (2) A little bit    (3) Moderately (4) Quite a bit     (5) 
Extremely 
 
 
These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 
way you have been feeling. (Circle One Number on Each Line) 
9. How much of the time during the past 4 weeks . . . 
 All of 
the 
Time 
Most 
of the 
Time 
A good 
bit of the 
Time 
Some 
of the 
Time 
A little 
of the 
Time 
None 
of the 
Time 
a. Did you feel full of 
pep? 
1 2 3 4 5 6 
336 
 
b. Have you been a 
very nervous 
person? 
1 2 3 4 5 6 
c. Have you felt so 
down in the dumps that 
nothing could cheer 
you up? 
1 2 3 4 5 6 
d. Have you felt calm 
and peaceful? 
1 2 3 4 5 6 
e. Did you have a 
lot of energy? 
1 2 3 4 5 6 
f. Have you felt 
downhearted and 
blue? 
1 2 3 4 5 6 
g. Did you feel worn 
out? 
1 2 3 4 5 6 
h. Have you been a 
happy person? 
1 2 3 4 5 6 
i. Did you feel tired? 1 2 3 4 5 6 
 
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? (Circle One Number): 
(1) All of the time  (2) Most of the time  (3) Some 0f the time 
 (4) A little bit of the time (5) None of the time 
 
 
 
 
 
11. How TRUE or FALSE is each of the following statements for you. 
(Circle One Number on Each Line) 
 Definitely 
True 
Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definitely 
False 
a. I seem to get sick a 
little easier than other 
people 
1 2 3 4 5 
b. I am as 
healthy as 
anybody I 
know 
1 2 3 4 5 
c. I expect my health to 
get worse 
1 2 3 4 5 
d. My health is excellent 1 2 3 4 5 
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INFORMED CONSENT FORM 
IRB Research Approval number:   
This approval will elapse on:  
TITLE OF THE RESEARCH:   
HEALTH RELATED QUALITY OF LIFE AND ITS PREDICTOR MARKERS AMONG 
SICKLE CELL PATIENTS IN IBADAN, SOUTH WEST NIGERIA. 
Name(s) and affiliation(s) of researcher(s): 
The study is being conducted by Adedokun O. Ojelabi, a PhD student of the 
Department of Pharmacy, Health and Well-being of the University of Sunderland, 
United Kingdom.  
 
Sponsor of research: this is part of a Ph.D programme sponsored by the University of 
Ibadan  
Purpose of Research: 
The purpose of this research is to investigate the quality of life of adults (18 years and older) 
living with sickle cell disease and to examine the effects of sickle cell disease on quality of 
life. 
Why have I been chosen? 
As a person living with SCD your views are important. As part of the investigation, the 
researcher would like to collect information from a sample of patients, 18 years and above, 
living with SCD. You along with other people in the same condition are being asked if you 
would like to take part in this project    
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Do I have to take part? 
It is entirely voluntary. Whether or not you take part should be your decision. Any 
identifying information about those taking part will be kept confidential.  If you do decide 
to take part you will be given this information sheet to keep and you will be asked to sign a 
consent form.  If you decide to take part you are free to withdraw at any time without giving 
a reason. If you do chose to withdraw, any data collected up to the point of withdrawal will 
be destroyed and will not be used in the study.   
A decision to withdraw at any time, or a decision not to take part, will not affect you in any 
way. 
 
What will happen to me if I take part? 
You may be asked to take part in completing a questionnaire and your height and weight 
might be taken.  The entire process will last about one hour. A token may be given to cover 
cot of transportation of participants. 
 
What do I have to do? 
If you decide that you would like to take part, please sign the consent form that is attached 
to this information sheet and return to me. You will be contacted on the date and time, the 
activities will take place. 
 
 
 
What will happen to the results of the research study? 
The report of the analysis will be used for a PhD and may be used in published journal 
articles, which is expected to generate further research to improve quality of life of people 
living with SCD, however participants will not be named, and you will not be able to be 
recognised by any comments you make. 
 
Will my taking part in this study be kept confidential? 
All information supplied will be treated as confidential and will be used for research 
purposes only. 
Who is organising and funding the research? 
This is a research project in partial fulfilment for the award of a PhD from the University of 
Sunderland.  
 
Ethical approval.   
This research has been approved by UI/UCH Ethics Committee.  If you have any concerns 
regarding the conduct of this study please contact the Chairman, UI/UCH Ethics Committee, 
Biode Building, Room 210, Institute for Advanced Medical Research and Training, College 
of Medicine, University of Ibadan, email: uiuchirc@yahoo.com and uiuchec@gmail.com.  
In addition, if you need any further information, please contact AO Ojelabi,  
Department of Pharmacy, Health and Well-being, University of Sunderland,  
United Kingdom or via email at adedokun.ojelabi@research.sunderland.ac.uk. 
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STATEMENT OF PERSON GIVING CONSENT 
- Please put your initials in the column provided beside each statement to show that 
you agree with the statement and give consent.   
- Please sign and date this form to show you give consent to all statements that you have initialled. 
Statement Initials 
I consent to take part in this research project.  
I understand that a researcher from the University of Sunderland is 
carrying out a study on Health-related quality of life among people 
living with sickle cell disease (SCD). I understand that the data 
collection is for research purposes. 
 
I confirm that I have read and understood the enclosed Information Sheet 
for this study, and have had plenty of time to decide whether or not I 
wish to participate. 
 
I understand that my participation is voluntary, and that I am free to 
withdraw at any time, without giving a reason. 
 
I understand that I will be given a copy of this signed consent form.  
I have been told that the completed questionnaires will be securely kept 
until after the end of the project when they will be destroyed. I am aware 
that all documents will remain confidential and these will be securely 
stored with only the researcher having access to them. 
 
I am aware that information on the questionnaire may be used in a final 
report, but understand that individual participants will not be identified. 
 
 
Signed ……………………………......……………..Date …………………………… 
Name……… …………………………………………….. 
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TO BE COMPLETED BY RESEARCHER on attendance at the interview: 
I can confirm that I have explained to the above-named participant the nature of this study, 
and I have given adequate time for any questions to be asked and answered regarding the 
study. 
 
Signed ……………………………………………………… Date …………………… 
Name (in capitals) ……………………………………………………………… 
Post ……………………………………………………………………………… 
 
 
 
 
 
 
 
 
 
 
 
